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Abstract
This thesis reports four studies that evaluated the usefulness of written medicines
information provided as a leaflet, and on the Internet, for improving people's
understanding about medicines. Three of the studies used mixed methods. Study one
used two methods. A systematic review evaluated 36 randomised trials that examined
the effectiveness of leaflet-based medicines information for changing knowledge,
attitudes and medicines-taking behaviours. Two sequential workshops enabled
stakeholders to input into the review aims, and then give feedback on the findings. The
review concluded that leaflet-based information can improve knowledge, but there
was no evidence that it can change attitudes or behaviour. Study two analysed ten
websites that contained information about medicines and found considerable variation
in their quality, content, and design. Study three examined the usability and
readability of five sites sampled from Study two. Fifteen participants were randomly
allocated to use one site, to locate and explain information about the safety and efficacy
of the medicine. Their performance was measured using four concurrent methods:
observation, online tracking, thinking aloud, and User Testing. The design of the sites
and how their content was written impeded participants' performance on the task.
Evidence-based recommendations were derived for improving the sites' design. Study
four was a pilot of an intervention for redesigning Internet-based medicines
information, including a crossover study design and tools for measuring the outcomes.
Thirty participants viewed both the original and revised web pages in a random and
counterbalanced order to see if the redesigned web pages containing information about
medicines improved participants' ability to locate and understand specific information.
The study design and limited redesign of the webpages may not be appropriate for a
full RCf. Applying User Testing to the evaluation of websites appears to be original,
and using a mixed methods approach has been beneficial to the research.
Improvements are needed to leaflet-based and Internet-based medicines information to
make it easier to read and understand. This could make written medicines information
more useful for medicine users, enabling them to make an informed choice about
taking medicines, or be better informed about their safety and efficacy.
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Chapter one
Background
l.l.Introduction
Medicine users need sufficient information about medicines (Raynor et al., 2007a). This
information should be useful to enable them to understand and appreciate how to
effectively take medicines, and to understand the risks and benefits in doing so (Raynor,
2007). Written medicines information (WMI), also known as consumer medicines
information (CMI), is normally provided as leaflet-based information accompanying
medicines, and is also available on the Internet. This thesis evaluates the usefulness of
leaflet-based and Internet-based medicines information (mM!) for aiding people's
understanding about taking medicines. It does not seek to identify the circumstances in
which WMI can be useful - this is a wider question that would necessitate examining the
social context in which WMI is provided.
In the European Union (EU), WMI is provided as a patient information leaflet (PIL)
accompanying both prescription-only medicines (PaM) and over-the-counter (OTC)
medicines (see 1.2.2). Coulter (1998) has proposed that if WMI is evidence-based and
presented in an acceptable and useful format, this could enable the medicine user to be an
active decision maker in her or his healthcare. Other means to support medicine users to
take their medicines as prescribed include counselling, simplified dosing, and medication
charts (Haynes et al., 2008). These interventions are necessary because, while medicines are
the most commonly provided health care intervention by the National Health Service (NHS)
in the UK (Anonymous, 2002a), not all people take their medicines as intended (Haynes et
al., 2008). This is a worldwide public health issue that could have life-threatening risks, as
well as negating the effectiveness of treatment (World Health Organisation (WHO), 2003).
There has been a call in the UK for' an increase in public awareness of the availability of
PILs in different formats (Medicines and Healthcare Products Regulatory Agency, 2005).
The Internet offers an alternative resource for information on healthcare and medicines
2information, known as e-health (see 1.3). mMI is a category of e-health and is introduced
in 1.4.
The following is a short overview of the work presented in this thesis. Study one (Chapter
three) evaluated the role, value and effectiveness of PILs, as research of secondary data.
This study was part of an Health Technology Assessment (HTA) Report (Raynor et al., 2007a)
that was commissioned by the NHS R&D Health Technology Assessment Programme. This
project was based on a systematic review. Medicine information stakeholders provided
input into the aims, and the conclusions of the review through two workshops.
The three other studies in this thesis were primary research that evaluated mMI.Study
two (Chapter four) assessed the design features, quality, and general and specific content
of a sample of sites with information about the medicine simvastatin. Study three (Chapter
five) examined the usability and the readability of the information contained in a sample
of these sites. A series of evidence-based recommendations for improving the design of
mMI sites were derived. Study four (reported in Chapter six) was a pilot study of an
intervention for redesigning Internet-based medicines information, including a crossover
study design and outcomes measure tools. These could be used in a full trial evaluating
whether redesigned web pages containing information about medicines improved
participants' ability to locate and understand specific information. The precise aims and
objectives of the work reported in this thesis are presented in detail in 1.6.2. The following
four sections provide an overview of the concepts and research base underpinning this
thesis.
1.2.Written medicines information (WMI)
This section provides an introduction to PILs, which are examined in Chapter three. There
is an overview of PILs in a wide context: the provision of WMI in the EU (and associated
problems); the need for WMI to be readable (understandable) to be useful; WMI enabling
......
the medicine user to make an informed decision; and the links between provision of WMI
and the pharmaceutical industry. Several of these concepts are also relevant to mMI.
Firstly there is a brief overview of the PIL.
31.2.1. The patient information leaflet
The main mode of providing WMI is the PIL. This is a sheet of paper with written
information, usually accompanying all medicines in the EU; see Figure 1 for an example of
a PIL. Raynor et al. (2007a)have proposed that the PIL has two functions:
(i) To enable an informed decision to be made about taking medicines, and
(ii) To enable the patient to take and use the medicine effectively and safely.
These functions are examined in greater detail in section 1.2.6.The PIL is available to
varying degrees and in different formats throughout the world. It is useful to look at three
reported examples from around the world as a point of reference for PILs in the present-
dayEU.
InAustralia CM! is required by law to provide information in English that is easily
understood, to accompany all medicines (Koo et al., 2003). InBelgium, patient package
inserts (PPIs) have accompanied medicines (to varying degrees) since 1964,preceding EU
legislation (Vander Stichele, 2004).There is no legal stipulation for WMI to accompany
medicines in the USA, but a computer-generated leaflet (if available), can be printed by the
pharmacist to accompany the medicines (Raynor et al., 2007a).
Reviewing factors that determine the use of WMI, Koo et al. (2003)have categorised these
as:
1. Relating to the leaflet: for example, the readability of its content (see 1.2.5),and the
presentation of the information on the leaflet; and
2. Relating to the medicine user: for example, their health literacy (see 1.2.4),the role
of caregivers, the medicine user's demographics, etc.
Two observations are drawn from this. Firstly, that the relationship between the leaflet
and person is similar to that of user and website. Secondly, that the readability and
presentation of the leaflet is dependent on how it is designed (see 1.5.2).This can equally
apply to IBMI, and underlies the examination of IBMIin Studies two and three in this
thesis.
4Figure 1:Abridged example of a patient information leaflet
SIMVASTATIN
Read this leaflet carefully before you start taking this medicine.
• You may need to read this leaflet again.
• If you have further questions, speak to your doctor or your phannacist.
• Do not share this medicine with others as It could hann them.
1. What Simvastatin is and what it Is used for?
Simvastatln (also known as ·statln·.) is a medicine that lowers lipids. They work by lowering lipids (fats) such as
cholesterol and triglycerides in your blood. Simvastatin Tablets are recommended for patients with high cholesterol and
triglyceride levels, and for patients with cardiovascular diseases (heart and blood vessels diseases) and/or diabetes
mellitus with either high or nonnal cholesterol levels.
2. Before you take Simvastatin
Do not take Slmvastatln:
• If you are allergic to simvastatln, or any simlar medicines.
• If you have liver problems.
Take speCial care:
SlmVlllltatin can c.u .. muscle problema. This risk Is greater In higher doses .nd for c:artaln patients. You should
.Iso tell your doctor If you:
• Have medical conditions inciuding allergies;
• Have kidney problems;
• Are over 70 years of age;
3. How to take Simvastatin Tablets
Do not take more than what was presaibed by your doctor. If you take too much, go to the nearest hospital casualy
department or tell your doctor immediately. Do not take two doses at onee If you miss a dose.
4. POSSible side effects
The following side effects are rare (between 1 in 1000 and 1 in 10,000 people are likely to be affected):
• Nervous system disorders: h.. dache, dizziness, numbn ... or lose of .. nsatIon In the .rms .nd legs.
• Gastrointestinal disorders: sickness, constipation, diarrhoea, tiatulence.
• Hepato-blliary disorders: liver disease (possibly presenting as yeHowing of the eyes and/or skin, Itchiness of the
skin, dark colored urine, pale colored stools),
• Skin and subcutaneous tissue disorders: hair loss, rash, Itchiness,
• Musculoskeletal, connective tissue and bone disorders: muscle damage (see below),
• Allergic reaction to Slmvastatln Tablets. The allergic reaction may include some of the following: swelDng of the
faee, tongue or throat (in which case you should contact your doctor immediately), joint pains, joint.nd blood
vessel infiammation, unusual bruising, skin eruptions, swallng, hives, skin sensitivity to the sun, a high
temperature, flushing, ditllculty in breathing, or tiredness.
Speak to your doctor IrnmeclIIIteIy If you have muac:1e.c .... and pain .. tendemeas. _kness, or cramps.
5. Storing Slmvastatln Tablets
Do not take slmvastatln attar the expiry date.
[Based on the Dexcel Pharma simvsstEtin PIL accessed online In May 2008 at
http://emc.medicines.org.uklemaassetslcJhtmllDispiayDoc.asp?format=original&documentid=19028]
1.2.2. The provision of paper-based WMI in the European Union
The provision of WMI has been subject to legislation in Europe since the mid-1960s
(Vander Stichele, 20(4). The development and existence of PILs and their content, in
5member states of the EU,was regulated by Article 6 of the 1992EU directive (92/27IEEC)
(Council Directive, 1992),fully implemented in 1999.This made it a legal obligation for a
comprehensive information leaflet to accompany all licensed medicines, (POM and OTC)
in EUmember states.
The 1992Directive has now been superseded, with revised legislation stipulating the
specific information to be contained in a leaflet. Directive 2004/27IEC of the European
parliament and of the council of 31March 2004 amending Directive 2001/83IECon the
Community code relating to medicinal products for human use (European Commission,
2004), set out five obligatory items of information for PILs in the EU (see also Figure 1):
(i) What the medicine is and what it is used for;
(ii) Before you take or use the medicine;
(iii) How to take or use the medicine;
(iv) Possible side effects; and
(v) Storage of the medicine.
The mandatory headings for each section, were laid out in a document by the Quality
Review of Documents (QRD)Group of the EU in 2005 (Quality Review of Documents
Group, 2005).
The 2004Directive allows the inclusion of some non-promotional information about the
benefits of taking a medicine. How balanced the perspective of the risks and beneficial
effects of taking a medicine is could have implications for people's intentions to take a
medicine. Bersellini and Berry (2007)examined this using a hypothetical scenario and
found provision of a benefit message increased participants' intention to take a medicine.
Research in the UK has shown that EU legislation may not yet be providing full benefit to
patients. For example, a telephone survey in 1999of 215 people who were dispensed
medicines at three UK pharmacies found one third of medicines did not have a leaflet.
,.
When the leaflet was available, 83%of participants noticed it; and of those who did so,
40% reported reading at least some of it, and around 21% said they read all of it (Raynor
and Knapp, 2000).This study was updated in 2003by Raynor et al. (200s); and again in
62006 by Raynor et al. (2007b), when 97% of 456 respondents reported noting the insert. Of
those receiving a medicine for the first time (122 people), 87 (71%) reported reading it.
However, nearly two thirds of those receiving a repeat prescription had not read the PIL
on that occasion (Raynor et al., 2007b). So, despite the inclusion of the PIL being legislated
for, a large number of people receiving long-term medicines in the UK did not read the
information accompanying it, other than when they first received the medicine.
1.2.3. The relationship between information provision and health
It can be reasonably assumed that a key purpose of providing WMI will be to have a
beneficial effect on the medicine taker's health, by encouraging him/her to adapt their
health-related behaviours. However, it is important to critically examine the plausibility of
this relationship.
There appears to be no evidence that clearly shows a direct relationship between provision
of health information on (any) health-related behaviour. Rosenfeld and Morville (2002)
have provided the example of the simplistic information model where 'black magic'
occurs between the person asking a question and receiving an answer. They have criticised
this as a mechanistic view of how people search for information, where it wrongly
assumes that the individual is predictable inbehaviour and rational in motivation. The
same problem underlies the notion that giving information (the stimulus) will lead to a
change in someone's health (the response). This ignores mediating variables: how the
person processes the information, as well as environmental factors acting on the health
and well-being of the individual.
The Theory of Planned Behaviour (TPB) (Ajzen, 1991) seeks to explain individual behaviour
in terms of underlying intentions, rather than as a direct response to stimuli. TPB proposes
that an individual forms an attitude towards an object, based on his beliefs, which then
shape her or his intentions to behave in a particular way. The individual's attitude then
shapes his intentions to behave in a particular way. It is this intention that solely and ....
directly determines her or his behaviour. It follows that the effect of WMI on behaviour
7(e.g. taking the medicine as instructed) is mediated by an attitude change, and not a direct
stimulus-response relationship.
For the reasons above, providing WMI probably does not have a direct impact on the
medicine taker's health. This is reflected by EU legislation, which does not seek to change
health-related behaviour, but legislates for readable information (see 1.2.5).This thesis
examines the readability of mMI: if the information can be read and understood, this
could enable the medicine user to make an informed choice about her or hismedicine-
taking behaviour. One role of WMI will be to (potentially) enable the medicine user to
make an informed choice, and is examined in 1.2.6.
1.2.4. Health literacy
Koo et al. 's (2003)categorisation of aspects determining WMI use highlighted that one of
the factors attributable to the individual user was their health literacy. This is an important
public health phenomenon said to represent:
"The cognitive and social skills which determine the motivation and ability of
individuals to gain access to understand and use information in ways which
promote and maintain good health ... health literacy is critical to
empowerment" (World Health Organization (WHO), 1998),pp10.
Speros (20OS)proposed that an individual's health literacy is dependent upon her or his
literacy (reading and computational levels) and health-related experience. In this respect,
an individual's need for WMI may vary in relation to her or his state of health. However, a
high level of health literacy in the general public will not be enough for them to make an
informed choice, and safely and effectively take the medicine. As Raynor (2008a)has
noted, usable information that people can interpret and understand is as important for
their understanding about their health and healthcare.
1.2.5. Readability and medicines information
The readability of written text refers to its understandability (Ley and Florio, 1996).The
US Pharmacopoeia has proposed that usable medicines information is that which can be
understood (Hartzema et al., 1999).Adding to this, the Communication Research Institute of
Australia have defined usable medicines information as that which is understandable, easy
8to find, and appropriately acted upon (SIess,2001).The usability of WMI will to an extent
depend upon its perceived role. For example, Grime et al. (2007)have noted that WMI can
encourage compliance or enable decision making, depending on whether one is a patient
or a doctor (see also 1.2.6.).
The readability of information has typically been assessed using a formula. Bailin and
Grafstein (2001)have proposed that the use of readability formulae is attractive because it
offers an apparently objective and quantifiable evaluation of the difficulty of reading
written material. An example of a readability formula is the Flesch Reading Test (Flesch,
1948)which measures sentence length (the number of words), and word length (the
number of syllables) to calculate a reading ease scale which ranges from 0 (unreadable) to
100 (very easy to read). Other examples, based on similar principles include the Fog Index
(Gunning, 1968),and the Simple Measure of Gobbledygook - SMOG (McLaughlin, 1969).An
evaluation using a readability formula of USMedication Guides providing information
about prescription medication found that none met the national recommendation for a
reading level of 6th to 8th grade. This led to the conclusion that the reading level
requirement should be reduced to make WMI in the USA more understandable to all
sections of the community (Wolf et al., 2006).
The rationale for examining the readability of WMI is that if the medicine user can
understand the information (having found it) this would enable her or him to make an
informed, evidence-based choice about their treatment. While it is important to examine
whether WMI is understandable for the above reason, the usefulness of 'readability
formulae' is questionable, as it may be neither necessary nor sufficient to examine this.
Bailin and Grafstein (2001)have proposed that existing readability formulae do not
measure what they purport to, because there is no set criterion that comprises a universal,
unified concept of readability. Friedman and Hoffman-Goetz (2006)have indicated that
the main difficulty with readability formulae is the reliance on word and sentence length,
which ignores the effects of reader motivation, design and graphics on readability and
comprehension. There is also the problem that the readability score for text will be the
9same whether it is written forwards or backwards (Raynor, 2005):clearly someone would
not be able to understand information when it is written backwards.
Article 59(3) of the 2001 EU Directive (2001l83IEC) (European Commission, 2001) stipulated
that paper-based medicines information should be the subject of consultation with target
groups to ensure it is legible, clear and easy to use. This can be interpreted to mean that
the information must be understandable for the medicine users. This legislation has paved
the way for the user testing of all medicine information leaflets produced by
manufacturers and supplied in all packets of medicines in the EU (European COmmission,
2004).User Testing of the content of a leaflet is a performance-based method for testing
readability, devised in Australia (SIessand Wiseman, 2004).The performance being
measured is the behaviour of the person reading the leaflet, specifically their ability to find
and then understand precise information (see 5.2.1).The examination of the readability of
the web pages by the research reported in this thesis adopts the User Test, legislated by the
EU for evaluating the readability of PILs. mM! sites are not regulated in a similar way, but
there remains a need for them to be easy to use, and for the information they contain to be
understandable.
Dickinson et al. (2001)compared a leaflet based on EU guidelines (Council Directive, 1992)
with a leaflet based on best practice in information design, on a sample of 40 adults aged
55-85years (Dickinson et al., 2001).They found that the 'best design' leaflet was more
understandable than the EU leaflet as well as demonstrating that user testing (see 5.2.1)
provides a means for examining if a person understands the information. The review by
Raynor and Dickinson (In press) of best practice in information design derived the
following set of recommendations for writers of WMI. The expectation is that applying
such recommendations to the design of not only PILs, but also mMI, can make the
information easier to comprehend. The recommendations are based around four themes:
• Words:
Choose short, familiar, everyday words of few syllables, which are concrete rather than
abstract. Minimise jargon, and provide an explanation if technical terms are used. Use
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different voices for different messages: an active voice to explain or warn; an imperative
voice to relay instructions; do not use a passive voice. Use short sentence length of 15-20
words, with simple grammar. Convey attitude and meaning in a relaxed, straightforward
style. Use positive phrasing, unless warning not to do something. Use an appropriate,
conversational tone, e.g. 'we' and 'you'.
• Type:
Use a large font to maximise legibility. Use colour sparingly, and try to have black print on
white paper to maximise contrast and legibility. A conventional typeface that is familiar is
best, and bold fonts are more legible. There is no consensus on the use of serif or sans serif
font.
• Lines
Left justification (non-justified text) is easier to read. Have 8-12words per sentence: more
or fewer hinders reading. Have short paragraphs. Do not wrap words around graphics.
• Layout
Bullet points can help to organise text. To emphasise words, use bold lower-case text,
because words in capitals or italic are harder to read. Have plenty of white space, i.e. the
absence of print. Use short headings that stand out. Have a clear organisational structure
to aid finding information. Pictures or graphics do not necessarily improve documents;
therefore they need to be used with care. Numbered lists should be used for sequences or
lists of instructions. Page column breaks should not split sections. A table of contents will
be helpful with a long document.
A study interviewed 40 patients using a questionnaire to evaluate understanding of the
information in a random selection of PILs and found that although most information was
well understood, information about drug interactions and contraindications was not
(Gustafsson et al., 20OS).
The EU Guideline on the readability of the label and package leaflet of medicinal products for
human use (1998) (European Commission Directorate-General Ill, 1998)proposed that the
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side effects of a medicine should be categorised according to frequency, and described
using verbal terms in WMI; for example, the risk of having a side effect that is 'very
common' represents a risk greater than 10%numerically. However, there is consistent
evidence showing people do not accurately interpret a verbal risk descriptor (see 3.5.5). It
has therefore been proposed that the EU rescind the use of verbal risk descriptors until
there is greater evidence to support them (Berry et al., 2003c).The evidence base, from
which this argument is derived, forms part of the first empirical study of this thesis (see
3.5).
1.2.6. The role of WMI
It is as important to understand the purpose of WMI, i.e. what is it used for in the context
of social relations, as well as whether or not it works. WMI can be considered to inform the
patient and to enhance the shared decision-making process between the medicine user and
health professionals. WMI can also be seen to be a means for facilitating compliance.
However, compliance reflects a paternalist doctor-patient relationship (parsons, 1951),
where it is believed that the doctor 'knows best' and that the patient should comply (agree
to the doctor's instructions) without question. Non-compliance (and its synonym non-
adherence) can then be seen as negative behaviours. However, these may not be helpful
concepts because they make no distinction between those who take some or none of their
medications, and do not explain motivations relating to a patient's medicine-taking
behaviour (Wride et al., 2007).A further criticism of compliance is that it suggests that the
provision of WMI directly impacts on a person's medicine-taking behaviour, which has
been shown to be problematic, (see 1.2.3).
The development of the ethos of increased patient involvement in their care (from the
1980sonwards) saw the choice-making informed consumer as being central to UK health
policy (Huntington et al., 2007).The philosophy and practice of patient-centred medicine
arising from this is marked by mutual participation, whereby responsibility for patient
care is shared between the patient and doctor (Mead and Bower, 2000).Giving information
about medicines provides an opportunity for the medicine user to be an equal partner in
the doctor-patient relationship. Ratzan (2007)has proposed that this has great potential for
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public health, because the 'informed patient' will be the basis for a healthier society,
because she or he can contribute to her or his healthcare. However, there are arguments
why this is may not be achievable (see below).
The World Health Organisation (WHO) (2003)has distinguished between 'adherence' to
medication or any other regimen, which is a behaviour, and 'compliance', a passive act
which does not require the medicine user's agreement. In the UK, the Medicines Partnership
program has stated a need for concordant relations between healthcare professionals and
patients (Medicines Partnership, 2005),whereby decision making is shared between the
two parties. This reflects an active role for the patient seeking to process knowledge to aid
decision making, rather than passively complying. Pound et al. (2005)have proposed that
this process requires patients and doctors to be equal partners in treatment decisions. The
process of concordance can (in part) be supported by the provision of tailored, clear,
accurate, accessible, and sufficiently detailed information (Medicines Partnership, 2005).
Therefore WMI, either paper-based or Internet-based, remains necessary for medicine
users to be equal partners. However, this will only benefit people who are able to read.
One way of providing information about medicines to people who cannot read includes
the use of pictograms. (This is not examined in this thesis). The two other means to
support concordance are prescribing consultations involving patients as partners; and
patients being supported in taking medicines (Medicines Partnership, 2005).
WMI can then enable the individual to make an informed choice about taking medication
or not. As such, it should be pivotal in enabling concordance. But Raynor and Britten
(2001)have argued that current WMI may undermine concordance because it arrives too
late for patients, i.e. only after they open the medicine package. Aamio and RaitohaIju
(2007)refer to as the concept of time specificity, where there is a need for having
information about medicine in a short time-frame. Raynor and Britten (2001)have also
noted that the information is only about the medicine, so there is no information about
alternative treatment options; and the information is not balanced because of its focus on
negative aspects (for example, side effects). Ithas been noted above that although it
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appears logical, providing information with the aim of changing behaviour may not have
an effect at all (Ferner, 2003).
A qualitative synthesis of previous research found that medicines users did not take their
medicines because of concerns about taking them (Pound et al., 2005).This contradicts
theories of compliance which attribute this to a failing on the part of the patient.
Interviewing women receiving hormone replacement therapy, Henwood et al. (2003)
found there were constraints on the women becoming informed patients (through
accessing the Internet): their lack of health literacy skills for finding and appraising
information; reluctance on the part of the General Practitioner (GP) to facilitate the person
to have an equal role in the process; and many patients not wanting to have responsibility
for finding information, instead uncritically accepting their GP's decisions. Whether
medicine users will be empowered to use WMI to make informed choices about taking
their medicines (or not), this does not negate the need to evaluate WMI.
Matters are complicated by disputes surrounding the issue of concordance. Some have
cast doubt on the value of the term concordance, arguing it is synonymous with adherence
or compliance (Aronson, 2007a), and therefore presents no difference or benefit to the
patient. The response to this has been that concordance refers to a process of negotiation
between doctor and patient, while compliance/adherence refers to the patient's medicine-
taking behaviour (Bellet al., 2007).However, in a convincing argument, (Aronson, 2007b)
has highlighted how, in the treatment of a critically illpatient, there is no scope or need for
negotiation. Whether this is a semantic debate about a sociological label, or a more
fundamental debate on the relationship between doctor and patient, does not negate the
need for trustworthy, evidence-based WMI.
These points indicate that WMI has a potential role as a means for aiding compliance,
and/or shared decision making. Raynor et al. (2007a)evaluating the role and value of WMI
for patients, and health professionals, have found that these stakeholders have different
perceptions of the role and value of WMI. Some patients felt WMI had an empowering
role to facilitate their involvement in their treatment, and so they valued information that
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was condition-based and personalised; particularly when it provided information about
alternative treatments. In comparison, professionals saw WMI as a tool to lead to patient
compliance with treatment; valuing short and simple information, as they thought that
more complex information might overwhelm the patient.
Newby et al. (2001)conducted a telephone survey of 786people, and a follow-up in-depth
interview with a random sample of 58 of those participants. They found that medicine
users reported wanting advice about how the medicine works for the condition, and the
reason for taking the medicine, to enable them to make a treatment choice. With this
information available online, e-health could be seen by medicine users as an empowering
tool enabling them to make shared decisions with their GP. However, this hope may be
forlorn, when considered in relation to Henwood et al.'s (2003)finding that there are
constraints on people becoming Internet-empowered shared decision makers (see above).
The work reviewed in this section highlights a potential tension between the WMI as
devised by pharmaceutical companies and what it is used for by patients. The purpose of
WMI is not evaluated in this thesis. Examining the purpose ofWMI can provide insight on
what it is used for by medicine users, whether or not it meets their needs, and whether or
not they value WMI. This, however, does not consider if users understand the information.
It is perhaps not difficult to appreciate that before the person can use WMI in a particular
way (i.e. act upon reading it), they must first have understood the information. Therefore
it is argued that it is first necessary for research to determine if WMI (leaflet or Internet-
based) is easy to read and understand.
1.2.7. The pharmaceutical industry and WMI
The most important sponsor of medical research worldwide, and the principal generator
of WMI, is the pharmaceutical industry (Collier and Iheanacho, 2002).The pharmaceutical
industry also produces direct-ta-consumer (OTC) drug advertising; in 2008 the only places
in the world where OTC advertising was legal was inNew Zealand and the USA. In 2001
regulatory guidelines (European Federation of Pharmaceutical Industry, 2001) for OTC on
the Internet came into force in the EU, limiting the information available to technical
details and further information for health professionals.
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It is important to distinguish between WMI and DTC advertising. WMI accompanies the
medicine, whilst DTC advertising promotes the product (medicinal drug) to potential
consumers. Some have sought to blur the barriers between the two concepts, with calls to
use DTC advertising as a means to meet medicine users' demands for better information
(Holmer, 1999). This proposal has been criticised on the grounds that profit will become
more important than the actual information (Alper, 1999).
There is no evidence that DTC advertising can improve health. This was the conclusion of
a systematic review of four studies evaluating the impact of DTC on health-seeking
behaviour and other related outcomes (Gilbody et al., 2005). There is evidence that DTC is
not understandable to a large number of people. A study evaluating the readability of
DTC magazine advertisements in the USA, using a readability formula, concluded that the
material was written at a level only a college student or graduate would understand
(Kaphingst et al., 2004). This would probably make the information difficult to understand
for the vast majority of the public who would not have been educated to that level.
However, this finding is based on a readability calculation, which may be an invalid
measure of the understandability of written information (see 1.2.5). Instead a user test
would be required to examine how understandable this information actually was. While
DTC advertising is not permitted in the EU, the Internet makes this information available
to EU residents, as well as the prescription drugs it advertises.
1.3.0verview of e-health
DTC advertising is one element of healthcare information available on the Internet, known
as e-health. Three studies in this thesis evaluate mMI, a specific type of e-health. This
section provides an overview of e-health, looking first at the Internet in general and then
issues of relevance to e-health. These issues are also relevant to mMI, covered in 1.4.
1.3.1. The Internet and the World Wide Web
The Internet and World Wide Web ('the web') are terms often used interchangeably,
although they are not the same: the web is a service available on the Internet. (This thesis
will use the term 'the Internet'). To access the Internet, three pieces of hardware are
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necessary: a computer, a telephone or cable connection to the Internet, and web browser
software to enable the user to navigate the Internet. The two most commonly accessed
browsers are Microsoft Internet Explorer (www.microsoft·com/window/ie) and Mozilla Firefox
(http://www.mozilla.comlfirefoxl) (source: http://en. wikipedia.org/wikillmage: Webapps.svg
accessed September 2008).Pages on the web are held on servers, i.e. computers
permanently connected to the Internet which send, store or receive information, and are
identified by a unique name, a uniform resource locator (URL):for example,
http://www.bbc.co. uk.
In the UK there are approximately 38million Internet users, more than 62%of the
population (http://www.internetworldstats.com/stats9.htm. Accessed November 2007).
Eysenbach and Kohler (2003)estimated that approximately 4.5%of all searches on the
Internet (worldwide) are health-related. While less than one tenth of these relate to
medicines (Eysenbach and Kohler, 2004), this is still a vast number of searches when it is
considered that in February 2007nearly seven billion searches were performed worldwide
(http://www.tmcnet.com/usubmit/2007/07112/2778610.htm. Accessed November 2007).
Several functions have been noted for interactive health care applications, (a definition
that includes the Internet), including to relay information, and to enable informed decision
making, both of which are commonly cited reasons for providing WMI (Robinson et al.,
1998).The interactive nature of the Internet is important to note, because Berry (2006)has
argued that the Internet could personalise large amounts of medicines information to
individuals: for example, where a medicines user enters details about her or his medicines
and receives information that is specifically tailored.
1.3.2. Internet search engines
Search engines are a tool for finding information available on the Internet. The individual
searches by typing a word or phrase, which retrieves a list of sites with information
relevant to that search. This may be helpful when an individual seeks information about a
medicine but does not know the URL of an mM! site. Constraints exist on what the
individual can find, however, and this will structure the web use experience of the
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individual (Seale, 2005).Beyond the individual's Internet proficiency, two technical
aspects of search engines determine what can be found: indexing, and ranking.
Indexing of web pages involves assigning keywords to the sites, which aid their retrieval
using a search engine (if the site's URL is not known). This carries immense power
because, to exist as a website, it has been argued, is to be indexed by a search engine
(Introna and Nissenbaum, 2000).Search engine databases are either directory based,
where pages are manually submitted (for example, Yahoo!TM), or they are created by a
'spider' automatically searching the Internet. It is not, however, transparent how a spider
works (Introna and Nissenbaum, 2000).
After a site is indexed, it can then be ranked. There is competition to receive a high
ranking. Introna and Nissenbaum (2000)have suggested that, as search engines display
sites in blocks of ten, website designers covet ranking in the first ten to 20 positions. This
becomes more important when it is considered the search strategies the public use (see
1.3.5).The way that search engines rank sites is not disclosed (Seale, 2005),which means
the process of ranking is not transparent.
This lack of transparency can be seen to give search engine companies an element of
power. Because it is argued that search engines' indexing and ranking of websites has a
political feature over and above a technological dimension this will constrain the
information the Internet user can and cannot find (Introna and Nissenbaum, 2000),
including information about medicines.
1.3.3. e-health
Eysenbach (2001)has defined e-health as a form of health service and information
delivered and/or enhanced through the Internet and related technologies. e-health
encompasses a range of websites, including support group sites offering individuals a
forum for discussing health issues; Government-developed websites providing
information as fact sheets; pharmaceutical company sites providing (and promoting)
product information; and media sites, providing health news (Sillence et al., 2006).To this
list can be added advocacy group websites, which promote patients' and relatives'
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interests (Iergensen and Gatzsche, 2004), and non-industry developed mMI. Whatever the
type of site, Eysenbach (2001) proposes that e-health should enhance quality and be:
efficient, evidence-based, empowering, encouraging, educating, enabling, extending the
scope of health care, ethical, and equitable. It may be asked if it is possible or realistic to
expect e-health to be able to meet all these features. Furthermore, this list does not address
the accessibility of the Internet to the public, which will also determine whether or not e-
health is beneficial (see 1.3.4).
There are a couple of points to note when evaluating the Internet. Because it is not a static
medium, research findings cannot reflect the possibility for changes in their content over
time. Furthermore, evaluators of the Internet need to be aware that a website cannot be
assessed as if it is a leaflet (Eysenbach, 2002). This is because it can be assumed that people
may be accessing more than one website, whereas if they have a leaflet in their hands, they
will only look at that. (It remains possible that some people will look at more than just the
leaflet in their hands). Furthermore, a website requires navigating, and this requires the
person to have a level of proficiency in using the Internet, whereas a leaflet only requires
the person to read it.
The patient making an informed decision about healthcare treatment (see 1.2.6) can do so
using information accessed from the Internet. McMullan (2006) proposes that the Internet
could facilitate patient-centred interaction between the patient and health professional, by
opening access to information for the patient. Kivits (2006) has suggested that the person
using the Internet to become an informed patient is (in part) taking responsibility for his or
her health. The potential benefits from Internet use may be attractive to those patients who
want to be more informed about their healthcare and take an active role in decision
making. However, not everyone will want to, or have the resources to adopt this role
(Raynor et al., 2007a). Furthermore, if the person accessing e-health looks at information
which contradicts that given by their healthcare professional, or if the information
discusses alternative treatment options to those offered by their healthcare professional,
and the person acts on this, there is the potential for them to incur a health problem.
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1.3.4. Public access to e-health
It is important to consider who usually accesses e-health; their rationale for accessing e-
health, and socioeconomic factors determining access. Knowing who does and does not
access e-health could inform public health attempts to improve access to health
information and could aid the tailoring of sites to the intended audience.
Demographics of e-health users
The evidence shows that individuals may have differing information needs dependent
upon their state of health and well-being or disease progress. A study of 50 young Finnish
people (mean age 27 years) with or without a health condition found that women who
were pregnant and men or women with diabetes accessed the Internet more often and
viewed e-health more often than non-pregnant women, including e-health sites (Eriksson-
Backa, 2003).Cotten and Gupta (2004)interviewed 385 people in the USA and found that
those who accessed e-health were in general healthier, younger, had a higher
socioeconomic status, and were educated to a higher level than those who did not.
Alternatively the Pew Internet and American Life Project, a nationwide US survey
examining the impact of the Internet on households, found those with poorer health made
more frequent use of health information on the Internet, compared to those in better health
(Houston and Allison, 2002). Inequalities in access to the Internet are referred to as the
,digital divide'. Ithighlights that those who are most disadvantaged, and more likely to
have the poorest health in developed countries, have least access to the Internet (Brodie et
al., 2000).This reflects the broader observation by Hart (1971)that the provision of good
medical care varies inversely with the needs of the population ('the inverse case law').
Dolan et al. (2004)distributed a questionnaire to 851patients in an affluent and a deprived
general practice in Wales, and found that older patients (> 55 years) had significantly less
access to the Internet than younger patients; while younger patients (24-54years) were
significantly more likely to use the Internet for accessing healthcare information. In time
the difference is likely to be reduced as the current older generations decline, because
younger people are (on the whole) Internet literate. However, the digital divide will
probably not be resolved, and so universal access to e-health will not be realised. A
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telephone survey in Finland of 714medicine users similarly found that more young
respondents than older participants reported accessing mM! (Narhi, 2007).Huntington,
Nicholas et al. (2007)examined use of the NHS Direct (http://www.nhsdirect.nhs.uk) and BBC
Health (http://news.bbc.co.uklhealth) websites in a sample of 923people (who were
predominantly male, in full-time employment, and aged 25 to 52).Around one quarter
reported accessing NHS Direct, while one fifth visited the BBC Health web pages.
As a whole, these studies have increased our understanding about e-health, who accesses
it, and the socio-economic factors determining people's access to it. However, they have
tended to be based on either large random samples, or small purposive samples, fitting
their quantitative or qualitative design respectively. Each approach is beset with its own
advantages and problems (see 2.5.1).1n general it is difficult to gather a sample of
participants in any survey that reflects the wider population. The sampling frame used by
several of the studies was not representative of everyone that accesses e-health; therefore
the external validity is limited. Firstly the results may be a product of respondent bias; i.e.
it is not certain that what a respondent in a survey says reflects their actual Internet
behaviour. This can also explain apparently contradictory findings: for example, those of
Cotton and Gupta (2004)and Houston and Allison (2002).A common limitation of much
research is that participants may be self-selecting and therefore more motivated to take
part than those who do not. This again will constrain the generalisability of the findings,
because the sample will not be a true reflection of everyone who uses e-health.
Motivation for accessing e-health
It is important to know the reason(s) for people accessing e-health. These may be varied
because the Internet offers a number of potential benefits for health information seekers:
widespread access to health information, the potential for interactive communications,
tailored information, facilitation of interpersonal interaction, and the potential for
anonymity (Cline and Haynes, 200~).
A study of Best Treatments (http://besttreatments.bmj.comlbtuklhome.jsp) a UK-developed site
offering condition-based information for patients and doctors, (Anon, Unpublished)
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conducted individual interviews and group discussions to evaluate if the site helped the
public make choices and enabled them to share decision making with their doctors.
Respondents reported that they trusted the site because it was explicitly evidence-based,
linked to the British Medical Journal, and used the same information source as Clinical
Evidence (www.clinicalevidence.com). a website aimed at health professionals. Participants
reported feeling more comfortable discussing treatment issues with their doctor after
using the site. A second study found this site scored high for readability, making the
information easy to understand (Kamel Boulos, 2005).
In general, e-health is well received by the public. A series of focus groups examining UK
and US adolescents' perceptions and experiences of online health information, found the
Internet can empower adolescent users by offering personalised healthcare information,
which increases the salience of the information (Gray et al., 2005).If this is reflected in
general, e-health may have a valuable role in informing adolescents (who may not
regularly access a GP). A three week online questionnaire survey of users of NHS Direct
(http://www.nhsdirect.nhs.uk!J, the NHS website, providing information about health, illness
and health services; received 42 replies (25 from men). Most commented that they liked
the convenience and anonymity of the Internet for health information (Williams et al.,
2003).However, the very small number of self-selected respondents makes this finding
difficult to generalise. By comparison, Nicholas et al. (2002)conducted an online
questionnaire on the NHS Direct website which recruited 3,374respondents. They
identified four broad reasons given for accessing the site, with people saying that they
wanted information:
(i) About a condition when they or a relative were ill; so as to know what to do;
(ii) About a condition when they thought they were ill, so as to know what to do;
(iii) About avoiding illness;
(iv) About the NHS.
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A web-based questionnaire of l,103lnternet users found they reported accessing e-health
in preference to other sources of information, because it provided advice on sensitive or
stigmatising issues, and it offered the opportunity to self-diagnose. They also preferred its
ability to be a social-support mechanism (Sillence et al., 2007a).
A focus group session evaluating young people's perspectives on using the Internet to
obtain health information and resources found the quality of access to the Internet was felt
to be as important as having access to it, if not more so (Skinner et al., 2003). Four factors
affected the reported quality of access:
• Privacy - searching for personal or sensitive topics without intrusion;
• Gate-keeping - access being blocked or restricted;
• Timeliness - access when required and for as long as needed;
• Functionality - the personal computer (PC) operating adequately (Skinner et al.,
2003).
While this study examined the views of young people, factors influencing access may be
different for the rest of the general public: for example, it may be dependent on gender,
ethnic background or socio-economic status.
In summary, these findings suggest that the public favour e-health when it: (i) is explicitly
evidence-based; (ii) is easy to understand; (iii) offers personalised healthcare information;
(iv) offers convenience and anonymity re sensitive issues; and (v) is easy to access.
However, the validity of some of these findings can be questioned as they were acquired
from small studies with samples that are not representative of everyone who uses e-health.
1.3.5. Searching for healthcare information on the Internet
It is important to know how people conduct searches on the Internet for healthcare and
medicines information, because this will impact on what people do and do not find (and
then read). Eysenbach and Kohler (2002) sought to ex~e the techniques that the general
public used to retrieve and assess health information on the Internet. They conducted
focus group sessions with 21 participants (five males, mean age 37 years), and usability
tests and semi-structured interviews with a further 17 participants (six males, mean age 38
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years) in Germany. None of the participants reported using a medical portal as the starting
point for their searches. Instead they used a search engine and looked at only the first few
links on the page. When the researchers observed the participants using the sites, they
noted that the participants did not look for information about the source of the site, i.e.
'about us' sections, disclaimers, or disclosure statements to ascertain the source of
information. However, the same participants when interviewed said that they would look
for this information in the future to assess the credibility of a site. The authors noted that
the study had no consequences for the participants, and so they may not have conducted
the search as thoroughly or with as much motivation as someone with an illness. While
this reflects the possibility that people (may) have differing information needs dependent
on their current health status, there has been little research examining the impact of
disease progress on the amount of, or quality of, information sought.
Goldner (2006) randomly telephoned 2,038 adults in the USA to examine whether a
person's health status determined what information was sought. Sixty-three percent of
respondents said they looked for information on disease or medical conditions (the most
commonly searched term), but only 34% of people looked for information on 'drugs', the
fifth most commonly searched for health-related term. Respondents with a disability or
medical condition were significantly more likely to have searched for information about
'medical conditions' or 'treatments', compared to 'healthy respondents'; but there was no
difference for searching for information online regarding 'healthy lifestyle' issues.
1.3.6. The quality, trust, and reliability of e-health
Because incomplete or inaccurate information on the Internet can potentially have a
bearing on the health and well-being of an individual (Eysenbach et al., 2002), it is
important for e-health users to be able to adequately assess the trustworthiness of the sites.
The general public need high quality information about health, prevention, detection and
treatment of disease in order to be able to manage their health (Ratzan, 2007).
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Research has sought to identify standards for evaluating the quality of healthcare
websites. A systematic review of 79 studies assessing the quality of e-health found five
recurring criteria, that are features of the Internet site (Eysenbach et al., 2002). They were:
• Technical criteria: for example, disclosure of authorship, or e-mail contact details;
• Design features: for example, layout of the site;
• Readability: based on sentence/word length and complexity;
• Accuracy: the concordance between information and best evidence;
• Completeness/comprehensiveness: of the information covered.
Adams et al. (2006a) has similarly noted that reliability is a property of (Internet-based)
healthcare information; (see below for a further discussion of the reliability of e-health).
Therefore the quality or reliability of information is external to the person.
Eysenbach et al. (2002) found that the majority of the 79 studies (70%) reported that the
quality of e-health was a problem. However, the authors warned that the prevalence data
for inaccurate or incomplete web information that was reported in the studies was difficult
to interpret, and thus compare. They also warned that it was not likely to be generalisable
or representative.
Eysenbach and Diepgen (1998) have proposed that the variability of the quality of
information available on the Internet limits its use as a credible source, where information
can still harm even if not necessarily false. Furthermore, research has found that
consumers have difficulty finding complete and accurate information (Berland et al., 2001).
Risk and Petersen (2002) have suggested that the quality of an e-health site could be
measured by whether or not the site has a positive effect on the person's health outcomes,
quality of life, or clinical end points. However, this argument takes a 'black box' approach
to understanding the role of information on people's health, ignoring how the person
processes the information (see also 1.2.3).
Suggested ways for the public to assess the quality of e-health
There are many recommendations on how the general public should assess the quality of
e-health sites. A review by Wilson (2002) identified five competing approaches to
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assessing English language sites that are available to the consumer: codes of conduct,
quality labels, user guidance systems, filtering tools, and 3rd party certification.
• Codes of conduct make recommendations for the development and content of the
websites _ for example, the Internet Healthcare Coalition's e-health Code of Ethics
(http://www.hi-europe.co.uklftles/1998_9lcodeofethics.htm) _ placing the emphasis for
the assessment of quality on the user of the site. This may be unrealistic if web
users do not have the time and skills to commit to this process.
• Quality labels on a site, displayed as a logo on a site, show that it meets a pre-
determined criterion _ for example, the Health on the Net Code of Conduct (HaN
Code) (http://www.hon.ch/HONcode/Conduct.html). (see Appendix two). The
responsibility lies with the site developer to ensure the site meets the criterion, and
with the user to check for a logo, which assumes that the user will know to check
for this. The site offers a HaN Code toolbar which can be downloaded to check the
accreditation status of the website currently accessed. Again the responsibility lies
with the user to be aware of the logo and the toolbar. Breckons et al. (2008)
published an evaluation of the quality of websites containing information about
complementary medicines, the aim of which was to compare the performance of
different evaluation instruments. They concluded that the HaN Code did not
correspond with other tools' ranking of site quality.
• User Guidance systems allow users to check if a site and its content meet standards
_ for example, DISCERN (www.discern.org.ukldiscern_instrument.php), (see
Appendix two). Again the burden is on the user to assess the site, and likewise
assumes the user will be adept at this task.
• Filtering tools enable users to set criteria for automatically accepting or rejecting
sites _ for example, OMNI, now Intute: Health and Life Sciences
(www.intute.ac.uklhealthandlifesciences).This places little demand on the consumer
as the assessment has been conducted by a reviewer, although the user would have.....
to be proficient in using the tool.
• Third party certification displays logos (for a fee) to show that the site meets a set
of standards for content _ for example, MedCertain (http://www.hi-
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europe.co.uk/filesI2000Imedcertain.htm). Again there is no burden on the consumer,
(although knowledge and awareness of this system would be necessary).
These initiatives have been criticised for having general limitations, placing a great burden
on the providers and seekers of ffiMI,having development costs and, because they are
English-language based, not meeting the needs of users in the developing world (Risk,
2002).
The importance of e-health being trustworthy
Sillence and Briggs (2007)propose that trust is the process of seeking and acting upon
advice, with associated risks. Trust is therefore a cognitive process internal to the
individual, (unlike quality, which is a feature of the site or leaflet). Thiede (2005)has noted
that health information needs to be trustworthy and understandable for the average
healthcare user. The potential danger is that if the information is not trustworthy or
understandable, the person may act inappropriately upon reading it, and endanger her or
his health. However, similar to the point made above about the quality of the information,
any relationship between untrustworthy information and negative health consequences is
indirect, for the reasons explained in 1.2.3.
Most people seeking medical care do not have the same level of knowledge of medicine as
healthcare professionals. Therefore, Oark (2002)has argued that trustworthy information
is vital because it redresses the vulnerability of the patient as a health consumer. The trust
placed in a website is pertinent to the Internet in general and not just e-health. For
example, Resnick and Zeckhauser (2002)examined how users of the popular auction
website eBay assessed the trust of buyers and/or sellers, and found evidence that users do
so based on the buyer's or seller's online reputation.
How the public assess the quality of e-health
This section has identified a range of formal methods for the public to use to assess the
quality of e-health. However, the evidence shows that people (largely) do not adopt such
approaches. For example, research has found that consumers do not always look for the
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source of information as evidence of the credibility of a website (Eysenbach and Kohler,
2002).
How the public assess the trustworthiness of e-healik
It is important to understand how people assess the trustworthiness of e-health. Sillence et
al. (2007c)observed 15women (mean age 49, 41-60years) looking for online information
about the menopause. They found that the women's judgement of whether the websites
were trustworthy (or not) was based on their look and feel; e.g. whether or not the site
referred to the source of the evidence, or how up-to-date it was. Observing 13people (six
female, age range 33-68years) interacting with an e-health site, Sillence et al. (2007b),
found that participants' impression of mistrust was based upon the visual design of the
site, while trust was based on the option to personalise information. (Sillence et al., 2007a)
conducted an online survey to record how people reported searching for health
information and judging its trust. From 1,480responses, they found that the three trust
markers that were considered most important were: the ease of use of the site, advice from
a knowledgeable source, and advice from an expert source. These studies suggest that the
general public use methods for assessing the trust of a website that are more makeshift
than the suggested formal methods listed above.
Sillence et al. (2006)devised the Staged Model of Trust for web-based health advice as a
way of explaining the process by which the public develop trust in e-health. It proposes
that those who access e-health analyse the trust of the information to different depths,
depending on when they access it. At an early stage people use heuristics (cognitive
shortcuts) to make a cursory analysis of trust, based on the look and feel of the site: for
example, whether the balance of text and graphics is visually appealing, if the site has
social identity cues that signal that it will be of interest, the number of adverts it has,
whether the site features branding of its image, and the layout and navigation of the
pages. In the longer term, people's engagement with websites is based on the credibility of
the content and the ability to personalise the content: e.g. sites that are interactive, and
have user-generated content.
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This model predicts:
(i) How people assess the trustworthiness of information, and
(ii) How reliable their assessment will be.
These studies have improved our understanding about how people assess the trust of e-
health, and acts as a frame of reference for the examination of how people assess the trust
ofmMI sites in Study three (see Chapter five). Future studies of the assessment of trust of
e-health could recruit from a wider sample; e.g. more men, and younger and older people,
to broaden understanding of this process in other groups.
How the public assess the reliability of e-health
The Oxford English Dictionary Online defines 'reliable' as:
"that may be relied upon; in which reliance or confidence may be put; trustworthy,
safe, sure" (http://www.oed.com/accessed online May 2009).
Reviewing the concept of reliability with regards to e-health, Adams (2006a)has argued
that the literature deals with this in a clear-cut manner, promoting professional expert
criteria, for example, looking for the presence of a quality seal or comparing the
information with a checklist to the detriment of the individual's situation. Instead of
adopting such 'formal' techniques, she has suggested that people construct the reliability
of information acquired from a website by cross-referencing with other sources: for
example, a GP, friend or family member, or another website (Adams, 2006b).However, it
can be argued that people should not depend on only cross-referencing material to assess
a website's reliability. It is possible that a person could find different sources of health
information providing the same incorrect information. While this replication may appear
to give the information greater credibility, it would only be repeating incorrect
information. Information like this could be potentially dangerous for the medicine user to
conclude that the repeated information is therefore reliable. People accessing e-health need
to be able to assess the absolute reliability of the information on a website, rather than the
relative reliability between sites.
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Concluding remarks on the quality, trust, and reliability of e-health
Because of the open nature of the Internet, e-health cannot be regulated (Bonaccorso and
Sturchio, 2002).Therefore the possible impact of poor site quality remains a concern, and
may (at the very least) provide people with inaccurate, inconsistent, or incomplete
information. At worst it could have indirect detrimental consequences for the health and
well-being of the medicine user, if they act on the information. It is therefore important
that research examines the quality of information, as this can highlight when it is
incomplete, inadequate or incomprehensible.
The trustworthiness (or not) of the websites may not necessarily deter people from using
the Internet. As Wofford et al. (2005)have argued, regardless of its endorsement or not,
patients will use the Internet to learn about their healthcare. Furthermore, Kivits (2004)has
noted that the idea of the online health information seeker is ambiguous, because that
person may actually be searching for information for friends or family, and not for her or
himself.
Byhighlighting the (potential) impact of the quality of websites, this has necessitated an
analysis of the quality ofmM! as a possible determinant of their usefulness. A range of
assessment tools are available, and principles from the following two will be used to guide
the content analysis (Study two reported in Chapter four):
• The HON Code,
• Recommendations from the DISCERN website.
The reasons for applying aspects of these tools are:
(i) The HON Code seal shows sites meeting its quality criteria. This may be
reassuring to the Internet user who recognises what it stands for, and may
spare the person from assessing the quality; and
(ii) Both enable users to assess the Iquality' of the sites, therefore are potentially
empowering (albeit to the competent user). Filtering tools are not used because
there may be an issue of their ease of use; which is a separate (but related)
research question to that examined in this thesis.
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1.3.7. Personalisation of e-health sites
Medicines users have indicated that they would value receiving personalised information
about medicines via the Internet (Howarth et al., 2000), yet no known study has examined
the worth of personalised mMI.Jones et al. (2006) have examined the benefits of
personalising information about cancer treatment on PCS. They randomised 400 people
starting radiotherapy treatment to one of eight groups based on three binary factors:
personalised or general information; information from a PC or from a booklet; and
additional anxiety management information or no such information. Patients receiving the
personalised information felt it informed them more than the general material, and they
were more likely to share this with friends and family. This is likely to be a robust finding
despite 43% of the participants being computer naive at the start of the study. As the
authors note, this would have affected their performance with the PC, but should not have
impacted on the benefits from the personalised information.
1.4.0verview of Internet-based medicines information (lBMI)
Having reviewed e-health, the focus now shifts to mMI. In this thesis it is considered that
a site which provides information solely or primarily about a medicine is an mM! site.
Sites that provide general information about a range of treatments, where the information
about medicines is not the main focus, are not considered to be an mM! site. Sites that
have been developed by a pharmaceutical company to provide information about a
medicine are not excluded from the definition of mMI, even though medicine users have
reported disinclination to access pharmaceutical developed sites (see 1.4.2). It is
considered that this is not a reason to not evaluate these websites, because they are aimed
at the general public, and some people will access them. It is important that all mM! (and
e-health) websites are easy to use, and have understandable and trustworthy content.
1.4.1. Medicine users access to IBMI
People are known to search for mM! after being prescribed medication, e.g. see the
literature review by Morahan-Martin (2004). A survey of 1,322 people found that 54%
accessed the Internet for information about prescribed medication (Nicholas et al., 2003). In
the Pew Internet and American Life Project, researchers found that 40% of Internet users
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searched for mMI; and of those who reported doing this, adults (50-64years), and
experienced Internet users (six or more years' experience) were more likely to do so (Fox,
2005).Focus groups in Australia found that medicine users reported using limited
strategies to search for mMI, i.e. typing the name of the medicine into a search engine, and
not looking beyond the first page of links (Peterson et al., 2003).This corresponds with the
limited techniques people are seen to use for searching for information about healthcare in
general (see 1.3.5).
While it is known that people look for mMI after being prescribed a medicine, the precise
reason for doing so remains unclear. It has been suggested that this could be because WMI
accompanying medicines is not felt to match medicine users' needs (Sidhu et al., 2006).
More work is needed to answer why people use this medium to access WMI, and this is
explored in research reported in Chapter five. The better our understanding of how and
why medicines users access mMI, the better evidence designers of mMI will have to tailor
it in a way that will benefit the user.
1.4.2. Medicine users' views on IBMI
Focus group studies have assessed medicines users' opinions about mMI. An Australian
study found that, on the whole, respondents regarded the Internet as a beneficial and
convenient source ofWMI, in spite of doubts about the quality of the information
(Peterson-Clark et al., 2004).Many of the participants reported concerns about the
credibility of the site, preferring government or professional health care sites to
pharmaceutical sites, while some respondents spoke of concerns about the quality of the
information, and described a range of different quality assessment strategies (peterson et
al.,2003).
1.4.3. The content and quality of IBMI
Huh and Cude (2004)investigated the content and presentation of risk information for
prescribed medicines on direct-to-consumer drug websites. Using a sample of 60 sites,
they found that almost all sites (59/60)presented both benefits and risk information
32
anywhere on the site, and half of those sites displayed the benefits information in a larger
font than the risk information.
Sidhu et al. (2006)found that, in comparison to paper-based WMI,mM! had incomplete
and inaccurate information. This could have implications for people who cross-reference
mM! against PILs to assess the reliability of its content. An analysis of 150websites
providing information about popular complementary and alternative medicines found
that over 95%omitted important information: drug interactions or contraindications, for
example (Walji et al., 2004).An evaluation of the content of 208websites covering St John's
Wort, used different websites' recommendations (HoN Code; and e-Health Code of Ethics), as
well as a question based on the subjective experience of the authors. It found that the
majority inconsistently reported information about St John's Wort (Martin-Facklam et al.,
2002).
1.4.4. General appraisal of previous research of IBMI
In general the findings have been derived from focus groups and content analyses. These
designs can be considered less dependable than those using direct methods of
examination. There is the potential for a discrepancy between respondents' reported use of
mM! and their actual use. Research using focus groups, like that using interviews or
questionnaires, gathers opinions, and does not directly observe behaviour (see 5.2).
Respondents may voice socially acceptable opinions in a sterile context; for example,
participants may feel social pressure to comply with the opinions of other respondents. In
considering these shortcomings, this thesis concurs with the suggestion of Bessell et al.
(2002)that e-health research should use well-designed, controlled studies, and not be
based on anecdote and opinion. However, the trade-off between ecological validity and
internal validity is a common consideration when examining lab-based studies of
behaviour. Lab-based studies of the Internet may not truly reflect how people interact with
websites in the real world. However, a real-world study observing how someone interacts
with a website would have less experimental control, and so the results can be less
inSightful. It may be more important for a study to be able to control for extraneous
variables, even if that leads to reduced external validity.
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The content analyses of mMI sites to date have largely focused on assessing the quality of
the sites, and in particular the presence or absence of markers of trust. This is an important
facet to examine, but it is not the only feature of mMI sites that is important. Less has been
said about the nature of the medicines information content (for example, how the risk of a
side effect is presented) or sites' features (for example, the presence of a table of contents).
The medicines information content is important to examine because this is the reason why
people access the sites. The design features of the site are important to examine because
this impacts on the usability of the sites (see 1.5.2), and therefore should also be examined.
This thesis considers that an evaluation of the quality, content and design features of an
mMI site is a valuable and necessary basis for examining usability.
Previous research has been limited because it has not examined the person using mMI, i.e.
whether or not the sites are easy to use, or if their content is understandable (Nicolson,
2007). Only a usability study can do this. For example, Kaufman et al. (2003) used a
Icognitive walkthrough model' to assess the usability of a horne-based telernedicine
system for 25 diabetic patients, and found it to have problems. The lack of research
evaluating the usability of mMI (and e-health sites), is an important deficit; forming a
basis for the research question examined in this thesis. It is therefore essential that the
evaluation of mMI is placed firmly on the research agenda (Nicolson, 2007).
1.5.The theoretical framework underpinning this research
This section examines the role of theory in this thesis, and explains the theoretical
framework employed. Firstly arguments are examined for conducting research with and
without theoretical input, as a base for understanding the role of theory in this thesis.
1.5.1. The value of theory
McLaren (1998) has argued that the starting point for scientific investigation is theory; i.e.
the research question is derived from a theory. For example, in a study by Bergus et al.
(2002), the theory of the information-order effect guided the researchers to ask if the order
in which risk and benefit information on a leaflet was provided affected the person's
decision to take a medicine. (It was not). Theory is beneficial to research because it
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provides a structure to guide the course of research. A theory can then be considered
practical; offering a framework from which to organise data, a structured direction on
which to devise new research, and an explanation for events and patterns (Melnyk and
Handfield, 1998).A theory allows a hypothesis to be made in advance of the data
collection; thereby researchers can make a prediction that can explain the data, rather than
look for potentially spurious explanations after the data has been gathered. The predictive
quality of a theory enables the development of a research question seeking to examine a
process or mechanism linking the stimulus and response being measured. However,
despite its potential benefits, Brazil et al. (2005)have noted that the incorporation of theory
has largely gone unrealised in Health Services Research (HSR).
Theory-driven research can also be problematic. Mellenbergh et al. (2003)have argued that
theory-driven research can only be an approximation to reality. This is because theory can
sometimes assume an abstract nature, and so its relevance to the real world becomes
blurred. A second problem is that theory-driven research can obstruct the progress of
research when it primarily seeks to test a theory (Greenwald et al., 1986).Thus the real
world problem may be viewed as less important than the theory being examined.
The converse of theory-based research is results-driven (or data-driven) research, where a
stimulus and a response are measured. This can show a correlation between measures, but
it cannot explain why they are supposedly related as there is no hypothesised process
(theory) linking the two events. The research question is derived from previous findings.
This approach is problematic because results-driven research cannot explain data out-with
the sample it was drawn from (Mellenbergh et al., 2003).
Research does not always have a theoretical basis. Often it is practical in nature, being
based on a problem or need in the 'real world' that is legislated for, e.g. EU legislation for
the user-testing of leaflets (see 1.2.5).These points are reflected in the discussion of mixed
methods research (see 2.3).
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The basis for the research conducted in this thesis is that there is a need to know ifWMI
(leaflet or on a web-based) is useful. The research is not theoretically driven, but has a
framework guiding the analysis of the outcomes measured. The theoretical framework
underpinning this work is now explained.
1.5.2. The theory underpinning this thesis
This thesis presents work predominantly based in cognitive psychology and human
computer interactions (HCI) research, which reflect the theoretical interests of the author.
A component of the first study utilised to a lesser extent, a medical SOciology framework.
Theory considered but not adopted by this thesis
At the outset of this thesis, competing theories from Cognitive Psychology and HCI were
considered for providing the theoretical framework for this thesis; e.g. The Technology
Acceptance Model (TAM), (Davis, 1989) and (Davis et al., 1989). This developed from
Ajzen's (1991) Theory of Planned Behaviour (see also 1.2.3). TAM predicts the intention to
use IT is determined by the individual's perceived usefulness of the IT to benefit her or
him in some way; and that it would require little effort to use it (Davis, 1989). This model
was rejected because it examines intention to use, and not actual use, which is the focus of
this thesis.
Theory from Medical Sociology
Dixon-Woods' (2001) patient information discourse model proposes that there are two
different (but not distinct) styles of patient information: 'patient education' and 'patient
empowerment', The professionally oriented 'patient education discourse' was considered
rooted in the biomedical model, where the patient who lacked knowledge about their
medicines required education to bolster her or his competence, The 'patient empowerment
discourse' driven by consumer advocacy considered information as the entitlement of the
individual and as a means for realising patient choice and autonomy (Raynor et al., 2007a).
Theory from Cognitive Psychology and Human Computer Interaction
Cognitive Psychology proposes that behavioural reactions to a stimulus are best
understood by mediating cognitive processes; whereby behaviour results from how the
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information has been processed. The research in this thesis examines the cognitive
processes facilitating the user's interface (interaction) with mMI. Theory from Cognitive
Psychology and HCI research are applied to offer insight into how the design ofmMI sites
can determine how easily the information can be accessed and understood.
The psychology of knowing and understanding
The primary outcome measure of the systematic review of the effectiveness of WMI (in
Study one) is 'knowledge'. The outcome measure of the User Test questionnaire (in
Studies three and four) is 'understanding'. These are (probably) distinct cognitive
processes. The purpose of this section is not to present a lengthy review of this extensive
area, but to briefly examine them, to enable the reader to distinguish between them.
The noun 'knowledge' has a vast number of definitions. The Oxford English Dictionary
Online provides over ten definitions, which include:
"acknowledgement or recognition of the position or claims; to become aware of, the fact
of knowing a thing, state, etc., acquaintance with afact; perception, or certain
information of, afact or matter; acquaintance with ascertained truths, facts, or
principles; information acquired by study" (http://www.oed.com/accessed online
November 2008).
The basis for this thesis examining understanding of WMI as an outcome measure follows
from EUpolicy (see 1.2.5).What does it mean to 'understand'? The Oxford English
Dictionary Online provides a range of definitions of the word 'understand'. These include:
"to comprehend, to apprehend the meaning or import of, to grasp the idea of, to
comprehend by knowing the meaning of the words employed; to grasp as afixed or
established fact or principle, to have knowledge of, to know or learn, by information
received; to take or accept as afact, without positive knowledge or certainty; to get as
an impression or idea, to believe; to have knowledge or information, to learn, of
something" (http://www.oed.com/accessed online November 2007).
From these definitions, it is noted that the process of knowing appears to require less effort
than understanding. This can be related to Craik and Lockhart's (1972)model of levels of
information processing, where information that is processed at a deep level is found to be
meaningful to people, unlike information processed at a shallow level. It follows that a
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consequence of this is that the person may know information about their medicines, but
not necessarily understand it.
Mazur (2000) has asked how exactly is 'understanding' to be defined and measured? And
Edwards et al. (2006) have noted that examining understanding at a level greater than the
mere recall of information requires a complex assessment. These points can be seen as a
challenge for research measuring patient understanding (of WMI) as an outcome measure.
While it is important to recognise this, this does not have a bearing on the examination of
understanding in this thesis, because the EU stipulated user test (see 5.2) is adopted.
Understanding and cognitive load
One role of WMI is to enable people to understand how to take their medicines safely and
effectively (see 1.1). This can be seen to suggest that WMI is (in part), a set of instructions.
Understanding instructions, it has been argued, is difficult if multiple elements of the
information interact, whereby individuals must assimilate these elements simultaneously
which produces an excessive demand on working memory, i.e. a high 'cognitive load'
(Marcus et al., 1996). An example would be learning the grammar of a foreign language
which requires the individual to relate each word to the other in a sentence to be able to
put them in the grammatically correct order (Sweller et al., 1998).
There are two types of cognitive load. Intrinsic cognitive demands are faced by an
individual's working memory due to the inherent characteristics of the material, i.e. what
is to be understood. Extrinsic cognitive demands are faced by an individual's working
memory from the way the material is presented (i.e. its design features), or the activities
required by the person interacting with the material (Sweller et al., 1998). Intrinsic
cognitive load can be changed by providing information in an understandable format,
extrinsic cognitive load results from how the material is presented, and so changing the
way it is designed can partly lessen cognitive demands.
The theory of cognitive load has implications for the way WMI (either paper-based or
Internet-based) is designed, because it will determine the cognitive demands faced by the
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individual, and thereby can facilitate ease of understanding information. To adapt a
proposition made by Carlson et al. (2003),by identifying the cognitive mechanisms
involved in assimilating mM! and the design features of an mM! site that are most
important, this can increase knowledge about how to design mM! to be as useful (easy to
use and reliable) as possible.
Distributed cognition
The classical view of cognition is that it is a set of mental processes within the individual.
The theory of distributed cognition, however, proposes that cognition is a process of
coordinating distributed internal representations (for example, memory) and external
representations (for example, written instructions) (Horsky et al., 2003).This theory,
developed from anthropological studies of how knowledge is shared between people, was
applied to Information Technology (IT)to examine how the interaction between airplane
pilots and IT in a cockpit enables the pilot to compute and remember the correspondence
between airspeed and wing configuration (Hutchins, 1995).
The Distributed Information Resources Model (Wright et al., 2000), adapted from the
theory of distributed cognition, seeks to understand what information is necessary to carry
out a task and where the information should be stored. The model entails six abstract
information structures which can be represented either internally as cognitive processes
within the ITuser, externally in the IT, or distributed between both resources (Wright et
al.,2000).
The design features of Internet sites are of central focus to Ha research; which aims to
produce usable computer software and hardware (Olson and Olson, 2003);seeking to
understand and support human interaction with technology (Carroll, 1997).
The following examples of internal and external information representations are based on
the work of Wright et al:'<~OOO)as applied by Horsky et al. (2003).Inthe study reported in
Otapter five, they are applied to code participants' behaviours and online actions in the
usability study.
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• State: refers to the current set of resources (for example, information displayed on
screen) and is an external representation only.
• Internal and external plans: internal plans are sequences of actions based on
system knowledge (for example, when the individual employs prior knowledge to
use a website without the need to refer to instructions). External plans are
sequences of actions that are performed to achieve a goal, which rely on, for
example, a help page of a site.
• Goal: an outcome formed by the user (for example, information sought). This is an
internal representation only and differs from a plan because it refers to the
outcome alone, and not the process used to achieve the outcome.
• Affordances: possible next actions (for example, a drop-down menu). This is
external to the IT alone.
• History: an external history provides a visible record of actions undertaken (for
example, previous URLs accessed). An internal history is the recall of previous
states (for example, recognition of where information is when it is not displayed).
• Action-effed relations: this is the causal relation between an action and an effect
(for example, the recollection of the consequences of an action [internal], or an
onscreen warning when an action is about to be committed [external]).
In addition to the six categories above, Horsky et al. (2003)added two further categories of
internalised knowledge:
• Knowledge about medicines: refers to current or previous specific and general
knowledge about medicine (for example, the person relates information to her or
his knowledge or experience of taking medicines).
• Conceptual system knowledge: refers to knowing how to use a site (for example, a
sequence of actions required to complete a task).
This model was applied to evaluate ~medical information system for physicians ordering
patients' medication, and found that the configuration of the system placed undue
demands on the user (Horsky et al., 2003).
40
This theory can account for how the design features of an mM! site have the potential to
lessen the cognitive demands on the individual interfacing (interacting) with the site. Thus
the properties (design features) of mM! sites (in theory) can potentially store information
externally, thereby reducing the user's cognitive load because she or he does not have to
actively recall this when using the mM! site. As a result, the user can focus on trying to
understand the information.
The structural design of a website represents its information architecture. Rosenfeld and
Morville (2002) propose information architecture has the following concepts underpinning
it:
(i) Information is the link between data (facts) and knowledge (known facts);
(ii) Information architecture refers to the structure, organisation, and labelling of
information; and
(iii) The information should be easy to find by browsing, searching, and asking.
Individual factors still playa role in determining the individual's level of understanding of
WMI. Accounting for ways to reduce cognitive load for understanding WMI, the
Pharmacokinetics Communication Model (Morris and Aikin, 2001) contend that
individual differences as well as design features of WMI (the authors' focus was on PILs
and not mMI), will determine the users' comprehension of WMI. The three personal
factors are: motivation to read the information (including time and effort given);
opportunities they have to read the information (including available time), and their
ability to process the information (including literacy levels).
The psychology of design
The information architecture of an mM! site will determine whether or not the person
interfacing with a site is able to find information or not. This necessitates an evaluation of
the design features of sites. As Norman (1988) has noted; applying psychological
principles to poorly designed objects can make them more usable, and therefore reduce
the demands (cognitive load) for the user to remember large amounts of information.
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Preece et al. (2002) have devised a set of design principles, based on understanding of
cognitive processes, that suggests how knowledge of how people process information can
be applied to website design to make the site easier to use. These offer a means for
evaluating the usability of websites in relation to their features. The six design principles,
with examples of implications provided by Preece et al. (2002) are presented below.
Examples (by the thesis author) of the possible effect of mM! design impacting on
participants' use of it are related to these.
(i) Attention
This refers to the processing of information on the site. The information should be salient
when needs be, so it can be more easily processed. Guttered information should be
avoided, because it makes excessive demands on attention; and the site should be made as
plain as possible (for example, like Google™), to make it easy to use. Evidence of the design
of the mM! sites affecting users' attention would be, for example, if participants complain
about cluttered information being a distraction.
(ii) Perception
This relates to the perception of text and graphics on the site. The use of icons can enable
their meanings to be easily distinguished; and it is important to ensure that text is legible
and distinguishable from the background. Evidence of the design of the mM! sites
affecting users' perception would be, for example, if participants click on icons for finding
information.
(iii) Problem-solving
This refers to the provision of support for using the sites. It is suggested to provide
additional information to aid those who wish to understand how to interface more
effectively. Evidence of mM! sites problem-solving capabilities would be, for example, if
participants use a further information resource or access online help.
(iv) Memory
This is in relation to the retrieval of information on the site. It is recommended to not
overload users' memories with complicated task procedures; and to (aim to) draw on
users' recognition rather than recall of information, as the former is more effective for
retrieving information. Evidence of the design of the mM! sites impact on users' memory
42
would be, for example, if participants are able to recognise the site features once familiar
with them.
(v) Learning
The focus here is on supporting the user of the site. Interfaces should encourage
exploration and provide guides to allow users to select appropriate actions. Evidence of
the design of the mMI sites impact on learning would be, for example, if users are able to
quickly explore the site with ease.
(vi) Reading
This relates to reading the site's information. It is best to aim for large text without
affecting formatting. Evidence of problems with reading the mM! sites would be, for
example, if users struggle to read the information because of the text font size.
InChapter five these design principles are utilised to code verbal protocols, because it is
considered that this can provide an insight into the cognitive processes that the individual
is using when interfacing with the site.
It is contended in this thesis that the principles of attention, perception and problem-
solving are relevant to the content of a website: for example, how information is presented
on screen can have different demands on attention, whether or not information is
provided as an icon can influence perception, while an option to access 'help information'
can support problem-solving. The latter three principles (memory, learning and reading)
can be relevant to design features of a website. For example, a site that enables recognition
of information on how to use it, rather than requires the information to be recalled, can
reduce demands on memory.
A site designed to encourage the user to freely navigate it may enable the person to learn
to use it with ease; and a site with a text size change option may be easily read. It is
necessary to analyse the content and design features of mM! sites, as these may impact on
how readable and easy to use they are; and therefore ultimately h~w useful they are to the
medicine user. Each principle necessitates focusing on mM! sites' content and design in
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relation to their usability: for example, cluttered text (with little 'white space') may impact
on the accessibility of mMI, by appearing off-putting to the reader.
An example of research examining the effect of information designed in different formats
is by Edwards et al. (2006). They conducted a randomised controlled trial (RCI') examining
four different ways of presenting risk information on the Best Treatments website. They
looked at the effect on reducing decision conflict (recorded on a scale, which measures a
persons confidence or uncertainty about whether or not a choice is right for them). 508
individuals were shown the information numerically, graphically, as anchored
information, or as a combination of the three. A fifth group acted as a control and received
the standard information from the Best Treatments website. The study found no difference
between the interventions, but qualitative feedback indicated that information presented
as a bar chart was more favourable than the other graphical formats.
Usability research principles
The theory of distributed cognition predicts that the design features of mM! sites will
impact on their ease of use for people finding and understanding information about
medicines (i.e. usability). This section introduces the principles guiding usability research.
An overview of research methods for examining usability is presented in 5.2.
The ethos of usability and user testing is to examine the usability of the site, or the
understandability of the information. It does not examine the knowledge or expertise of
the user. The aim therefore is for designers to adapt the site/information to make it more
easy to use or understandable, as opposed to the user having to adjust to the site and its
information. Nielsen (1993) has proposed that the usability of a website can be changed by
adapting it to have the following features:
• Leamability, where the system is easy to learn;
• Efficiency, allowing for a high level of productivity;
• Memorability, so the user does not have to relearn the system on separate
occasions;
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• Low possibility of errors, or if errors are possible, they should be easily
recoverable. A similar concept is I safety' to ensure the prevention of serious errors
(Preece et al., 2002);
• Satisfaction, because the system is deemed to be pleasant to use.
Preece et al. (2002) add the following:
• Effectiveness to use, i.e. how well a system does what it is supposed to;
• Utility, the system provides the correct function to allow users to do what they
have to do.
Norman and Panizzi (2006) have argued that the major goal of usability-testing for
computer-based information is to discover major problems which could result in user
errors and thereby frustrate the user. This assertion further highlights the importance of
the design of mM! sites in facilitating their ease of use.
1.5.3. Concluding remarks
The role of theory in this thesis is to provide a framework for the evaluation of:
(i) The quality and trustworthiness of information,
(ii) The information content, and
(iii) The design features of the sites.
The evaluation of these three concepts to an extent reflects criteria drafted by Tweddle et
al. (1998) for evaluating a cancer information website. Rogers (2004) has argued that theory
derived from studies examining cognition in a laboratory cannot be applied simply. She
notes that cognitive processes underlying HCI in the real world are 'messy'; unlike the
neat uniformity of cognitive processes measured in a laboratory. This does not negate the
use of laboratory -derived theory, but provides a reminder of the limits of the
generalisability of usability study findings. Nevertheless there remains a need to
understand the cognitive processes of the person interfacing with a website. This thesis-
contends that laboratory -based research enables these processes to be examined in a
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controlled environment, where there is less chance of extraneous variables biasing this
investigation.
Drawing from these disciplines, three concepts are used to underpin the evaluation of
mM!: if the information is trusted; if its content (information about medicines) is
understandable; and if the design of the site makes it easy for the user to navigate the
page(s). Each of these concepts has a theoretical rationale, which is explored below.
Trust
An assessment of the trustworthiness of mM! is important for determining if they are
reliable and trustworthy. There is the possibility (though far from straightforward), that
Internet users accessing poor quality information may, as a consequence, act in a way that
is detrimental to their health (see 1.2.3). The trust markers of the mM! sites will be
examined in two ways: firstly in the analysis of mM! content reported in Chapter four,
and secondly in Chapter five by assessing whether participants displayed evidence of
considering the trustworthiness of the site they used.
Content
This thesis examines if the information about medicines on mM! sites is understandable· ,
therefore the readability of the content of these sites is measured. Readability of leaflet-
based (but not Internet-based) WMI and its measurement have been defined by EU
legislation. Understanding will be measured by participants' explanation of the
information, which is a proxy measure of their understanding of it or not, and is reported
in Chapters five and six.
Design features
Because extrinsic cognitive load is determined by the way that information is presented,
this highlights the consequences that the design of mM! sites (and probably also leaflets)
can have for understanding its content. Poorly designed mM! sites may not be easy to use,
and therefore the individual may be less able to locate the specific information sought. The
way an mM! site is designed can make it more or less easy to use, irrespective of the users'
underlying Internet skills; impacting on the cognitive demands on the person accessing it.
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These points necessitate the need to examine the ease of use of the site in relation to its
design. These are measured by participants' verbal protocols, their online actions, and
their observed behaviours when interfacing with the sites in the study reported in Chapter
five, and by using indirect methods in the study reported in Chapter six.
What can the theory potentially reveal?
The following applied example anticipates what the data may tell in relation to the
theoretical framework. The participant has a goal to find information to explain a question
about taking a medicine. The state is the onscreen display, i.e. the homepage of the site,
presenting a range of affordances for the participant, including a search bar, links to
external sites, and links to different sections of the same web page. An online help page
provides an external plan to support the participant. Clicking on a link opens an external
page, and acts as an external action-effect letting the participant know she or he entered a
new site. Recognising this, the participant shows conceptual system knowledge. Closing
the link, she or he scrolls down the page reading the content, and then identifies the
information to answer the question.
1.6.Aims, objectives, and outline of thesis
1.6.1. Overall aim
This thesis evaluates leaflet-based and Internet-based WMI, to examine if they are useful
for aiding people's understanding about taking medicines.
This is an applied piece of research, drawing on theories (see 1.5.2)and methods of others
(see the methods section of each study). The contribution of this thesis to knowledge seeks
to be two-fold: (i) knowledge ofWMI, and in particular ffiMIj and (ii) the use of mixed
methods to examine WMI.
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1.6.2. Specific aims and objectives
Study one: an evaluation of the effectiveness of written medicines information
(i) To examine medicine users' opinions about written information for individual
medicines
This study was patient centred, giving WMI stakeholders the opportunity to express their
opinions about WMI at two workshops, at the beginning and end of a research project.
• The aim of the first workshop was to elicit stakeholders' perceptions of key issues
regarding WMI, so that these could be taken into account when shaping, planning
and executing the systematic review, thereby enabling it to be user-centred.
• The primary aim of the second workshop was to elicit views about the review
findings from the stakeholders involved in workshop one, in order to make
interpretation of the findings and the conclusions drawn user-centred.
(ii) To evaluate the effectiveness of WMI
The systematic review of effectiveness sought to examine the evidence for paper-based
and Internet-based WMI changing medicine users' knowledge, attitudes and behaviours
relating to taking medicines.
• How effective is WMI about individual medicines in improving patients'
knowledge and understanding of treatment, and improving self-management of
illness and health outcomes?
Study two: an evaluation of the quality, content and design features of websites with
information about medicines
An evaluation of the quality, content and design features of a sample of mM! sites
provided a basis for the subsequent evaluation of the usability of the (same) sites and the
readability of their information.
• To determine how frequently the most popular mM! sites in the UK and USA are
accessed.
• To compare the quality, content and design features of the mM! sites.
48
Study three: an evaluation of the usability and readability of websites with information
about medicines
A purposive sample ofmM! sites from Study two were tested for their ease of use and the
readability of their information by people who take medicines.
• To assess participants' prior experience of WMI and mM!.
• To examine how participants searched for information about medicines using an
Internet browser.
• To examine the ease of use of the sample ofmM! sites.
• To examine if the information on the sites was understandable.
• To determine participants' views on the ease of use of the sites; readability of the
information; and if they will access the Internet again to find information about
medicines.
Study four: a pilot examining the appropriateness of the design and methods for afull
ReT evaluating changes to web pages with infonnation about medicines
The final study was a pilot to examine the appropriateness and feasibility of using a
repeated measure with counter balance study design, an intervention for redesigning web
pages containing information about medicines, and tools for measuring the outcomes.
These could be used in a full trial to evaluate whether redesigned web pages containing
information about medicines improved participants' ability to locate and understand
specific information.
• To pilot an intervention based on content and general content formatting.
• To pilot a repeated measures with counter balance design.
• To pilot a set of proposed tools for measuring participants' ability to locate and
understand specific information about medicines on a website.
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Overall discussion of the findings, limitations and implications of the research in this
thesis
The discussion chapter brings together:
• A summary of the four studies.
• A discussion of the limitations of the research reported in this thesis.
• An examination of how the findings in this thesis add to the knowledge base.
• A discussion of the implications arising from the research in this thesis.
• Concluding remarks regarding WMI.
This thesis uses mixed methods in three of the four empirical studies and this method is
examined in detail in the following chapter.
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Chapter two
The methodological foundations of
the research
2.1.Introduction
The research reported in this thesis mixes qualitative and quantitative methods, to gather a
fuller picture of WMI. This chapter examines methodological issues that underpin mixed
methods: the different paradigms and epistemologies that underlie research; the problems
associated with mono-methods and the rationale for using mixed methods; the possibility
of pragmatism as the epistemological basis for mixed methods research; and procedures
for using mixed methods. There is an appraisal of mixed methods research, and then it is
explained how these methods are applied to the research reported in this thesis.
2.2.Research paradigms
The concept of research paradigms, conceived by Kuhn (1962),seeks to explain how
science is conducted, and specifically, how developments in science arise. Breaking this
concept down, Creswell (2003)talks of 'three elements of enquiry', i.e. three stages that
combine to form the process of conducting research:
1) The philosophical assumptions that underlie knowledge claims; e.g. what it is
possible to know, and what knowledge is. This can be broadly considered to be
epistemology (the theory of knowledge), although this has a more specific meaning
in philosophy.
2) Strategies of inquiry, i.e. they are general procedures regarding the research
design, based upon knowledge claims; i.e. broad methodological paradigms, such
as positivism, postpositivism or constructivism.
3) Methods: specific procedures for collecting and analysing data.
These three elements highlight how the method(s) available to a researcher are grounded
in a distinct methodological paradigm, which follows from a specific philosophical
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outlook. The consequence of this process for Creswell (2003), is that research can be
exclusively quantitative or qualitative (mono-methods), or a combination of both (mixed).
Figure 2 highlights this in pictorial form. The difference in approaches to research
(methodology), and the methods that researchers use, result from the different
philosophical positions that researchers take regarding knowledge (see Table 1).
Figure 2: Overview of the three research paradigms, including sub types
The broad overlap of mixed methods
Qualitative II Equal status i Quantitative',
dominant I(mixed methods)1 dominanL
I I• ---.
Pure r Qualitative r Quantitative Pure
qualitative mixed Pure mixed I
mixed quantitative
methods methods methods methods methods
Adapted from Johnson et al. (2007), pp 124
Creswell (2003) discusses the epistemological paradigms of postpositivism and
constructivism; pragmatism; and advocacy/participatory research. The latter seeks to
combine research with a (political) agenda in seeking reform, addressing social issues and
involving the public's collaboration. This approach is not discussed, as it is not relevant to
the research in this thesis. Pragmatism is examined in 2.4.
In the social and behavioural sciences, two mono-methods have been dominant:
quantitative and qualitative research. The positions are presented in Table 1as polar. But
as Johnson and Onwuegbuzie (2004) acknowledge, they share several features: they are
based on empirical observations, each incorporate methods that safeguard their inquiry
from bias, and they both provide defensible assertions.
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Table 1: Comparisons of postpositivist and constructivist paradigms
Methods Primarily quantitative Qualitative
InductiveLogic Primarily deductive
Epistemology Modified dualism. Findings are
probably objectively 'true'
Subjective point of view.
Knower and known are
inseparable
Axiology Inquiry involves values, but they may Inquiry is value-bound
be controlled
Ontology Critical or transcendental realism Relativism
Causal linkages There are some lawful, reasonably
stable relationships among social shaping each other. It is
phenomena. These may be known impossible to distinguish
imperfectly. Causes are identifiable in causes from effects.
a probabilistic sense that changes over
time
All entities Simultaneously
Adapted from Tashakkori and Teddlie (1998), pp 23
2.2.1. Quantitative research paradigms
Quantitative research is grounded in the philosophy of postpositivism, which holds that
social phenomena can usually be reduced to their constituent parts, and measured to
derive reasonably stable relationships (Tashakkori and Teddlie, 1998). Postpositivism is a
descendant of positivism, the philosophical tradition that formed the basis for modem day
science.
Quantitative research has an objective, naive realistic outlook on the world, and seeks to
develop lawful cause and effect links (Baum, 1995). Broadly speaking, this approach
attempts to observe and measure social phenomena in the same way that a scientist
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observes and measures natural phenomena (Bowling, 2002); and considers that findings
are probably objectively true (Tashakkori and Teddlie, 1998). It is primarily quantitative,
and uses controlled conditions, measuring the outcomes, and analysis (usually) by
statistical methods (Malterud, 2001). Ituses the hypothetico-deductive method of analysis,
which seeks to derive a logical conclusion from a premise (Fuller, 2003). The research is
therefore theory driven, where a tentative hypothesis (initial prediction to explain the
phenomenon) is tested, and the data gathered either supports or refutes this.
2.2.2. Qualitative research paradigms
Qualitative research has its basis in the constructionist paradigm which seeks to
understand, rather than measure or reduce phenomena, recognising the importance of
context (Baum, 1995). Qualitative research focuses on interpreting, and analysing textual
data (Malterud, 2001). This position views the meanings that individuals attribute to a
situation as being constructed, which directs research attention to interpreting others'
meaning of the world (Creswell, 2003). Here knowledge is derived through an inductive
analytic approach, where the codes are derived from the data itself (Draper, 2004). Thus a
researcher induces a general statement from a limited number of observations. This is data
driven research, where a theory explaining the phenomenon that has been examined
emerges from the data set. (There are also many examples of qualitative work that are
driven by theory). Fuller (2003) has proposed that this method can be considered to hold
the future to hostage; because knowledge is derived through a limited number of
examples, and it would only take one (future) negative example to negate this.
2.2.3. Paradigm wars and Communities of Practice
The postpositivist paradigm, with its emphasis on the quantifiable, has led to a number of
important scientific discoveries (Flynn, 2006). However, quantitative research has been
criticised for ignoring how science and its methods are socially constructed (Flemming et
al., 2008), and that its findings are not valid as they do not reflect the real world. By
comparison, qualitative research has been criticised for being too small scale, and
impossible to generalise from, because its data are said to represent little more than
interpretations and anecdotes (Flemming et al., 2008). Not only are there problems with
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using either of the mono-methods, it is also argued that they are incompatible. Tashakkori
and Teddlie (1998)have reported how some commentators have argued that the
quantitative and qualitative positions are 'incommensurate' (i.e. incompatible) because
their differences are so fundamental. It is therefore impossible for researchers to enquire
about questions that are both quantitative and qualitative. The idea of incompatibility
came to a head in the social and behavioural sciences with the 'Paradigm wars' of the
1970s-1990s(Tashakkori and Teddlie, 1998)when the contrast between proponents of the
dominant postpositivist paradigm, and constructivism disputed the merits of the other.
For Kuhn (1962),the day-to-day work of science (normal science) represents puzzle
solving, where scientists conduct the business of working on problems. It is contrasted
with revolutionary periods in science where the dominant paradigm is overthrown in
favour of a new paradigm to explain phenomena. Normal science can be seen to be
reflected in the idea of Communities of Practice. Denscombe (2008)notes that the concept
of 'Communities of Practice' presents the work of science and research as a collective
process of shared activity between colleagues. This replaces the idea of supposed conflict
between paradigms; and instead looks upon the acquisition of knowledge (the process of
research) as a social activity where knowledge is pooled. For Denscombe (2008),
Communities of Practice permit mixed methods research, because there is no clear
distinction between practice and research, therefore enabling researchers not only to have
awareness of the knowledge and skills of another paradigm, but also to be able to practise
it.
Denscombe (2008)has proposed that Communities of Practice can explain the
methodological choices made in mixed methods research. This dispenses with the idea
that decisions are either solely individual or rational; and instead recognises that social
factors can underlie the methodological choices of the researcher. In Studies three and four
the readability ofmMI is examined by the method of 'User Testing'. EU law (see 1.2.5)
legislates that this is the sole means for examining the readability of PILs, and therefore
represents an example of a social factor underpinning the direction of research.
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2.3.The rationale for mixed methods
The problems associated with either of the mono-methods can provide a rationale for
combining quantitative and qualitative methods; i.e. mixed methods research. This section
examines the rationale to do so from the perspective of the benefits this offers, as well as a
response to the criticisms of the individual mono-methods.
First it is important to be clear upon a definition of mixed methods. Johnson,
Onwuegbuzie and Turner (2007)interviewed leading methodologists in mixed methods
research who constructed 19 separate definitions of mixed methods research. From this
they have offered a definition of mixed methods research as an intellectual and practical
synthesis of quantitative and qualitative research to offer the most complete, balanced and
useful results.
Figure 3 (from Johnson and Onwuegbuzie, (2004)shows how mixed methods research fits
in between the quantitative and qualitative paradigms at either end of this spectrum
(numbers1 and 8). The six categories in between (numbers 2 to 7) are examples of research
that mixes methods to varying degrees and at different stages in the research process.
There are several reasons for using a mixed methods approach, which seeks to overcome
the problems of adopting a mono-method. Firstly Creswell (2003)has argued that research
can better understand problems by converging quantitative and qualitative data rather
than adopting a mono-method. Both quantitative and qualitative research examine
problems that are guided by their methods: i.e. the research questions themselves are
based on what they measure and how they measure. In mixed methods research the
question drives the methods, and not vice-versa (Greene, 20OS).'Therefore the researcher is
not constrained because she or he can adopt tools from quantitative or qualitative research
to examine the question. The notion that the question/problem precedes the method is
important from a practical perspective. The Health Development Agency in the UK has
co~t~ded that failing to examine health inequalities because of philosophical or
methodological differences cannot be justified, because these are considerable problems
that need to be addressed (Kelly and Swann, 2004).
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Figure 3: Typology of mixed methods research
Qualitative research Quantitative research
I I I I............. ""'"""1 I: - II Collect I II Collect ICollect Collect
a_ualitative data ntitative data I~~tive data l~antitative d~j...,- , . .-........ ,....'" , ....
J I I I
I I I I I I I I
Perform Perform Perform Perform Perform Perform Perform Perform
qualitative quantitative qualitative quantitative qualitative quantitative qualitative quantitative
analysis analysis analysis analysis analysis analysis analysis analysis
#1 #2 #3 #4 #5 #6 #7 #8
Adapted from Johnson and Onwuegbuzie (2004), pp 21
Secondly, following on from a point made in section 2.2, quantitative and qualitative
research share several tenets. At a broad level, both seek to understand and improve
human conditions (Sale et al., 2002). Furthermore, Abushaba and Woelfel (2003) have
proposed that all data, i.e. quantitative and qualitative, have both an objective and
subjective component. They cite the argument that numbers can be allotted to qualitative
data in a survey, and numerical data gathered in a quantitative study can be analysed in a
subjective or qualitative manner.
Thirdly, Sale et al. (2002) acknowledge the argument made by commentators that, because
there appears to be no way of reconciling the quantitative-qualitative debate, one should
not focus upon choosing between epistemological stances, as this will not help in getting
the research done. Instead they argue, the phenomena being investigated should be clearly
labelled with regard to the method being used. Thus a phenomenon can be labelled and
measured one way for a qualitative study, and in a separate way for a quantitative study.
These different labels they propose, add value to each other.
Fourthly, Abushaba and Woelfel (2003) have proposed that combining the two approaches
will cancel out to some extent their respective weaknesses (see 2.2.1 and 2.2.2). Similarly,
Johnson and Onwuegbuzie (2004) have argued that epistemological and methodological
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pluralism (in educational research) can increase researchers' epistemological and
methodological possibilities, making for more effective research. There is no reason why
this should not hold true for research conducted in HSR, in particular the research
conducted in this thesis.
Lastly it should be pointed out, as Johnson and Onwuegbuzie (2004)have noted, that
while there are differences between quantitative and qualitative work, the two approaches
are in broad agreement on a number of philosophical points:
(i) Reason is relative, and can vary between people;
(ii) Observations are theory-laden;
(iii) Evidence does not always determine a theory, because more than one theory
can fit a set of data;
(iv) There are alternative ways of explaining data;
(v) Because of the problem of induction, evidence can only be probabilistic;
(vi) Research is a social enterprise, so researchers are affected by the beliefs, values
and attitudes of communities; and
(vii) Inquiry is value-laden because researchers cannot avoid their values affecting
what is examined and how it is interpreted.
2.4.Pragmatism and mixed methods
The epistemological bases for quantitative and qualitative research are positivism or
postpositivism, and constructivism, respectively. Mixed methods research does not yet
have a similar base in epistemology. Johnson et al. (2007)note that some commentators
consider that pragmatism can act as the philosophical basis for mixed methods research,
by providing an epistemological justification, and a logic for mixing methods.
Tashakkori and Teddlie (1998)propose that pragmatists consider the research question
they are investigating is more important than the methods they use, or the worldview
underpinning it. Thus the method follows from the question, rather than the question
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being based on the methods, as can be the case with mono-methods. This opens up the
possibility of mixed methods research examining a wide range of questions, as it is not
constrained by the methods that it can use. Tashakkori and Teddlie (1998)suggest that a
pragmatic approach avoids the metaphysical concepts that are associated with the mono-
method, offering a practical, applied approach to research.
Creswell (2003)cites the adage that lies at the heart of the pragmatist philosophy: that
truth is what works at the time. From this he argues that mixed methods research draws
on quantitative and qualitative methods because this works to provide the best
understanding of the research problem, compared to using a solely quantitative or
qualitative approach. The upshot of this approach for Creswell (2003)is that the researcher
is not constrained by one paradigm and one broad way of collecting and analysing data,
and so has freedom to mix different methods to try to answer a research question.
Denscombe (2008)has proposed that pragmatism is sometimes considered to mean
expedient; a commonsense way for justifying an 'anything goes' approach to conducting
research. However, he notes this is not the philosophical meaning of pragmatism and
provides examples of mixed methods research that are based on this approach.
While this approach can offer much potential to mixed methods research. it has several
weaknesses, according to Johnson and Onwuegbuzie (2004).A pragmatic approach to
research can favour applied research to the detriment of basic research, as the former
produces more immediate and practical results. Similarly Johnson and Onwuegbuzie
(2004)have noted that pragmatism may offer incremental change, but not a more
fundamental, structural change to society. This can probably also be applied to the
diScipline of HSR.
2.S.Procedures for using mixed methods
Having provided the rationale for conducting mixed methods research, and the
epistemological basis for it, the focus now turns to an examination of procedures for
condUcting mixed methods research.
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2.5.1. Sampling
Sampling is of importance to the social and behavioural sciences in general and not just
mixed methods research. Sampling is the method of taking a sub-section of a population
that is being examined. How a sample is selected will impact on the results of a study, as
well as the researcher's ability to generalise their findings to the wider population, i.e. its
transferabili ty.
Teddlie and Yu (2007)have referred to four broad techniques for sampling: probability,
purposive, convenience, and mixed methods. Probability sampling is used in quantitative-
based research to derive large numbers of people picked from the population at random,
who will be representative of as many people as possible. Purposive sampling is used in
qualitative research to select units of investigation (e.g. people or websites) specifically for
the information they can provide. Convenience sampling is used to gather people who are
easily accessible, and willing to take part in research. Mixed methods sampling combines
both probability sampling (to increase the external validity), and purposive sampling (to
increase the transferability of the findings).
Mixed methods research sampling, represents an overlap between quantitative and
qualitative methods. As Teddlie and Yu (2007)explained, mixed methods sampling
employs both probability and purposive sampling with the aim of being both
representative, and having information rich cases. They note that there is no widely
accepted typology for mixed methods sampling strategies. However, drawing on the
literature, they offer the following guideline for a sampling procedure for mixed methods
research:
1. The sampling strategy should follow the research question, and will usually
involve both probability and purposive sampling.
2. There should be adherence to the assumptions of using a probability sample or
a purposive sample.
3. The strategy should be sufficient to answer the research question, ensuring the
data are both representative, and that there is saturation.
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4. The sample should have credibility and internal validity, so that clear
inferences can be made.
5. The strategy must be ethical, feasible and efficient.
6. The sample should permit the generalisability or transferability of the results
(Teddlie and Yu, 2007).
Collins et al. (2007)have reviewed the minimum sample size recommendations for most
common quantitative and qualitative research designs. For the research designs carried
out in this thesis, Collins et al. (2007)suggest that the minimum sample sizes should be the
following:
• Focus groups have between 6 and 12participants;
• Case studies have between 3 and 5 participants;
• Experimental studies (trials) have a minimum of 21 participants per group.
These are only recommendations, and sample size calculations depend on many factors. It
needs to be asked therefore if these are reliable estimates. The recommended range for
focus groups appears to be feasible. Too few participants may be a barrier to maintaining a
discussion, while too many participants may not enable everyone to give their responses.
The numbers cited for a case study appear to be reliable, as long as data saturation is
reached in the case studies; i.e. no new findings emerge after the nihstudy. However, the
recommendation of as few as 21 participants per arm in a trial is far too low. In reality
trials are usually conducted with many more participants, so that they are adequately
powered to be able to detect a meaningful and statistically significant difference between
the interventions.
2.5.2. Decisions determining mixed methods
Creswell et al. (2007)have reported a decision matrix for determining a mixed methods
design (see Figure 4). This shows that decisions have to be made regarding four concepts
for determining a mixed methods design. Implementation refers to whether the different
61
methods are conducted sequentially, or concurrently. Priority relates to whether one
mono-method or both are given precedence in terms of analysis and data collection.
Integration of the data can occur at anyone of three stages, or in combination. Lastly
Creswell et al. (2007) ask whether a theoretical perspective is operating explicitly or not.
Figure 4: Decision matrix for determining a mixed methods design
Implementation Priority Integration Theoretical
perspective
No sequence At data collection
concurrent
Equal At data analysis
Explicit
Sequential:
qualitative first
At data
Qualitative
interpretation
Sequential:
Implicit
quantitative first Quantitative With some
combination
Adapted from Creswell et al. (2007), pp 171
The adoption of strategies for using mixed methods reflects the rejection of the separate
mono-methods. For example, quantitative research uses the process of deduction; while
qualitative research adopts an inductive method. Morgan (2007) notes that mixed methods
research does perceive this dichotomy; instead the logic is based on abduction, where
there is a moving back and forth between theory and data. Thus the researcher can derive
a theory from observation, and then test the theory (for example, by using a ReT). This
point is crucial to mixing research methods, because it explains the grounds for
interchang betwcen different methods, rather than the adoption of one approach and the
rejection of the other.
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Section 2.2 highlighted that a key distinction between quantitative and qualitative research
was the objective nature of the former, and the subjective nature of the latter. Morgan
(2007) has argued that there is not such a clear distinction, because research cannot solely
be one or the other. He proposes that, instead, most researchers exhibit 'intersubjectivity',
whereby they move back and forth being objective and subjective. This view can be
extended to provide a means to overcome the problem of quantitative and qualitative
research being incompatible, which makes it impossible to mix methods (see 2.2). Thus the
mixed methods researcher can accept that there is a 'single real world', and that
individuals have their own personal and unique interpretations of it.
2.5.3. The different strategies for using mixed methods
Creswell (2003) has broadly classified the methods by the type of implementation strategy
they adopt: sequential or concurrent. Within each of these are three sub-categories.
Sequential
Creswell (2003) discusses three types of sequential strategies, where one method follows
the other:
1. Explanatory: this has an initial (dominant) quantitative study, with a follow-up
qualitative component; and is used to aid the understanding of the initial
quantitative data. This is a straightforward design, but can take a lot of time to
conduct.
2. Exploratory: this has an initial (dominant) qualitative study feeding into a follow-
on quantitative study; and is used to provide the elements of an emerging theory
for testing. This is a useful design when the researcher is building a new
instrument, but can also be time-consuming to conduct.
3. Transformative: the sequence and priority of methods can alternate in this design,
to best suit the theoretical perspective of the researcher. This has the same
strengths and weaknesses as the previous designs. However, little has been written
on this, and so it is not well guided.
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Concurrent
Likewise Creswell (2003)discusses three types of concurrent strategies, where both
methods are conducted simultaneously:
1. Triangulation: this uses two different methods within a single study, to confirm,
corroborate, or cross-validate findings. This strategy involves gathering different
data on the same phenomenon from different methodological perspectives
(quantitative and qualitative), to obtain the most adequate account of it (Malterud,
2001), and can highlight when results do or do not converge. It is, however, not
easy to conduct, as it requires a great effort to examine the same phenomena with
separate methods.
2. Nested design: in this approach one predominant method has a smaller (less
dominant) method embedded within it. This method allows the researcher to gain
a broader perspective from using different methods, rather than using a different
predominant method. This is advantageous because the researcher can use
different methods simultaneously in one data collection phase, and it offers the
chance to explore different perspectives. However, this is a poorly understood
method, and not easy to conduct.
3. Transformative: this takes on the design features of either the triangulation or the
nested methods, to best suit the theoretical perspective of the researcher. This has
the same strengths and weaknesses as the individual designs that it borrows from.
2.5.4. Transferability of the knowledge gained from mixed methods research
Research seeks not only to answer the research question, but also to contribute to wider
knowledge. Inquantitative research, this relates to the generalisability of the research;
where it is held that the findings are universal and can be applied to other similar
situations. Qualitative research rejects notions of generalisability, because its focus is on
the specific context of the research. Thus no attempt is made to apply the results to a larger
level. Mixed methods research by comparison seeks to ensure that the findings are
transferable, distinguishing between the mono-methods. As Morgan (2007)notes, instead
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of querying whether or not the findings are universal, mixed methods research seeks to
examine the transferability of the findings; thereby taking the knowledge gained from one
method in one setting, and applying it to a different setting.
2.6.Appraisal of mixed methods methodology
Section 2.5 has (in part) highlighted the potential benefits of adopting different procedures
for using mixed methods research. However, several commentators have noted reasons
for being cautious about adopting a mixed methods approach. Those that are most
pertinent to the research conducted in this thesis are now examined.
Mixed methods research has aligned itself with the philosophy of pragmatism, in an
attempt to lend it the same credibility that postpositivism and constructivism give to
quantitative and qualitative research, respectively. But is this necessary? Johnson et al.
(2007)have proposed that mixed methods research should distinguish itself by not having
a guiding philosophy, but instead be self-reflexive, and contribute to discussions on the
philosophy of science. The concept of 'Communities of Practice' appears to provide a
practical and realistic description of how the business of research is conducted day-to-day.
The researcher is not faced with the necessity to reflect on matters of the philosophy of
Science,or making a choice between paradigms, and so can concern him or herself with
the design and conduct of research that is valid and reliable.
Furthermore, mixed methods research has sought to distinguish itself from mono-methods
by being driven by the question and not the method. This is very much a feature of
contemporary research. It is commonly the case that the research question will have been
defined at the outset by the funding body, and researchers compete to win a tender for
condUcting the project. The successful applicants, depending on the research question,
may then have scope to choose the methods to examine the question.
Mixed methods research is an emerging discipline, compared to quantitative and
qualitative research. Collins et al. (2007)have dted four methodological issues that remain
to be resolved:
65
(i) The challenge for sampling to be conducted to enable the research to be
representative;
(ii) The difficulty in generating findings that are 'legitimate', i.e. credible and
transferable;
(iii)The challenges of integrating quantitative and qualitative data, with regard to the
relative weight given to quantitative and qualitative data and how to integrate
them; and
(iv)The problems that arise when there is an apparent discrepancy between qualitative
and quantitative data.
This uncertainty in mixed methods research methods and the underpinning methodology
can be contrasted with the stability of the mono-methods. The consequence for this thesis
is that it is that it is adopting a developing methodology that may be seen as less reliable
than either mono-method. This presents a challenge for the validity of research conducted
in this thesis to be safeguarded, and offers a potentially novel methodological approach to
examining WMI.
2.7.The application to this thesis
This thesis reports applied research seeking to answer a real world problem, driven by the
research question, and not a particular methodology. It uses a mixed methods approach to
provide the best means for answering the research question. Adopting a mixed methods
approach will be invaluable because it will provide a more comprehensive picture of the
usefulness of WMI, in particular mM!. Thus it will be possible to examine not only what
features of mM! sites facilitate or impair their efficient use; but also to gain an
understanding of why they do so. This will therefore necessitate record quantitative and
qualitative data simultaneously, at stages in the research in this thesis.
The mixing of methods to examine questions relating to WMI represents a novel approach
to eXamining this area of research. There is no known example of such research in this area
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to act as a template to guide this; and so this makes the conduct of this research in a valid
and reliable manner a challenge.
Mixed methods are used in three of the four research studies in this thesis.
• Study one: the examination of the effectiveness of WMI and the examination of the
views of WMI stakeholders represents the combination of primary research using
qualitative methods, and secondary research using quantitative methods. The first
workshop enables stakeholders to input into the aims of the systematic review. The
follow-up workshop provides an opportunity for stakeholders to feed back on the
findings of the review.
• Study three: utilises a triangulation of concurrent quantitative and qualitative
methods to examine the readability and usability of mMi. This is complemented by
a sequential explanatory component: a post-study interview with the participants,
to gather their opinions on the readability and usability of the website. It is
considered that the use of concurrent methods is essential for examining the
usability and understandability of mMI sites as it will highlight problems that the
person has when using the website and at the same time bring to light the
participants' perceptions of the reasons for their having problems. This will be
conducted by measuring participants' ability to find and understand specific
information on the mM! sites, and simultaneously observing their actions while
interacting with the websites as they think aloud (see 5.2). By triangulation of this
data, it will enable a picture to be developed of what features of the site are easy to
use or not, and why they are so.
• Study four: the User Test task is the main focus of this study, followed by a
sequential explanatory post-study questionnaire for examining the ease of use of
the site, and the participants' satisfaction with using it. As with Study three, this
provides an opportunity to examine participants' explanations for their
interactions with the web pages, but by using different methods (see 6.5.2).
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2.8.Conclusion
This chapter has explored the methodological issues that underpin the four studies
reported in this thesis; and explained how the methods are mixed in each of these studies.
The next chapter reports the first empirical study. This study mixes focus groups research
with a systematic review of trials to evaluate the effectiveness of paper-based information
about medicines.
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Chapter three
Study one: evaluating the
effectiveness of written medicines
information
3.1.Introduction
This chapter reports research of secondary data that evaluated the effectiveness of WMI as
a leaflet (usually) accompanying medicines. This study formed part of a Health Technology
Assessment (HTA) report by Raynor et al. (2007a),and has recently been updated for a
Cochrane Review by Nicolson et al. (2009).The author of this thesis was an author on both
the HT A report and the Cochrane Review, and his role on these projects is set out in
Appendix one.
This chapter is based on the updated Cochrane Review. The inclusion criteria of the
Cochrane Review differed from the original HT A report in that it evaluated trials that used
medicine user participants, but not trials conducted with general public participants. As a
consequence, the Cochrane Review excluded trials that examined the impact of information
about the risk of a side effect presented in different ways to the general public. These trials
were included in the HTA report (which included trials recruiting non-medicine users),
and are reported in this chapter.
This chapter also reports the findings from two multi-stakeholder workshops that formed
part of the HT A review project. The first workshop informed the aims and objectives of the
review. The themes that emerged from this workshop were compared to themes in
previous reviews ofWMI, conducted by Nicolson et al. (2006b)j and this work is referred
to in this chapter. The second workshop enabled the stakeholders to feed back on the
findings of the review, so that the conclusions of the report could reflect their comments.
An examination of methods issues surrounding the review (see 3.7.2)were presented by
Nicolson et al. (2006c)at the International Social Pharmacy Workshop conference.
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This is the first of three studies in this thesis to utilise mixed methods (see 2.7). The
workshops, using qualitative methods, ran sequentially before and after the quantitative
systematic review of effectiveness. This chapter now examines the methods underpinning
a systematic review, which is the dominant research method adopted in this chapter.
3.2.Systematic reviews
The evaluation of WMI is conducted by a systematic review synthesising the best available
evidence from previous research. The systematic review process is closely linked to
evidence-based medicine.
3.2.1. Evidence-based medicine
Evidence-based medicine (EBM)is a modern approach to medical practice which explicitly
uses high quality evidence to make decisions about the healthcare of individual patients
(Sackett et al., 1996).This evidence is essential for healthcare professionals to ensure that
they use effective, efficient, and up-to-date practice. Many healthcare professionals,
however, do not have the time to locate, appraise and assimilate the vast quantities of
evidence (Earle and Weeks, 1999).To overcome this, the evidence is often disseminated to
professionals by means of a systematic review.
At the forefront of systematic reviewing in healthcare is the Cochrane Collaboration. This
prOvides up-to-date information on the effectiveness of healthcare treatments (Grimshaw,
2004), through the development of systematic reviews and meta-analyses, published on
the Internet in the Cochrane Library (http://www.thecochranelibrary.com). The NHS Health
Technology Assessment (HTA) (http://www.ncchta.orgl) and the National Institute for Health
and Clinical Excellence (NICE) (http://www.nice.org.ukl) are UK based organisations that
produce evidence based guidance for clinical and healthcare professionals, derived from
systematic reviews. The HTA (in part) produce research examining the effectiveness of
healthcare treatments (http://www.ncchta.orgl accessed online May 2008).NICE produce
national guidelines on public health, health technologies, and clinical practice
(http://www.nice.org.uk! accessed online May 2008).
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3.2.2. Randomised Controlled Trials (RCTs)
Much of EBMis based upon findings from systematic reviews of RCTs,which are
considered to be the best evidence for the effectiveness of an intervention, (discussed in
greater detail in the following section). This section examines what safeguards are in place
to ensure that potential bias in a trial of WMI leaflets is reduced. These principles informed
the conduct of the systematic review.
• Selection bias can occur when participants are allocated to the intervention or
control (Moher et al., 1999).The allocation of participants to the intervention has
two components: the generation of allocation, and then the concealment of the
allocation process (Khan et al., 2001).Random allocation of the participants to the
intervention or control groups can be adequately carried out if the sequences are
unpredictable; by using a computer program, or a random numbers table ijiini et
al., 2001). In a trial ofWMI, participants then have an equal chance of receiving the
experimental leaflet or control leaflet. The second part of the process is the
concealment of allocation from the experimenter so that she or he cannot subvert
the allocation process. This is adequate if it cannot be foreseen which intervention
each individual has been assigned to, e.g. by putting the name of each intervention
('experimental leaflet' or 'control leaflet') in sealed opaque numbered envelopes
(Moher et al., 1999).
• Detection bias occurs when the outcome assessor allows knowledge of what
intervention the participant received to affect her or his measurement of the
outcome (Moher et al., 1999).This can be minimised by concealing knowledge of
whether the participant received the 'experimental leaflet' or 'control leaflet' from
the outcome assessor. (It is not possible to conceal the type of information from the
participant or the treatment provider ijiini et al., 2001».
• Attrition bias refers to the loss of participants to follow-up, and bias in the
OCcurrenceand handling of deviation from the protocol ijiini et al., 2001).This can
be controlled by conducting an intention-to-treat analysis, where participants'
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outcome measures are still analysed when they drop out of the trial. All measures
should be recorded for the participants, so that there is a complete set of data, and
when there is not, the number of people who were lost to follow-up should be
recorded so that this can be taken into consideration when analysing the results
(Khan et al., 2001).
3.2.3. The rationale underpinning a systematic review
A systematic review is a means for synthesising primary research, providing a robust
summary of the best available evidence. Cook et al. (1997) note that a systematic review:
(i) Clearly states its aims and objectives as a focused question;
(ii) Aims to be comprehensive in the identification of studies relevant to the
review;
(iii) Has explicit inclusion criteria;
(iv) Rigorously assesses the quality of the methods used by the research;
(v) And often (though not always) provides a quantitative summary statistic.
A systematic review uses these scientific methods to minimise bias and error (University
of York NHS Centre for Review and Dissemination, 2001). This contrasts with a
'traditional narrative review' which does not attempt any of the five steps above, and so is
prone to bias and error. Systematic reviews benefit EBM, because they constantly update
the evidence on the effectiveness of treatments, preventing the unnecessary reproduction
of research while ensuring that the best available evidence is kept up-to-date.
A systematic review of RCTs is widely perceived as the 'gold standard' for evaluating the
effectiveness of an intervention (Sackett et al., 1996); placing it at the peak of the hierarchy
of evidence. The hierarchy of evidence is not accepted by all within pharmacy practice
research (or HSR); for example, Harding and Taylor (2006) repeat an argument by some
researchers to reject the hierarchy in favour of criteria based on the quality and robustness
of the evidence, whether from qualitative or quantitative research. Such arguments are
rejected in this thesis because the RCT is widely accepted to be the most rigorous method
for eValuating the effectiveness of an intervention. The RCT equally distributes
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confounding and extraneous variables between the intervention and control groups, so
that the only difference between groups is the intervention. Therefore any differences that
exist between the intervention and control groups on the outcome measures can be
attributed with greater confidence to the intervention differences.
Meta-analysis is a statistical technique for pooling the results of different studies to
produce an overall summary estimate and confidence interval (University of York NHS
Centre for Review and Dissemination, 2001).This increases the sample size and therefore
the power of the combined studies, making a significant effect more detectable (Mulrow,
1994),and the conclusion more certain. The Cochrane Collaboration logo depicts a meta-
analysis of seven trials evaluating the effectiveness of corticosteroids for reducing
complications when given to women who were expected to give birth prematurely (Antes
and Oxman, 2001).Only two of these individual trials found statistically significant results
in favour of this treatment. But when pooled, the sample size and power increased and a
statistically significant effect was discovered (Mulrow, 1994).
Meta-analysis is a valuable tool in the systematic reviewer's arsenal, but it is not always
necessary. Petticrew (2001)has noted that systematic reviews do not automatically
warrant a corresponding meta-analysis, as a narrative synthesis of studies may be more
appropriate and, perhaps all, that is possible.
A systematic review provides a basis for primary research by enabling researchers to
identify which research questions have already been answered, so as not to needlessly
replicate previous research; and to identify limits and gaps in the evidence base. The
Medical Research Council funding body requests that a systematic review precedes any
proposed new primary research (Glasziou et al., 2006).
3.2.4. The limitations of systematic reviews
Systematic reviews have limitations. There may be publication bias in the studies.
Publication bias occurs because journals may only be willing to publish results with
positive outcomes, thus holding back findings which dispute the evidence base (Wormald
and Oldfield, 1998);for example, small trials which are inconclusive or have negative
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results are less likely to be published. Poor reporting of the methods used in a trial can
mask inadequate methods, and thus cast doubts on the validity of the results (Wormald
and Oldfield, 1998).
Systematic reviews are not wholeheartedly embraced because they can produce unclear
findings. For example, Petticrew (2003) has noted that they are often unable to find specific
evidence in favour of an intervention. Furthermore, Waters and Doyle (2002) have noted
that a systematic review can only reflect the evidence from primary studies, which
immediately constrains the conclusions it derives.
3.3.Examining the views of stakeholders about WMI
The first workshop gave stakeholders an opportunity to shape the aims and objectives of
the HT A funded project, before the systematic review was conducted. Data was gathered
by recording and analysing the themes which developed during the discussions.
3.3.1. Aims and methods of the first stakeholder workshop
The aim of the first workshop was to gather stakeholders' opinions about the importance
and purpose of WMI, through group work. The workshop ran for four hours with a
structured format of presentations, group work and feedback. The participants were nine
medicine users, four representatives of NHS National Patient Organisation groups, four
project collaborators, and 12 project members; (see Table 2 for further details). A broad
range of stakeholders was recruited to ensure that the opinions of different stakeholders
were all represented (Rowe and Frewer, 2000). The sample of medicine users were
identified through the local Expert Patient Programme. The sample of National Patient
Organisation groups and project collaborators were picked because of their close working
relations with the team that developed the report.
The workshop followed a structured format of group work and feedback, with
presentations by project staff. (See Appendix three for the programme of this and the
feedback workshop). The numbers of consumers, collaborators, and project staff were
balanced between five groups for the table discussions. The objectives of each activity
were explained to the groups at the beginning of the tasks. At each group, one project
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member per group facilitated the activity, supporting the flow of discussion and reflecting
on pertinent points made by the participants. A second project member recorded on paper
the key comments made. Audio recording of the group discussions were not possible
because of the close proximity of each group, which may have lead to individual group
conversations being less audible. Because no audio record was kept, it was not possible to
determine which comments related to which of the stakeholders recorded on paper.
We asked the participants to consider five points for discussion, framed as questions.
These were:
(i) To provide examples of good and bad medicine information leaflets.
(ii) To describe what they feel are the most important things about medicine
information leaflets.
(iii) To state what they feel the role (purpose) of medicine information leaflets is.
(iv) To state what they think makes medicine information leaflets effective.
(v) To state what they think makes medicine information leaflets valuable to them.
At the end of the activity, there was a discussion of this task between all the groups. A
project member recorded the main points arising from each group on a flip-chart.
The author categorised the records for each group's discussions into overarching themes.
For example, comments about 'type size of patient information leaflets' and 'the flimsy
paper they are printed on' were considered to be categorically similar and condensed as
'visual presentation'. A PhD supervisor (who also worked on the project) checked the
derived themes against the workshop records, and differences were reconciled by
discussion.
The groups were given 25minutes to discuss the first point, and 55minutes to discuss the
remaining four points in one exercise.
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Table 2: Characteristics of participants in the first workshop
• The medicine users were from a city in the north of England.
• Their mean. age was 63 years (range 50-77), five were male and all
participants were retired.
• They had personal experience of a range of medical conditions, and were
currently prescribed a mean of 6 medicines (range 2-11).
• Diabetes UK.
• Multiple Sclerosis Trust.
• AsthmaUK.
• Arthritis UK.
• www.patient.co.uk.
• NHS Direct Online.
• Association of the British Pharmaceutical Industry (ABP!).
• Medicines and Healthcare products Regulatory Agency (MHRA).
3.3.2. Themes discussed in the workshop
What aregood and bad medicine examples of information leaflets?
The participants mainly focused on negative examples of leaflets; speaking about
difficulties of readability (for example, tiny print and flimsy paper making the leaflet
difficult to read), complicated content and the use of over-technical language. Itwas noted
that delivery of the information comes too late, i.e. after the medicine has been prescribed
and dispensed: Stakeholders spoke of how too much information can be overwhelming
and, if it was not understandable, they said it can be frightening.
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What is most important about medicine information leaflets?
Participants highlighted the importance of readability: for example, the size of the text,
and the provision of meaningful information for them. They identified information about
dosage and ingredients; when/how long to take it; the likelihood of it being successful;
side effects (for example, how likely they are); and factors relevant to their personal
medical condition (as opposed to any other condition for which the medicine is taken), as
being important.
What is the purpose (role) of medicines information?
Itwas felt that a role of WMI was to provide practical information on how to take the
medicine effectively, and its potential side effects and interactions. They felt information
should complement but not replace a consultation with a doctor or other healthcare
specialist. They also indicated the information should inform them of the purpose of the
treatment in relation to their specific diagnosis, as well as what condition the medicine is
treating.
What makes medicines information effective?
Stakeholders considered information would be more effective if it was available during
the consultation with a health professional. They felt that non-technical information
Written in plain language was most effective. They also indicated that the content of the
information was important, such as whether it provides basic information about what the
medicine contains.
What makes medicines information valuable?
Participants indicated they valued information when it enabled them to make an informed
choice; was reassuring and reduced concern, conflict and anxiety about whether the
medicine was the right one for them; and when it gave them confidence in taking
medicines.
3.3.3. Discussion:
The themes generated by the workshop underlined the aims of the systematic review. As a
primary research exercise, the workshop provided an invaluable insight into consumers of
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medicines' (and the other stakeholders') feelings about WMI. For example, workshop
participants spoke of wanting information about medicines that is understandable.
The participants wanted information to be available during the consultation, rather than
only after they receive the medicine and read the insert. It remains to be seen if mM! could
meet this need. The participants also reported they would like to receive information
providing personalised and treatment specific information, which may again be possible
withmMI.
Stakeholders' comments about what makes the information valuable appear to suggest
that they value the information for providing a purpose rather than what it is: a legally
sanctioned piece of information accompanying a medicine.
3.4.A comparison of workshop and review themes
As a secondary exercise, we compared themes covered in previous reviews of medicines
information leaflets with the themes that emerged from the workshop. The aim was to
compare how far the themes emerging from previous reviews of medicines information
leaflets reflected the current priorities and concerns of those who use medicines
information (and attended the initial workshop). These findings would be used to feed
back into the aims of the systematic review.
3.4.1. Methods
Previous reviews were identified from searching Medline and Embase from 1970to
October 2004 for:
(i) Systematic reviews, meta-analyses, or narrative reviews of studies of the
effectiveness of patient information leaflets about medicines; and
(ii) Reviews of research on patient information leaflets for medicines information
in a 'wider context'.
Non-systematic reviews were included in the search because there were no known
previous systematic reviews which specifically focused on the effectiveness of patient
information leaflets. The following sources were excluded:
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(i) Book chapters or university degree theses;
(ii) Reviews of the actual patient information leaflets (rather than reviews of
primary research);
(iii) Reviews (of any design) evaluating patient information leaflets as one of a
range of interventions to improve patient compliance that could not be
separated from the overall synthesis.
The themes which emerged from the comparison of the previous reviews and the
workshop were related to categories of 'patient education discourse' (Dixon-Woods, 2001)
(see 1.5).
3.4.2. Themes discussed in the previous reviews
Five reviews of research of WMI meeting the inclusion criteria were found: (Morris and
Halperin (1979), Arthur (1995), Buck (1998), Kenny et al. (1998), and Koo et al. (2003).
A brief overview of how the five reviews were conducted and what they found is
presented in Table 3.
There was variation in how the reviews were conducted. Two did not report methods
(Arthur, 1995, Morris and Halperin, 1979) while one mentioned only the search strategy
(Kenny et al., 1998). One review reported its objectives, search strategy, data extracted and
data synthesis (Buck, 1998); and one stated its search strategy, inclusion and exclusion
criteria and data synthesis (Koo et al., 2003). No reviews were considered to have been
conducted in a systematic way; (see 3.2.3 for the criteria of a systematic review). Two
meta-analyses (Haynes et al., 2002, Roter et al., 1998) evaluated a range of interventions to
improve patient compliance (including 'written materials'). Because patient information
leaflets for medicines was a minor aspect of these papers, and could not be separated from
the overall synthesis, these were not included.
In summary, the reviews reported some imp<?rt;ant points, but because they were not
systematically derived, their usefulness as reports of robust evidence is limited. Points
from the review to note were: WMI has the potential to impact positively or negatively on
users (Koo et al., 2003), but patients want and use WMI (Kenny et al., 1998). Morris and
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Halperin (1979) and Arthur (1995) both reported studies that found that providing WMI
did not increase adherence. Buck (1998) noted limitations in the information that the
leaflets provide.
Table 3: Summary of previous reviews of patient information leaflets
Morris and Halperin (1979)
'Effects of written drug
information on patient
knowledge and compliance: a
literature review.'
Arthur (1995)
'Written patient information: a
review of the literature.'
Buck (1998)
'Providing patients with
written medication
information.'
Kenny et al. (1998)
'A PIt for every ill? Patient
information leaflets (PIts): a
review of past, present and
future use.'
Koo et al. (2003)
'Factors influencing consumer
use of written drug
information.'
None
None
Objectives; search
strategy; data
extracted; data
synthesis.
Search strategy.
Objectives; search
strategy;
inclusion and
exclusion criteria;
data synthesis.
• Adequate patient
information leaflets alone
will not aid compliance.
• Few studies have evaluated
patient information leaflets.
• There is little research on
the impact of patient
information leaflets on
consumers.
• Patient information leaflets
can serve as a useful
addition to verbal
counselling.
• Some patient information
leaflets are limited in the
information they provide.
• Patient information leaflets
have been poorly written.
• Patients want medicines
information leaflets and use
them.
• Patient information leaflets
have positive and negative
impacts on consumers.
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Table 4: Comparison of themes emerging from the MILK workshop, with themes in the
literature
ti nt inf rm ti n
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3.4.3. Comparison of themes from the workshop and previous reviews
No review addressed all the themes arising from the workshop. The more recent reviews
reflected a greater number of workshop themes than the older reviews, suggesting a
probable temporal trend of increased professional sensitivity to consumer issues, by both
primary research and the review authors.
Workshop themes most often reported in the reviews were 'language' and 'visual
presentation' (which are cognate themes) and appear to reflect the patient education
discourse model, because the latter has a focus on design features (see Table 4). The
workshop themes less often reflected in reviews, ('patient-relevant information', and
'timing'; or not reflected at all, 'informed choice and autonomy'), and can be mapped on to
the 'patient empowerment model', because the information allows patients to playa more
active role in making dedsions about treatment and managing their health (Dixon-Woods,
2(01).
3.4.4. Discussion
Comparing the themes arising from workshops and previous reviews identified evidence
of an apparent mismatch between what current medidne users consider important
regarding WMI and what past research focused on. Considered in relation to Dixon-
Woods' (2001)patient information discourse model, it suggests that there has been a
change in the direction of WMI research from being based on 'patient education' to
fOCUSingon 'patient empowerment'. This exerdse crystallised the need for research of
WMI (PIt or mMI), including that in this thesis, to be patient-centred.
3.S.Systematic review of trials evaluating the effectiveness of
WMI
3.5.1. The aim of the effectiveness review
The aim was to systematically review Refs evaluating the effectiveness of paper-based or
Internet-based WMI for changing knowledge, attitudes and behaviour related to taking
medidnes.
82
3.5.2. Search methods
Twelve electronic databases were searched: Medline, Embase, Cochrane Library, ClNARL,
Digital Dissertations, HMIC, Index to Theses, lSI Proceedings, Pharmline, PsychINFO,
Sociological Abstracts, and Web of Science, for published and grey literature from 1970to
October 2004 on the effectiveness of WMI. This was augmented by searching the table of
contents of six electronic journals, and checking the reference lists of published reviews.
3.5.3. Inclusion criteria for study inclusion in the review
Inclusion criteria were based on study design, participants, interventions, and outcome
measured.
Types of studies
• RCTs published in English language from 1970onwards;
• RCTs that provided the intervention group with written information and
compared this to a control group receiving no intervention or a second intervention
group receiving a different version of written information.
In the protocol it was anticipated that there would be an absence of RCTs, and so
including non-randomised controlled trials, and controlled before and after studies was
considered. However, as the RCT represents the most robust form of evidence of
effectiveness (see 3.2.3), and a sufficient number of RCTs for the review were found, no
other type of study design was included.
Usability testing studies and studies of the readability of WMI were excluded.
Types of participant
• Studies of medicine takers, or informal carers of any age were included;
• Trials examining the presentation of the risk of a side effect on the general public
were included (see also 3.1).
Types of intmlmtion
• Written medicines information was defined in terms of the EU categories of
information, (see 1.2.2);
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• Studies providing WMI for POM or aTC medicines were included;
• Studies providing WMI that was leaflet or Internet-based were included.
Studies examining the following types of information were excluded:
• Information designed to inform decisions about taking a drug;
• Condition-based leaflets containing brief information about medicine;
• General information about treatments for the public;
• Information solely using icons;
• Information about non-drug forms of contraception or alternative medicines.
Types of outcome
Four types of outcome data were extracted:
• Treatment-related knowledge;
• Treatment-related attitudes;
• Treatment-related behaviours;
• Treatment-related health outcomes.
Two reviewers independently extracted descriptive information and outcome data.
Differences were reconciled by discussion and authors were contacted for missing data.
3.5.4. Collection and analysis of the data
The thesis author sifted the title and abstracts of the references on Endnote. One PhD
SUpervisor checked a random sample of 10%of the references. The author and two PhD
SUpervisors independently assessed each paper that was retrieved for consideration for
inclUsion, and agreement was reached by discussion.
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Trials were categorised according to the comparison between the intervention and the
control:
• Trials examining the absolute effectiveness of WMI for changing knowledge,
attitudes, and behaviour: these trials isolated the effectiveness of written
information by comparing WMI versus nothing; or WMI and spoken information
versus spoken information alone. Trials that compared WMI versus WMI and
spoken information were not included, because they isolate the effect of additional
spoken information, and not written information.
• Trials examining the relative effectiveness of different ways of presenting WMI for
changing knowledge, attitudes, and behaviour: these trials compared WMI versus
WMI.
• Trials examining the relative effectiveness of different ways of presenting
information about the risk of a side effect for changing knowledge and attitudes.
(These trials did not measure behaviour as an outcome, and most enrolled non-
medicine takers).
The data from each of these categories were grouped together for knowledge, attitudinal
and behavioural outcomes, and presented in a descriptive way to highlight the effect of
WMI on each of these outcomes. This method was undertaken because it was anticipated
(at the outset of the project) that a statistical synthesis would not be possible.
When inferential statistics, and/or probability values (p-values) were not reported in
papers, but sufficient raw data was available (such as group data, means or standard
deviations), statistics were calculated. For categorical data a chi-square test of association
was conducted. Similarly, when data was aggregated across groups to fit the purpose of
the systematic review, their statistics and p-values were recalculated by using a chi-square
test. For example, in trials where participants received both written information or not,
and spoken counselling or not; the data was aggregated over those receiving spoken
counselling or not to isolate the effect of receiving WMI or not.
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The author and one supervisor independently assessed the quality of trials, following
guidelines written by the University of York NHS Centre for Review and Dissemination
(2001)and Verhagen et al. (1998).Trial quality (see 3.2.2) was considered for:
• Adequacy of randomisation, which seeks to control for selection bias;
• Concealment of allocation, which seeks to control for selection bias;
• Blinding, which seeks to control for detection bias; and
• Reported loss to follow up, which seeks to control for attrition bias.
The quality of the information in the leaflet was examined in two ways:
• The EU categories of information to be contained in a leaflet (see also 1.2.2).
• Two categories were devised for evaluating presentational aspects of the leaflet: (i)
'easy to read', indicated by the absence of complex words or unexplained jargon;
and (ii) 'good layout', indicated by headings being separate from the main text.
It Was also noted if the intervention was developed from an explicit theory or evidence-
base and if the leaflet was available in the report (or subsequently obtained from the
authors).
The author and one a supervisor independently extracted data from all included studies,
using a standardised form. Differences were reconciled by discussion, or in conjunction
with a second supervisor. When papers had missing data or incomplete information about
the conduct of the trial, we contacted the authors.
3.5.5. Results
Description of the mlds
Thirty six trials enrolling 8,270 participants met the inclusion aiteria. The trials were
reported in 31 papers. (See Appendix four for the full references of these papers). Four
papers (Berry et al., 20018,Berry et al., 2002b, Berry et al., 2003a,Berry et al., 2003b) reported
nine trials in total. Twelve papers reported the source of funding of the trial.
Pharmaceutical companies sponsored three trials (Desponds et al., 1982,Labor et al., 1995,
Vesco et al., 1990).The trial by Peveler et al. (1999)received funding from both a UK
Government research council and pharmaceutical company. The other papers that
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reported funding received it from a national funding body. The remaining papers did not
declare the funding source.
The trials were conducted in nine countries: nineteen in the UK; eight in the USA; two in
Belgium; two in Canada; and one each inFinland, France, Hong Kong, Switzerland and
Turkey. The earliest trial was published by Clark in 1972,and the most recent in 2004 by
Knapp. The mean length of follow-up in the 32 trials that clearly reported it was 25 days.
This ranged from same day follow up in 13 trials to 111 days (Pope et al., 1998).
Description of participant demographics
Seventeen trials reported participants' age, which was on average 43 years: this ranged
from 16 to 88 years. Twenty-nine trials reported how many participants were male, on
average 40%. One trial (Little et al., 1998),examined WMI for the contraceptive pill (and
therefore enrolled only women). Excluding these 636women, the average number of male
participants was 44%. Two trials reported the ethnic background of participants (Morris
and Kanouse, 1982,Vander Stichele et al., 1992).Overall, 69% of the 333 participants in
these trials were from a non-white background; although none of the 74 participants in the
trial by Vander Stichele et al. (1992)were from a non-white background.
Ten trials enrolling 911 participants in total reported withdrawal: 131people in total
withdrew. This ranged from none (Clark and Bayley, 1972,Knapp et al., 20(4) to 56 (37%)
(Labor et al., 1995).The average rate of withdrawal was 14%.
Description of the intervention (WMI content)
Nineteen trials provided information for medicines for long-term conditions: five for non-
steroidal anti-inflammatory drugs (NSAIDs); and nine for cardiovascular medicines. Five
trials provided information about a medicine to treat an acute condition. One trial
provided information about medicines used to treat a chronic condition (methyldopa for
high blood pressure), and an acute condition (ampicillinfor bacterial infection). (For the list
of these trials, see Appendix five).
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Ten of the 13 trials that examined perception of the risk of a side effect used information
about a hypothetical antibiotic. The other three trials provided information about a real
medicine.
The information provided ranged from minimal information to a well detailed document.
Twenty-nine trials either published a full or partial copy of the WMI intervention, or the
authors later provided a copy on request. The information in the interventions was
matched to the five content categories recommended by the 1998ED Directive. A
considerable amount of heterogeneity in the content of the WMI between trials was noted.
The information in the leaflets was compared with the five ED recommended content
categories. Most trials provided WMI about 'possible side effects' (see Table 5). Over half
(19) the trials WMI mentioned 'what this medidne is and what it is used for', and 'how to
take the medicine' (18).Less than half the leaflets in the trials (12) gave information
relevant to 'before taking the medicine', while less than one quarter (6) provided storage
information. Six trials provided information pertaining to all five categories: (Gibbs et al.,
1989,Peveler et al., 1999,Regner et al., 1987,van Haecht et al., 1991,Vander Stiche1eet al.,
1992,Vesco et al., 1990).e1veof the 13 trials examining perception of risk (Berry et al.,
2002a, Berry et al., 2002b,Berry et al., 2003a, Berry et al., 2003b, Berry, 2004,Berry et al.,
2004, Knapp et al., 2004)only provided information about 'possible side effects'.
No trials were found that had examined the effectiveness of IBMIwhen this review was
conducted in 2005, or when it was updated in 2007.Ten trials reported that the design of
the WMI was theory driven or evidence-based: see below. The remaining trials did not
explain why the WMI intervention was designed as it was. It is unclear if the design of
these trials interventions was based on theory or evidence.
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Table 5: Specific content of the trials interventions
used for
Before taking th 2 0 12
medicin
How to take the 12 6 0 18
13 4 13 30
5 1
th or ti 1basi for th interv ntion:
• B k r et al. (19 1): Plain nglish Campaign involv din WMI de ign.
• B rgus et al. (2002): inform ti n- rd rift.
• dd (19 6): r omm nd tion of Drugs and Therapeutic Bulletin, 1981.
linky tal. (1 3):th ory of r ad- rgani -attend.•
Th foll wing tri 1 for th int TV ntion:
iff rd (19 8): b d n th Flesch reading levels test (FIe , 1948).
I rk nd Bayl y (1 72): inl TV nti n ba don T ults Er m qu tionnaire.
nth finding ofB II ntuono tal. (1980) and
•
•
r(197 ).
): int rv nti n h db en pr vi u ly pi! t d by rg tal. (1983)•
• L bor tal. (1 95): T vi in pilot tudy, nd using Fl ch r ading 1 vels t t
,1 48).
• 11(2001 ): int TV nti n h db pr viou Jy pil ted, by Strydom et
al. (20 Ib).
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Description of the outcome measures
Trial measures were categorised into one of three generic outcomes: knowledge, attitudes,
or behaviour. No trials were found that measured the effect of WMI provision on a health
outcome, and no trials that reported an adverse effect from giving WMI to the
participants.
Twenty-nine trials, reported in 24 papers, measured knowledge (see Appendix five). The
measure varied between trials, and included knowledge about the medicine, recall of
medicines information, or estimation of the probability of a side effect.
Seventeen trials, reported in 13 papers, measured an attitude (see Appendix five). Again
the method differed between trials, and included satisfaction with information, or
intention to comply with or favour the treatment.
Nine trials measured behaviour as an outcome (see Appendix five): for example,
adherence to treatment recommendations. Nineteen trials examined two or more of the
categories of outcome measures. No trials measured a health outcome. The results for each
of the three outcomes across the different intervention categories were pooled.
Description of the categorisation of included trials
Trials were categorised in terms of what they compared the intervention to:
• 20 trials examined the absolute effectiveness of WMI i.e. comparing the effectiveness of
WMI against nothing: (Arthur and Gifford, 1998,Baker et al., 1991,Clark and Bayley,
1972,Dodds, 1986,Dolinsky et al., 1983,Gibbs et al., 1989,Johnson et al., 1986,Kumana
et al., 1988,Little et al., 1998,McBean and Blackburn, 1982,Morris and Kanouse, 1982,
Peura et al., 1993,Peveler et al., 1999,Pope et al., 1998,Regner et al., 1987,Robinson et
al., 1986,Savas and Evcik, 2001, Strydom and HaIl, 2001a, Vander Stichele et al., 1992,
Vesco et al., 1990).
• 6 trials examined the relative effectiveness of WMI presentation: i.e. comparing the
effectiveness of different ways of presenting WMI: (Clark and Bayley, 1m, Desponds
et al., 1982,Dolinsky et al., 1983,Labor et al., 1995,Little et al., 1998,van Haecht et al.,
1991).
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• 13 trials, reported in eight papers examined the relative effectiveness of the
presentation of information about the risk of a side effect: i.e. comparing the
effectiveness of different ways of presenting information about a side effect:
(Bergus et al., 2002, Berry et al., 2002a, Berry et al., 2002b, Berry et al., 2003a, Berry
et al., 2003b, Berry et al., 2004, Berry, 2004, Knapp et al., 2004)
3 of the above trials compared the effect of more than one way of presenting
WMI, and no information, and so are included in both the absolute and relative
effectiveness categories: (Clark and Bayley, 1972, Dolinsky et al., 1983, Little et al.,
1998).
Trial quality
Reporting of the methods was frequently incomplete; and when trials reported the
methods clearly, they often highlighted inadequate methods. Eleven of the 36 trials (31%)
reported a process of randomisation that was considered adequate. A further 11 trials
randomisation process was confirmed to be adequate after contacting the authors. The
remaining 14 trials either failed to report their randomisation method, or reported it in an
unclear manner (that could not be discounted as inadequate). Seven trials reported a
method of concealing allocation. This was judged adequate in five of the trials (14%). The
trial by Pope et al. (1998) randomised by coin tossing, thus concealment was not possible.
In the trial by Knapp et al. (2004), the paper explicitly stated that concealment was not
adequate. The eleven trials by Berry and colleagues did not report how concealment of
allocation was conducted. From further information received from the authors, we judged
their method as inadequate. The remaining 18 trials either did not report concealment of
allocation, or reported it in an unclear way.
Eight trials (22%) adequately masked the outcome assessor to the intervention, while 15
did not. It was not possible to judge whether or not this was adequate in the remaining 13
trials, as it was not clearly reported. Twenty trials enrolling 3,472 participants in total
reported loss to follow-up. This ranged from no loss to follow-up in 12 trials that were
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followed up on the same day, to 67 (67%) (Robinson et al., 1986). The average rate of loss to
follow-up was 19%.
Results from trials examining the effect of WMI provision on knowledge
Thirty-five trials measured a knowledge based outcome. As predicted in 3.5.4, a meta-
analysis could not be conducted, due to the heterogeneity of outcome measures for
knowledge. There were four main categories of knowledge outcome:
(i) Knowledge about the medicine or recall of medicines information;
(ii) Recognition or recall of side effects;
(iii) Estimation of probability or likelihood of a side effect; and
(iv) Judgement of the risk of a side effect or health risks.
• The absolute effectiveness of WMI
Twelve trials evaluated the absolute effect of WMI on knowledge; i.e. the effectiveness of
WMI to improve knowledge compared to no information, (see Table 6 for an overview of
trials examining the absolute effectiveness of WMI provision). Six trials found a
statistically significant effect favouring WMI for improving knowledge (Arthur and
Gifford, 1998, Clark and Bayley, 1972, Johnson et al., 1986, Little et el., 1998, Robinson et al.,
1986, Savas and Evcik, 2001).
Four trials (Dolinsky et al., 1983, Kumana et al., 1988, McBean and Blackburn, 1982,
Strydom and Hall, 2001a) found no difference in improvement in knowledge for those
given WMI or not. Of these four trials, McBean and Blackburn (1982) did not report
statistical significance, and this could not be calculated from the available data. Dolinsky et
al. (1983) compared two different WMI leaflets against no leaflet. They did not find any
significant differences in knowledge outcome between the three groups.'
IThey however did not report iKflviduai statIstIcaJ comparisons between the three interventions II1d • was not
possible to calculate.
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The remaining two trials (Gibbs et al., 1989,Pope et al., 1998)found a statistically
significant effect favouring both WMI and no information, depending upon the outcome
measured. Gibbs et al. (1989)found that significantly more participants receiving written
information gave the correct answer to questions about the medicine, for four of nine
questions (p<O.05).However, more people who received no WMI (73%)knew the name of
the medicine compared to those who received WMI (66%), (p<O.05).Pope et al. (1998)
found a statistically significant effect for two of the eleven knowledge outcomes: one
favouring WMI, and one favouring no information; (both p<O.05).Morris and Kanouse
(1982)did not test for statistical significance.
Four trials (Baker et al., 1991,Dodds, 1986,Little et al., 1998,Peura et al., 1993)examined
participants' recall of information about the medicine that they received. Dodds (1986)
found that participants given WMI had significantly higher endpoint recall of the
infonnation than those receiving no intervention.
Little et al. (1998)used a factorial RCI' design to compare the effectiveness of an
experimental evidence-based summary leaflet, a standard leaflet and no leaflet, on
women's knowledge of an oral contraceptive. In addition to receiving one of the three
interventions above, participants were also randomised to be asked questions or not by a
healthcare professional. A questionnaire designed specifically for the study was validated
for face-, content- and construct-validity. For the purposes of the systematic review, the
results were aggregated over those asked the questions or not, and it was found that those
receiving the experimental leaflet correctly answered more questions about oral
contraceptives (33%)compared to those receiving no leaflet (17%), (p<O.05).However,
there was no significant difference in the number of questions correctly answered by those
receiving the standard Family Planning Association leaflet (24%)or no infonnation (19%).
Baker et al. (1991)and Peura et Ill. (1993)only found significant differences (p<O.05)in
recall for half of the questions they asked participants.
Six trials (Baker et Ill., 1991,Gibbs et Ill., 1989,Morris and Kanouse, 1982,Peura et al., 1993,
Pope et Ill., 1998,Regner et Ill., 1987)examined participants' recall of the information about
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a side effect. The trials by Baker et al. (1991),Gibbs et al. (1989),Peura et al. (1993),and
Regner et al. (1987)found that participants had significantly greater recall of the
information when they received WMI, than when they received none. Gibbs et al. (1989)
found 38% of participants receiving WMI had an awareness of side effects (aggregated
over all study drugs), compared to those receiving nothing, 15% (difference p<O.OO1).
MOrris and Kanouse (1982)found participants given WMI named more side effects at
follow-up compared to the control group, but also more incorrect side effects. However
they did not report statistical significance and this could not be calculated from the
available data. The trial by Pope et al. (1998)found a statistically significant effect for two
of the eleven knowledge outcomes: one favouring WMI, and one favouring no
information. They found that participants who received spoken information alone, listed
more side effects than those who had received additional WMI, (p<O.05);but there was no
Significant difference between the groups for the number of correct side effects named.
• The relative effectiveness of different WMI
Four trials measured the relative effectiveness of presenting WMI in different ways for a
knowledge outcome (see Table 7 for an overview of all trials examining the relative
effectiveness of WMI provision).
Clark and Bailey (1972)found that participants receiving a programmed WMI instruction
booklet had a significantly greater understanding of the drug than those receiving the
standard information (P-()'OO8).Aggregating the results of the trial by Little et al. (1998),no
significant difference was found between those receiving the evidence-based summary
leaflet (33%)and those receiving the standard leaflet (24%)for answering questions
correctly about oral contraceptives. Dolinsky et al. (1983)did not find any significant
differences between the WMI in their trials. Desponds et al. (1982)did not report statistical
significance, and the raw data was not available to calculate the p-value.
• •
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• The effect of the presentation of side effect risk information on knowledge
Thirteen trials (reported in eight papers) compared the effect of different ways of
presenting infonnation about a side effect on a knowledge outcome, (see Table 8 for an
overview of trials examining the presentation of side effect risk information). Twelve of
these studies were conducted as part of a series of trials by Berry and colleagues which
presented participants with a hypothetical, but realistic situation relating to taking a
medicine. Berry et al. examined the effects of giving information about a side effect as a
written verbal descriptor, recommended by EUGuidance (see 1.2.5):for example,
'common' or 'rare', or as a percentage, on a set of outcomes that were COnsistently
measured and statistically examined:
(i) Estimate of probability of a side effect occurring (Berry et al., 2002a, Berry et al.,
2003b).
(ii) Estimated likelihood of a side effect occurring (Berry et al., 2002a, Berry et al.,
2002b, Berry et al., 2004,Berry, 2004,Knapp et al., 20(4).
(iii) Judgement of side effect/health risk from a side effect occurring (Berry et al.,
2003a, Berry et al., 2003b,Berry et al., 2004,Berry, 2004,Knapp et al., 20(4).
Two trials found that participants who were given descriptive infonnation significantly
over-estimated the probability of a side effect occurring, compared to those given numeric
infonnation Berry et al., 2002a, Berry et al., 2003b). Probability was measured by asking the
participants to estimate it as a percentage. Participants significantly over-estimated the
likelihood of a side effect occurring when given descriptive infonnation compared to
numeric infonnation (Berry et al., 2003b). Likelihood was measured by asking the
Participants to estimate it on a Likert scale (from 1-6). Participants presented with
infonnation about a side effect as a percentage estimated the risk of a side effect to be
higher than those receiving the side effect as a frequency (Berry et al., 2002a).
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Participants more often over-estimated the probability of a side effect occurring when it
was designed for a parent of a child, rather than for an adult (Berry et al., 2004);and when
there was no information about control of side effects (Berry et al., 2002a).
Individuals were found to judge the likelihood of a side effect to be significantly higher
when presented with the risk verbally rather than numerically (Berry et al., 2oo2a, Berry,
2004, Knapp et al., 2004).
In a trial measuring participants' judgement of side effect risk, participants given
impersonal information made a significantly greater judgement of side effect risk,
compared to those given personal information (Berry et al., 2oo3a).
Participants given WMI that described the risk of a side effect to be as 'common' judged
the risk to be significant higher than those told it was 'rare' (Berry et al., 2003b).
Participants told that the risk was rare judged the risk to be significant higher than
participants receiving one of two numerical values (Berry et al., 2003b).
• Summary of the effect of WMI on knowledge
The large heterogeneity of the outcome measures precluded a statistical synthesis of the
results being conducted, and so it was difficult to make firm conclusions regarding the
effectiveness (or not) of WMI to change knowledge. The following points can be made:
(i) Six of 12 trials found that people receiving WMI had significantly greater
knowledge about the medicine than people receiving no WMI. Two of the
twelve trials also found this effect for some outcomes, but also found a
significant effect favouring no leaflet provision.
(H) Two of four trials found that people receiving WMI had significantly greater
recall of information about a medicine compared to people receiving no WMI.
The two other trials found a significant effect favouring WMI, but not for all
outcomes measured.
(iii) Three of four trials found that participants had significantly better recall of
information about side effects when they received WMI than when they did
not.
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(iv) The results varied between trials examining the effectiveness of presenting
WMI in different ways; but tended to show that the experimental intervention
either improved knowledge or made no significant difference.
(v) Two trials found that participants significantly overestimated the probability of
a side effect from taking a medicine when presented with verbal information
compared to numerical data about the risk of the adverse event.
(vi) Three trials found that participants significantly overestimated the likelihood of
a side effect from taking a medicine when presented with verbal information
compared to numerical data about the risk of the adverse event.
Results from trials examining the effect of WMI provision on attitudes
Seventeen trials (reported in 13papers) measured an attitude outcome. Unique outcomes
were measured and so again the results could not be statistically pooled. There were four
main categories of attitude outcome:
(i) Satisfaction with the information given;
(ii) Perceived health or side effect risk;
(iii) Intention to comply with or favour treatment;
(iv) Rating of side effect severity.
• The absolute effectiveness of WMI
Three trials (Baker et al., 1991,Gibbs et al., 1989,McBean and Blackburn, 1982)examined
the attitudes of those given written information or not, specifically for their levels of
satisfaction with the information provided. Baker et al. (1991)gave all participants spoken
information, and the intervention group received additional WMI. They found that
significantly more participants receiving WMI thought that the information received was
easy to understand (90%)compared to those receiving spoken information alone (33%).
Likewise, significantly more participants (84%)receiving additional WMI felt the
information received was useful (or extremely useful), compared to 33% of participants
Who received spoken information alone.
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Baker et al. (1991)also found participants given the additional WMI reported significantly
less worry about the medicine than those not given the WMI: 53% compared to 25%
(p<O.05). Participants, who did not receive the WMI, were more likely to feel that
information could be improved (64%) than those who received it (27%),which was again
statistically significant.
Gibbs et al. (1989)found a statistically significant association between participants' levels
of reported satisfaction and whether or not they received WMI. 401 of 419 people receiving
WMI said that they were satisfied or completely satisfied, a greater proportion than those
giving the same reply that did not receive WMI, 235 of 300 (p<O.OOl). McBean and
Blackburn (1982) similarly reported that participants who received WMI in their trials
expressed greater satisfaction with the information provided. This trial did not test for
statistical significance, and did not report sufficient data to be able to calculate a p-value.
• The relative effectiveness of different WMI
Two trials (Desponds et al., 1982,Labor et al., 1995)compared the effect of presenting WMI
in different ways on attitudes. Desponds et al. (1982)evaluated experimental PIL that had
more text than manufacturer PIL, less medical terminology, and included precautions
about side effects, including addiction. They compared this to a manufacturer's PIL that
contained more information on the therapeutic effect, no mention of action to take in the
event of accidental overdose or that the medicine required a prescription. They found that
participants given the experimental WMI said that they felt the text to be easy to
understand (P<0.01),complete (P<O.05),and had a lot of new information (p<O.05).They
found no difference in participants' views about the information being considered 'easy to
read' or 'interesting'.
Labor et al. (1995)examined the effect of five different leaflets, which varied according to
the wording ('professionally worded', 'simply worded', or 'normally worded'); and
number of information topics provided (two, seven or twelve). They found that
Significantly more partidpants who received written 'normal' worded information of
seven topics felt the number of topics, and the complexity of the information in the leaflet,
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was 'about right'. Participants who received information that was professionally worded
and had two items, most often felt that the information left them feeling 'confused',
'unsure', 'doubtful', 'overwhelmed', or 'foolish', which was a significant result.
• The effect of the presentation of side effect risk information on attitudes
Twelve trials (reported in eight papers) examined participants' attitudes about the way a
side effect risk was presented. Eleven trials were conducted by Berry and colleagues.
These trials measured one of four outcomes:
(i) Satisfaction with information (Berry et al., 2002a, Berry et al., 2002b, Berry et al.,
2oo3a, Berry et al., 2oo3b,Berry et al., 2004,Berry, 2004,Knapp et al., 2004);
(ii) Perceived health or side effect risk (Berry et al., 2oo2a,Berry et al., 2002b, Berry
et al., 2004,Berry, 2004,Knapp et al., 2004);
(iii) Intention to comply with or favour treatment (Bergus et al., 2002,Berry et al.,
2oo2a, Berry et al., 2oo2b,Berry et al., 2oo3a, Berry et al., 2003b, Berry et al., 2004,
Berry, 2004,Knapp et al., 2004);and
(iv) Rating of side effect severity (Berry et al., 2002a, Berry et al., 2002b, Berry et
al.,2003b, Berry et al., 2004,Berry, 2004,Knapp et al., 2004).
Trials measuring satisfaction with information about side effects consistently found that
participants significantly favoured numerical information over verbal information (Berry
et al., 2oo2a, Berry et al., 2003b, Berry, 2004, Knapp et al., 2004).Further trials examining the
effect of: providing personal information (Berry et al., 2oo3a);mild side effect information
(Berry et al., 2002b); information about the positive benefits of side effects (Berry et al.,
2oo2b); information offering encouragement to take the correct dose (Berry et al., 2OO2b);
information presented in a specific numerical manner (0.02%) (Berry et al., 2003b); and as
information aimed at a parent (Berry et al., 2004), all found numerical information was
favoured significantly more than verbal information.
People have been shown to perceive the risk of a side effect from taking a medicine to be
significantly greater when presented with: verbal information (Berry et al., 2002a,Berry,
2004, Knapp et al., 2004); information reporting severe side effects (Berry et al., 2002b);
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information presenting unknown benefits of side effects (Berry et al., 2002b);no statement
on the control of side effects (Berry et al., 2002b); information about the side effect
presented in an impersonal manner (Berry et al., 2003a); and information for the parent of
a child (Berry et al., 2004).
Bergus et al. (2002)found that people, who received information about the likelihood of a
side effect occurring after receiving information about the benefits, favoured the treatment
less than participants who received information about the risk first. This effect was
statistically significant.
Trials consistently found that participants had a significantly greater intention to take the
medicine when risk information was presented numerically, rather than verbally (Berry et
al., 2002a, Berry et al., 2003b, Berry, 2004,Knapp et al., 2004).Furthermore, participants
were significantly more likely to report an intention to take the medicine when the
information reported mild side effects (Berry et al., 2002b) or positive benefits of side
effects (Berry et al., 2002b),or similarly when the risk of a side effect was presented as a
specific numerical figure (for example, 0.02%) (Berry et al., 2003b), or the risk of a side
effect was presented in a personalised manner (Berry et al., 2003a), and when information
was aimed at parents (Berry et al., 20(4).
Participants who received verbal descriptor information anticipated the risk of a side effect
to be significantly greater than those who received numerical information in four trials
(Berry et al., 2002a, Berry et al., 2003b,Berry, 2004,Knapp et al., 2004).Participants who
received information about severe side effects (Berry et al., 2002b); and information aimed
at parents of children (Berry et al., 20(4), anticipated the risk of a side effect to be
significantly greater than those who received numerical information.
• Summary of the effect of WMI on attitudes
Again the inability to derive a summary statistic has made it difficult to draw firm
conclusions regarding the effectiveness of WM1to change attitudes relating tomedicines
taking. Nevertheless, several trials repeatedly found similar effects from the presentation
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of the risk of a side effect either numerically or descriptively, which were statistically
significant, and from these, the following points are made:
(i) Four of four trials found that participants presented with numeric data about
the risk of a side effect were significantly more satisfied compared to
participants presented with descriptive information about the risk of a side
effect.
(ii) Three of three trials found that participants perceived the risk of a side effect to
be greater when presented with verbal (rather than numeric) side effect
information.
(iii) Four of four trials found that participants had a statistically greater intention to
comply with taking the medicine when information of the risk about a side
effect was presented numerically than descriptively.
(iv) Four of four trials found that participants estimated the risk of a side effect to
be significantly greater when receiving descriptive information compared to
those who received numeric information.
Results from trials examining the effect 0/WM1 provision on behavioll1'
Ten trials (reported in nine papers) measured behaviour as an outcome. They did so in
different ways and so the results could not be combined in a meta-analysis. The main type
of behaviour measured was compliance to treatment.
• The absolute effectiveness of WMI
Eight trials compared the effect of participants receiving WMI or not, on a measure of
behaviour. Six trials (Dodds, 1986,McBean and Blackburn, 1982,Peveler et al., 1999,
Robinson et al., 1986,Vander Stichele et al., 1992,Vesco et al., 1990)examined compliance
with instructions. Compliance was measured in four ways.
Four trials measured compliance by counting tablet count, to see if the number remaining
to be taken corresponded with the number that the medicine taker was prescribed to have
taken up to that point. Dodds (1986) found that participants given WMI complied
significantly more often with taking the medicine than those who did not receive WMI.
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Robinson et al. (1986) measured adherence by tablet count along with clinician's
judgement and patient interview, and found a small significant difference favouring
written information. Vesco et al. (1990) found no significant difference between those
receiving the written information or not. McBean and Blackburn (1982) did not report a
probability value, and for those receiving WMI or not, the differences were small.
Two trials monitored when the tablet container was opened, as a proxy measure of the
person taking the medicine. In the trial by Peveler et al. (1999), the outcome of self-
reported continuation of the medication after 12 weeks was aggregated over those groups
receiving counselling or no counselling. No statistical difference was found between
participants receiving a medicines leaflet or no intervention at six months. Similarly
Vander Stichele et al. (1992) found no difference between the group receiving WMI and the
group receiving none.
Dodds (1986) was the only trial to examine self-reporting of compliance (by questionnaire
and interview); and found that participants receiving the WMI scored significantly higher
than those receiving no WMI. Vesco et al. (1990) was the only trial to measure adherence as
a physiological measure; by measuring blood levels of theophylline (the active ingredient
in the study drug). They found a very small difference between the intervention and
control group on a whole, but this was not statistically significant. In contrast they found
that significantly more people receiving WMI reported a side effect (p<O.05).
In the two trials that did not measure compliance, Morris and Kanouse (1982) examined
participants' reporting of a health problem, while Dolinsky et Ill. (1983) measured the
participants' application of the information. Morris and Kanouse (1982) found that those
receiving WMI reported slightly more problems. (This study did not test for statistical
significance). Dolinsky et Ill. (1983) reported no significant difference between those given
one of two WMI interventions and those receiving no intervention in correctly applying
the information about the two study drugs. However, they did not report individual
statistical comparisons between groups.
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• The relative effectiveness of different WMI
Van Haecht et al. (1991)found no significant difference in the number of participants who
reported reading the leaflet thoroughly when they received the experimental WMI (with
improved readability and layout), or the standard leaflet (without improved readability
and layout). Dolinsky et al. (1983)reported no significant difference between those
receiving either of the two WMI interventions for correctly applying the information.
• Summary of the effect of WMI on behaviour
The inability to statistically synthesise the results has compromised the ability to make
firm conclusions regarding the effective of WMI on behaviour. It therefore cannot be said
if WMI is effectiveness for encouraging the medicine user to comply with instructions
about taking a medicine, or if the provision of WMI affects side effect reporting.
• Two of six trials found compliance was significantly greater for those who received
the WMI than those who had not.
3.5.6. Discussion
The review highlighted that the trials as a whole poorly reported how they were
conducted; e.g. the randomisation process was unclearly reported (or not reported at all)
in around 40% of the trials. The poor conduct of previous research had provided a firm
basis for recommending improved standards of research examining WMI. The poor
conduct of the trials is further examined in 3.7.2.
As anticipated, there was great heterogeneity amongst the outcome measures of the trials,
and so a meta-analysis could not be conducted. Because no overall summary statistic of
the effectiveness of written medicines information could be derived, this made it difficult
to provide clear evidence to indicate if WMI is effective for changing knowledge, attitudes
and behaviours relating to medicine taking. No trials reported adverse effects from the
provision of WMI.
Because attitudes are difficult to quantify, and difficult to compare when they are not
quantified (Littlewood et Ill., 2005), and because there was considerable heterogeneity in
the way that attitudes were measured as an outcome by the trials; it is concluded that the
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review found no convincing evidence of the effectiveness of WMI (compared to none) for
changing attitudes. Likewise no convincing evidence of the effectiveness of WMI
(compared to none) was found for increasing the medicine user's adherence with
treatment instructions. The lack of evidence that provision of WMI increases compliance to
taking the medicine is not necessarily a disappointing result, because the person receiving
information may make an informed decision not to take a medicine (Raynor et al., 2007a).
There was some evidence to show that provision of WMI can improve aspects of
knowledge. For example, two trials found that participants receiving WMI had
significantly better recall of information about a medicine (than participants receiving
none). Two further trials found this, but not consistently across all outcomes measured.
Three of four trials found that participants receiving WMI had better recall of side effect
information than participants receiving none.
The evidence showed that the way that the risk of a side effect is presented impacts on
readers' knowledge and attitudes. For example, a numerical description of the risk of a
side effect was consistently shown to lead to a more accurate estimation of the probability
of likelihood of side effects, compared to verbal risk descriptor information, as stipulated
by the 1998 EU Directive (European Commission Directorate-General rn, 1998). There was
similar evidence for the effect on attitudes. Participants presented with numeric
information about the risk of a side effect were significantly more satisfied; and had a
greater intention to comply with taking the medicine compared to participants presented
with verbal descriptor information.
Conversely, participants presented with verbal descriptor information about the risk of a
side effect perceived the risk of a side effect from taking a medicine to be greater and
anticipated the risk of a side effect to be significantly greater as compared to those
presented with numerical information.
The content, length and layout of the information, and the way it was provided, differed
between trials. The majority of studies were found to have adopted atheoretical or non-
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evidence-based interventions, and outcomes unique to that trial. Durand et aI. (2008)
examining trials in a systematic review of patient decision aids, similarly found a lack of
theoretical input in the interventions. Research of an intervention whose design is
atheoretical or not evidence-based can be problematic because it essentially examines a
stimulus-response relationship. Findings from such trials can still have an important and
relevant impact on practice. However, because they only show a correlation, they cannot
explain why the intervention was effective or not. This is not helpful in aiding the
understanding of what makes WMI effective or not for changing knowledge, attitudes and
behaviours.
The average age of participants in the trials was 43 years of age. However, most people
who take medicine long term, and have most need for WMI, are older. Therefore the
participants in these studies may not have been representative of everyone who takes a
medicine and needs WMI. A large number of the trials had follow-up periods of one week
or less; and thirteen trials followed up participants only for one day. Doubt can be cast as
to whether trials of such length offer a reliable indicator of the long-term effects of
providtng WMI, because many people relying on WMI take medicines for chronic
conditions over a long period of time.
The review reported in this chapter was the first to systematically gather and analyse
previous research of WMI; and generate recommendations based on these findings. Berry
(2006)made recommendations for how WMI should be presented, based on a non-
systematic review of studies of information giving. Not all studies included in this review
were RCTs and the information was not for medicines alone; therefore the inclusion
criteria and the conclusions differed from that of this study. Nevertheless there was some
overlap between the findings of Berry's (2006)review and the review reported in this
chapter.
• The risk of a side effect from a medicine should be framed both positively and
negatively, so as not to make the information biased either by being persuasive, or
appearing threatening; for example, the evidence shows that when information is
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framed positively (e.g. emphasising a 95% survival rate rather than a 5% chance of
mortality), people are more likely to choose the treatment.
• Care should be taken in how information about risk is portrayed, because the
perception of risk can be determined by producing it as a relative risk rather than as an
absolute risk: for example, the evidence shows that a reduction from 10% to 5% risk of
harm described in absolute terms as a 5%, or relatively as a 50%, will be perceived and
favoured differently.
• Providing information in a personal manner: for example, saying 'your symptoms'
rather than the impersonal'the symptoms' can make people more satisfied with the
information and so WMI should be tailored in such a way. Providing further support
for the personalisation of information; Jones et al. (1999) have shown that when
participants were randomised to receive general computer-based information,
personalised computer-based information (providing details about their medical
record) or information in a booklet, they most often favoured the personalised format.
• Important information should be presented at the start of the information, because the
order effect shows that information provided at the beginning of a leaflet is more
easily remembered and is probably perceived to be more important, than when it is
presented elsewhere.
• Medicine users should be encouraged to actively process information about risk,
because the evidence shows when people do so, their estimate of the risk improves, as
does their satisfaction with the information, compared to passively reading the
information.
3.5.7. Implications of this research
The findings of the systematic review have implications for the provision of WMI, and
future research evaluating this. These are set out in set out in Table 9 below.
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Table 9: Evidence-based recommendations for WMI
1. The effectiveness of WMI: evidence from individual trials suggests that WMI can be
eft ctiv for changing knowledge. There is no evidence that WMI is effective for
eh nging ttitud s or b h viours, or that ithas any adverse effects when provided.
• Recommendation: provision ofWMI is justified because it can improve
knowl dg , and does not have adverse effects.
2. Poor reporting of trial conduct: everal trials were poorly conducted, and several
report d poorly how th y were conducted.
• Recommendation: futur trials valuating WMI should apply recognised
standards to th ir d sign, conduct and r porting.
3. Ath or tical interventions: trials commonly us d unique outcome measures.
• Recommendation: futur trials of WMI should evaluate interventions that have a
cl ar rationale, b ing ith r th cry-driven or evidence-ba ed.
4. Heterogeneous outcomes: trials commonly used unique outcome measures.
• Recommendation: futur trials valuating WMI should use consistent and
v Iidat d outcom m asur S that will facilitate a statistical analysis.
5. Length of follow-up: Lh r wa variance in the J ngth of follow-up and a number of
trials only foll w d up for one day.
• Recommendation: itmay b us fu] to id ntify an optimal] ngth of follow-up for
tria] of WMI.
6. Evidence gap: no pr vious trials had valuated lBMI.
• Recommendation: th r is and for th valuation of lBMI.
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3.6.Stakeholders' feedback on the project findings
3.6.1. Aims and methods of the second stakeholder workshop
The aim of the second workshop was for stakeholders to reflect on the findings of the
project, and offer feedback. The workshop followed a similar format to the first, and was
composed of the same attendees as the first workshop, except for one person, a medicine
user who could not attend.
3.6.2. Stakeholder feedback on the results of the systematic review
The group work activities generated useful discussions regarding the findings of the
review. Stakeholders were initially asked what findings they hoped would have arisen
from the review. The rationale for doing this was because of the threat of hindsight bias,
i.e. where people claim to have known the effect in advance (Trout, 2(02). This is a
powerful effect because people given information retrospectively claim this was inevitable
in hindsight (Fischoff, 2003).
The stakeholders hoped that the evidence would support the importance and packaging of
WMI, make the information more understandable, and highlight the importance of
focusing on positive aspects instead of negative aspects of information. There was
disappointment that the findings from the effectiveness review were largely inconclusive;
and stakeholders called for future research of better quality, perhaps using a different non-
RCf study design. They were disappointed at the lack of research into the effectiveness of
mMI. Stakeholders were surprised that WMI was valued by participants who had been
intelviewed in the studies examining the role and value of WMI (see 1.2.6); and yet it was
not clearly understood if WMI was effective (for changing knowledge, attitudes and
behaviour). This led some to wonder why information should be given if it was not
effective.
The stakeholders made a number of important observations throughout the discussions
about the research in general. Firstly they did not distinguish between spoken and written
information, which was not reflected in the previous research. Secondly they queried some
of the outcomes that trials measured: e.g. 'compliance', and anxiety about taking the
medicine. With the latter they felt that having increased anxiety about taking a medicine
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would not necessarily be a negative outcome from reading the WMI, which was the
opposite to the conclusion to a trial measuring this.
Stakeholders were asked to recommend priorities for future research and they made a
number of suggestions, including future research focusing on understanding as an
outcome, and the need to investigate how the Medicines Guide website and NHS Direct deal
with WMI.
3.6.3. Discussion
The stakeholders were surprised that the review did not find clear evidence of the
effectiveness of WMI; and that no research had examined the effectiveness of mMI. They
disagreed with some of the outcomes that had been measured by the trials, e.g. measures
of compliance. The stakeholders again stated the need for evaluating the
'understandability' of information by research. The findings of this workshop not only
crystallised the conclusions of the systematic review; but have reinforced the aim of
evaluating mMI in this thesis.
3.7.Discussion of the strengths and limitations of the studies
3.7.1. Stakeholder workshops
The workshops were valuable in helping to define the aims and then conclude the findings
of the systematic review. The first workshop gave the stakeholders, including medicine
users, the chance to input into the goals of the project at the outset. The second workshop
gave the stakeholders the opportunity to give feedback on the results, for how the findings
and conclusions could impact on WMI, and what that would mean to medicine users.
The workshops were of great importance, but had restrictions. The key limitation of the
workshops was the inability to analyse the medicine users' verbal protocols. This could
not be done for two reasons. Firstly no audio recording of the discussions in the individual
groups at either workshop could be made (see 3.3.1). Secondly, the discussion groups were
mixed between the participants representing the different stakeholder constituencies:
National Patient Organisation groups, project collaborators, and project members. Therefore
the comments and thoughts of the medicine users alone could not be isolated. This
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constrained the analysis and may have detracted from specific opinions of the medicine
users by their not being picked up. However, by aggregating the views of all stakeholders
together, this can be seen as having enabled a stronger synthesis of all participants'
viewpoints.
The sample of medicine users was not representative of everyone who takes medicines
long-term: e.g. none were under 50 years of age, and none were from an ethnic minority
group. Nicolson et al. (2006b)have acknowledged that this probably impacted on the
issues that were and were not raised by the medicine users at this workshop.
3.7.2. Systematic review
The systematic review reported in this chapter represents the first systematic retrieval and
analysis of research evaluating the effectiveness of WMI. Byhighlighting problems with
previous WMI research conduct, as well as gaps in published WMI research, this has
provided a firm evidence base for future research to examine WMI (both leaflet and
Internet-based) using more rigorous methods, outcome measures that are patient-centred,
and better designed interventions. The lack of research evaluating mM! has reinforced
examining it in this thesis. This review of the effectiveness of WMI had limitations based
on the poor quality of several of the included trials, and doubts regarding the usefulness
of RCf-based research for examining WMI. Doubts about its research question being
answerable or not are raised first.
Examining the effectiveness of WMI
The aim of the review was to examine the effectiveness of WMI for changing knowledge,
attitudes and behaviour related to taking medicines. However, it can be suggested that it is
not straight forward to answer the question 'Is WMI effective for improving an outcome'
because there is not one but two questions to answer here: (i) has WMI ever been shown to
be effective for improving an outcome; and (ii) if it has been shown to be effective, when
and where did this occur. Arguing this point, the systematic review can be said to have
undertaken the first question, but not the second. The second question would have
required a sub-group analysis, but this was not possible because a meta-analysis was not
poSSibleto conduct.
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The poor quality of previous trials evaluating WMI
In countries where PILs are legislated for, research evaluating them has to provide
minimal patient care, i.e. WMI. Thus at the very least, research will examine the effect of a
standard PIL against an experimental one. Therefore there has been a rise in trials
comparing the presentation of different types of WMI; and demise of trials examining the
comparison of WMI against no intervention. Nevertheless, this thesis contends that the
inclusion of these categories of trials was beneficial. It is not enough to only know if WMI
is effective. It is also important to compare different ways of presenting WMI, to find out
the most effective.
The review was hampered by the poor reporting of trial conduct (see 3.5.6), and there is
reason to doubt the adequate conduct of some of the trials. Most papers did not report
how the trials concealed allocation, and when further information was received from
authors, it was clear that a number of these trials did not adequately conceal it. Because
this is the greatest source of overestimation of treatment effects Oiini et al., 2001), doubt is
cast on the reliability of these trials results. The discovery that several of the included trials
were poorly conducted is a standard finding of many systematic reviews.
The trials largely used outcome measures that were unique to that trial. This made it
impossible to combine and compare results statistically; although this is neither a pre-
requisite of a systematic review, nor an uncommon outcome when conducting one.
Interventions were often heterogeneous, but it was only possible to categorise by
intervention and control for descriptive purposes alone. Nearly one quarter of the trials
compared WMI to no intervention which does not reflect practice in the real world, where
EU regulation has determined that information should accompany the medicine. (These
trials were conducted before this legislation came into place.) A degree of heterogeneity is
acceptable (and inevitable) in systematic reviews, but the extent of heterogeneity in the
interventions and outcomes of the trials meant it was impossible to combine the results
because they were so different.
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Several trials (for example, Berry et al. (2oo2a)or Berry et al. (2003a», enrolled non-
medicine users as participants, providing them with a hypothetical scenario about taking a
medicine and one of two (or more) types of side effect risk descriptor. An argument can be
made that testing medicines information on people who do not take the medicine cannot
be generalised to medicine users - for example, because the emotional state of the person
reading the information may playa role. This is an important point and probably beyond
doubt for some types of information (for rare conditions, for example). But in defence of
this method, it is important to recognise the assertion that processes underlying
understanding of WMI for most people most of the time, like other cognitive processes,
arc (presumably) universal. The series of trials by Berry and colleagues examined the
general public's understanding of the presentation of information about the risk of a side
effect from taking a medicine. The study by Knapp et al. (2004)examining the same
outcome in people taking simvastatin for high cholesterol, found no differences in the
results from the previous studies conducted in the general public. One conclusion that can
be drawn from this finding is that because there was no difference between people with a
condition and the general public, it is valid to examine some WMI on the general public
using hypothetical scenarios.
The trials by Berry and colleagues have made important findings that aid our
understanding of how people evaluate the risk of a side effect from the way the
information is presented. They are, however, limited by (arguably) being 'black box
studies' that examine an input and output. It is argued that they have found a correlation,
but are not able to explanation for why people overestimate the risk of a side effect. One
way that this could be overcome would be to record participants' verbal protocols (see
5.2.3) to enable an insight to be made on their cognitive processes.
It is important to consider the context of time in relation to the trials; in particular the
conduct of the RCfs being relative to when they were carried out. The CONSORT
Statement (Begg et al., 1996)has changed the quality of reporting of trials since its
inception, and this may explain the poor quality of many of the older trials. Poor reporting
of trial methods can be due to constraints in publication space even when the methods
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used may have been adequate. Therefore it cannot be said with certainty that the trials
were poorly conducted; only that their conduct was poorly reported.
Reporting of the source of funding of the trial was not reported by the majority of trials.
This is relevant as there is dear evidence that funding is a source of bias in research (for
example, see Lexchin et al. (2003». There is no reason to question whether the results in the
included trials were related to the funding source; but the lack of transparency over
funding, does not inspire confidence on this point.
The usefulness of the ReT for evaluating WMI
The systematic review was based on the best available evidence, i.e. Rcrs. However, some
commentators have suggested that the Rcr study design is inappropriate for evaluating
the effectiveness of information, (a criticism not unique to that design). It has been argued
that the Rcr design may not reflect the typical uses of an information system in day-to-
day practice (Heathfield et al., 1998). Similarly, Rcrs are noted to be poor for
understanding issues pertaining to system use (Kaplan, 2(01); which has implications for
the examination of the effective use of IBM! (as well as PILs). The Rcr has been an
invaluable tool for determining the effectiveness of drug treatments, for example, but IT is
not similar to a drug (Heathfield et al., 1998). The assimilation of information requires
active cognitive processing, while the intake of a drug is largely autonomic.
The effectiveness review sought to evaluate ifWMI was effective; not how or why it works.
In spite of the criticisms raised above, the Rcr when conducted correctly remains the
study design most capable of determining if an intervention is effective, with the least bias.
Therefore it was appropriate to include Rcr -based evidence alone for examining the
question. The inability of the project to highlight ifWMI was effective was (probably) not
due to the inclusion of Rcrs alone, but rather the poor quality of their conduct. The
findings do not provide evidence to reject the Rcr for evaluating the effectiveness of
WMI. While not all evidence in phannacy research is garnered from'an Rcr, some is
(Bond, 2006). Evidence produced by using this method can justify its use. For example, the
series of trials by Berry and colleagues, which have been well conducted and have derived
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consistent results, are evidence for this. Despite the problems noted with it; the RCI'
remains a rigorous means for exploring if WMI (both paper-based and Internet-based)
'works'.
The issues arising from the review have prompted consideration about the optimum study
design for evaluating the ease of use and understandability of IBMI.An examination of
home healthcare technology called for a better need to understand the usability of such a
system (Kaufman et al., 2003);while it has been argued (in general) that there is a need to
gain insight into the 'black box' to understand why interventions are successful or fail
(Hulscher et al., 2003).This may be pertinent to WMI, as information can be seen as a sum
of specific points rather than as a whole, and so it will be important to know which aspects
of the information are more (or less) effective than others.
3.S.Concluding remarks
The research presented in this chapter conducted the evaluation of leaflet-based WMI, by
secondary research. Using sequential focus groups to enable stakeholders to prime the
review and feed back on its findings had led to the following conclusions being drawn:
• Evidence from individual trials suggests that WMI can be effective for improving
knowledge relating to medicine taking;
• There was no clear evidence to show that leaflet-based WMI is effective for
changing attitudes and behaviours relating to medicine taking;
• There was no evidence to suggest that the provision of WMI has an adverse effect
for its readers;
• The way information about the risk of a side effect is presented will impact on the
readers' understanding of the information;
• Many of the trials that examined the effectiveness of WMI were poorly conducted.
Future research should be conducted more rigorously;
• No bials examining the effectiveness of IBMIwere found .
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The outcomes of this study represent the first set of findings in this thesis. They also
impacted on the direction of the remainder of this thesis. Finding no trials examining mMI
has solidified the focus on evaluating mMI in the remaining studies. The remaining three
studies evaluate mMI, examining its content and design to see if it is easy to use and
understand, and if evidence-based changes can make it easier for medicine users to
navigate redesigned web pages and understand its information, The next chapter reports
the first study to evaluate mMI: presenting an audit of the quality, content and design
features of a sample of sites. This serves to identify a sample of websites whose usability is
examined in the study reported in Chapter five.
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Chapter four
Study two: evaluating the quality,
content and design of web sites with
information about medicines
4.1.Introduction
The systematic review reported in Chapter three found no trials that examined the
effectiveness of mMI. This chapter reports an evaluation of the quality, content and design
features of a sample ofmM! sites, and forms the base for evaluating the usability of the
same sites, reported in Chapter five. Part of this study was presented at the EACH
International Conference on Communication in Healthcare (Nicolson et el., 2006a).
No known studies to date have evaluated the content of mMI against the EU directed
categories of WMI (European Commission, 2004),or specific content recommendations
(Quality Review of Documents Group, 2005). The value of doing this is that it provides a
checklist for auditing the content ofmMI. We know that medicine users consider
information about safety and efficacy issues to be essential (Dickinson and Raynor, 2003),
therefore it is important to have a clear understanding of the specific information that
mM! sites contain, and in particular if they correspond with users' wants.
The systematic review in Study three found that understanding of the risk of a side effect
varies depending upon whether it is presented as a numerical value, e.g. greater than 10%;
or as a verbal risk descriptor, e.g. very common. Therefore it is important to examine how
sites present information about the risk of a side effect
This study (and the study reported in Chapter five) examines websites which have
information about simvastatin2 (a medicine). This is used for treating hypercholesterolemia
(high cholesterol), i.e. too much fat and oil in the arteries. It lowers cholesterol in two
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ways: (i) decreasing low density lipoprotein (LOL, known commonly as 'bad cholesterol'),
and triglycerides; and (ii) modestly raising high density lipoprotein (HOL). The combined
level of LOL and HOL is total serum cholesterol. Epidemiological evidence shows a causal
relation between total serum cholesterol and atherosclerosis (the narrowing and hardening
of the walls of the arteries over time), which can result in coronary heart disease (ai~)
and other atherosclerotic diseases, such as ischaemic stroke (Clark, 2003). By reducing total
serum cholesterol and LOL, simvastatin is effective in lowering the risk of CHD (The
Scandinavian Simvastatin Survival Study Group, 1994).
Simvastatin is a commonly prescribed medicine in primary care. For example, in the last
quarter of 2001, 3.5 million prescriptions of statin were made in the UK, and simvastatin
was the most frequently prescribed statin (Anonymous, 2002b).1t is normal that the person
prescribed simvastatin will be expected to stay on it for the rest of her or his life, because
high cholesterol is a chronic condition in most people.
Examining data from the Doctors Independent Network, DeWilde et al. (2003) found
prescription of simvastatin was more common in patients younger than 64 years, and that
more men than women were prescribed it, although this difference disappeared after
adjusting for age and severity of disease. The points in this section highlight that
prescribing of simvastatin is common, and that the efficacy of simvastatin is well established
in reducing the risk of 0iD.
As with any medicine, simvastatin has adverse effects. In a review of the risks and benefits
of statin treatment, Oark (2003) notes that its use is not advisable for certain patients (for
example, those with liver or muscle disease), and that interactions with other drugs (for
example, warfarin) are possible. It is imperative that someone taking this medicine does
not take grapefruit juice: the interaction between simvastatin and grapefruit juice can
increase the amount of simvastatin in the blood stream. Another side effect that can be
unpleasant and harmful for the person taking a statin is muscle weakness.
2 Brand names for slmvsstfJln include Sinv8CO"and Zocor. Another member of the ~fJin family is roslN8Stfiin
(brand name Crestot).
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Many people do not take simvastatin long term, despite its effectiveness. Reasons for this
include the side effects above, as well as the inconvenience of taking a medicine daily for
the rest of one's life. Furthermore, because high cholesterol is a condition without
symptoms (before the onset of a stroke or heart attack), there are no tangible benefits for
the person taking a statin. A cohort study in Canada of older adults (greater than 66 years)
found 25% discontinued statin therapy within six months of starting, and less than half of
the patients continued treatment after two years (Iackevicius et al., 2(02).
For the reasons above, simvastatin is an appropriate subject for the information examined
in this chapter. Information about its effectiveness, side effects, and how to take it safely,
can support the medicine taker; enabling him or her to take the medicine effectively, as
well as make an informed decision about taking it or not.
4.1.1. Aims
The aims of this study were:
(i) To identify a purposive sample of commonly accessed websites providing
information about simvastatin, which will be evaluated in the usability study;
and
(ii) To compare the quality, content and design features of the sample of websites.
4.2.Content analysis
This study uses a content analysis method to evaluate ffiMI. Bere1son (1952) has defined a
content analysis as a "research technique for the objective, systematic, and quantitative
description of the manifest content of communication" (pp 18). As such it can allow for the
systematic evaluation of the content of a variety of media; from newspapers to websites. In
this thesis the content analysis provides a preliminary analysis of a sample of websites to
be examined in the usability study described in the next chapter.
4.2.1. How to condud a content analysis
Drawing on Weare and Lin's (2000) procedures for conducting a content analysis of
websites, five practical issues are discussed.
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• A sample of messages is selected from a pre-defined population. How the
sampling frame is defined is an important first step, because it determines the
scope of sites which will be retrieved for the analyses. There are several competing
methods, each with their own merits; including sampling by Internet address,
using a sample retrieved from a search engine result, and conducting a purposive
sample (Weare and Lin, 2000).
• The unit of analysis is identified. This refers to the objects of the study (Graneheim
and Lundman, 2004). In this study they are quality indicators; specific medicines
information and general site content, and the design features of the site.
• A categorisation scheme is devised whereby messages can be validly and reliably
classified. As with a systematic review, this scheme is devised a priori, so as to not
introduce bias.
• Coders are trained to code a sample of the messages. As with a systematic review,
there is greater reliability if two people independently code a sample of messages.
They then compare their coding for inter-rater agreement. Methods include taking
a simple percentage agreement, whereby a specified percent of difference between
the two assessors coding is accepted; to more elaborate schemes using a statistical
calculation - for example, Cohen's Kappa (Lombard et al., 2(02). When coders do
not agree, disagreement may be reconciled with the intervention of a third party.
• The data is analysed and interpreted.
4.2.2. Strengths and limitations of a content analysis
Any content analysis has strengths and limitations.
Strengths
Kondracki and Wellman (2002)have noted strengths of conducting content analyses:
• Content analyses can be used to track messages over time, comparing them at
different points;
Content analyses are unobtrusive, as there is no interaction between the subject
and researcher;
•
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• Content analyses can use any material that is archived, expanding its potential
sample; and
• Content analyses are usually inexpensive.
Limitations
Kondracki and Wellman(2002) have also noted limitations of conducting content analyses:
• Depending on the sampling procedure, the conclusions of content analyses may
not be generalisable,
• While identifying relationships between variables, content analyses cannot explain
them, nor attribute causation;
• A content analysis can be time-consuming to properly conduct.
4.3.Methods
4.3.1. Inclusion criteria
The inclusion criteria for the websites were:
(i) English language;
(ii) Providing information about simvastatin;
(iii) Professionally developed (for example, by a healthcare authority or
pharmaceutical company).
Sites were excluded if:
(i) Registration was required, as this may put people off accessing them in the
short term;
(ii) Content was only about the condition (hypercholesterolemia) and did not
include information about the medicine;
(iii) The site was a portal (providing links to other sites) and did not present
information of its own.
4.3.2. Search strategy
Medicine users have reported finding IBMI by using a search engine; in particular GoogleN
because it is straightforward to use, and YahoO!TM because it often appears as a default
page when accessing personal emails (peterson et al., 2003). Therefore to replicate a search
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strategy medicine users might employ, and because the most frequently accessed search
engines used when this study began in January 2006 were Google™ and YahoO!TM
(Source:http://urww.alexa.com/accessed January 2006); these two search engines were used
to search for sites. The phrase 'simvastatin' was searched on both sites, because medicine
users have reported finding information about a medicine by typing its name (peterson et
al., 2003). There is evidence to show that users of the Internet rarely open any link found
after the first ten from a search for healthcare information on the Internet (Eysenbach and
Kohler, 2002). The first 50 sites provided on both search engines were examined, which
more than covered this. Language was limited to English, the language of the two
reviewers, and no other limits were set.
To maximise the possible mMI sites available for analysis, the search was augmented from
two other sources: web page links to medicines information sites on the Patient.co.uk
website; and websites reviewed in two content analyses of information for commonly
prescribed medicines: Hatfield et al. (1999) and Doupi and van der Lei (1999), (see
Appendix six). These two analyses were found by conducting a search on Embase and
Medline for analyses of mM! sites (from 1995 to 2005). Four content analyses studies were
found in total, but two, one of asthma education (Croft and Peterson, 2002), and one of St
John's Wort (Martin-Facklam et al., 2002), did not have their websites considered, because
they did not relate to simvastatin.
To summarise, the search for mM! was conducted using three sources:
(i) Sites identified from Google™ and Yahoo!TM, using the phrase simvastatin
(limited to the first 50 sites on each search engine);
(ii) Web page links to medicines information sites on the Patient.co.uk™ website;
and
(iii) Websites reviewed in two content analyses of information for commonly
prescribed medicines by Hatfield et al. (1999) and Doupi and van der Lei (1999),
(see Appendix six).
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Two reviewers (the author and a research colleague) independently evaluated the sites for
inclusion in January 2006.
A decision was made to analyse a criterion sample of the ten most commonly accessed
mM! sites, for the purpose of analysing the most commonly accessed websites with
information about medicines. The decision to look at the top ten sites was made on the
basis of knowledge about the public's search strategies. Medicine users have reported that
they do not look beyond the first page of links (usually ten) on a search engine (Peterson et
al., 2003).Medicine users have also noted a difference in material presented by US and UK
health websites: "American and English web sites sometimes gave conflicting information"
(Interview T29Transcript DIPEx.org www.DIPEx.org Accessed: July 2006).For this reason,
the sample of ten sites was divided between the five most frequently accessed mM! sites,
developed in the USA and UK.
From the sample of websites found, the most frequently accessed sites were identified by
using the Alexa.com (http://www.alexa.com/}website.This provides data for the frequency of
access to websites, called 'reach' data. The mean number of people accessing each website
that met the inclusion criteria over a three-month period was obtained by typing their URL
into the search bar on the Alexa.com website (in ApriI2006) to ascertain this data.
4.3.3. Descriptive review of websites
A qualitative description was made of aspects of the site: the brand name of the drug; the
appearance of the homepage (for example, if it had pictures or icons); and any
navigational steps required to locate the information about simvastatin. Because this was a
descriptive process and did not include an analysis, this was performed by one reviewer,
the author. Recommendations for design principles (see 1.5.2)were applied to inform:
(i) If the layout appeared cluttered, (impacting on attention);
(ii) If the site used icons (to aid perception); and
(iii) If the text was legible and distinguishable from the background.
Preece et al. (2002)have noted that sites that are cluttered with information can place great
demands on the user's attention (sce 1.5.2)and have provided the example of Google™ as a
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site that is judged to be clutter free. The reviewer used this as a benchmark for assessing
which sites were considered to be cluttered, and which were not.
The specific location of the search bar was noted (if one was available), because medicine
users have reported using search engines (featuring search bars) to find WMI (Peterson et
al., 2003).The way that side effect risks were described (if at all), was noted because
understanding has been shown to differ depending on whether it is numerical or verbal
(see 3.5.5). Information was extracted from the web pages in May and June of 2006.
4.3.4. Coding frame
Referring to a standardised protocol (see Appendix seven), the same two reviewers who
considered the sites for inclusion, assessed the general and specific content data of the
websites and their design features in January and February 2006.The reviewers recorded
if each website had corresponding content and design features, and made an assessment
of the site's quality, on a standardised form (see Appendix eight). Differences in decisions
were reconciled by discussion.
The features of the mM! sites being checked were divided into five categories:
• Design attributes: the features of the site which pertain to its use. For example,
whether there were links to external sites, whether or not the site had a search bar.
Nine design attributes were assessed (see Appendix seven).
• Quality: indicators of the quality of the information and its source. These were
derived from recommendations of the HoN Code, and the Discern handbook (see
Appendix two). Examples included noting if the site made reference to scientific
evidence to justify claims (and provide the source). Eight indicators of quality were
assessed (see Appendix seven).
• Medicine information content the information about the medicine provided by
the site. In total, fourteen aspects of medicine information content were checked
(see Appendix seven). The content to be checked was derived from:
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(i) The 1998European Commission Directorate-General III directive for categorisation
of information to be contained in a medicines information leaflet (European
Commission Directorate-General Ill, 1998);and
(ii) Recommendations on medicines package leaflets (Quality Review of
Documents Group, 2005).
• General site content: the non-medicines information on the site. Eight items of
content, including whether the site promoted a pharmaceutical product, or if it
disclosed its rationale, were assessed (see Appendix seven).
• Piloting the User Test: as a precursor for the usability study reported in the next
chapter, each site's content was examined to see if it provided indicative
information to answer ten factual questions (see Appendix sixteen). These ten
questions were adopted from a User Test used by LUTO Research Limited
(www.LUTO.co.uk) for assessing the readability of a paper-based simvastatin leaflet.
The ten questions were designed to largely reflect the safety and efficacy issues that
pharmacists consider to be essential information about simvastatin. For example,
the indicative infonnation to answer the question 'Is there specific food or drink
you should avoid when taking simvastatin?' was grapefruit or grapefruit juice. This
task identified the sample of sites that met the criteria of having the indicative
information to answer all ten questions, and could therefore be evaluated in the
usability study reported in the next chapter. mM! sites that did not provide
indicative infonnation to answer to all ten questions were considered 'incomplete'
and not included in the final usability study, because it would be unethical to ask
participants to look for infonnation which was not available.
For each site the total number of design attributes, quality indicators, and content items it
had were tallied.
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4.4.Results
4.4.1. What the search found
Searching Google™ returned over 850,000 web links, and on YahoO!TM over 500,000 when
the search was conducted in January 2006. Itwas not possible to determine the level of
duplication. Fifty-eight websites (see Appendix six) were considered for inclusion:
• 38 sites were found from the first 50 sites on both search engines;
• 15 sites from previous analysis by Hatfield et al. (1999) and Doupi and van der Lei
(1999); and
• Five sites were from links on the Patient.co.uk™ website.
Thirty-three sites met the inclusion criteria (see audit trail in Table 10). Three of four sites
(Medicine Net, DruginJonet, and Rxlist) evaluated by one of the reviews (Hatfield et al.,
1999) met the inclusion criteria. Five of 14 sites (Healthtouch Online, DruglnJoNet, Mayo
Clinic, Medicine Net, and RxList) evaluated by the other review (Doupi and van der Lei,
1999), met the inclusion criteria.
The most common reasons for sites not meeting the inclusion criteria were: it was a portal
to other sites (seven sites); or did not provide information about simvastatin (six sites).
These sites were found in the general content analyses that looked at general information
about medicines. Appendix nine shows the reason for exclusion of all sites.
The earliest site available was US Food and Drug Agency (http://wwwjda.gov), first
developed in April 1993 (Source:http://www.alexa.com/accessed April, 2006). Considerably
more people accessed the US developed sites. The five most frequently accessed US, and
UK developed mM! sites are inTable 11.The only UK site with a similar level of access to
any US site was Net Doctor.
4.4.2. Descriptive review of websites
Typing simvastatin in the search engines returned links to pages with specific information
about simvastatin, and not any of the ten sites' homepages. Five sites (Medicine Net, Rxlist,
Medicine Guides, Net Doctor, and Drugs.com) provided information for the Zocor brand; two
did not specify a brand (Best Treatments and Patient UK); and one each provided
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information about the Simvacor (Electronic Medicines Compendium) and Crestor (US Food and
Drug Agency) brand. The Mayo Clinic site provided information for Vytorin (a drug
combining a cholesterol absorption inhibitor and statin). The Medicine Guides site also
provid d information for this brand, as well as information about the Zocor brand.
Table 10: Audit trail of IBMI sites considered for inclusion
Audit trail of IBMI sites , ,
Sites idcntifi d using s arch strategy 38
Sites identifi d from previous analyses 15
Sit s identif d from Patient.co.uk (12*) 5
Total sites considered for inclusion 58
Sit s xclud d for not m ting inclusion criteria 22
Sites not abl to b fully c ss d 2
Sit s duplic ling information from other site 1
Total sites excluded 25
Total sites included 33
Purposive sample of sites analysed 10
• 5 most access d UK IBMI sites for simvastatin
• 5 most ac s d US roMI sites for simvastatin
*S v nits w r duplicat d from Lhes arch strategy; thus only five new sites were found.
Most hom pag s wer clutter d with a m ss of links to other websites, or to pag s within
th App ndix t n). Fiv it had ions, but this was largely limited
(for xample, h ving only a print r i on). Patient UK di played different icons highlighting
th typ s of inform tion availabl (for exarnpl ,'information leaflet' or 'medicines'), when
th narn of th drugw s typ d in the arch bar. On sit (Electric Medicines Compendium)
provid d th informti n as Portabl ocum nt Format (PDF) only. It also provided
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Summary Product Characteristics information, which is more extensive information about
th drug, not written in plain English (because it is designed for health professionals), and
submitted by the medicine manufacturers as part of the licensing process.
Table 11:Five most often accessed US, and UK developed Internet-based medicine
information sites
MedicineNet http://www.mdidnnet.com/seript/main/hp.asp 494.0
US Food and Drug Agency http://www.fda.gov/ 490.5
Mayo Clinic http://www.mayoclinic.com/ 403.5
Drugs.com http://www.drugs.com/ 397.0
Rxlist http://www.rxlist. om/ 303.0
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Net Doctor http://www.n tdoctor.co.uk/ 270.0
Patient UK http://www.pati nt.co.uk/ 86.5
Best Treatments http://www.besttreatm nts.co.uk/ 19.5
Electronic medicines compendium http://emc.medicines.org.uk/ 7.4
Medicine Guides http://m dguid s.mcdicincs.org.uk/ 5.7
*M an ov r 3 month p r million peopl accessing the Internet
Figur 5 show a er n h t of a IT quently access d website with information about
m di in sMayo Clinic (http://www.mayoclinic.coml). App ndix ten provides screen shots of
n ten it s analy d.
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Figure 5: Screenshot of an example of a website with information about medicines
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Four US ite homepage contained advertisements for pharmaceutical products; the US
Food and Drug Agency did not contain adverts. Two UK sites featured sponsorship: Net
Doctor promoted treatm nts for topping smoking, and coping with erectile difficulties;
and Patient UK adv rtis d mobil t I phone networks.
Thre sites did not provid information about the ri k of a side effect: Patient UK, Best
Treatments, and Medicine Guides. Th r maining sites provided this information, as a verbal
description. Only on it (Patient UK) provid d comments from users about the
xperienc of taking th m dicine, and it ff cts. For a complete d cription of all ten
web it s, Appendix I v n.
4.4.3. Design of the IBMI sites
Th r wa Iittl differ nc in th rang of it I w b-d ign charact ristic ( e Table 12).
More than half of th site had v nor mor f atur s: th rest had fiv or six. All sites
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provid d a link wh r by users could make direct contact with the site (see Table 13), and
similarly all sites provided links to external sites.
The Medicines Guide was the only site not to have a search bar. Of those that did, it was
most oft n t th top middle of the screen, thus prominently displayed to attract the user.
The RxList sit had four s arch bars. Its most prominent search bar 'search for a drug name',
was displayed at the top centre of the home page.
S von sit ran an email list, allowing users to correspond. The Medicines Guide was the
only sit to provid the opportunity to personalise i.nformation. The 'My medicines' box
allow d us rs to enter th dosage of the medicine, their age and sex, to receive more
p r onally r 1 vant information, dep ndent upon thes variables. However, this option
was n t irnrn di t ly visible, and therefore ould be missed by the user. (This function was
no 1 ng r av Hable on th site in Apri12008). Only two sites (Mayo Clinic and Medicines
Guide) pr vid d a t xt siz change function. Thr sites did not provide an instruction or
help pag : Net Doctor, Patient UK, and US Food and Drug Agency. Four sites provided a
tabl of ont nts: Drugs.com, Medicine Guides, Best Treatments, and Mayo Clinic.
Tabla 12: Number of design, quality and content characteristics of the mMI sites
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4.4.4. Quality of the mMI sites
Th re was large variation in site quality. Two sites (Mayo Clinic and Medicine Net) had all
eight quality indicators; a further five sites met five or fewer quality indicators (see Table
12). All sites presented a specific date when their simvastatin information webpage was last
updated (s c Table 14); Wald, Dube, and Anthony(2007) refer to this as the site's currency.
Three lBMI sites had updated the page within three months of the date of assessment
(Medicine Net, Drugs.com and Best Treatments), (see Appendix eleven). Net Doctor and
Medicines Guide updated the page between 13 and 24 months before it was accessed
(january-February 2006), while Electronic Medicines Compendium had not been updated in
rnor than two years before itwas accessed. Only four sites reported when the site was
first d veloped (Mayo Clinic, Medicine Net, Medicines Guide and Patient UK).
Table 13: Design features of the IBMI sites
Links to xt rna) page 10
Contact site link 10
Search bar 9
Printer friendly option 9
Contains pictur 8
InStructions or help pog 7
Interactive facilities 7
Tabl of cont nts 4
Text siz chang ab] 2
..
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Table 14:Quality of the IBMI sites
Specific date of last update 10
Funding source stated 9
Disclaimer 9
Statern nt of confidentiality/privacy 9
Ref r nee to evidence 6
Authorship 6
Adv rtising policy 6
Dat sit d v loped 4
Six sit s provided details of authorship. AJIsites (except RxUst) reported sponsorship.
Patient UK was the only site not to display a confidentiality or privacy statement. Six sites
refcrr d to evidence, but only Best Treatments and RxList presented the references to
articles. Medicine Net provided links to further information and evidence. Four sites: Mayo
Clinic, Medicine Net, Net Doctor, and Drugs.com were accredited by the HoNCode.
4.4.5. Medicine information content of the IBMI sites
Information about rnedicin s on the sites varied greatly; ranging from as few as four items
(Best Treatments), to 12 it ms (Medicines Guide, and RxUst), (see Table 12).All sites
provid d om information about 'what the medicine is' and 'side effects' (see Table 15).
Two sit (Medicine Net, and Best Treatments) did not provide information about 'before
taking a m dicine'; and two sites (Net Doctor, and Best Treatments) did not provide
information on how to take the medicine. Three sites (Net Doctor, Best Treatments, and US
Food and Drug Agency) did not provide storage information. Best Treatments provided only
broad ondition-bas d information about hypercholesterolemia, and lifestyl and drug
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tr atments for the condition. It did not offer the same level of information about medicines
as the other sites.
Table 15: Medicine information content of the IBMI sites
'What the medicine is' 10
'Side effects' 10
Notify GP if side effects occur 7
'Before you take' 8
Int ra tion with other drugs 8
'How to take' 8
Action to take ifmiss a dose 6
Action to take if ov rdose occurs 5
Consequences if drug not taken 2
'Storage' 7
Other items
Information about 9
hypercholesterolemt a
Complementary or alternative 7
tr atm nts (for exa:mpl I dietary)
Information about impact on 1
quality f life
Expert ntial comm nts 1
138
Overall the provision of information relevant to taking the medicine was variable. Eight
sites provided information about the possibility of interactions with other medicines - Best
Treatments and Patient UK did not. Seven sites stated that the medicine user should notify
their GP if side effects occur. Six sites mentioned what to do if the medicine user missed a
dose. Only two sites (Mayo Clinic and RxList) spoke of the consequences if the user chose
not to take the medicine. Conversely seven sites provided information about treatments to
complement taking the medicine (for example, dietary changes), or alternative treatments.
All sites provided information about hypercholesterolemia, except the US Food and Drug
Agency site. Only the Medicines Guide provided information about the impact on quality of
life when taking the medicine.
4.4.6. General site content
The general content of the sites varied. Four sites (RxList, Medicine Net, Mayo Clinic, and
Drugs.com) promoted a pharmaceutical product. A further three sites (Medicines Guide, US
Food and Drug Agency, and Electronic Medicines Compendium) had links to pharmaceutical
companies, but did not promote a pharmaceutical product. The RxList was the only site
not to declare its purpose.
Three sites provided explicit information that could potentially enable the medicines user
to share decision making with a healthcare professional (see Table 16).For example, Mayo
Clinic encouraged the medicine user to reflect on several questions when taking the
medicine. Best Treatments explained how to use the research to support decisions about
which treatment to opt for. Drugs.com raised points the individual should discuss with her
or his GP before taking the medicine.
Three sites (Mayo Clinic, RxList, and Medicines Guide) gave answers to frequently asked
questions. All sites were judged to be written in plain English language (by the two
reviewers). Only Drugs.com and US Food and Drug Agency provided a translation of
information about the medicine into another language (Spanish). For both sites, this option
was not clearly available. Patient UK provided translations for some condition-based
information into foreign languages.
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Table 16: General content of the IBMI sites
Medicines information written inplain 10
English
Site content written in plain English 10
Purpos /rationale of site stated 9
Promoting a pharmaceutical product 4
Sit develop d by a pharmaceutical 3
company but not promoting a
ph rmaccutical product
Information enables shar d decision 3
making
Provid san wers to FAQ
3
Off rs translations in other languages
2
4.4.7. Piloting the User Test
Only fiv sites provid d indicative information to all ten User Test questions (see
App ndix twelve and Table 17):Mayo Clinic, RxList, Medicines Guide, Electronic Medicines
Compendium, and Drugs.com. All sites provided examples of side effects, explained the
ben fits of taking simvastatin, and provided information about lifestyle changes needed
whilst taking th drug. All sites xc pt US Food and Drug Agency reported the danger of
too much chol st rol, explaining the benefits of lowering cholesterol. Six sites explained
what action to take if a dose was missed. Not all sites provided information about what
action to tak if the medicines user suffered muscle pain from taking the drug, a
potentially s rious side ff ct. Likewise not all sites noted that the user should not take
grap fruit juice when taking simuastaiin.
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Table 17: Indicative information to answer the User Test on the IBMI sites
Is it okay to drink alcohol when taking
simvastatin? 9
Why should you take simvastatin? 10
Pleas name thre unwanted outcomes from 10
taking sirnvastatin
Can you name me at least two lifestyle changes 10
you should make whilst taking sirnvastatin?
What eff t could having too much cholesterol
in your blood have on your body?
9
If you ar pr gnant or consid ring becoming
pr gnant, should you take simvastatin? 9
Is th re sp cific food or drink you should
avoid wh n taking simvastatin? 7
Suppos you ar taking Erythromycin, an
antibiotic, and th doctor starts you on
simvastatin. Is it okay to take it?
7
Suppose you take Simvastatin and you find
that your joints start to ache. What should you
do?
7
What should you do if you forget to take
simvastatin?
6
4.5.Discussion
4.5.1. Overview of main findings
The modest rch found a large number of links to IBM! sites through search engines.
This may b surplus to th ne ds of m dicin sus rs, when it is considered that people
rar ly look b yond th first pag of links wh n searching for healthcare information
141
(Eysenbach and Kohler, 2002). Because of the power of search engines to promote popular
sites and constrain the promotion of others (Introna and Nissenbaum, 2000), and the
public's use of limited search strategies, this will probably impact on what they do and do
not find.
Information found on the Internet is a product of the search strategy adopted: where the
person searches for information (using a portal or a search engine, for example) will
determine what is found (Adams, 2006b). This study found that typing simvastatin into the
search engines led directly to a specific page with information about the drug simvastatin
on the site, bypassing the homepage. This potentially made the homepage redundant, and
therefore if it had any important information about a medicine on that page that it is not
repeated elsewhere, it may never be viewed by the person accessing the site. This can be
considered to represent what Eysenbach and Diepgen (1998) refer to as a 'context deficit',
whereby information can be harmful, even though not false. It is therefore important for
site designers to ensure that this information is repeated elsewhere on the site.
The design of IBMI sites
There was little difference between the design features of the sites. All provided links to
external sites, and all provided a contact link. Most sites had external links, either on the
home page or on the web page with information about simvastatin. This may benefit
medicine users; because some people cross-reference this information(Adams, 2006b).
However, links may also distract the user. Many of the sites' home pages were cluttered
with links, which may make it difficult for the user to navigate the site and process
information. Electronic Medicine Compendium was the only site to provide links to external
sites on a page devoted solely to links (and clearly labelled 'links'). Links to external sites
that have little or no relevance to people's information needs when accessing the site, may
distract their search.
Nine sites provided a search bar thereby enabling the individual to search for any
medicine, by typing the name in the search bar. This is a useful design feature because
users can access information by typing the name of the drug, rather than navigating
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complicated menus (which they may not have the skills or the confidence to negotiate).
Paradoxically it may be a redundant feature of the sites. As noted before, when medicine
users type the name of a drug into a search engine, they are normally taken to a specific
web page on a site and bypass its homepage, and so they may fail to see the search bar on
this page. Most sites lacked a table of contents which may be a missed opportunity to
optimise the interactive nature of the Internet.
A site with a printer-friendly option allows the user to print the information for later use.
Printing from a web page itself can sometimes result in text at a margin being cut off. One
site (Electronic Medicines Compendium) provided the WMI in a PDF format. However, this
format fails to utilise the interactive nature of the Internet. Most sites did not take
advantage of technological features of the Internet, such as the option to change text size;
thereby missing an opportunity to aid medicines users with visual impairments. On
Internet browsers, readers can increase the font size from the 'View' drop-down menu;
therefore this may not be a detrimental issue to the person who is aware of this. However,
if the person accessing the site does not know this, she or he may not get the most benefit
from using the website.
Only the Medicines Guide site provided the option to personalise information. This could
easily be missed by the person accessing the site, as this was contained within an
introductory section that medidne users may perceive as irrelevant and therefore ignore.
This was limited to spedfying the sex of the medidne user, and the type of medidne,
therefore offering little scope for personalising. Only two mM! sites provided foreign
language translation (Spanish) reflecting the US origins of the sites; but neither site
presented this option explidtly; for both sites this was found by chance. A Spanish
translation would probably not be helpful to many people from ethnic minorities in the
UK, whose first language would reflect their Asian or Eastern European ancestry. The
Welcome to NHS Direct Online website (http://www.nhsdirect.nhs.ukl) provides translation
fadlities in a number of Asian and African languages, for some information, but not
medidnes (when accessed in April2006)
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The quality of IBMI sites
The number of quality indicators that sites featured varied, with two sites having only half
of the eight items. Websites can be updated daily; therefore it was good that all sites
declared how recently they had been updated. However, three sites last updated the
information more than one year before the site was accessed. Information which has not
been updated regularly could quickly become out-of-date and may not be considered
credible by a medicine user.
Nine of the ten websites provided a disclaimer, and confidentiality and privacy
information. The availability of this information may encourage people to access these
sites. Medicine users have reported not trusting websites developed by pharmaceutical
companies (Peterson et al., 2003).Therefore it may be reassuring to people accessing the
sites that nine of them reported details of sponsorship. This could enable the person
accessing the site to make a choice about whether or not to read and trust the information,
based on this knowledge.
Nearly half the sites did not refer to evidence to support claims made about the medicine.
This is not helpful for people who specifically look for evidence-based information, and
may deter them from accessing the site. It is important to note that the sites may have
provided evidence-based claims, but they did not provide reference to this.
The content of IBMI sites
The sites provided inconsistent information. This reflects the finding of an evaluation of
leaflet-based WMI that found the provision of important information - for example, action
to take if missing a dose, or the warning about the risk of an interaction with another
medicine - was variable(Gustafsson et al., 2005).
Few sites were judged to have provided information explicitly intended to enable shared
decision making. All WMI can have the potential to enable shared decision making
because it can change someone's level of knowledge about a medicine. The crucial point
about the definition in the study reported in this chapter was that the site had to provide
content that explicitly sought to enable shared decision making, rather than merely inform
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the person. Participants in the stakeholder workshop (see 3.3.2) spoke of wanting WMI
that would complement the consultation with the doctor, and that would enable them to
make an informed choice. By providing detailed information about medicines, medicine
users could be better informed to be a more equal partner in the decision-making process.
However, the social circumstances underlying concordant relations between the doctor
and the patient are as important: for example, the differences in the power and knowledge
held by the doctor and patient. Therefore the information on a site (or leaflet) alone may
not be enough.
Respondents in the workshop (see 3.3) strongly felt that condition-based information was
an important component of WMI. Best Treatments was the only site to provide information
on treatment options - for example, advice on changing lifestyle - as well as medicines
information. Nine sites provided information explaining how simvastatin lowers
cholesterol to reduce the risk of having a heart attack or stroke. This is important because
it outlines the purpose and benefits of taking the medicine.
All sites provided information about 'what the medicine is', and 'side effects'. This
information could enable the medicine user to have a balanced picture of the risks and
benefits of taking the medicine, to make an informed decision about taking the medicine.
Several sites did not provide specific information about the medicine: for example, what
action the medicine user should take if they overdose, the consequences of missing a dose,
or the impact on quality of life. This is not only a missed opportunity, but could have
potentially serious consequences for the medicine user. An analysis of the content of a
random sample of leaflets by Raynor et al. (2007c)similarly found variation in the presence
of this information, which could have serious implications for the medicine user
depending on WMI alone.
Only one site (Patient UK) reported the experiences of people taking the medication. This
is information that participants in the workshop stated they would value, and so in this
respect it is disappointing that most sites did not provide this material. Few sites provided
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information about the impact of taking the drug on the quality of one's life, again not
providing information medicine users have said they want.
Information about the risk of a side effect is particularly sought by medicines users
(Raynor et al., 2007a). Sites provided information only as a verbal descriptor. This is a less
than effective means for communicating the risk of a side effect (Berry et al., 2003c),and
may therefore be of limited use to people accessing those websites. An analysis of
pharmaceutical websites by Davis et al. (2007)similarly found that the sites presented a
verbal description of the risk of a side effect that was ambiguous and inconsistent.
Only half of the sites provided indicative information to answer ten safety and efficacy
questions (chosen for the User Test). While sites provided information complying with the
recommended EU categories, some provided in a cursory and not specific form. This
information can be seen as useful, if not essential to the user, and yet not all sites provided
it. The omission can be considered an oversight on the part of the writers of IBM! site
content, if the User Test reflects information priorities of medicine users.
Websites and the phannaceutical industry
No pharmaceutical company websites were in the five most frequently accessed US or UK
developed sites. However, four sites, all US developed, promoted a pharmaceutical
product; and a further three sites (Medicines Guide, US Food and Drug Agency, and Electronic
Medicines Compendium) had input from the pharmaceutical industry, but did not promote a
pharmaceutical product. This finding may reflect medicine users preferring government
or professional developed websites to pharmaceutical company websites (Peterson et al.,
2003),but the reason remains to be clarified. It also reflects a conclusion reached by Raynor
et al. (2007a)examining the role and effectiveness of WMI: medicine users have in broad
terms expressed reservations about trusting information provided by pharmaceutical
companies. Medicine users' doubts about the trustworthiness of information provided by
pharmaceutical websites may not be unfounded. For example, an evaluation of 51 sites,
the majority developed by Turkish pharmaceutical companies, found that most did not
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meet quality guidelines for IBM!set by the Turkish Pharmaceutical Manufacturers
Association (Yegenog1u et al., 2005).
4.5.2. Comparison with previous findings
Two sites evaluated in this study (Medicine Net and Rxlist) were examined by Hatfield et al.
(1999), who assessed the quality of IBM! for commonly prescribed medicines. They found
Medicine Net had no search function when the analysis was conducted (before 1999). The
study reported in this chapter found the same site had a search bar, prominently placed on
the homepage. Hatfield et al. (1999) were unable to locate references to evidence when they
analysed the site. The current analysis found that the site had supplementary reading
called 'Suggested reading by our doctors', which provided evidence about the drug, although
it did not provide a reference for the evidence. There was no difference between
evaluations of the Rxlist. The differences between the findings of Hatfield et al. (1999) and
this study highlight the transient short-lived nature of Internet sites.
The study reported in this chapter has found variability in site content which mirrors
previous content analyses of IBMI.Doupi and van der Lei (1999) examined whether 14
sites offering information about general prescribed medication conformed to a quality
criterion, and found this was patchy. Other content analyses - for example, Croft and
Peterson (2002)examining sites with asthma education, and Martin-Facklam et al. (2002)
assessing sites with information about St John's Wort - have similarly reported variation in
the content and quality of sites.
Sidhu et al. (2006)analysing the content of websites providing information on NSAID
analgesics, found they had incomplete and inaccurate information. The present study has
similarly found incomplete information on sites (for simfXlStatin), but did not assess the
accuracy of the information. However, the omission of important infonnation about not
taking grapefruit juice, or the dangers of erythromycin interacting with simfXlStatin, presents
an inaccurate account of the drug which could have serious consequences.
Previous research has found that some sites that displayed the HoNCode accreditation
symbol did not match the criteria for displaying this (Croft and Peterson, 2002).This could
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be a cause for concern, as people who saw the insignia may have assumed that the quality
of the site was assured, (if they recognised what it was). Of the ten sites that had their
design features, quality and content examined in this study, four were found to display
the HoNCode accreditation symbol; (Mayo Clinic, Medicine Net, Net Doctor, and Drugs.com).
All met the criteria for this accreditation. A study of 100 sites providing information on the
treatment of fever in children, found that only 14 displayed the HoNCode insignia (Fallis
and Fricke, 2002). The current study has found a greater proportion of accredited sites
than previously reported. However, the HoNCode is only one means for assessing the
quality of an e-health website, and different measures, (e.g. Discern) may have produced
different results for the assessment. Furthermore, the quality of a website does not
necessarily relate to its trustworthiness. Therefore; this docs not automatically mean that
the sample in this study was any more trustworthy than other content analyses, or that the
quality of IBMI in general has improved.
Dickinson and Raynor (2003) propose that an ideal source of WMI would have the
following eight features. This is used as a checklist to assess the usefulness of the mMI
sites.
(i) Accurate and up-to-date: while all sites reported when they were last updated,
three last updated the information more than one year before it was accessed
(in early 2006).
(H) Able to be personalised or customised: only one site had a (limited)
personalisation option.
(iii) Available in different levels of detail at different times: the only site to offer
different levels of information was Best Treatments, which provided the same
information written for either a patient or a doctor.
(iv) Available at the consultation: this was not examined in this study.
(v) Balanced in reporting of adverse and beneficial effects: the sites have in general,
provided a balanced reporting of beneficial and adverse effects.
(vi) Accessible in language, format and tone: the ten sites were considered (by the
two reviewers) to be written inplain English, which may make them
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understandable to the medicine user. Whether or not the information is
understandable can only be tested by a performance-based study, such as the
User Test reported in Chapter five.
(vii) Linked to other reliable sources of information: most sites had links to external
sites, which could benefit medicine users looking for information from more
than one source. However, presenting links to external sites that have little or
no relevance to the medicines information searched for may be irrelevant or
distracting to medicine users accessing the site(s).
(viii) Provide information about the condition as well as the treatment: most sites
provided varying degrees of condition information.
Most of the sites therefore provided some of the features that Dickinson and Raynor (2003)
recommended. These features alone will not make the sites useful to the medicine user.
The ease of use will impact on whether or not the user will be able to find specific
information; and the wording of the content will determine whether or not the
information is understandable. These issues are examined in the next chapter.
4.5.3. Consideration of study limitations
The inclusion criteria impacted on what IBM! sites were found and therefore counted in
the results; a different set of criteria would have found a different number of sites, and
excluded some of the sites that were analysed. By considering for inclusion professionally
developed sites, including those by a pharmaceutical company, this does not necessarily
reflect the real world choices of medicine users who largely do not trust information from
this SOurce. However, it can be said that there is ambiguity regarding the role of the
pharmaceutical industry and IBM!. For example, the Medicines Guide and Electronic
Medicines Compendium were developed by Dataplumn Communications; a 'not for profit'
company set up by the Association of the British Pharmaceutical Industry
(hltp://medguides.medicines.org.uk/about.aspxlsupport accessed October 2008).
Furthermore, the Medicines Guide website reported receiving financial support from 30
pharmaceutical companies (http://medguides.medicines.org.uk/about.aspx'support
accessed October 2008). There could have been grounds to exclude these sites on the basis
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of their pharmaceutical links. However, these sites were in the sample of top five UK
developed sites accessed. It is not known if people accessing these sites recognise their
phannaceutical industry links, and if so, still chose to access them.
Sites that required registration were excluded (because this may put people off accessing
them in the short term). However, people interact with websites in different ways in the
short and long term. Sillence et al. (2006)Staged Model of Trust has shown that in the long
term, people engage with websites that offer personalised content, interactivity, updated
content, and user-generated content. It may be that people who have accessed a website
over a long period of time would not be deterred from registering to it. This criterion may
have lead to some sites being omitted. Furthermore, because sites requiring registration
may often be those that offer personalisation (Sillence et al., 2006), this can account for why
none were found.
There were shortcomings with the search strategy. While identifying a large number of
sites; the search introduced bias by considering sites for inclusion from the reviews by
Hatfield et al. (1999)and Doupi and van der Lei (1999),and the Patient UK website, and not
sites linked from elsewhere. Itwas an unnecessary step to consider sites from different
SOurcesbecause the content analysis of the sites focused only on the five most commonly
accessed UK and US developed sites; that were found by the search engines. Using the
search engines to find sites was a better method: it identified more sites, and reflects how
medidne users search for IBMI.Weare and Lin (2000)have similarly stated that sampling
by the search engines is beneficial because it is relatively quick and inexpensive, and it
reflects the way that medicine users search the Internet.
In this study the ten sites that were the subject of the analysis were drawn from the Aleu
Web Search 'reach' data. This was not a representative measure of how many people
accessed the sites specifically for infonnation about simvastatin, but rather a record of the
number of people accessing the sites as a whole. The Alexa site did not offer the level of
spedficity where it would be known how many people accessed specific pages about
simvastatin only. Thus Yahoo! Health™ was ranked the most frequenUy accessed site,
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because this took into account everyone accessing any web page on Yanoo.comt», and not
necessarily the Yahoo! Health™ pages relating to information about a simvastatin alone. This
was similarly the case for the about.com site. Because of the exaggerated figure for people
accessing the information about simvastatin on these two sites, they were excluded from
the analysis. Constructing a perfect sampling frame for Internet sites (of any content), is
probably impossible; and wholly depends on the purpose of the research.
A range of different sampling strategies could have been used in place of the purposive
sample; e.g. a random sample of the 33 web pages that met the inclusion criteria, or web
pages that represented typical cases. These sampling frames may have derived different
results to those found here; and so the findings of this study are not necessarily
transferable to all other e-health and mMI sites. However, this study sought to analyse the
most commonly accessed websites with information about simvastatin. The sampling
frame offered an indicator of how many people, on average over three months, have
accessed the sites. Despite these drawbacks it is considered that the purposive sampling
frame served its pragmatic role.
A further limitation of the Alexa Web Search 'reach' data was that it is not broken down by
country, so there is no indication of how many people from the UK accessed a given site.
Therefore the sample of mMI sites is not necessarily representative of those accessed by
people in the UK. This would require a different method which was not available when
the study was conducted.
Analysis of the content of mMI sites can be difficult. The Internet has been likened to a
'moving target' (Berland et al., 2001),because it is constantly evolving; a point which
presents a challenge to research (Weare and Lin, 2000). Evaluation of the same site at
different times can be difficult, and several sites have changed their features since they
were analysed for this study. For example, the Medicines Guide site is no longer a pilot, and
has U;ereased its content, while Best Treatments now requires people to subscribe to it.
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This study was conducted two years before Breekons et al. 's (2008)reported finding
limitations of the HON Code (see 1.3.6),and so this finding could not have impacted on the
decisions to apply the principles from the HON Code (along with the DISCERN website)
for assessment of the sites' quality. However, it was not an aim of the content analysis to
compare different tools for assessing an IBMIsite's quality.
The readability of the IBMIwas conducted by two researchers who applied good practice
principles. However, they may not have been the most suitable people to judge this: the
person best placed to comment on the readability of the information is the end user. The
readability of the infonnation for the medicine user will be more apparent after the
usability study reported in the next chapter.
4.5.4. Implications
• There was variation in the quality and content of the sites. Medicine users should
be aware that they will find more or less information, of greater or lesser quality,
depending on the site they have accessed.
• This study did not examine if the sites provided infonnation about the benefits of
taking s;mvastat;n, other than if it reported why it should be taken and the
consequences if not Future analysis of mMI content could examine what
information about benefits is and is not provided.
• Sites need to clearly state when they are, and are not, evidence-based; e.g. by
providing references to evidence.
• Typing the name of the medicine into the search engine often returns pages
dedicated to that specific medicine rather than the homepage of the sites. The
homepage may then be a redundant feature to many people. However, this may
remain a reassuring design feature, allowing the person accessing the site to more
easily access infonnation about more than one medicine on the same site.
• Providing infonnation as a 'printer friendly option' will enable users to print off
for later reading. However, providing infonnation in PDF file format alone may
make the site less appealing to the individual because it does not offer the potential
interactive nature of an HTML web page.
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• Only one site was found to offer an option to personalise information. This may
have been a product of excluding sites that require registration.
4.6.Concluding remarks
This study has found a large number of websites containing information about medicines
by using a limited sample frame. This number may be surplus to the needs of many
medicine users, because we know that most people do not look beyond the first page of
links when searching (see 1.4.1).There was little difference between the design features of
the sites. Several sites' homepages were cluttered with links, and this may have a negative
effect on some people interfacing with them. Of the most frequently accessed sites, only
one provided the option to personalise the information. This option was limited and may
be missed by users. There was variability in the quality markers of the sites. This mayor
may not be an issue, depending on whether or not users look for these features.
There was inconsistency in the medicines information on the sites, and several sites did
not provide detailed information. Furthermore, of the ten most frequently accessed
websites, only half provided information on ten important safety and efficacy issues. The
usability and readability of these sites is examined in the next study, reported inChapter
five.
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Chapter five
Study three: evaluating the usability
and readability of web sites with
information about medicines
5.1.Introduction
The previous study examined quality indicators, content, and design features of fivemM!
sites. The study reported in this chapter follows this by observing people interacting with
these websites to determine if the sites were easy to use and if their information was
readable. Participants were asked to think aloud while using these sites, and at the same
time a computer programme recorded their online actions and verbal protocols. A User
Test questionnaire was administered to determine the readability of the information.
This study used a mixed methods design, as set out in 2.7, to identify when a participant
was able to navigate a site with ease to find and understand its content, and to provide
insight into their perceptions of these difficulties from their concurrent verbal protocols.
This work was complemented by gathering participants' opinions on the sites. This study
was presented at the Health Services Research and Pharmacy Practice conference (Knapp et al.,
2008, Nicolson et al., 2008a).
5.1.1. Theoretical framework for the study
The theoretical framework of this thesis was outlined in 1.5.2. The following is a summary
of some relevant aspects.
The framework of distributed information resources (Wright et al., 2000) was applied to
code the observations and online actions data from the usability study. The coding
framework was:
• State: information displayed onscreen.
• Plana: actions based on knowledge, internal to the person or external to the
website.
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• Goal: an outcome formed by the user.
• Affordances: possible next actions.
• History: internal to the person and external to the website.
• Action-effed relations: the causal relation between an action and an effect.
• Knowledge about medicines: individuals' knowledge or experience of taking
medicines.
• Conceptual system knowledge: a sequence of actions required to complete a task.
The design principles of Preece et al. (2002) were based on an understanding of cognitive
processes, and were applied to code the participants' verbal protocols. They are:
(i) Attention: online information should be salient when it needs to be, for easy
processing. Guttered information making excessive demands on attention
should be avoided.
(H) Perception: icons can enable meanings to be easily distinguished.
(iii) Problem-solving: information on the site to aid interacting with the website
more effectively should be included.
(iv) Memory: Internet users should be able to recognise rather than recall
information, as the former is a more effective method of retrieval.
(v) Leaming: websites should encourage active learning by the user.
(vi) Reading: aim for large text without affecting formatting if the text is a struggle
to read.
5.1.2. Aims
The aim was to identify common features of a sample of websites containing information
about simvastatin which facilitated, or were a barrier to, locating and understanding the
information about medicines. A set of evidence-based recommendations for the design of
mMI will be derived from these findings. The aim is to apply these to a site in the final
study to examine if they improve readability.
The specific aims were:
(i) To examine how medicine users searched for information about medicines on
the Internet;
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(ii) To examine whether the design of IBMIsites helped or hindered medicine
users to locate specific information about taking medicines; and if the
information was understandable.
(iii) To understand how medicine users assessed the trust of the sites;
(iv) To record the participants' thoughts and feelings about the usability of the sites,
and the understandability of sites' content.
5.2.User Testing and usability research
The research in the last two studies (this chapter and Chapter six) largely employs User
Testing and usability research to examine the ease of use of the sites and the readability of
their content.
5.2.1. Examining the readability of IBMI with a User Test
Readability formulae are insufficient for examining the understandability of information
(see 1.2.S).The method for assessing the readability of PILs is largely interpreted to be the
User Test (European Commission Directorate-General III, 1998).This study applies the
method of User Testing to mM! sites. Because this method is currently used for evaluating
only leaflets, the literature has only focused on User Testing of PILs. User Testing
examines the information and not the user; a principle that also underlies usability
research. A User Test requires the individual to use the information as it is intended to be
used. The observer notes how the participant uses it and what problems she or he has, to
find out what is wrong with it, and not merely confirm that it works (Siess and Wiseman,
20(4). A User Test seeks to examine:
(i) If the user can easily find key information, and
(H) If the user can express the information in his or her own words (Raynor, 20(5).
The insistence on expressing the information in his or her own words requires that the
individual explains the information in a way that shows that it was understandable.
Partidpants in User Tests are recruited from the target group for the medicine, although
they are not actually taking the medicine themselves (Raynor, 200s). It is assumed that
partidpants bring no prior knowledge to the test, as it aims to mimic the situation of a first
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time medicine user. They are given a scenario to consider: for example, they have been
prescribed simvastatin for the first time, and are asked to read the leaflet to find out about
it. Using the PIL, they are asked to find information to answer a number of factual
questions in a User Test. Usually 12 to 15 questions are asked, as this is a sufficient number
to identify problems (Blenkinsopp, 2(05). The questions are asked in a random order,
rather than the order in which the required information appears on the leaflet, to make
less obvious the position of the answers.
As a benchmark, at least 90% of participants must be able to find information to answer
the questions; and of those who do, 90% must be able to understand it (Raynor, 2005).
These thresholds are applied to PILs in EU legislation (European Commission, 20(4).This
is an iterative process, whereby the PIL is modified and retested until it reaches the
90%/90% pass mark (Anonymous, 2005). The information participants are asked to find
reflects all five EU categories for WMI, particularly safety and compliance issues (Raynor,
2007).
User Testing PILs determines if the infonnation can be found and understood. This is a
perfonnance-based test in contrast with the readability formulae (see 1.2.5). However, the
review of literature reported in the background chapter (1.4) failed to find any previous
studies that had conducted a User Test of IBMI. Because User Testing was designed for
evaluating PILs and not IBMI, this presents three issues. Firstly, User Testing has not been
validated for this medium; secondly, this method alone does not provide the means for
assessing whether the participant can use the site with ease to find the infonnation (before
trying to understand it); and thirdly, a distinction between evaluating the readability (i.e.
understandability) and the ease of use of a site is necessary.
5.2.2. Examining the ease of use of • website with • usabiUty study
To examine how participants navigate a site to find the infonnation, and what difficulties
they have in doing so requires a usability study. Usability studies can be broadly
categOrised as indirect or direct in their design (Nielsen, 1993).
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Indirect study design
Indirect methods measure the user's interactions in a (sometimes) concealed manner: for
example, studying Internet activity by logging file use. This approach can offer a reduction
in the bias associated with observational methods (see below), but there is an ethical
concern about invasion of privacy; and although this method documents activity, it cannot
explain it (Norman and Panizzi, 2006).
• Interviews
Interviews indirectly explore the reasons why people act as they do, permitting the
interviewer to interact with and react to the interviewee, clarifying matters as and when
they arise (van Teijlingen and Forrest, 20(4). Problems can arise if interview bias occurs,
where the interviewer steers the interview in a certain direction, either knowingly or not
(van Teijlingen and Forrest, 20(4). Furthermore, because an interview is indirect, it does
not study how the user interacts with IT in real time (Nielsen, 1993).As a means for
recording user reflections in conjunction with a direct method, this may offer a reliable
means for gauging usability. However, there will be the drawback that the findings may
not be generalisable to other populations.
• Focus groups
Focus groups fadlitate the expression of like-minded people's ideas and experiences
(Kitzinger, 1995).They can be problematic if participants express only 'socially desirable'
views (van Teijlingen and Forrest, 20(4). Furthermore, testing information in a group
environment can obscure individual (mis)understanding and (in)comprehension
(Shrensky and Siess, 2005), therefore valuable data may never be recorded. A further
problem with this method is that of self-selection: those most likely to give feedback will
be the most dissatisfied with the system, and the most vocal users; therefore the findings
will not be representative of all users of the system (Nielsen, 1993).
Dinct study b.lgn
Direct methods measure users interfacing with IT in real time. This can be a demanding
process for both observer and participant.
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• Observation and online tracking
Observation is one means whereby participants use the computer system as they would in
their normal user environment, without interference (Nielsen, 1993). This is done by
making a detailed observation of behaviour, and watching and recording what people say
and do. However, this method may prompt changes in the behaviours or actions of those
being observed, i.e, the 'Hawthorne Effect' (Mays and Pope, 1995), which can lead to bias.
Tracking the actions of the person using a website can offer a reliable measurement.
Mouse tracking can be used as a proxy for following the attention of the user, because
there is a close (but not perfect) correlation between visual gaze and attention (Norman
and Panizzi, 2006). Computer software (for example, Macromedia Captivate™) tracks online
activities by recording aU onscreen actions and instantly creating a flash simulation.
5.2.3. Think aloud and verbal protocols
The 'think aloud' method requires the user to express her or his thoughts that arise during
a task. This approach contrasts with asking them to describe or explain how she or he
solved the task retrospectively (Ericsson, 2002), because this could lead to biased
justification of task performance in hindsight. An alternative is to ask the user to report
what she or he did at the end of a task. This allows the participant to complete the task
without the distraction of interrupting their cognitive processes by explaining their actions
in real time (Norman and Murphy, 20(4). This method is problematic if the participant
cannot later retrieve the reasons for their actions.
Concurrent think aloud (CTA) requires the participant to think aloud during a task. while
retrospective think aloud (RTA) allows the individual to carry out the task in silence, and
then verbalise his thoughts afterwards on viewing a recording of their task performance
(Van den Haak et al., 20(3). A comparison of CTA and RTA for evaluating an online
library, found that both methods detected a similar number of problems, but differed in
how these problems were detected: CTA highlighted more observable problems in the
participants' actions, while RTA discovered more verbalised problems (van den Haak et
III., 2(03).
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The think aloud method is central to the evaluation of the usability of mMI in this thesis,
because verbal expressions generate a source of direct data for thought processes involved
in the task (laspers et al., 2004), referred to as verbal protocols (Ericsson and Simon, 1980).
The insight that this method gives into the user's thought processes makes this an
invaluable method for examining usability. Thinking aloud, it is noted, can be difficult to
do because of its unnaturalness, as (i) it slows the user's performance, becoming less
representative of their actual behaviour, and (ii) it can influence the user's problem-
solving behaviour because they are verbalising their thoughts (Nielsen, 1993), which may
introduce bias, and make the outcomes less valid.
There are benefits and disadvantages to both the Cl'A and RTA methods. The research in
this thesis will adopt Cl'A for the following reasons. Verbal expression of thoughts has
been shown not to significantly disrupt cognitive processes (Ericsson and Simon, 1998), a
commonly held criticism of 'introspective methods'. U gathered and interpreted correctly,
the method offers a valid and reliable insight into the user's cognitive processes during a
task (Ericsson and Simon, 1980). Because the user voices her or his cognitive processes at
the time of acting, she or he later avoids rationalising her or his actions (Nielsen, 1993);
giving the method high face validity (van den Haak et al., 2003).
5.2.4. 'Discount usability'
Nielsen (1993)has proposed that researchers should apply the concept of 'discount
usability engineering' to usability studies. These are simpler methods that reflect practical
design situations, based on the argument that they can be almost as successful as
theoretically driven usability studies (which demand greater money and expertise to
conduct), for identifying problems with IT usability. This approach does not seek
perfection in research. but rather to identify usability problems, using four techniques
below (Nielsen, 1993).
• Observing users in an unobtrusive way allows them to work as they normally
would, without interference.
• Devising a scenario to reduce the demands of the usability test.
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• Simplified thinking aloud allows the observer to determine why as much as what a
participant is doing.
• Observation notes suffice because discount usability is not aiming for perfection
and therefore video recording of sessions is not necessary.
The sample size in usability testing is a contentious issue. Nielsen (1993) proposed that a
usability-test can be conducted with as few as five participants. nus has been challenged
by Faulkner (2003) who found that, while a five-participant study can identify major
problems, a usability-test with 20 participants has far less variance in results, and does not
miss subtle errors that a smaller study would. While this is important to note, it ignores
practical considerations: for example, time and financial resources available for conducting
the study. Furthermore, the evidence shows that a study with five participants has a 90%
probability of getting within 24% of the true mean level of problems identified. nus would
be an acceptable level of accuracy for many usability studies (Nielsen, 1993).
5.2.5. Concluding remarks on usability research
There is a need to understand how people use a website to access and understand
information about their medicines effectively. Usability research will have an increasingly
important role in identifying problems with the safe and productive use of e-health as it
continues to grow (Kaufman et al., 2(03). The position of this thesis is that it is essential to
conduct a usability study for evaluating participants' use of IBMI sites in conjunction with
a user-test examining the readability of its contenllntemet-based information is not the
same as paper-based information; therefore a User Test alone is insufficient. The first goal
of research of IBMI should be to examine how the user locates and draws on the
information, because the ease of use of a site will precede the user's attempts to
understand its information (Nicolson, 2007).
A usability test will be employed to evaluate the features of the IBMI sites whim
potentially facilitate or impede locating and understanding of information. This will
provide actionable data, indicating what needs improving (Rubin et al., 2001) and offering
recommendations on how to make IBM! sites more effective. Because of financial
161
constraints in this PhD research project, the tenets of discount usability have been adopted
for the design of the usability study in this thesis.
S.3.Methods
5.3.1. Research ethics application
Research ethics approval for this study was obtained from the University of Leeds, School
of Healthcare, Educational Research Ethics Group in June 2006.
5.3.2. Participant criteria for inclusion and exclusion
The inclusion criteria for participants were:
• People who had taken a POM or OTC medicine in the previous year.
• People with prior experience of using a website, (because participants with no web
experience would have required extensive training before conducting the tests).
People were excluded if:
• They were under 30 years of age, as they may have less experience of taking
medicines and therefore value less the importance of this study.
• They were current members of the medical or healthcare professions; or
conducting any form of research.
5.3.3. Recruitment of study participants
The participants in this study were drawn from a convenience sample. Participants were
recruited in person (by the author) from a busy pharmacy in a Leeds suburb. Recruitment
took place over the course of seven visits (lasting around three hours each) between
August 2006 and February 2007. Pharmacy customers were approached by the author and
asked:
(i) If they could use the Internet;
(ii) Their age (if there was doubt that they may be under 30 years of age);
(iii) Whether they had taken a prescribed or OTC medicine in the last year.
Those who answered yes to all three questions were given a verbal overview of the study
and invited to take part. Because of the large volume of people approached in a relatively
short period of time, the author was unable to keep a record of how many people in total
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were asked if they would take part. Finding people who met the indusion criteria and
showed an interest in the project was a lengthy process. Many people were not recruited
because they were unable to use the Internet. Most participants who could use the Internet
(in general younger adults in employment), said they would be unable to come to the
University to take part in the study.
Thirty people meeting the indusion criteria verbally agreed to take part in the project and
gave contact details. They were given full information about the nature of the study,
verbally, and in writing (see Appendix thirteen). They were asked to return a signed
consent form (see Appendix fourteen), and a short questionnaire (see Appendix fifteen).
After the study completion they were given a £10 gift voucher as a token of appreciation.
Six participants withdrew from the study, and six who did not respond to telephone calls
or emails for morc than one month were considered lost to attrition. One person agreed a
study date, but did not appear nor return the consent form or questionnaire. Seventeen
people returned the questionnaire and completed the consent form. Around the time of
collecting from the 12111 participant, it was noted that 'data saturation' had been reached;
i.e. no new concepts were emerging from the data (see 5.3.6 for further details). For this
reason it was decided not to run any studies after the 15th (at which point equal numbers
of participants had viewed each of the websites used in the study).
5.3.4. Conducting the usability study
The study was conducted one-to-one in the University of Leeds, School of Healthcare.
Each participant sat at a work station. The author sat adjacent to the participants, to
observe their interaction with the Internet, and to be able to ask them the User Test
questions (see below). A computer programme, Macromedill CtlptitNlte™ recorded the user's
on-line activities and vocalisations. The author noted the outcomes for the three tasks, and
made notes of the participants' actions when using the IBMI sites. Participants were
instructed to 'think aloud' during all tasks and wore a microphone to record their
vocalisations, conrurrently saved with their online actions by Macromtdill CllptitJtJte™.
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trustworthiness of the site they had used. They were asked to explain the information in
their own words, a proxy measure for understanding the information. U it was thought
that a participant was reading verbatim from the screen, they were asked to tum away
from it to give their answer. The participants were taken straight to the web page for
simvastatin rather than the site's homepage, because medicines users have reported finding
infonnation using a search engine (Peterson et al., 2003), which usually provides a link to
the specific medicine's web page, and not the homepage of the ffiMI.
The User Test was adapted from one used by the LUTO Research Ltd for assessing the
usefulness of a paper-based WMI; providing a tool for measuring finding and
understanding the infonnation. (This has been validated for examining leaflets, but not
IBMI sites). Ten questions of practical importance for taking simvastatin were piloted on
the ten sites in the previous study, see 4.4.7. Usually 12-15 questions are asked in a User
Test (1993), but because participants were also asked to'think aloud', this was reduced to
ten questions, to lessen task demands. These questions were designed to require
information which reflected all five EU categories for medicines information, particularly
safety (side effects) and compliance issues. Figure 6 provides an example of the rationale
for questions in the User Test.
Figure 6 Example of the rationale for a set of questions in the User Test
Respondents on the DIPEx website (http://www.DIPEx .orgl) have talked about side
effects from taking statins; cough, some hair loss and vivid dreams (Interview
HAn Transcript www.DIPEx.org, Accessed July 2006); and the importance of diet
change to maintain a low cholesterol level when taking a smtin (Interview HA21
Transcript www.DIPEx.org, Accessed July 2006). These concerns of people taking a
statin are the basis for five User Test questions (see Appendix sixteen for the User
Test).
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If participants were unable to find the indicative information, the author intervened at
three points:
1. The participant was reminded that this was a test of the website and not his or her
knowledge or skills, as recommended by Nielsen (Blenkinsopp, 2005);
2. If participants had difficulties after the first prompt, the author offered to repeat
the question.
3. If the participant still failed to find the information at this point, they were directed
to it by the author.
This enabled data on the understandability of the information to still be gathered, even
when the information could not initially be found. This ability for the author to be
responsive to problems occurring during this research is considered a strength of
conducting qualitative research Oohnson and Onwuegbezie, 20(4). For scoring the User
Test in this circumstance, the participant received 0 for finding the information. In
addition to these prompts, if the participant was silent for a length of time (e.g. more than
ten seconds), they were reminded to keep talking aloud.
Examining participant assessment of the trustworthiness of the sites
Immediately after completing the User Test, participants were asked if they thought the
information was trustworthy or not, and their reason for their answer.
5.3.5. Outcome measures
The Internet search, User Test, and trustworthiness assessment had separate outcome
measures:
Internet search
This task had five measures:
(i) The search strategy and search term participants used;
(ii) The URL of the site opened, and how the site was entitled on the search engine
(if found by a search engine);
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(iii) How many search results pages were viewed, and the position of the link on
the page that it was opened (for example, third link);
(iv) How long they searched for the information; and
(v) Participants' responses to the question 'Why did you search for information
this way?' at the end of this task.
User Test
This task had four measures:
(i) Participants' successful location of the indicative information to answer each
question. This was measured by the participants showing where the
information was located on the web page. Finding the correct information
received a score of one mark, noted by the observer on the User Test form. The
inability to find the information received a score of O.
(ii) Participants' understanding of the information to answer the User Test was
measured by their explanation of the information in their own words, verbatim
transcribed on the verbal protocols. A correct explanation received a score of
one mark, noted by the observer on the User Test form. An incorrect
explanation or the inability to explain the information received a score of O.
(iii) Participants' online activities for navigating mM! sites, denoted by (a) verbal
protocols, and (b) online actions, recorded by Macromedia Captivate™;
(iv) Observed problems and case of use when interfacing with mMI sites.
Participl",ts' assessment 0/ the trustworthiness 0/ the sites
This task had three measures:
(i) Whether the participant said if they thought the information was trustworthy
or not;
(H) Participants' reported reasons for considering if the information was
trustworthy or not; and
(iii) Participants' reported strategies for assessing trust
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5.3.6. Data analysis
Two methods of data analysis were used for the usability tasks: emergent themes for the
search strategy; and a-priori codes for the analysis of the usability data (online actions and
observations), and the User Test data.
Internet search
Participant's search strategy was analysed, and details of the site that they had opened
were noted. Analysis of their online actions, observed behaviours, and responses to the
question at the end of the task was based on Grounded Theory (Glaser and Strauss, 1967),
where the themes emerged from the data. The analysis was made by the author alone. This
is a common approach to analysing qualitative data, where the researcher is considered
the instrument of research, using his or her judgement as the data collection and analysis
processes are intertwined (Bradley et al., 2007). The author examined the transcripts and
noted themes consistently raised by several participants, and themes made by only one or
two participants. The themes were iteratively categorised, until no new categories were
found to emerge from the transcripts. The quotes presented in the results section are
examples of the consensus and atypical themes that emerged during the task. Examples of
these are provided in Figure 7 below.
Figure 7: Examples of consensus and atypical themes that emerged
"That's the way Ialways searchfor information basically. I'm II Google man;
in fact it's a verb now: to Google, isn't it?" (participant 119).
This was categorised as 'previous experience determining search strategies'
because the participants were relating their search strategies back to previous
actions.
1. Examples of iteratively derived themes that emerged from remarks made by the
participants.
"That's down to inexperience err, really, because I've never been taught
computer skills, I've what I've picked up myselffrom manuals" (participant
'7).
2. Examples of remarks made by participants that typified the broad consensus.
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"It's just the way that it's presented and the form that it's presented, it does
seem to be well researched" (Participant #6).
"I can't see a site called MayoClinic.com err being able to put up a website like
this without it being, ertn, correct" (Participant #16).
This was categorised as 'reasons for trusting the website'.
3. Example of a remarks made by a participant that was untypical of the broad
consensus.
"Well yes I would have imagined they would have erm, revised it a bit more
recently than that. This is obviously an old ... this is old information, isn't it?
There must have been something more up-to-date than this?" (Participant
#10).
This was categorised as 'reason for trusting the website'.
Analysis of the User Test and ease of use
The author analysed the User Test by counting the number of participants who could find,
and then explain the indicative information to answer each question. The results for
locating the information were scored as 0 .. no and 1=yes, as used by Dickinson et al.
(2001).For example, the indicative information to answer the question 'name three
unwanted effects from taking simvastatin' was any three from muscle wastage or pain,
constipation, wind, flu-like symptoms, and headache. H the participant highlighted where
these answers were on the page, they received a point. H they were then able to explain the
indicative answer, they received a further point, making this a performance-based test.
For each question a comparison was made between how many participants did or did not
find and explain the information. Examples of participants failing to locate, and/or explain
the information were more important for this analysis, because they indicated problems
with the ease of use of the mMI site(s), making them less useful to users.
A random sample of 20% of User Test scores were independently scored by a PhD
supervisor, who has considerable experience of conducting User Test studies. The scores
had a 97% agreement rate. This was much greater than 80% agreement that Miles and
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Huberman (1994) have considered to be a reasonable level of reliability. This was a
satisfactory indicator that the scores were reliable and so there was no need for a second
scorer to check the remaining User Test scores.
The analysis of the usability data (observations, verbal protocols and online actions) was
conducted using a set of a priori developed codes (see 5.1.1.). This is a deductive approach
to conducting data analysis that utilises a framework to analyse the data (Bradley et al.,
2(07). This method was chosen because it is said to be both valid and reliable (pope et al.,
2(00).
The verbal protocol data were analysed, as recommended by Ericsson and Simon (1984),
by segmenting the verbal protocols and then encoding them; ensuring the encoded
categories correspond to the verbalisations to assure validity and reliability. The process of
verbal protocol analysis had the following stages:
(i) The author played back the Macromedia Captivate™ recordings and transcribed
the verbal protocols in full.
(ii) Participants' online activities were noted; and observation records added.
(iii) The records were segmented at a question level for each participant; thus
giving 150 potential examples for coding; ten for each of the 15 participants.
(iv) Participants' verbal protocols were coded for questions where they were unable
to find, or explain, the indicative information to answer the User Test. It was
presumed these were examples where the sites were not easy to navigate and
the information not understandable.
(v) The data were indexed with the a priori codes (see 1.5.2), and more than one
code could be applied to the observations, verbal protocols and online actions
of each segment.
(vi) Example of an a-priori coded verbal protocol:
.NThere·s" problem here, because my joints do ache because lluroe arthritis. But 1saw
something earlier on, hmmm; now then. Other medical problems, di-dum; I'll see if1
can find it again. I thought 1saw something about joints as 1was scanning past, now
here: side effects of this medicine; joint pain" (Participant 112).
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This was coded as internal history because the participant referred to information that
she had seen when navigating the page.
Online actions and observations were analysed using the distributed information
resources model (Wright et al., 2(00), as a framework. Verbal protocols were analysed
using the model of design features aiding cognitive processes (Preece et al., 2(02) as a
framework. The author used these frameworks to code and analyse the verbal protocols,
online actions, and observations for all questions where participants were unable to find
the indicative information to answer the User Test.
A second researcher independently coded a sample of these records, and the separate
codings were compared. The two assessors discussed the coding scheme and reconciled
differences in coding. This was again much greater than the 80% agreement and the
author's coding was therefore considered reliable (when compared to that of an
experienced usability tester), and the remaining coding was not checked.
Participants' assessment of quality
The analysis was the same as for the Internet search strategy task (see 5.3.5).
5.3.7. Conduding the interview
The post-study interview gave participants the chance to express opinions about the site,
the information, and the tasks, and whether they valued the site and its content. The
interview was conducted immediately after the usability study, to minimise disruption
during the task and to make it easier to recall the reasons for actions.
The questions (see Appendix sixteen) were influenced by the concepts of usability (see
1.5.2). The question 'Did you feel it was easy to use the site?' related to 'leamability'; 'Did
you feel the site was pleasant to use?' asked about levels of satisfaction with using the site;
and 'Did you feel the site was helpful for finding the information?' related to efficiency.
Participants were asked whether they felt the information was understandable; which
complemented the objective User Test results. Because of doubts over whether or not the
thinking aloud task disrupts processing (see 5.2.3), participants were asked if it had
affected their performance.
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The interview took a semi-structured format. The last question let participants introduce
issues not previously discussed; and for the author to follow-up observations made during
the usability study and issues raised by the participant. Using a semi-structured technique
allowed flexibility in the interview (Britten, 1995,van Teijlingen and Forrest, 20(4).
Outcome data
The outcome data were:
(i) Participants' opinions, both typical and uncommon, about the usability of the
site, and the readability of its content.
Interview data analysis
Although this was a semi-structured interview, no a priori framework for the analysis was
used. Participants' remarks were transcribed in full. The analysis of this data was the same
as for the search task (see 5.3.6), based on Grounded Theory (Glaser and Strauss, 1967),
where the themes emerged from the data. The analysis was made by the author alone. The
themes highlighted the main issues that arose when participants interacted with the web
pages.
Reporting the interviews
All interview extracts are quoted verbatim, with pronunciation and grammatical errors
deliberately left in. A series of dots indicate an elapse of time when the participant was
silent; or a deliberate gap in the verbal protocol where the individual spoke either about
an irrelevant matter, or about person specific or sensitive information. When the
researcher interjected, this was mentioned in parentheses. Participants are distinguished
by the number they received for the study, and the site that they were randomised to for
the User Test task.
S.4.Participant demographics
Partidpant demographics, their previous and current use of medidnes, and experience of
accessing e-health and IBM!were assessed using the 22 item questionnaire (see Appendix
fifteen), designed specifically for this study. Questions about medidnes and medidne
taking were based on those used in the 2003MORl'Medidnes Use Questionnaire' (Market
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& Opinion Research International for Medicines Partnership, 2(03). Questions about
previous use of mMI were devised to assess participants' feelings about the quality of the
sites, the readability of their content, and the ease of use of their design features.
Participants' ages ranged from 37 to 70 years with a mean age of 54 years (see Table 19).
There were more male than female recruits and only three participants were from an
ethnic minority group. Their education level varied; seven were graduates, while four had
completed their education by the age of 16 years. Five participants were retired. Twelve
participants had been taking medicine(s) for more than one year. Most participants were
currently taking two or more medicines, and five were taking a stalin. All participants
recounted seeing PrLs accompanying medicines. Most said they read them 'always' (7
participants) or 'sometimes' (5 participants). One person said they never read the
information. When asked why they read the leaflets, several said they wanted to know
about possible side effects, which was the most commonly read section of the leaflet. Most
read the information for practical information about taking the medication: for example,
what it is for, and how to take it. No participants strongly agreed with the phrase 'they get
enough information about their medicines', although most tended to agree. Most
participants (11) said that they valued medicines information from different sources, and
the same number felt it was good to have more than one source of medicines information.
Eleven participants who had five or more years' experience of Internet use were
considered highly experienced; only one participant had less than three years' experience.
Ten participants accessed the Internet daily; and fourteen had access at home. The
majOrity accessed health or medicines infonnation on the Internet, using a variety of
SOurces: for example, three participants reported accessing the NHS Direct website. Seven
participants said they looked for e-health because it was convenient (quick and easy to
access). One person reported searching for infonnation online when no leaflet
accompanied their medication. All sai,d they found the website by using a searen engine.
Half the participants felt e-health sites were easy or very easy to use; the rest felt they were
neither easy nor difficult. Most felt the infunnation was useful or very useful; three felt it
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Figure 8: Summary of participants' search strategies
• Participants spent a mean 106seconds searching (range: 31-239seconds).
• No participant looked beyond the 5th link on the first page of search results.
• 14participants typed 'simoastatin', One typed 'simvastatin - drugfor cholesterol'.
• 14 participants accessed the site via a search engine; one searched using the NHS
Direct portal.
• The most frequently accessed site, opened six times, was the medic8.com site; with
a page entitled' Simvastatin - a Patient's Guide'.
• No participants opened a pharmaceutical company developed website, or a site
with 'amateur input'.
Search strategy used
Most participants searched by typing simvastatin into a popular search engine. Three
examples were observed where participants used a different approach (see Table 21); and
these are important to note. One participant searched on the NHS Direct website,
(www.nhsdirect.nhs.uk); explaining that he did so because of previous experience, and
because he trusted the site to give good information (see Figure 10:).The second case was
where a participant searched the University intranet; (Participant 117 Medicines Guide). The
third example was where a participant specified the search, typing' simvastatin - drug for
cholesterol'. She explained when she searches for artists on the Internet; she clarifies the
search with the word 'artist'. Hence she said:
"The word simvastatin, 1know we know it's a drug name, but it could, erm, it could be
anything. So if 1just give the computer a reminder that it's the drug, that the word is
for the drug that 1am looking for, I thought it might help it" (Participant 13,
Medicines Guide).
Another participant expressed she would specify the search to UK only sites.
Participants gave several reasons for using a particular search engine (see Figure 9:).
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Figure 10: Example of searching for information using NHS Direct
Participant #13, Electronic Medicines Compendium:
"Okay. What a would normally do, erm, yes okay, is get to Google. We just go to
NHS search engine. And there probably in this case I'll just try on the NHS
website; okay". [Online action: types NHS into Google search bar on tool
bar]. /I Erm, okay on this website I know you've got this erm, 24 hour nurse-led
telephone advice service, yeah(?) ... Erm I think that's what I need okay. Erm;
then when Iget there; okay obviously there are quite a number of, erm, submenus
1uh-huh], so what I'll probably try and do is, erm ... I'm trying to get particular
information on a medicine, the simvastatin, yes(?) Okay so maybe let me see,
'health encyclopaedia, common health questions, self-help guide'. Okay now I've
looked, I suppose the specific drug that I want; I'll probably just try and eh, go via
the search engine". [Online action: types simvastatin into the search bar}. "So
I'll just type in sim-oa-sta-tin. I suppose it I'll probably try and go ... if there's
any information I'm hoping it should come out, okay yeah. Well here I've
probably got most of the information that I need for simvastatin, yeah? Okay the
information; what one was to know just probably what the drug is for and ...
Okay the .1can see the information that I'm getting"
[Online action: clicks on the first link:
http://www.nhsdirect.nhs.uklarticleslarticle.aspx?articleld=202&sectionld=24580
(entitled Hyperlipidaemia and lipid-lowering medicines: Treatment)}
[Author - Why did you search for the information this way?}
Participant #13, Electronic Medicines Compendium:
"I thought probably I would do ... get better results if I was to search the NHS
website 1comparing site to Googlel, probably I'd get information from lots of other
websites, yeah, and I'd probably end up getting ...... But I suppose Ithinlc I,
because I've used the NHS website before Iwant specifically to that website and
the information that I find there"
Assessment 0/qulllity ad trust
Participants were not asked about their judgement of the quality or trustworthiness of the
site at this point because it may have primed them ahead of the question about the
trustworthiness of the site used in the second task, therefore biasing results. Observing
their behaviours suggested that some participants may have assessed site quality,
although not by using a recognised method. For example, no participants opened sites
labelled as sponsored links, and several showed discernment in what information the
search engine said the sites covered. One noted:
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"Now let's see if some of them look more reliable than others. 'Cause there's lots of
stuff on, which is why I don't normally use it. Doh heck! Medicine plus drug
information simoastatin. Du-dum; erm. Zocor, ....contraindications, ... healthy, ... if
it's anything, it looks more official than the others" (Participant '12, Mayo Clinic).
She reacted to seeing a link to Wikipedia, saying" Erm, Wikipedia is not reliable, I know that
FOR A FACT, ... .through experience" and further noted how "some of them (links on Coogle)
look more reliable than others" (Participant '12, Mayo Clinic).
Looking at the site labelled 'Simvastatin: a Patient's Guide' and noting the uri
(www.medicS.com). a participant said: "Err; but 'Simvastatin a patients guide' might give me it.
To me 'medicS' means it's probably biased anyway, because it's probably some company"
(Participant 119,Drugs.com). He still opened the link despite these doubts. A further five
people opened this link, making it the most commonly accessed site. Nine different
websites were opened in total (see Table 21).
Readability
The WWW.medicS.com site appealed to participants because it stated that it provided
information for the patient. One participant said: "that looked tome as if it was aimed at TIlE
patient" (Participant '12, Mayo Clinic). Another participant made a distinction between
information for a patient or a doctor:
"Well erm I chose a patients guide because I would normally be a patient if I was
receiving it '" Erm I'd certainly not want to read what a doctor reads because I
wouldn't understand it." (participant no, Electronic Medicines Compendium).
The medicine users appeared to want basic information that they could build upon. For
example, explaining why he opened the link to Wikipedia, a participant said:
"I use Yahoo! and I know that Wilkipedia is the next stage where I go because that's
like, if you want to call it; it's an encyclopaedia, it's the basic one. And then I go bacJc
and I say well what else do we want to look at?" (Participant '18, RxUst).
Information content
Links labelled 'side effects' provoked immediate reactions: "Side effects, '" sounds
interesting; tells you about side effects" (participant '8, hList); "it mentions side effects ... so
I'm just going to see what effects are on there" (Participant '2, hList); and "SIDE EFFECfS! ...
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RiKht, let me have a look at, ... side effocts, what shall J watch for while using simstatin"
(Participant #1,Mayo Clinic). Participants were equally interested in finding out beneficial
effects of the drug, noting: "it may do more harm; well J want to know what it does first"
(Participant #3, Medicines Guide); and "the one that immediately looks interesting is the one that
tells you it's a cholesterol lowering drug, which is used to prevent stroke or heart attack"
(Participant #11, Drugs.com).
It was important for the site to mention the name of the medicine, as there were
reservations about a link (www.lesscholesterol.co.uJcl) labelled 'Cholesterol and health'. The
participant said: "cholesterollevels and cholesterol lowering agents, so err it doesn't actually say
simvastatin in the, err, actual information here" (Participant #6, Medicines Guide).
Other points raised
The quantity of available information surprised participants. One asked, "Gosh; does every
sort of drug have this information?" (Participant #11, Drugs.com. Another said: "Drug uses, uh
wow! What can J see here from the web; side effects, drug uses, interactions, warnings, recalls, for
patients,from medical authorities; .... wow! There's so much!" (Participant #1,Mayo Clinic).
The search was seen in a broader context of information provision, where a participant
would seek information if it was not provided by his GP:
II J wanted to know that the medication, erm suited the application of my complaint.
Err, you don't always get afull erm, description of the side effects from your GP. 1
always look now to see what the side effects might be in terms of whether it would make
me feel drowsy when I'm driving, etc etc." (Participant #16, Mayo Qinic).
S.6.Results of the User Test
This section presents a summary of the results of the User Test. Analysis of the
participants' online activities and verbal protocols is presented to explain why they did or
did not find indicative information. The verbal protocols highlighted when the
information was adequately explained, or not, (as a proxy measure for understanding the
information). These results have been categorised according to the concepts arising from
the theories in Cllapter one.
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5.6.1. Summary of the results of the User Test
The results for locating and explaining the indicative information are in Table 22. There
were four questions where the indicative information was located by less than 80% of
participants (questions I, 2, 5 and 7), and two questions (7 and 8) where fewer than 80% of
participants understood the answers. Ten participants failed to explain adequately what to
do if side effects were experienced; most stating to seek advice, but failing to mention to
stop taking the medicine. Just fewer than 80%of participants understood what effect
haVing too much cholesterol in your body could have, mentioning blocked arteries, but
not that it could lead to a heart attack or stroke. Aggregating the results by mMI sites for
all ten questions; indicative information was not found for the minimum 80% of the time,
by participants using three mMI sites: RxList, Medicines Guide, and MayoClinic. Information
was understood at least 80%of the time by participants using all sites except MayoOinic.
5.6.2. Reasons for failing to locate and understand the information
Site IllyOllt (stllte)
It seems that participants struggled or were unable to find the indicative information due
to site layout. This was most evident for answering the first few questions, as participants
became accustomed to the layout of the site. For example, some participants were unaware
that they could scroll beyond the initial screen shot (on different sites) to the indicative
information (see Figure 11 for example).
Sites with a clutter of links (see Figure 12 for example) made effective processing difficult,
because they distracted the user's attention: for example, participants clicked on links to
external sites: "l'll try thllt. I'll just press on cholesterol levels (clicks on link to
e.cholesterollevel.injo, see Figure 12) ... and I'm now clicking on 'dTtmUlticlllly reduce cholesterol
levels'N (see Figure 13) (Participant IS, Drugs.com). These are also examples of the use of
affordances. This strategy was not helpful to the participant because the information
needed to answer the questions was on the initial site.
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Figure 11: Example of a site (Medicines Guide) where a participant failed to scroll
beyond the initial screen shot
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Figure 13: External page from activation of link on the Drugs.com site
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Figure 15: Example of a missed table of contents on the MayoClil1ic site
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Figure 16: Examples of the conflict between personal knowledge and online
information
Example one:
Author: "Please name three unwanted effects from taking simvastatin"
Participant #10,Electronic Medicines Compendium:
"Erm, unwanted effects, so this must be side effects. Erm, well, are
they patients who should not take these tablets? Erm, well; if, erm, there's a
number of cases here where people are not to take them. People who have
previously suffered allergic reaction to a medicine containing simvastatin.lJ
you are allergic to any of the other ingredients in the medicine, of which there's
a list above; if you're pregnant, planning to become pregnant or breast feeding.
If you discover you are pregnant while taking simvador which is ... "
[Author notes: Participant immediately recognises this is a question about side
effects, but is confused by the wording on the site].
Participant #10,Electronic Medicines Compendium:
"This leaflet provides a summary of the information available on your
medicine; please read it carefully before you start to take your medicine. "
[Author: Uh-huh; would you like me to remind you of the question? It's please
name three unwanted effects from taking simvastatin. I think you were, you
seemed to be; you first of all when you had started, I think you were correct when
you said side effects if that helps?]
Participant #l0, Electronic Medicines Compendium:
"Ah so it's really about side effects and not erm, reasons not to take. Right
erm, this could possibly be it you should check with your doctor
before, ah no that's before, not after. You have unexplained muscle pain,
tenderness or weakness. Is this what we're referring to here? This list? ..... .It
does, well if it is, it seems to be before, in which case it is badly worded. So it's
not an after ... If this is a side effect, it should have been worded 'after taking
these tablets', not 'before taking these tablets'"
Example two:
Author: "Name me two things you can do to improve your health while taking
simvastatin"
Partidpant '5 Drugs.com:
" ... It doesn't seem to say whether, what say, you should have lifestyle changes
or anything like that; although it does say where 1can get more information,
but it just says your pharmacist. 1was expecting it to say lifestyle chllnges
somewhere; changing your diet, whlltever. But it doesn't seem to; it may
just be me it tells you what you should avoid, the alcohol; but 1was
expecting it to have something about exercise, and something like changing
vour diet, but there's nothinR that 1can see; ... 'cause we've all hetlrd whllt
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you're supposed to do to lower your cholesterol, and 1can't see it anywhere ....
Maybe it's just me! (Laughs)".
[Author redirects her to answer on the page).
Participant #5 Drugs.com:
IIAaah; well it's not very obvious! It's on a very; ... it's under how should 1
take simvastatin. Now if it were me, 1wouldn't put it there. I'd have put it on
it's, err, you know; a low fat, low cholesterol diet in a box on its own, because 1
actually felt 1didn't see that scrolling up and down."
Fil~re 17: Example of trust and distrust of the same site
Example one:
Author draws the participant's attention to the date the Electronic Medicines
Compendium was last revised as a quality marker (last updated in June 2003). "Now
that you've seen it was last updated in 2003, does that change your thoughts about
it?"
Participant #13, Electronic Medicines Compendium:
"Okay; my assumption is, if there's no any other revision that has taken place.
I'd only be worried if, let's say, I'm talking about injrmtultion that is more than
ten years old. Okay, probably that's when I would; probably but if it's three
years old, like; probably there isn't going to be much change since then. But I
am sure this is the date it become effective, isn't it? Okay, so it means this
information is effective from; okay say it is useful from June 2003 up to now so
for me 1would still be comfortable with it, yeah. But probably if it is ten years
old or say maybe, ... there some other website with more updated injrmtultion,
okay but then I would believe that honestly, okay, the people that run the
Internet that are responsible for manning it and posting this injrmtultion; they
should actually be aware of this, probably take out the information that they
know"
Example two:
Author: "This leaflet was last updated in June 2003. Is that at all important to you?
Participant #10, Electronic Medicines Compendium:
"Well yes 1would hIlve imagined they would hIlve erm, revised it a bit more
recently than that. This is obviously an old ... this is old information, isn't it?
There must have been something more up-to-date than this?'"
Some participants wanted the site to be as up-to-date as possible: for example, "'Oh it SIlYS
06/08/05 .... Erm, I think I'd search the medical directory'" (Participant '18, RxUst). When
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asked how recently a site would need to have been updated to be trusted, a participant
said:
"Hard to say but I'd have to at least feel it's been updated in the last three or four
months. Though if I was researching something that was very new which was, you
know, just come on the market or something; I'd maybe want something a bit closer to
hand, a couple of weeks or a month maybe" (Participant 19, Drugs.com).
The last reported update was vague for some:
"It tells you two things: it tells you there's nothing more been found out about
simvastatin since it was updated on the 26th of October 2004; or it could tell you they
haven't bothered doing anything about it since the 26th of October 2004" (participant
#17, Medicines Guide).
PhRnnRceuticRI CompRny websites
Participants commonly did not trust the websites linked to industry. For example, it was
remarked:
"Err note from our sponsors; drugs information online. I'd have to take it with a pinch
of salt. I tend to think anything sponsored by a drugs company is going to have, err,
their own slant on it" (Participant 19, Drugs.com).
This was reflected in another comment:
"Err; RxList the Internet drug use index. Who produces it? That's what my question
would be. It's from First Data Bank. I would go onto First Data Bank and found out
who it is, and I would look at afew other drugs just to see what else they do"
(Participant '18, RxList).
The objectivity of the sites was questioned: "you're taking the word of the, err, manufacturer
on his product; which he could be, he can be biased, can't he?" (participant '7, Electronic
Medicines Compendium); and:
"1 suppose if you were cynical you could say the drugs company would want you to
take their drug, and therefore they would not put in a lot of things that they think that
might stop you taJcing it" (participant '11, Drugs.com).
This mistrust extended to advertising:
"Because if you look at the top, it's talking about breast cancer (the top banner says:
'breast cancer: dispel the myths) so you're looking at all this and I'm trying to think is
this a drugs company site or what is it?" (participant '11, Drugs.com).
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Lay user assessment of trust
When asked if they thought the sites were trustworthy, participants were often unaware of
how to assess this: for example, "How long is a piece of string?!! Weill wouldn't know whether
it is trustworthy or not" (Participant 117, Medicines Guide). Instead they spoke of ways to
assess trust which did not correspond with recommended methods for assessing the
reliability of the websites (sec Figure 18).
Some participants were wary of trusting a US developed site. One asked:
"Is it an American site?" (Speaking about the Mayo Clinic website). [Author - It is]
"Is that why it comes out, err, err; is that why it's erm, designed that way?" [Author
- I don't know. I don't think that would.] (Participant #1,Mayo Clinic).
Another offered:
"Mayo Clinic, I would take notice of that; yeah, yup.lf I was really seriously wanting
information, from there, then I would also cross-reference it with something like British
Medical thing-a-me-bob, because the American and the Brits may have a slightly
different opinion" (Participant #12,Mayo Clinic).
Thefailure to recognise quality assessment stals
Medicine takers appeared naive to 'recommended' quality assessment tools, in particular
the Health on the Net Code of Conduct (HONcode) seal. For example, on being shown the
HONcode emblem, a participant remarked:
"No I didn't notice it; I haven't heard of it. Is it just specifically for websites then? ...
Aaah! And that's so to speak a kite mark symbol to say this is afairly reliable,
trustworthy site ... Actually well that's kind of reassuring then, but I've not heard of
that" (participant #11,Drugs.com).
Another participant said:
"What's that HoNcode thing, I've never seen before? ... Health on the Net, HoN?
ThIIt's Health on the Net presumably? And the HoNcode is some sort of thing they've
signed up for ... Ah that would be something I've learned today then. Yes to look Ilt the
whole website and see what the HoNcode things isl" (participant 19,Drugs.com).
While this was novel to the participants, they immediately appreciated it:
"1, 1see that it's accredited to the S!J!7Iesort of H-O-N, 1suppose that means honours
code, 1don't know; but I'd haven't Il clue what that meant ... unless 1clicked on it ... 1
think it does give it utmost respect ... It tells you that somebody whose erm, drawn up
some sort of code of conduct, has chec1cedthis information and this site complies to the
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Code of Conduct that's been strictly set up by some medical foundation in America
presumably" (Participant #l6, Mayo Clinic).
Fi ~re 18:Examples of lay user methods for assessing trust
• Cross-referencing
Participant #6,Medicines Guide
"If I were looking for information, I wouldn't just take it from this site; I'd
probably go to another one as well and just compare the level of information
.... that each one provides. If I found that this one gave me more information or
that the information provided was, was better then, you know, maybe two or
three others that I've tried, then I'll probably come back to this one"
• Site appearance
Participant #l6, Mayo Clinic
"It looks very professional; lots of links, lots of information ... "
Participant #l8, RxList
"Err, sometimes you can tell just by the way it's written"
Participant #7, Electronic Medicines Compendium
"You can generally tell, erm, well, well if you stray off the reputable websites;
you're going to get yourself into a load of quacks toho're selling all sorts of
wonderful remedies ... Like the left leg of a toad and all that stuff enhanced my
life amazingly".
• Site ranking
Participant #16,Mayo Clinic:
"Err the only thing I'd ask about the site is ifit's on the top ten of the search ...
Because to scroll through one hundred recommended sites for information; if
it's down at number 50 or 60, it's not going to get used as much as ifit's up
near the top".
[Author - So you would trust one that's used very often?]
Participant #16,Mayo Clinic:
"1 would trust thRl, yeah"
'nformtdion from Mtdth professio1Ul1
Participants would check the infonnation with a healthcare provider to determine if it was
trustworthy:
.,Erm, the only way thRt someone who ;s not a medic would know whether it is
trustworthy is sort of getting a reaction from somebody, a doctor. Going to II doctor
lind saying 'I've been IIdvised by such lind such II website thRt this is the case; is this
correct?' 1/the doctor Mid this WIIS right, 1would hRve lin indiclltion this is
trustworthy; but not, not from my own, erm knowledge" (participant 12, RxList).
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5.7.1. Design features
Whilst some participants commented positively on the usefulness of the site in relation to
its design features, most were critical. The points raised about tables of contents (see
Figure 19) reflect this well. Some participants felt tables of contents (when noticed) were
helpful; but most failed to notice them throughout the task, until directed to them by the
author. Several participants felt that making the table more noticeable would benefit site
users.
Fi ~re 19: Examples of participants' comments (opinions) on tables of contents
• A useful feature
Participant #3,Medicines Guide:
"l haven't come across one of these (indicating to the table of contents) before
and it made it much easier".
• A missed feature
Participant #6,Medicines Guide:
" ... and the colour coordinated menu headings, erm which l didn't realise at
first, but once l, l, it occurred to me to use that it did, it was easier searching
for things just by scrolling up and down and on the right hand side, just
looking for the coloured headings".
• Make a more prominent feature
Participant #11,Drugs.com:
NActually looking now l can see, and I would have, l would have just gone back
to there (indicating to the table of contents) ... maybe if that had been a little
bit more bold, l might have picked that out sooner".
Participant #6,Medicines Guide.
N ••• you could probably make these a bit more like hyperlink (indicating to the
links on the table of contents). I know that you get like a little pointer there
when your cursor over it, err, but possibly if it underlined and you know that
you are actually clicking on that line, and just things like that .... And as Isaid
earlier, probably open up a new window when you do".
The layout of the site and the white space (absence of text) aided navigation for some
participants: for example,
"l lik« the idea of two blank bits down the side. Ilike this idea of space here bectlust it
doesn't, it's not all information in your face right across the A4 piece ofpaper ... lfyou
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have a big block and you read it all, sometimes it doesn't all go in" (Participant '16,
Mayo Clinic).
This was reflected by the comments of a participant who, having navigated. the Drugs.com
site, preferred the lower half of the page below the initial screen shot, which was free of
the clutter of hyperlinks which dominated the top half:
"That's a good, the second half of that page is good in, once you get beyond the top of
it, it does just actually simply tell you stuff. That's why, not being distracted by the
pictures, you're just being told stuff" (Participant 19, Drugs.com).
Although a printer-friendly option was rarely noticed, when participants were shown it,
most valued it. The notion arose of being able to print facilitating empowerment. For
example, a participant considered printing out the information to show her husband's GP:
"Erm, if I thought there was something affecting my husband's health that I thought
this drug might ... be affecting his health; I would print this off to tIlJce into the GP as I
have done before with things" (Participant #17, Medicines Guide).
There was a wish for symbols or pictures on the sites, and the lack of pictures in particular
was noted. For example, a participant who had initially queried the lack of pictures on the
site, when shown a picture of the med.icine at the bottom of the website page, responded:
"Yeah; hmmm.] would have thought that would have been better up Ilt the top ... if
you had it at the top, err you would see it there and you would, you might also cliclc on
the link. Whereas there, as it's set up, you wouldn't nece5Sllrily get down as for as that;
scroll down to the bottom of the pllge ... because you might thinlc it's another drug,
unrelated drug" (Participant #8, RxList).
The search bar was unnecessary for completing the tasks as all indicative information was
on the site. But there was a desire for a search bar similar to the 'find' function (Control F)
to help users locate information:
"1t would have been great to have had a search on it where we could put in the word
pregnant. Because in a sense you were asking basic questions so 1could hatJe had one
thilt said forbidden foods, another could have said side effrcts; and it just would hatJe
done them out in point form. ThIlt would have made it easier ... there are most prolNlbly
whilt, a hundred key words on the site. So you could put pregnancy or pregnant ~ if
you click thilt, it would just come up 'do not take it ifpregnant'. ThIlt would make it
easier. If (participant #18, RxList).
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5.7.2. Perceived information needs
Some participants did not want too many options on the site. For example:
"1don't want to begoing back and making it larger when I want to look the
information up. I don't want to be sorting out the print. Next you'll be telling me if I
want it italic, an this an t'other. All I'm interested in is finding out what this drug
does" (Participant n,Mayo Clinic). For this participant the content of the site
was what mattered; not its design features.
The amount of content was important, and some participants did not want too much:
"Sometimes to just find the one thing you want, there is a massive amount of
information and it's not always easy just to find two UT threefacts when finding fifty
thousand others ... I sometimes think you can have information overload"
(Participant #11,Drugs.com).
The amount of content would become a problem if the medicine user took multiple drugs:
"It's only two pages isn't it, so it's ... I mean, I take, I take err, a number of drugs erm;
...and I'm slightly asthmatic and I also takefour different, erm, drugs for epilepsy, to
prevent epilepsy ... 1don't read them every time, but I, I read them occasionally"
(Participant no, Electronic Medicines Compendium).
This highlights two important points: the potential negative accumulative effect of
information for various medicines; and the value of concise information.
The interactive nature ofmM! appealed to the information needs of participants:
"Maybe there should be links to other sites Or even a blog. Because the other thing
is; is there any way to come back to this? Is there any way you am actually SIlY to
them, look I'm taking simvastatin and this is happening to me; am I madr
(Participant #18,RxList).
Participants spoke of a need for balanced information, relating this to concerns about the
potential for information to provoke worry:
"It's sort of a balance between you ought to be aware of it, and then some people
become walking encyclopaedias ... they become nothing but ... how many side effects
they might have, and this, that, and the other. And I'm trying to surf offind a balance
... And when you go on the Internet, you have everything that is, erm; very serious
and very rare!" (participant 112, Mayo Clinic).
For others, information was empowering; providing a balance in the doctor-patient
relationship:
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"I'm not a cyberchondriac or anything like that ... but, I'm going to check up on all of
that ... Oh doctors are getting plagued by them now. (laughs). You see, a GP knows a
little about a lot, so a guy comes in who's got a specific complaint; he's learned up on it
on the web, hasn't he? He knows more about it than the doctor does. And he's telling
the doctor what treatment he should be getting! (Laughs) It can be a bit of a national
phenomenon really; but they've tagged it cyberchondriacs" (Participant 17, Electronic
Medicines Compendium).
Medicine users might be prompted by an item on television programs to seek further
information about medicines:
"Let's use 'This Morning', let's say. If they had something it tends to be if they had
something about health and I haven't heard it properly and I want to go on it, then I
click a bit like that" (Participant #12,Mayo Clinic).
S.7.3. Previous experience
The ease of use of the site was determined in part by participants' previous experience of
Internet use. A participant who considered himself a novice felt the site was easy to use:
"Somebody who's experienced with a computer should handle that no problem, and
err, as I say; I haven't been on computers long, so I got that easy enough, didn't I?'"
(Participant #7, Electronic Medicines Compendium).
Participants' intention to access IBMI in the future was also related to previous experience
of using the Internet, with one inparticular put off accessing IBMIbecause her PC was
inadequate: "I mean my computer is a bit like the cart and horse! It's quicker to drive down to the
chemist than to go on the Internet. (Laughs)" (Participant #12,Mayo Clinic).
S.7.4. Information content
Participants considered IBMIuseful if there was specific information about medicines. For
example:
", " it told you why you were taking the medicine; what possible side eJftcts which is
what would be useful to me, erm, ... an just helpful things Ilbout, you know changing
your lifestyle and '" improve your health and your cholesterol; things like that'"
(Participant 16, Medicines Guide).
ACcessing the Internet would also be useful for condition-specific material and
information about alternative treabnents.
198
Participants would be put off by sites with commercial interests, and some would look for
information elsewhere on the Internet for a more balanced perspective of the pros and
cons of taking the medicine. For example, it was offered:
"If there is any, erm ... a discussion group ... So I'm getting a different perspective
from the.from the company that make this. They say, oh it's quite safo. These are the
possible side effects, full stop; but when you go on a, on a website that says, this is what
is happening to people that are taking it and wefoel there is not enough researchbeing
done into it, that's something I lookfor as well. It gives a different perspective from the
manufacturer ... So I'd lookfor something that, erm, doesn't appear to be linked to the
product in any way but they're just giving, you know, information about that, err,
particular product" (Participant #6, Medicines Guide).
5.7.5. Information from health professional
It was felt IBMI would be useful when medicine users wanted more information and
could not talk to their GP. But rather than just balancing perceived gaps in GPs'
knowledge, mMI was seen as offering medicine users the opportunity to study
information before a hospital or GP appointment:
"I've just had an operation and before I went into hospital Iwas err, messing around
on the Internet and looking at all sorts of things to do with it ... printing stuff off and
also giving me something for when Iwent to the clinic; something to sort of talk about
and ask questions about, whereas you know, if Ihadn't used the Internet,foT that, I
wouldn't have thought of certain questions, and you know, doctors don't always
remember to tell you everything (laughs). 'Cause Ido like to know about things
beforehand" (Participant #8, RxList).
All things said; while mMI was valued as an additional source of information, it would
not replace a doctor's advice: "But at the end of the d/zy, erm Iwould have to trust my doctor to
give me, you know the ultimate advice on any condition" (participant #2, RxList).
S.7.6. Leaflet-bued information
For some participants, mMI was felt to be more useful than leaflet-based infonnation. For
example:
"It's easier to read than the little slip you get inside the pack which is in tiny writing
lind several diffrrent languages; and it takesforever to get through the English bits,
lind then it IS allfull off'tallc to YOUTGP about this, tallcto your GP about that'; it
doesn't go into detail, which this site does. There is more detail in this than there is on
the pack inserts" (participant '5, Drugs.com).
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IBMl convenience was valued, compared to print information:
"l]you just wanted to know 'oh gosh how many am I supposed to take today' and you
could just go to like an index or something and click on something and it brought you
to that bit, then that would probably be as quick as finding the information in a book ...
you can go to another site perhaps if that site didn't answer your question ... On the
whole this is better for getting more information definitely, because if you have a
question on the book, it's not going to be answered probably" (Participant '11,
Drugs.com).
Some participants still preferred paper-based materials:
"You can have a booklet in your bedside cabinet and you can pick it up and look at a
page if you want to ... when you have got a booklet and somebody tells you you've got
some disease, you can actually, your family worry, so you can actually give them the
booklet that's been given to you that's specific to the type of illness you have"
(Participant 'II, Drugs.com).
5.7.7. Understandable information
Medicine users valued mMI content for being understandable. For example: "Well it's, it's
basic and down-to-earth, which is what you want. It, it tells you what you want simply and clearly;
... the idiot's guide to simvastatin (laughs)" (Participant '3, Medicines Guide).
Another participant offered:
"It was, err, straightforward and it wasn't, it was written in reasonable English. It
wasn't written in a way that sort of makes you think what does this mean. It, it's
straightforward, it's easy to understand" (participant #2, RxList).
Having the headings as questions was valued: "They're (the headings) in as questions which
are, erm, questions are more stimulating than simple statements" (participant 110, Electronic
Medicines Compendium).
Although the content was largely felt understandable, some participants were confused,
by the word 'hypercholesterolaemia', for example. It was thought a glossary could help in
these situations:
"There's that bit about the HMV, m,HMC-COA reductor base co-inhibitor, I
wouldn't have minded a bit mort on that. Like ... like these littlt grem things; whllt
are they called? ... I wouldn't have minded something like thllt. " (Participant is
refrrring to the hyperlinks to a glossary). [Author - So are you saying you would hIIve
200
preferred if those words had, they were maybe defined in a glossary?] "Yeah, yeah"
(Participant 19,Drugs.com).
In situations where the medicine user was confused with the wording of the information,
they considered they would approach a pharmacist for an explanation.
While it was recognised that IBMIcould be beneficial by offering WMI before the
medicine was dispensed, it was felt that if the content was not understood, these benefits
would disappear:
"it's okay having it (JBMI access) in a GPs surgery, but erm, if you can't even
understand it in your GPs surgery, so he's gonna take up more time talking to you
through this thing what he's got on his screen, and at the end of it you're not going to
be able to say to your GP, well you couldn't print me off a copy of that, could you?"
(Participant #1, Mayo Clinic).
Information may not be intrinsically easy to understand for medicine users, but
participants felt it had to be so from necessity:
"... because after you have what they call 'an event', or a myocardial infarct which I
had, you have to assume, you become nearly PhD level in cardiac affair ... because they
drive you mad, and if you don't understand it you don't survive ... Strange thing"
(Participant #18, RxList).
5.7.8. Appeal of technology
Some participants found modem technology appealing, and so would access mMI in the
future: "Yeah I think it's just, it's the thing today, isn't it? It's what most people do; use the
Internet for anything and everything really" (Participant #8, RxUst). The ability to purchase
medicines via the Internet made IBMI all the more important:
"You can even order;you can even order prescription drugs off the Internet from other
countries, so if you do that and you miss out your doctor, you cerlIlinly need to know
what you're doing in terms of the inJonnation about that drug" (participant 116,
Mayo Clinic).
5.7.9. Access to IBMI
Accessibility was regularly discussed. Itwas felt that mMI should be available during the
consultation:
"That would be grtat you know, having my GP looking it lIP ... like side tjfocts, right,
this-that, and he's got it all lying in front ojya, and a can, a can just turn round and
say can a have a copy of that? II (participant 11, Mayo Clinic).
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A similar point was made about the want for access to mMI in a pharmacy before the
prescription was dispensed.
Some, though not all, older participants spoke of how they actively usc the Internet:
"I think I'm one of these 'silver surfers' ... The majority of people now who have
retired use the Internet ... I've used it about nine years ... I got it about ten years, and
I've always found it a great aid for all sorts of things" (Participant #17, Medicines
Guide).
Not everyone would want to immediately accessmMI after a diagnosis. Some spoke of
needing time to come to terms with illness first:
"I think at the time you go away if you're told something if it's a serious sort of illness,
that you need to get your head round that before you start reading about things; but
you would probably come to that later" (Participant #11,Drugs.com).
5.7.10. Pharmaceutical company websites
The medicines users were wary of accessing sites selling pharmaceutical products:
"At least this is free of pop-ups or interference or pestering you to buy stuff. I mean
that's the other thing I really hate, is the people, they're hassling you all the time to get
ten thousand of these tablets from Hong Kong, you know, jive pence a piece or
whatever" (Participant 19, Drugs.com).
The neutrality of pharmaceutical sites was again doubted (see also 5.6.4): "If the drugs are
put on by drugs companies, they have a commercial interest to some extent, haven't they? '" So
that would slightly worry me" (Participant #11,Drugs.com).
5.7.11. Patient/family relevant information
Several participants would search for information for themselves or others, explaining
they had done this before:
"I have been trying to jind a ctrtllin amount of injormlltion about my brother's illness,
'cause my brother's got a very rare ... erm, degenerative illness ... and I've been
looking once or twice to see if I can jind anything about that on the computer"
(Participant #10,Electronic Medicines Compendium).
S.S.Discussion
5.8.1. Review of the main findings from the usabiHty study
This section draws on the findings of the usability studies, relating them to the theoretical
base for the study, and previous research.
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How did medicine users search for online information about medicines?
The findings solidify understanding of how people search for IBMI.Most participants
typed 'simvastatin' into a search engine (Google™ or Yahoo! TM), because of its familiarity,
ease of use, and popularity, which reflects the findings of focus groups (Peterson et al.,
2003). Furthermore, only one participant searched using the NHS Direct site, reflecting a
previous finding that people searching for information generally do not use medical
portals (Eysenbach and Kohler, 2002).Medical portals, including NHS Direct, appear to
remain an under accessed resource for searching for information about medicines, in
comparison with the prominent use of popular search engines by the general public.
Further research should examine the determinants and barriers of access to medical
portals for search purposes.
One participant typed more than the name of the medicine alone, specifying Isimvastatin -
drug for cholesterol'; the other 14 typed only the medicine name. This reflects what
participants said in a focus group when asked how they searched for IBMI (Peterson et al.,
2003). No-one in the present study looked beyond the first page of links on a search
engine, which Eysenbach and Kohler (2002)and Peterson et al. (2003)have similarly found.
The findings in this study do not reflect the finding of Toms and Latter (2007)(2007) that
participants searching for infonnation about medicines opted to specify the search
strategy, and looked at an average of 5.4 pages. This may reflect the demographics of the
participants in Toms and Latter's (2007)study: 71%were 21-35years of age, and 50% were
students. The students may have had better search skills, and therefore opened more
pages. It may also reflect a difference in the task demands and instructions given to the
participants. Nevertheless, the fact that the participants in the study reported in this
chapter did not look beyond the first pages of links suggests that many IBMIsites may be
potentially redundant, depending on how they are ranked (see 1.3.2), if few people access
them.
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Toms and Latter (2007) also found that participants made three considerations when
opening a website:
(i) If the information met their expectations;
(ii) An assessment of the quality of the information; and
(iii) If the information was understandable.
Comparing this to the present study, participants reported assessing the quality of the
information, and said whether or not the information appeared to be understandable was
a reason for their opening the link. Some spoke vaguely about the information meeting
their expectations, (although they were not asked this). For example, one participant saw a
mention of side effects, and said she first wanted to know about the actions of taking the
medicine.
Participants were not asked at this point in the study to make an assessment of the site
they had opened - this may have primed them for being asked about the assessment of
trustworthiness of the site they used for the User Test. Still in some cases participants
appeared to have assessed the quality of the sites when they were asked how they
searched for the information. Most participants spent little time searching before opening
a link, and appeared to give little or no consideration to accessing the quality of the site.
No participant used a recommended approach for assessing quality. Instead untested
methods were employed, trusting sites with 'official appearance', for example, and relying
on previous experience. Participants saw the site for a short period of time, (at most a
couple of minutes), so they may have used heuristics based on visual appeal to make the
short-term decisions about the trust of such sites, as predicted by the stage model of trust
for Web-based Health Advice (SUlence et al., 2006). The most commonly accessed site,
labelled 'Simvastatin - A Patient's Guide', appealed to medicine users because it featured
the word 'Patient'in the title, therefore distinguishing the information from that for
doctors, and giving medicine users the impression that the information would be
understandable to them.
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What influenced medicine users finding the lBMl sites easy to use?
The analysis indicated that sites with a mass of text and hyperlinks were difficult to
navigate. For example, sites with a clutter of hyperlinks were not easily navigated at the
beginning of the task, suggesting that participants were distracted by the links. The stage
model of trust (Sillence et al., 2006) predicts users will exit sites with a cluttered homepage.
This was not an option for participants in this study as they looked at only one specific
site; and so the findings of this study cannot corroborate this.
Participants sometimes struggled to find information that they anticipated was the answer
to the User Test question. The problem was not participants' knowledge, because their
answer (expressed via verbal protocols) was more often than not correct. Rather the
barrier was that the information on the site did not match their knowledge and
expectations. Had this been better written to reflect users' knowledge, they may have
found it. The Information Resources Model (Wright et al., 2000) would suggest that the
problem lies not with the user, but with the site. Therefore the content needs to be written
to reflect users' knowledge and expectations. This could make locating the information
easier for the user.
The three participants who used the Electronic Medicines Compendium site, on which
information was available as a PDF, appeared to have little difficulty using it. Nielsen
(2003) recommends that PDFs should not be used for online reading because they can be
less easy to read than an HTML page, and so should only be printed off. It is unclear why
participants in this study were able to navigate the PDF with little difficulty. This may
have been because it was only two pages in length; or it may be that the participants (older
adults) were better able to navigate PDFs, which do not have distracting links or pop-ups.
Did medicine users firulIBMlrmderstl,rulable?
The majority of participants adequately explained the information suggesting they
understood it. These scores were consistent across all sites, except the Mayo Clinic site,
Where participants correctly explained the answers slightly less often. The purpose of this
study was not to compare results between sites, but to aggregate them. Doing so found
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common examples where the sites as a whole did not convey the information in a way that
was understandable: for example, only one third of participants understood the
information about what to do if they experienced muscle pain (a possibly fatal side effect
of simvastatin). For example, the sites may not be useful for the person seeking to become
better informed about medicines.
Participants' comments about the understandability of the information were largely
favourable (despite the difficulties), other than for the use of medical terms. Information
was considered useful because it explained why to take the medicine and its benefits, side
effects from taking it, and condition based information. The last topic is particularly
valued in leaflet-based WMI by medicine users (Raynor et al., 2007a); as is the importance
of having expert knowledge about conditions (Raynor et al., 2004).Few people reported
difficulties with the language used.
Medicine takers valued mMI because they perceived that it explained information that
CPs did not provide clearly, and that it filled gaps in CPs' knowledge. For some people,
mMI may have an empowering element in preparation for a CP's appointment, reflecting
Dixon-Woods' (2001)analysis of discourses in provision of patient information, whereby
information is useful when it empowers the patient.
Participants spoke of the information in relation to the medicine user's emotional state.
Some felt that the presence of too much information could lead to undue worry. However,
this is not to suggest the information was not wanted by them. Raynor et al. (2007a)have
argued that WMI may provoke anxiety, and medicine users want for WMI. are separate
matters. Others valued information for helping them to find out if they had genuine side
effects as opposed to irrational fears about their health.
How did medicine users IISSUS the trustworthiness oIIBM1?
Shon and Musen (1999)have labelled sites that have the HoNcode seal to be 'HONoured'.
Participants in the usability study did not recognise 'HONoured' sites; i.e. they failed to
notice when the sites displayed the HoNcode seal. U this finding is a reflection on the
general public, this seal for quality assurance may be under utilised. However, the trust
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that people have for such websites may not be adversely affected if they fail to recognise
the seal. This view is suggested because Shon et al. (2000)found no significant difference in
their participants' perception of the credibility of information on a website based on
whether or not it featured a fictitious logo stating approval from an invented physician
organisation.
Breckons et al. (2008)compared the performance of different instruments for evaluating
the quality of websites with information about complementary medicines, and found that
the HONcode did not correspond with other tools' ranking of site quality. If the HONcode
does assess quality in a different way to other tools, people's failure to recognise the seal
may not be so much of a problem.
The participants were on-the-whole aware of the need to assess the trustworthiness of the
sites. However, the methods they described for assessing trust did not reflect
recommended ways for assessing the quality of a website (see 1.3.6).Some participants
said they would give unconditional trust to whatever site they found. This may be
considered risky if the information is not accurate, and it could have potentially dangerous
consequences for the health and well-being of these participants if they act on it.
Other participants spoke about websites that were 'reputable'. This can suggest that the
appearance of the website is an important factor in determining whether or not it is
trusted. For example, Peterson-aark has noted that both pharmacists and the general
public consider 'professionalism' to indicate if a site is of good quality (Savage, 2008).
When participants in the usability study perceived a site to have a commercial interest,
they considered this to indicate it was not trust worthy. For example, they spoke of
distrust for industry related websites, and some extended this view to sites with
advertising. This reflects comments made by medicines users in the study by Peterson et
al. (2003);and GPs and pharmacists by McCaw et al. (2007).
Several partidpants spoke of wanting to cross-reference the information with other sites.
Adams (2006b) conducted an ethnographic study of 18web users in the Netherlands, and
207
noted that they cross-referenced the material they found. She has proposed that people
searching for health information (both online and through paper-based resources)
construct the reliability of information by cross referencing; therefore 'reliability' is the
process whereby information is pieced together from different websites. This is an
important proposition, but the method may be insufficient to gauge trust. It is not
inconceivable that individuals could consistently find material that is not trustworthy and,
if they follow Adams assertion, they may erroneously conclude that the information is
reliable. This thesis contends that cross-referencing information to make a judgement on
its trustworthiness, or quality, is not enough: those accessing mMI need to be able to judge
the absolute trustworthiness or quality of a site.
Participants trusted a site because of its professional appearance and recognisable name.
This suggests they adopted a heuristic approach, i.e. using cognitive shortcuts to analyse
trust, and again reflects the model of Sillence et al. (2006) for understanding how people
trust e-health websites.
Would medicine users access IBMI again?
Respondents said they would access mMI again to expand on information not given by
GPs, reflecting a finding that Dutch patients searching the Internet for information about
pain control do so because they have a need for additional information (de Boer et al.,
2007). Participants said they wanted access to mMI in a GP surgery or a pharmacy.
Reservations about promotional mMI would prompt medicine users to consider looking
to discusston sites to get other medicine users' perspectives, for information about side
effects, for example. Medicine users said they would access mMI for specific content (for
example, content-based information), reflecting a finding of the focus groups reported in
Olapter three. While mMI appealed to many participants, they would give greater weight
to their GP's advice. Conducting a focus group to gauge patients' opinions about e-health
websi~.s, Stevenson et al. (2007) have proposed that the Internet offers a means for
reinforcing the doctor-patient relationship. The findings of the study reported in this
chapter lend weight to a common observation that the advice of GPs remains paramount
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over WMI. mMI will not replace it, but it can be a useful additional source of information;
expanding on information or offering a second opinion.
5.8.2. Strengths and limitations of the study
Search task and User Test
These tasks had limitations, some noted by the participants in their interviews. Some may
have treated the search task as a time test, therefore biasing their results. This was not its
aim, nor were they given this instruction.
If a participant was unable to find the information, they were directed to the answer by the
researcher, (for the reason explained in 5.3.4); and so it can be considered that these
participants' User Test results were to some extent a product of the participant-observer
interaction. Kaufman et al. (2003) have noted that researchers in usability studies are also
participants, interacting with the 'real participants'. Tweddle et al. (2000) used this
approach in a similar usability study of a website with information about cancer
healthcare.
It was explained in 5.3.4 that there were practical reasons for the researcher to sit beside
the participants. However, this could have been distracting, and it may have been better
for the researcher to have left the room, leaving participants alone to have conducted the
search unaided. Had this happened, several participants may have struggled to have
found an appropriate site. Participants could have been given a set time for the task, so
they could have accessed any number of sites (and perhaps compared them for trust). This
could have provided an improved insight into whether or not participants disengage from
sites with a clutter of links. Some participants commented that they would have searched
differently at home, looking at other sites to cross-reference the trustworthiness, for
example. This was not permitted within the study protocol.
The User Test task began immediately after participants were shown the mM! site. They
did not have the opportunity to read through the site first to become accustomed with its
layout before being asked to find the indicative information. Prior reading is normally
encouraged for a User Test of a PIT.. If participants had this opportunity, it would have
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given them an advantage with using the IBMI sites and they may have displayed fewer
problems than found here. This may tell less about the ease of use of IBMI, which was the
purpose of this exercise.
The User Test (deliberately) asked questions in an order that did not match with the
infonnation on screen, which participants noted, and felt unnatural. This impacted on
participants' navigation of the sites. For example, a participant noted that the User Test
task did not reflect how she searched for information normally:
"I think the thing is when you're coming in cold and you're doing an exercise, you're
looking at it almost like an exam paper. If you ... turn your own computer on to look
up simvastatin, it's a totally different thing. You're doing it Jor your own benefit and
you're trying to find out as much inJormation ... If I wanted to know about simstalin,
I would have started at page one and scrolled right the way through" (Participant #17,
Medicines Guide).
The non-sequential order of the questions was necessary. Had the indicative infonnation
on the site followed in sequence, it would have probably been less of a challenge for the
participants to find it, and would have said less about the ease of use of the site.
Nonetheless, most participants displayed confidence navigating the site after the second
question, reflected by fewer errors in finding the indicative infonnation. This suggests that
they quickly acquired conceptual system knowledge of the site; therefore the site was
easy-ta-Ieam.
In the interview, some of the participants said they would have preferred to use a site of
their own choice, rather than the site they were assigned to. This was not permitted. within
the study protocol as participants were randomly allocated to one of the five sites. An
alternative method would have been to have purposively allocated participants to a
website based on their demographics, so that equal numbers of similar participants were
assigned to each website. However, this could only have been done with an Il priori list of
Participants. This was not possible because recruitment to the study was concurrent with
the running of the study.
2)0
Several participants felt the question about IBMI being 'pleasant to use' was an unfamiliar
concept. Instead they stressed the seriousness of the information, especially for a person
with the condition. It may have been better to have worded the question differently.
Most participants found thinking aloud unnatural, saying that it slowed their perfonnance
or that made it difficult to focus. Some found it complicated searching, but they either
became used to it, or felt they would after a time: for example,
/I Erm, trying to remember to, to read and talk at the same time and to lookfor
information is quite hard. After a period of time I'm sure it is something you would get
used to, but when you're not used to doing something like that" (Participant #8,
RxList).
Not all participants felt thinking aloud was difficult. Some had no problem doing this, as it
was normal for them: for example, a currently employed sales representative and a retired
teacher who referred to talking as a skill he had maintained in retirement.
It is unavoidable that a study conducted under controlled conditions will have less
ecological validity, but it was thought essential that the study was conducted in a
controlled, rigorous manner, to increase the reliability of the findings. As Ericsson and
Simon (1998) have noted; to study covert thinking requires a non-reactive setting where
thinking can be reproduced under controlled conditions. The study was considered a low
risk situation for participants (even for the five participants currently taking simvastatin),
presenting no threat to their health and well-being. Participants may then have been less
motivated to find the infonnation, making less effort compared to someone prescribed
simvastatin for the first time, as they were asked to imagine.
The PllrticiplUlts
People who are extroverted or who have firm beliefs may be more keen to be interviewed
than others (van TeijIingen and Forrest, 20(4). This is the problem of self-selection, and it
means that the participants in this study are not representative of everyone who uses the
Internet and take medicines. However, it is unclear if enrolling such people affected the
results. Extroverted people may be no better or worse at navigating websites and
completing User Tests than non-extroverls. Itwould have benefited the study to have
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enrolled more people from minority ethnic groups, who may have a poor command of
English; therefore making the readability of the information even more important to
assess. (However, their level of English may have posed difficulties for running the study).
This study sought to examine the website and information, and not the participant, which
are foundations of User Testing and usability testing (see 5.2). However, it could not be
discounted that participants' experience and knowledge of medicines, and Internet
proficiency, impacted on how easily they could use the sites, and how easily they
understood the information. Thus it was not just the design of the website, but also the
individual differences between participants that determined how easily they navigated the
site and answered the questions. This corresponds with the theory of Distributed
Information Resources (Wright et al., 2000)which indicates that it is the interaction
between the internal information of the user and the external information of the website
that determine how easily it can be navigated and its information understood. Therefore
participants' previous knowledge and experience probably impacted on their ability to
navigate the site and understand its content. If the ease of use and readability was a
product of website design alone, it could be expected that every participant using it would
have had the same results when using it. This was not the case and so there is evidence to
suggest that individual differences were operating.
The sample of participants was not representative of everyone that accesses IBMIor takes
a medicine; this therefore limits the transferability of the study findings. Firstly, the
participants were on average 54 years of age. Younger and older people will have different
Internet use proficiency, as well as different needs for IBMI.Secondly, the five participants
taking simvastatin during the trial were able to find and explain on average more
information (8.6 and 8.8 respectively), than all participants (1.7 and 8.3).They may have
had an advantage when looking for and explaining the indicative information compared
to those who were not taking this medicine. To.overcome this, an inclusion aiterion could
have been set for all participants to have either taken simvastatin or all not. However,
recruiting participants to this study was challenging, and therefore this limit was not set.
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Assessing Ilnderstanding
Participants were asked to explain the information to indicate that they understood it.
Understanding and explaining are not easily defined: there is no one accepted account of
what an 'explanation' is (Trout, 2002).1t is necessary to consider whether participants'
explanations were evidence of understanding, or mere paraphrasing of the information.
For some of the answers it was sometimes impossible to say anything other than the
answer (for example, 'to lower the amount of cholesterol and fats in your blood' to answer
the question 'why should you use simvastatin?'); yet in other cases there was greater scope
for paraphrasing.
Some participants may have struggled to find the indicative information to answer the
questions because they did not understand the questions rather than the website content.
In these circumstances, the online information may not have been at fault. (This may be a
moot point as no participants asked for clarification of the questions).
Scoring the User Test
When participants did not find the information, they were directed to it, and asked to
explain it. However, if someone failed to find the information in everyday life, help may
not be available to lead them to the information, and so they could not then understand it.
Giving participants who failed to find the information the chance to explain it means the
results overestimate understanding. However, an aim of this study was to examine if the
mMI content was understandable. Therefore, it was necessary to give participants the
chance to explain the information even when she or he could not find it. The User Test
could have been scored for finding alone, or not finding alone. Itwas considered if help
given was reflected in the score, this would give a misleading overall score for finding the
information. Therefore scoring was only made for finding alone, or not finding; and a
descriptive record was kept of participants requiring support to find the information.
The majority of participants had increased confidence in navigating the site by the third
question, evident by their reduced inability to find the information. This was unlikely due
to site features, and more likely an effect of the task requirements. Most had by this point
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navigated through the whole of the site, and so may have noticed the information often
(when scrolling) to recognise where it was. This may have been an effective 'method',
because recognition is more effective for retrieving information than recall.
Examining trust
The researcher's interactions with the participants likely biased their judgements of the
HONcode symbol. For example, participants who did not notice the HoNcode symbol, (if it
was displayed on the site), were purposively led to it by the researcher, so as to gather
their opinions about it. The researcher used different cues at this point, e.g. "does that
change your thoughts about it?" and "Is that at all important to you?", and these may have
impacted upon the participants' responses, and therefore findings. Furthermore the
researcher used the terms quality, trust, and reliability interchangeably on occasions
during interviews without a clear rationale for doing so, although they are not the same
concepts: see 1.3.6 for separate definitions of quality, trust and reliability. By using one
term or other, this will have determined to some extent participants' perception of the
question, and shaped their responses. For example, participants on the whole did not
recognise the HaN Code seal, but still spoke of the importance of the websites being
trustworthy. This suggests that the 'quality' of a website for consumers does not
correspond with its 'trustworthiness'. Therefore using these terms synonymously likely
led participants to engage with them in different ways, and so prompt different responses
dependent upon what term they were asked about. If this study were to run again, it
would be imperative not to repeat this error so as not to introduce error into the findings.
Using Macromedia Captif1ate ™
Macromedia CaptitHIte ™ tracking of the cursor movements was portrayed as a unifonn
flow rather than the jittery movements displayed by the participants during the tasks. This
was not problematic as the aim of the study was not to perfonn a fine grain analysis of
precise online actions. The programme remained an invaluable tool for keeping an
objective record of the participants' online actions and verbal protocols.
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2. Navigating lengthy web pages: at times participants experienced difficulty in
navigating lengthy web pages, and between web pages of several pages.
• Recommendation: sites should ensure that they are designed to be easy to
navigate. This could be achieved by enhancing their information architecture, e.g.
by the inclusion of left-hand navigation, sub-headings and/or a flow chart; and
with the addition of symbols and pictures to make the site more pleasant and easy
to use.
3. Information that is difficult to locate: at times participants had difficulty locating
specific information when the content of the site appeared to not correspond with
their knowledge; and some wanted to locate specific information by searching for
keywords on a website.
• Recommendation: content should be written to reflect medicine users'
expectations about the information available on the site, and be understandable to
as many people as possible.
• Recommendation: itmay be useful to have headings in the form of questions, or
have a frequently asked questions (FAQs) section.
• Recommendation: a 'find bar' may enable locating a keyword/phrase, by
reducing cognitive demands when searching, and to make the site appealing to
use.
4. No warning of online consequences: it was not always clear to the participants when
they left a site, or tabbed down a page.
• Recommendation: sites should provide explicit warnings when users leave it or
tab down, so that they are aware of their consequences.
S. Examples of when information was felt to be useful: some participants felt that the
information was useful when it explained why to take the medicine, the benefits and
side effects from taking it, and when it provided information about the condition.
• Recommendation: sites should ensure that they provide information explaining
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why to take the medicine, the benefits and side effects from taking it, and
condition based information,
6. Clusters of links were distracting: some participants were distracted by clusters of
links on the sites; e.g. accidentally clicking on them, or exiting the site because they
were off-putting.
• Recommendation: sites should try to avoid clustering hyperlinks on the
homepage, so that users arc less distracted and do not accidentally click on one,
or exit the site because they are off-putting.
7. The trustworthiness of sites: at times participants were largely unaware of how to
reliably assess the trust of health websites; and often used untested methods, e.g.
gauging trust on the professional appearance of a site.
• Recommendation: sites should aim to ensure that their content is accurate and
complete to make it as trustworthy as possible.
• Recommendation: sites that are considered to have a 'professional appearance'
are often regarded as trustworthy by users; therefore if sites display features and
markers that reinforce this image, they may eam users' trust.
8. Medicine users' search strategies: participants did not look beyond the first page of
links when searching for a site with information about medicines.
• Recommendation: links on the first few pages <at least) of search engines should
be to good quality sites.
• Recommendation: it may be useful for descriptive information about a site on a
search page to be written in a way that could reassure the general public: for
example, by citing the word 'patient' to indicate that the information is intended
for 'the patient'.
9. The general layout of IBMI sites: sites with a mass of text and links distracted some
users from navigating the pages with ease.
• Recommendation: it may be useful for IBMI sites to avoid cluttered text and
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S.9.Concluding remarks
This exploratory study has analysed the ease of use of a sample ofmM! sites and the
readability of their content. Four methods were used concurrently, with a follow-up
interview. Using mixed methods to evaluate mM! was a beneficial and innovative
approach, but also a challenge to operationalise.
The design of the sites, and how their content was written, impacted on the ease with
which people located and understood the information. Examining in real time how people
search online for information about a medicine has revealed that the search strategies used
may not be reliable, and that what a person does and does not find is largely determined
by search engines. This reinforces our knowledge of how people search for information
about medicines online, by providing robust observational evidence to complement
previous findings from focus groups. The way a website is described on a search engine
may determine if the person opens the link to it or not. From these findings a series of
evidence-based recommendations for improving the design ofmM! sites has been
derived. It remains to be seen if implementing these recommendations can make it easier
for people to find and understand specific content on an mM! site.
The next chapter reports a study that piloted (i) a repeated measure with counter balance
study design, (ii) an intervention based on changing the content and general content
formatting for redesigning web pages containing information about medicines, and (iii)
the proposed tools for measuring the outcomes. This study sought to determine the
appropriateness and feasibility of these three points for use in a full trial evaluating
whether redesigned web pages containing information about medicines improved
participants' ability to locate and understand specific information.
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Chapter six
Study four: a pilot examining the
appropriateness of the design and
methods for a full ReT evaluating
changes to web pages with
information about medicines
6.1.Introduction
The study reported in Chapter five examined the usability of a sample of IBMIsites,
deriving a series of recommendations on how their design could be improved to make
them easier-to-use and their information more understandable. This chapter reports a
study piloting the appropriateness and feasibility of using a repeated measures with
counter balance study design, an intervention for redesigning web pages by changing the
content and general content formatting, and the proposed outcome measures tools. These
are examined for use in a later RCf that could seek to evaluate whether redesigned web
pages containing information about medicines improved participants' ability to locate and
understand specific information.
Employing a mixed methods approach (see 2.7), the readability and usability of the web
pages were examined by triangulation of methods; with participants' opinions on the
pages complementing this. This study was reported at the InteTnlltional SociIll PIumruu:y
Workshop conference in July 2008 (Nicolson et al., 2008b).
6.1.1. The Cancer Help UK website
This study sought access to pages from a website with information about medicines in
order to trial the evidence-based recommendations made in the previous study (see 5.8.3).
Based on existing research contacts, a working relationship was developed with Cancer
Research UK (CRUK), a UK-based charity dedicated to cancer research. Following
negotiations about what changes would be possible; CRUK provided a set of web pages
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with information about analgesics (painkillers) on the CancerHelp UK website
http://www.cancerhelp.org.uklthatcouldberedesignedandtrialled.This was beneficial to
CRUK, as they wanted an evaluation of the ease with which people could locate and
understand information on the web pages with information about painkillers. Examining
a website that provided information about treatments for people living with cancer shifted
focus from the previous studies that had looked at websites with information about
simvastatin, but was made for the practical reason of third party connections. This had the
advantage of seeing if the recommendations from 5.8.3 could be generalised to another
type of site and information.
The content of the three web pages examined in the intervention were for pain controlling
medication; specifically:
• Types of Painkillers page
(http://www.cancerhelp.org.uk/help/default.asp?page-5976);
• The page with information about Ibuprofen
(http://www.cancerhelp.org.uk/help/default.asp?page-28429); and
• The page with information about Co-codamol
(http://www.cancerheJp.org.uk/help/default.asp?page-28422).
Had the site contained information about simvastatin, it could have been included in
studies two and three of this thesis because it was professionally developed, not a portal
site, provided medicines information, and did not require registration.
The CancerHelp UK website was accessed by around 25 in every million Internet users on
the week ending 5 April2008 (Source:http://www.aieXll.com/accessed April20(6). These
pages provide important information about drugs to reduce pain, some of which are
aVailable OTC, (i.e. without prescription). Analgesics are also given to people with
conditions other than cancer. People living with cancer, their friends, relatives and
caregivers, may all access the CancerHelp UK site.
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The web pages with information about specific drugs on the CancerHelp UK website were
developed in around 2000and the general pain control pages in 2004.The pages are
updated annually. The pain control pages had been last updated in March 2007. In
CancerHelp UK the updating of the pages follows a set agenda: all information is updated
annually, but if important new information about a drug changes in-between, ad-hoc
changes can be made.
At an interview with the head of the Cancerllelp UK website and a CancerHelp UK web
page developer, 26 July 2007, the following main principles guiding the writers of the
website were identified:
• The developers write everything in plain English, write in the second person, write
in the active tense, avoid medical jargon and make text as easy to read as possible,
and 'bullet' information to make it stand out.
• For categorising side effect information, they are grouped by frequency as
'common', 'occasional' and 'rare' with an attempt to quantify them with a
frequency where possible. The writers try to avoid the use of percentages to
describe the risk of a side effect, where possible.
• The web pages are not formally tested, but their readability is sometimes examined
using lay reviewers.
Ingeneral the information is user-led; therefore the content has been developed in terms of
what people have asked for. The pain control section was developed because there was
information about the cancer treatments, but not how people coped with pain. Because it
is a heavily used website, they receive lots of feedback. The CancerHelp UK writers use the
information gained from the CRUK nurse telephone helpline ('This information was
acquired from an interview with representatives of CancerHelp UK).
6.1.2. Previous evaluations of websites with information about cancer
Previous studies examining the usability and readability of web-based information about
cancer overlap with this study. Using various readability formulae to measure the
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reliability of 55 websites with information about cancer, Friedman et al. (2004)found that
two thirds of the sites had a high readability score, i.e. they required high levels of literacy
for reading; and sites that were easier to read were more often those developed by non-
profit organisations. While there are problems with using readability formulae (see 1.2.5),
the high level of literacy required to read the majority of these sites suggests they would
not be accessible to people with low levels of literacy. Tweddle et al. (2000)assessed the
usability of the CancerHelp UK website, using methods similar to those in the usability
study (see 5.3.4), and found that participants who had little or no confidence of using a PC,
were able to easily use the site.
6.1.3. Using a repeated measures study
This trial adopted a repeated measures design, i.e. a crossover study design. Fuchs and
Hippius (2007)used a crossover design to examine leaflet-based information, and found
that participants using a redesigned leaflet were significantly better at locating and
explaining information than when they used an original leaflet. No trials appeared to have
used this design for evaluating the redesign ofmM! web pages. The main reason for using
this study design was that participants receive both the intervention and the control, and
therefore it eliminates between person differences (see add cross ref to 6.2.1.), a common
criticism of a parallel RCf. This however introduces other problems, and these are
reviewed below (see add cross ref to 6.2.2.).
6.1.4. Overall aim of this study
The overall aim of this study was to pilot the appropriateness of (i) a repeated measure
with counter balance study design, (ii) making content and general content formatting
changes alone to the webpages, and (iii) the proposed tools for measuring the outcomes:
User Test Questionnaire; participants' satisfaction with the medicines information was
measured by Home's (2001)Satisfaction with Information about Medicines SaUe (SIMS); and
Participants' judgement of the ease of use of the pages measured by Lewis's (1992)Post
StUdy System Usability Questionnaire (PSSUQ). These could be used by a future trial
evaluating whether redesigned web pages containing information about medicines
improved partidpants' ability to locate and understand specific information.
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The study had three stages:
(i) Interviews with e-health stakeholders to gather their comments on perceived
strengths and limitations of the selected CancerHelp UK web pages;
(ii) Dissemination of the recommended changes to the design and wording of the
CancerHelp UK pages for the intervention; and
(iii) The pilot study to examine (i) the appropriateness of using a crossover study
design to evaluate whether or not redesigned web pages containing
information about medicines improved participants' ability to locate and
understand specific information; the appropriateness of the intervention,
making changes to the content and general content formatting as an
intervention for redesigning web pages containing information about
medicines; and (iii) the validity of the proposed outcome measures; for use in a
potential full trial.
6.2.Intervention studies of repeated measures with counterbalance
This study used a repeated measures (or crossover trial) design in which participants
received both interventions. Therefore it was the sequence in which they received the
intervention that they were randomised to because of the need to counterbalance the order
of presentation (EIboume et al., 2(02). The purpose of this section is to explore the
strengths and weaknesses of this design, and proposed solutions to the potential issues.
For issues pertaining to the running of an RCI', see 3.2.2.
6.2.1. The strengths of a repeated measures design
The repeated measures study design is beneficial for two reasons. Firstly, because the
same participants receive both interventions, this removes any differences between the
participants in the two groups which might determine the outcome (Armitage and Hills,
1982).Any extraneous variables will be the same across both groups; therefore there is a
greater chance that any difference in outcome for each variable can be attributed to the
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intervention and not between group differences. Secondly it increases statistical power. As
the participants act as their own control, this increases precision of the estimate of the
treatment effect given the same number of participants as a parallel study (Sibbald and
Roberts, 1998). In effect this doubles the number of people taking part in a crossover trial
(Armitage and Hills, 1982). As the statistical power of a trial increases, the chance of not
finding an effect when it actually exists (Type II error) decreases.
6.2.2. The weaknesses of a repeated measures design
The repeated measures design is weakened by the potential for a 'carryover effect', which
can bias intervention effects (Senn, 2001). There are two variants of this which are relevant
to this study: a learning effect, and a fatigue effect. A learning effect is when, for example,
information provided in the first intervention is retained and affects the outcome during
the second intervention. To minimise this there should be a washout period (no treatment)
between the intervention stages (Sibbald and Roberts, 1998). The learning effect is a
concern for many repeated measures studies, (although probably not drug trials). This
design has been successfully implemented in an evaluation of information giving. Fuchs
and Hippius (2007) evaluated original and revised versions of paper-based leaflets using
this design and found significant differences in favour of the revised leaflets for finding
and understanding information.
It can be argued that there may be no reason that the learning effect should differ for the
order of the intervention in a study of information giving (Knapp, personal
communication). If this assumption is true, any carryover effect would be the same
regarding the order of the intervention, and therefore the effect would be cancelled. The
carryover effect can be controlled by counterbalancing the order in which participants
receive the interventions.
The second issue is the potential effect of fatigue on participants viewing the second set of
pages (regardless of what version this is), which may determine their outcome more than
the pages being viewed. Again a washout period can provide respite before they view the
second set of pages.
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6.2.3. Practical considerations for running the repeated measures design
The difficulty of the carryover effect was identified as a potential problem for running the
study, and was addressed as follows. Methods to minimise this were to randomise
participants (i) to receive alternate sets of questions in the User Test for the two versions of
the web pages in different orders, and (ii) to view the pages in alternate orders. A
'washout period' (five minute break) between viewing the versions of the pages was used
in an attempt to reduce this, as well as reducing potential fatigue
6.3.Stage one: Recording e-health stakeholders' recommendations
6.3.1. Aims
To conduct interviews with stakeholders in order to gather their comments on perceived
strengths and limitations of the web pages, in relation to their ease of use, and the
readability of their content.
6.3.2. Methods
Ethics application
A research protocol was submitted to the University of Leeds, School of Healthcare,
Educational Research Ethics Group in July 2007 and approval was granted for all stages of
this study.
Recruitment and demographics of stakeholders
An e-health stakeholder was operationally defined as someone with a professional interest
in, or personal experience of, using an IBMI si~e. All stakeholders were given spoken and
written information about the study (see Appendix seventeen), and were asked to return a
signed consent form (see Appendix eighteen).
Professional stakeholders were sampled from critical-cases, to enable the gathering of
spedalist information. Five interviews with professional stakeholders were conducted.
Those recruited were: the head of the CancerHelp UK website and a OmcerHelp UK web
page developer (interviewed together); an experienced Ha researcher; a community
pharmacist; a health information expert; and a patient information expert. For each
professional stakeholder interview conducted, a medicine user interview was also
conducted with a partidpant who had taken part in the previous usability study; (an
226
example of convenience sampling). This was done to ensure that there were an equal
number of interviews for the two groups of stakeholders, but were not matched on any
other variables. None of the medicine users reported having a cancer-related illness when
they previously completed the demographic questionnaires for Study three.
Individual interviews were conducted to gather the views of stakeholders on the pages,
(except for the CRUK representatives who were interviewed together for practical
reasons). The informed consent of all participants was sought before the study, and
anonymity was assured. This study distinguished between the comments of professional
and medicine user stakeholders, and maintained their anonymity by referring to them
only by their assigned participant number and the date on which they were interviewed.
This was done because the participant information sheet guaranteed that the participants'
feedback would be anonymised to ensure that no comments could potentially be
attributed to a stakeholder, and therefore potentially deter someone from taking part in
the interview.
Interviews were conducted in person with the CancerHelp UK participants and the
pharmacist (for practical reasons). A Dictaphone™ was used to record these interviews,
and the participants looked at printouts of the web pages; having looked at the site before
the meeting. The remaining interviews with stakeholders were conducted by telephone
with the interviewee simultaneously accessing the Internet to view the web pages. The
interviews were recorded using Re-Tell™ and saved using the AudacityTM software
program.
The interviews were based on four statements for agreement or disagreement in the Post-
Study System Usability Questionnaire (PSSUQ) (Lewis, 1992)(see Appendix twenty-two).
They were based on the following statements: (i) It was easy to find the information on
these pages to answer the questions; (ii) I am satisfied with how easily I found the
information on these pages to answer the questions; (iii) the information on the pages was
easy to understand; and (iv) the information on the pages was organised clearly.
Participants were asked to use their expertise and/or experience to assess the pages. The
227
interviews were conducted in July and August, 2007 and lasted no longer than 30 minutes
each.
Outcomes
The outcomes were participants' comments on the strengths and limitations of the pages,
and recommendations on how to improve them.
Data analysis
The recorded outcome measures (reported strengths, limitations and recommendations)
were transcribed (not verbatim). The key points from each interview were extracted, and
the overall themes were categorised in relation to the concepts that have underpinned the
primary research in this thesis: (i) quality, (ii) content, and (iii) design features. The
discussions with the medicine users led to the iterative development of a fourth category:
consideration of the information needs of the target audience. From the discussions,
general recommendations on how to improve the ease of use of the web pages, and the
understanding of their content were made.
6.3.3. Key findings from interviews with professional stakeholders
The following points emerged from the discussions with the professional stakeholders.
Design features
Professional stakeholders considered that the design of the web pages impacted on their
ease of use, and they reported having difficulty navigating the site, because specific
information (for example, about particular medicines) was not easy to access: "People
loolcingfor information about specific drugs have to dig quite deep" (Pt, 23 July 2(07). Because of
the vast information architecture, they felt users could easily lose their way going up and
down the various paths. It was felt that the URL (see Figure 20) was not conducive to
finding the information, as it did not say, for example, 'Cancerhelp.orglpain' which may be
more intuitive for people using the site.
The stakeholders thought the links on the top banner (Home, Site MIlp, Search, Glossary),
and the crumb links, did not immediately appear to resemble links (see Figure 20).They
felt these features would not be clear or helpful to people using the site if they were not
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familiar with b nn r r crumb links. In particular, one stakeholder reported having
difficulti u ing th 'Menu for this topic' link; because it was unclear that he had moved to
it. Link f r tabbin down at th top of th 'Side effects of painkillers' page, were unclear; so,
although omething happen d, th u r was still on the same page which caused
confu ion ( Figur 21).
Figure 20: Unhelpful URL and unclear crumb links
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Som pr bl m with the layout of the content wer rais d. All stakeholders had difficulty
navigating th page, and particularly f It that pecific information (for example, for
particular medicine) wa quite deep within the site. It was felt that the hierarchy of the
informati n layout, in particular th headings, did not make it clear that there was more
informati n b ut painkill r und rn ath it. Furthermore, it was felt that the pages may
not b h lpful if u r w r 10 king for sp cific information about individual painkiller,
b cause thi wa n t availabl .
Figure 21: No indication of having tabbed down the page
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People doing so may not notice when particular content had been updated, or may
fail to see crucial information elsewhere on the site if only looking at specific pages.
A specific criticism of the 'Types of painkillers' page was that it stated that opioids were also
called narcotics, which was felt may be unnecessary information for the patient, as well as
cause for undue worry. The site explained the NSAID acronym, but participants failed to
notice this. The 'Types of Painkillers' page contained limited information about paracetamol,
but the stakeholders did not notice this. Itwas observed that the pages did not mention
pharmacists as a source for information about medicines. Itwas felt that the pages should
advise on this, as pharmacists are readily accessible to the general public.
It was suggested that the content should be written so that the person reading the
information could use it to make an informed decision. Instead, it was felt that the content
was based on a compliance, rather than a concordance framework: "non-compliance
becomes a 'badge of awkwardness'" (PI, 23 July 2(07). Itwas felt that there needed to be a
clear statement of intention regarding whom the information was for, and the purpose of
the information: "who is the audience, what is the intention of information, is it purely
informational or is it advice?" (pS, 7 August 2(07).
Quality assurance
The value of the links and logos in the left-hand column were queried. Participants noted
how the Plain English Campaign Crystal Mark, Most Popular Health Site and Best Health Site
logos did not provide links to information defining them. There were questions about why
the CancerHelp UK logo (beside the 'Treating Cancer pain' title) was there, as it did not add
to the page, by acting as a link, for example. A similar point was made about the 'Best' and
'Most Popular Health Site' award logos in the left-hand column. Itwas proposed that the
logos are "badges of clarity ... People who don't understand the badges may feel stupid" (PI, 23
July 2007).
Itwas also noted that the site mentioned 'NHS InfontUltion Partners', providing a link to
NHS Direct, which may be problematic for the CancerHelp UK website, as it could
potentially lose traffic to another site. It was asked:
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"It's unclear why this should happen. Is the link to NHS Direct an endorsement by
CRUK of all the information on NHS Direct? How do CRUKfeel about potentially
losing traffic to another site?" (PS,7 August 2007).
This may be a helpful link for the reader if they are willing to look at additional sources of
information. However, if the person does not want information from an external link; it
may be an unnecessary distraction, especially if they are unable to navigate back to the
CancerHelp UK pages.
6.3.4. Key findings from interviews with medicine user stakeholders
The following points arose in the discussions with medicine users. The themes which
developed from these discussions led to the development of a fourth category:
consideration of the information needs of the person with cancer.
Site design
The information was largely felt to be very easy to locate, and the features of the site useful
for accessing it. For example, some participants said the information was "very easy to get
at" (PI, 13 August 2007);and the site "very easy to use" (P2, 14August 2007). In particular it
was noted:
"I've just gone onto search, typed in painkillers and the ways of treating pain has come
up; what are pain killers, types of pain killers. It explains everything and I just found it
particularly useful" (P2, 14August 2007).
The functions at the top of the page were noticed by the participants and they found them
useful: "as soon as you put the web page up, you notice the headlines, and even the red section, the
pink section at the top, there seems to be plenty of options" (P4, 14August 2007).The
information was succinct and clear for the medicine users, with the large print being
particularly valued. It was as one participant said: "easy on the eye, not cluttered ... with the
headings ... done in nice size type" (P4, 14August 2007).However, clicking on the bullet
point hyperlinks (for example, on the Types of painkillers page) led to confusion because
tabbing down the page was not apparent
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Content
The medicine users felt the content to be informative, and aspects of it were felt to be
enlightening. For example, one participant considered the general public (including
himself) was under a misconception on treating pain: " Ialways thought there was a level you
would reach where the painkiller wouldn't do any good, but the information on the pages laid that
fear to rest" (P3, 14 August 2007). The pages were felt to tackle a similar misunderstanding,
where some people may think that if they get a painkiller and the pain stops that they are
cured: "Obviously it's not curing it; it's just dealing with the pain. But most people could
understand it" (P3, 14 August 2007).
The information was felt to be of practical benefit for the medicine users, by explaining the
importance of taking painkillers regularly:
"The importance of taking them (painkillers) regularly ... stood out for me ... You
know, and why you should take them regularly. To get to a certain level of the drug in
the body, the importance of taking painkillers at a certain time and the importance of
taking them regularly, every four or six hours" (pS, 20 August 2(07).
The warning about constipation was noticed and it was felt it was well explained.
"One thing they've put on here which is good is, if your doctor gives you this drug;
make sure he gives you something for constipation. It's good that it reminds you to
drink plenty of fluids and increase the fibre in your diet, vegetables and stuff like that.
And so they've went way beyond what a drug is. They've put ways for you to stop
being constipated and things like that" (PS, 20 August 2007).
All medidne users said they felt the information was understandable. One noted, "I
understand a lot more; Imean Idon't have cancer, but Ihave something Ido need to take painkillers
for" (PI, 13 August 2(07). Another participant suggested this was because of how it was
written:
"It's put down in laypeople understanding. They've not used a lot of difficult words
which sometimes if you read a lot of difficult long words which you can't relate to, you
turn of!; you look elsewhere" (PS, 20 August 2007).
The language was considered understandable to the medicine usersbecause there was
little jargon, and the content was felt to have been designed for a layperson to read. Unks
to words were valued (for example, 'Chemotherapy') as this helped explain what the words
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meant. Medicine users liked the way that the site spelled out very long medical words
phonetically, because if they had trouble with it, they might have skipped by it.
Respondents also felt it important that if readers wanted further information, the pages
should give terms they could search for elsewhere.
As with the professional stakeholders, several medicine users failed to notice the
definition for what NSAIDs were. One noted: "They used the word NSAID, which l1cnow of,
but they have not put that anywhere. They've not written it out in full and then in brackets
NSAIDs" (PS, 20 August 2007).
Quality assurance
Medicine users only recognised the logos on being directed to them by the interviewer;
and did not question their function. The author waited until the last question ('Is there
anything about the site Ihaven't asked you, which you'd like to mention?') to see if
participants noticed this. The last question allowed participants to raise their own points,
and for the author to follow up on observations made during the task. None of the
medicine user stakeholders noticed the logos; therefore the author directed their attention
to it to get their views. For example, asked if she wondered about the logos in the left hand
column, a participant said she had not, and thought:
"Oh that's good, 1just presumed 1was looking at a very good website. 1didn't consider
what they were. Ijust assumed they had won an award because they were the most
informative" (P2, 14 August 2007).
Another participant said:
"Well if people see something like them, the most popular one to go to, it makes them
feel what they're going to look at is well done and they're going to get lots of
information, which hopefully they want" (PS, 20 August 2(07).
When they tried clicking on the logos to no avail, expecting to get an explanation about
them, several felt the information should have been available. For example, it was
remarked:
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lilt doesn't actually say what they are; there must be a lot of health sites. Maybe it
should have said if this was for a site about the control of pain. Maybe it ought to have
said that" (PI, 13 August 2007).
The logos left some participants with more questions than answers:
"I clicked on it but nothing's coming up. I thought they were patting themselves on the
back or that. And also it's 2006 which puts it a year behind. I would probably think
myself that erm, this is just a recommendation they've given themselves; this most
popular health site. So it is pretty misleading. It looks a little self-congratulatory
doesn't it? When I saw the most popular health website, I thought this was an
accolade they'd given themselves" (P3, 14 August 2(07).
The currency of the pages was not an issue for another participant who felt if the site
displayed an award for 1998, that would have suggested it was a bit dated, but not for
2006.
A participant when asked what he thought the 2006 Best Health Site award meant said:
"well I would guess it's a highly used web page. (He then tried to run the cursor over logo). No
it doesn't give you an explanation. That does seem a bit odd really" (P4, 14 August 2(07). The
lack of information about the award and the inability to click on the logos to find an
explanation was therefore troublesome for some, but not all, medicine users. Itwas also
said: "Well it just says Best Health Site 2006. If it was me, I don't think I'd want to click on them;
I think it's quite clear what they mean" (pS, 20 August 2007).
Consideration for the target audience
Several participants thought the pages showed empathy for the person with cancer,
feeling they would place high value on the web pages. For example,
"I am sure if you were concerned about having cancer yourself, or luming a relative or
afriend who had cancer, and you went to this website, I'm sure you would be so honed
in on what you are lookingfor you would find it easy" (P2. 14 August 2007).
In conjunction with this thought, participants raised doubts about the validity of their
COmments because they did not have cancer: "it's one of these situations where if you were
unfortunate enough to be in this situation, you would probably be in a better situation to give a
response" (P4, 14 August 2007). Another offered;
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"Maybe if I'd got cancer or I had a relative who had cancer and I was stressed, it
wouldn't be as easy. I think that's something you have to think about on these websites.
People may be looking because they have cancer or have afriend who has cancer.
Because I don't, I was looking at it from a different position" (P2, 14August 2(07).
6.3.5. Discussion: stage one
Findings
The findings of this exercise have highlighted medicine users' favourable opinion of the
CancerHelp UK web pages, which mirrors a finding by Tweddle et al. (2000).This exercise
also found a difference with the stakeholder group's comments, which to an extent reflects
a previous finding that patients and pharmaceutical specialists had conflicting attitudes
about medicines (Ramstrom et el., 2006). In this study medicine users were far more
positive in their remarks about the site than the professional stakeholders. There are three
possible explanations for finding this difference. Firstly, they may genuinely not have
experienced any problems with the site. This cannot be discounted as no formal
observation of the participants using the site took place. However, none of the medicine
users appeared to recognise the accreditation logos (see Figure 22) as a quality marker or
thought to click on it for further information before they were shown it, suggesting the
pages were not as useful as they could have been. Secondly, they may have felt
intimidated to be overly critical of a recognisable charity website.
The third reason is that their level of critical insight may differ from the professional's. The
professional stakeholders, (perhaps to a lesser extent the pharmacist), work in a role which
demands critical thinking coupled with a well-developed academic knowledge of issues
relating to healthcare information. Whereas the medicine user's knowledge and interest is
arguably less academic, and more practically orientated in terms of seeking to learn about
their medicines from such sources. Thus they may have been less critical in their approach
to it. Professional stakeholders by comparison offered a more academic critique of the
content, criticising, for example, the pages' failure to adapt a concordance framework, and
the need for taxonomy by condition. Sillence and Briggs (2007)have noted a difference
between professionals' and patients' evaluation of e-health. They explained this as being
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due to profe ionals not having the same concerns as people with genuine health
cone rns, wh may I ok for upport and empathy, beyond mere medical content.
Figure 22: Accreditation logos that were missed by medicine users
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the web pages, and the readability of their content. The interview method enabled this and
provided a rich source of data; therefore it was considered a useful method.
At the end of the interview, participants had an opportunity to raise issues that they had
with the pages, and the interviewer took the chance to follow up issues arising from the
study. For example, participants were led to the quality logos and asked to comment on
them. This has introduced bias to an extent, but on balance it was considered more
important to gather as full a data set as possible.
The recommendations derived from this part of the study were not graded by the
stakeholders in terms of their perceived importance, which is a process sometimes used in
stakeholder-based research. This was not adopted because there was concern that
variation between professional and patients' grades would be great. While this would be
an interesting and important research finding, it would have perhaps distracted from the
study aim. Instead the author took account of the various views recorded in the interviews
and judged their relative importance and feasibility as options for change in the proposed
intervention.
This exercise found a difference between the comments of the professional and medicine
user stakeholders (as reported above). There was a second divergence in responses. The
professional stakeholders largely provided a critical appraisal of the pages, e.g. focusing
more often on difficulties with the pages; while the CRUK representatives were more
complimentary of their own site. This was not highlighted in the findings, because the
discussion of this would have eliminated the anonymity of the CRUK representatives
when their comments were reported. (participants' anonymity was guaranteed in 6.3.2).
CRUK representatives may have had a different perspective to the other participants about
the task, which led to responses biased in emphasising the perceived positive elements of
the site and not be critical about it in general.
Recruiting five medicine users from the previous study may have been problematic.
Because of their experience of taking part in the usability study, they may have become
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more experienced evaluators of e-health web pages than people normally accessing such
sites; and therefore their views regarding the pages may not be representative of those
people. They may have reinforced this experience by consulting mMI sites for their own
purpose since then. Sixmonths had elapsed since they took part in the previous study,
and it was hoped any benefit they had from taking part in it would have lessened. Their
comments did not appear to suggest that they had been primed by the previous event to
be more critical evaluators, because they were more positive in their praise of the pages
than the professionals.
6.4.Stage two: Dissemination of recommendations
6.4.1. Aim and methods
This section reports the recommendations made to CancerHelp UK, and the intervention
that was carried out. The aim was to convey the perceived strengths and limitations of the
CancerHelp UK web pages, and the recommended changes to the pages. This was done
using two methods:
(i) A short report detailing the main findings from the stakeholder interviews, and
the recommended changes to the intervention set of pages drawn from the
following sources:
• Interviews with e-health stakeholders (see 6.2);
• Recommendation for the design ofmMI sites (see 5.8.3);
(ii) Rewriting of the content and general content formatting of the web pages used
in stage three (see 6.5), highlighting the recommended changes to the pages.
These changes were made first by the author, then by two PhD supervisors.
The changes were based on the sources above, as well as the following:
• Dickinson, Raynor, and Duman (2001)design principles used to develop an
information leaflet;
• Supervisors' expertise in User Testing printed patient information leaflets
and usability research;
• The author's health information design expertise in evaluating Pll..sand
mMI sites.
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The recommendations made in the report to CancerHelp UK were derived by the author
using his expertise to synthesise the interview data to derive indicative examples of what
the stakeholders said was felt to be useful and difficult about using the current CancerHelp
UK painkiller web pages. These reflected issues that were frequently reported (in studies
of e-health), as well as some that were less common. The author made judgements on the
relative importance and feasibility of the problems highlighted and the various options for
change. For each problem noted with the pages, one or more recommendations were
proposed for the intervention.
A teleconference was then held between the head of the CancerHelp UK website and a
CancerHelp UK web page developer, the author, and one PhD supervisor. This ran for two
hours and followed a structured agenda to discuss the feasibility of making the proposed
changes to the pages.
6.4.2. Recommendations in the report and changes to the web pages
A report (see Appendix nineteen) was sent to CRUK documenting stakeholders'
perceptions of the strengths of the CancerHelp UK web pages, their difficulties with
navigating the pages, reading the content, and confusion surrounding the quality
assurance markers. This report also detailed recommended changes for the intervention.
Unfortunately following discussions it was agreed that changes would be limited to
content, and general content formatting; and no changes could be made to the design
features of the pages. Some of the recommendations were implemented by CRUK, e.g. the
rewriting of text in the attempt to make it easier to understand. But many
recommendations were not accepted because they would have required significant
changes to the design of the pages, e.g. providing a find bar on the pages. A screenshot of
a redesigned page is in Figure 23. A record of tracked changes made to the original version
of this page is in Figure 24. Table 26 indicates the intervention made to the web pages; i.e.
a record of the generic changes that were made.
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Figure 23: Screenshot of a redesigned page
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Figure 24:Tracked changes of the redesigned page in Figure 23
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1. Bullets were added: to make information stand out better and to break up dense text;
.g. to highlight' All contain 500 mg of paracetamol' (see Figure 24).
2. 'Back to top links' were added: to improve navigation.
3. Content was re-written: to improve the und rstandability of the information; e.g. the
text 'By r du ing th amount of prostaglandin, you fe J less pain or none at all' was
ang d to: ' rae tarnol r du s th amount of prostaglandin. This m ans you f cl
1 pain or n n tall' ( Figur 24).
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bout m di in s improv d p rti ipants' ability t 10 at and under tand sp cific
ti n, Itw s anticip 1 d th t participant u ing th r d sign d w b page would
indi ativ information, would rat more highly their
of u and und r t ndability of cont nt, and would
b mor ti fi d with th inf rm ti n, wh n mpar d to tho using the unchang d
pag s.
6.S.2.M thod
Participant crit: ria for inclusion and exclusion
Parti ip n1 w r dr wn fr m rnpl f staff at th Scho lof ealth ar ,
and In titut
publi ', Th r
t th Univ rsity f ds; i. . 'm mber of th gen r J
ns f r this w r : (i) Ih study valuat d pag s with informati n bout
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painkillers, which the general public are able to relate to, therefore they could be recruited
into the study; (ii) this was a pilot study of an exploratory evaluation of a sample of web
pages on the CancerHelp UK site, therefore it was legitimate not to test this on the 'affected
population group'; (iii) and it was hoped that there would be less difficulty recruiting
participants from the University than there had been recruiting from a pharmacy in the
study reported in Chapter five.
Participants were included if:
• They were administrative and clerical staff, cleaners or porters with any prior
experience of using a website.
Participants were excluded if:
• They were' academics'; i.e. teaching or research staff, or a student.
• Internet naive participants who would require extensive training before
conducting the tests.
Recruitment of study participants
Recruiting was carried out by approaching clerical and administrative staff, and inviting
them to take part in the study. They were given full information about the nature of the
study, verbally and in writing (see Appendix twenty); and were asked to return a signed
consent form (see Appendix eighteen). After completing the study they were given a £10
gift voucher as a token of appreciation.
Study design
A repeated measure design with counterbalancing (crossover trial) was chosen. This
design was beneficial because it examines (i) any difference between the two sets of pages;
and (ii) any order effects. Itmay be that the second site performs better regardless of
which site it is, due to the practice effect. (See 6.2.1 for a greater explanation of the
strengths and weaknesses of this study design).
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Intervention
Participants w re randomly assigned to the order inwhich they viewed the original or
redesigned s t of thr pag s (see 6.1.1). The rationale for this was to control for any order
effects of the pages viewed; because people are known to be sensitive to the order inwhich
they re iv information CB rgus et al., 2002). The original pages were those on the CRUK
w bite at th tim th trial was conducted (in Nov rob r 2006 to February 2007). A
description of th r de igned web pages was provided in 6.4.2.
Participants w r randomly sign d to the order in which they received the two sets of
U er T st qu lions. Two sets of questions were asked because the same qu stions could
not basked twi - particip nts would hav an advantage when asked the questions for
th nd tim . This unt rb lane sought to control for any order effect from the
qu ti ns a k d. Figur 25 hows th diff r nt possibl s quen cs of pages viewed and
qu pr dur of randomisation and cone alment of allocation was the
in th us bility study (s 5.3.4).
Wh n vi wing rh parat w b pag s,th Fll button was used to hide the URL in case
p rti ipants w r ab] to inf r which v rsion they w re using. (Se App ndix twenty-one
for th full proto 01 instructions for running the study).
Figure 25: Randomisation groups
(i) Original pag'S and Us r st v rsion ~
, > j ,
: ~~ ;; • '" -.. ~ , ..' j , ~;... • ." ] •
(li) riginal ,gc and User T sl von ion ~
(iii) edesigned p gcs find Us r Test version ~
(iv) edesig!}ed polge, < nd Us r Test vcr ion ~
At th st rt of th study only th assign d web
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another website. The study was conducted individually with the author. Participants sat at
a PC and performed the study, which had the following parts:
1. They looked at one version of the web pages. Using these pages, they were asked
to find information to answer eight questions about the medicines. They then filled
in a short questionnaire about what it was like to use the pages and what they
thought about the information.
2. After a five minute gap (washout period), this procedure was repeated for the
second version of the web pages.
3. At the end they were asked to answer two broad questions: (i) 'please tell me what
you think about using the different versions of the web pages' and (ii) 'did you
have a preference for one version of the site over the other?'.
The author asked them the User Test questions and noted whether they found the
information and what they thought the answer was. The questions differed for each
version of the pages so there was not a carry-over effect.
Outcome measures
There were three outcome measures.
• User Test scores: whether participants could find and then explain the indicative
information to answer the questions. Participants' explanations of the indicative
answer demonstrated their understanding of the information. The questions were
devised by the author from reviewing information about analgesics on the NHSDirect
website, which provides a large range of information about this. The CllncerHelp UK
web pages were checked for the indicative information to answer these questions:
there were no questions for which the answer could not be found using the web pages.
There were eight questions for each set of versions of pages viewed. This is less than
the normal number of questions for a User Test, to take into consideration the time
needed for the other outcome measures to be completed, having to navigate the web
pages, and having to do this for two sets of pages. The questions were independently
assessed for validity before the study by a PhD supervisor who was an experienced
User Testing researcher.
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Participants' satisfaction with the medicines information was measured by the
Satisfaction with Information about Medicines Scale (SIMS) (Home, 2001) 17-item
questionnaire (see Appendix twenty-two). Participants were asked to say whether they
felt the amount of information for specific statements was 'too much', 'too little', or
'none received', indicating a lack of satisfaction and scored as zero; or 'about right',
indicating their satisfaction and scored as one. Scoring could therefore range from 0-17,
with a higher score indicating greater satisfaction with the information.
• Participants' judgement of the ease of use of the pages was measured by the PSSUQ
(Lewis, 1992). They were asked to rate how much or how little they agreed with four
•
statements on a Likert scale about using the pages. For each statement participants
could give a score ranging from 'strong agreement', to 'strong disagreement' with the
statement. Therefore a lower score suggested greater agreement with the statements
about ease of use. They were asked to answer four follow-up questions. The statements
reflected the usability concepts of effectiveness, efficiency, and satisfaction (which
determine how easily or not web pages are to use); and were derived from a larger 19-
item instrument (Lewis, 1992), for assessing usability (see Appendix twenty-two).
Methods of analysis
For the numerical data, a repeated measures ANOV A was conducted. The primary
analysis was the effect of the different type of pages (old versus new) on the outcome
measures. The secondary analyses were (i) the effect of order of type of page presentation
(old first versus new first), and (ii) the effect of the User Test question set order for the
three outcomes. An examination was made of the type of page and also whether there
were interactions between:
• Page type and presentation order;
• Presentation order and question order;
• Page type and question order; and
• 'Page type and presentation order and question order.
It was not possible to conduct a sample size calculation prior to the start of the trial. Based
upon (i) the recommendation of Collins et al. '5 (2007) (see 25.1), and (li) this being a pilot
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study; it was decided that a minimum of 20 participants should be recruited, to try to
detect a difference in the outcome measures by type of page, if it existed. Had this been a
full trial, it would have required a much larger sample.
The four PSSUQ follow-up questions generated qualitative data. These were iteratively
categorised into four overarching themes which emerged from the data, using the same
method as described in 5.3.6. There were two questions at the end of the study, where
participants could provide comments about the web pages and the tasks:
1. Please tell me what you think about using the different versions of the web pages.
2. Did you have a preference for one version of the site over the other?
Their responses were categorised into four emergent themes by the author. A PhD
supervisor independently marked the responses against the categories. A random sample
of 48% was reconciled with the author, and there was agreement in 94% of instances,
which was considered sufficient not to warrant further reconciling.
6.5.3. Results
Participant demographics
Thirty seven members of staff provisionally agreed to take part. Two participants
withdrew their consent, and one participant was found not to meet the inclusion criteria.
Four other participants did not return their questionnaires or consent fonns and were not
followed up. Of the 30 who participated in the study, their mean age was 40 years (range:
21-61years), 21 were female, and all spoke English as their first language. A majority were
educated to graduate level (19).All participants used the Internet at least weekly, and
almost all (28) reported using it daily. Twenty-five had used it for more than five years. Six
Participants had taken a prescribed medicine for more than 12months; four for less than
12months. Nine had taken a short-term course of a medicine (for example, an antibiotic)
in the last year. A majority of participants (22)had taken one or more arc medicines in
the last year. Six participants reported having not taken any medicine in the last year. Only
two participants said they had previously viewed the OlncerHtlp UK website. No
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participants were lost to follow-up. (Note - all numbers in this section are not mutually
exclusive.).
Primary outcome measures
• User Test questionnaire results
Overall, there was no diff renee in participants' ability to locate the indicative information
when using the original pages or the redesigned pages: mean 6.8 (SD 1.0) for 8 questions
when using the original pages, and mean 6.S (SD 1.1) when using the redesigned pages:
{F=2.34; df=1,28; P--O.14).3There was no difference in correctly explaining the information:
m an 6.4 (SD 1.2) when using the original pages; and mean 6.1 (SD 1.3) when using the
redesign d pages: (F=2.24; df=1,28; P=0.13).
Results in relation to the question set
Th analysis how d no diff renee for indicative information found or explained in
r lation t th que tion s t that wa asked, and ther fore this variable was not examined in
any furth r nalys s (s e Table 27).
Table 27: Results in relation to question set
~"'".<', :Il!~'';(; . ,~. "., .:»........ r ' .. . -- " "''1~Pagc, .~...,~tI'.et:~~}'~:~~~N·;y~}l::~~i~Mean total (SO) 0f<l~:."I; F, df, P
Question set re locating
QUestion set A 30 6.6 (1.2) F=0.S3; df=l,28; P=O.82.
Question set B 30 6.6 (1.1)
Question set re expJaining
Question set A 30 6.1 (1.4) F=1.43; df=l,28; P=O.24.
Question set B 30 6.4 (1.0)
• Time taken
Participan w r signifi antly qui ker wh n viewing the second s t of pages (sec Table
28). Thr
Tab1 28).
in tim taken b tw en the original or the r d sign d pages
..
1 Participants received a score for each time that they found, and explained the information, for eight
questions. Thus a higher score was 'good' as it indicated that the participants could find/explain the
information.
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• Participant satisfaction with the information
There was no difference in participants' reported total satisfaction with the information on
the original or redesigned pages (see Table 29).
Table 28:Time taken (in seconds)
Table 29: STMS scores for the current and revised pages
Th SIMS qu tionnair ontained four st tementsthat were not applicable to th
information c ntained in the pages. The pages did not contain information on how to get a
furth r supply; wheth r you can drink alcohol whilst taking th medicines; whether the
medi in will aff t your s x life; or what you should do if you forget to take a dose.
Particip n should hav answer d 'non r c iv d' for these statements, but itwas not d
aft r th d t collection that 17 participants did not do this for one or more of the
qu stions, th r by inflating th it total SIMS scores. The results were r analysed without
th cor s f th s four qu tions, and there r maincd no difference in satisfaction for the
pag s vi w d (s Tabl 30).
Table 30:Reanalysed SIMS scores for the current and revised pages
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• Participants' views on the ease of use of the pages
The results of the PSSUQ measuring participants' feelings about using the pages showed
no difference (see Table 31).
Table 31:PSSUQ scores for the current and revised pages
Secondary outcome measures
• User Test questionnaire results by order of page presentation
There was a significant inter ction b tween the page version and order of viewing, for
finding nd expl ining th information (see Table 32).
• Participant satisfaction by order of page presentation
Thcr was no diff r nee in participants' reported satisfaction with the information on the
different pagcs, d p ndcnt upon the order of page presentation (sec Table 33). As
explain d abov ,th SIMS qu stionnaire contained four statements which were not
applicabl to th information contained in the pages. When th scores of these items were
removed, and the r sults were reanalysed, there remained no difference in satisfaction
according to the ord r of pages viewed (see Table 34).
Table 32: Finding/explaining by order of page presentation
Page' : . . , Mean total (SD) F, df, P/ N . "
Order of pres en tation of pages for finding
First set of pages 30 6.4 (0.9) F=S.68; df=l,28; P=O.02
Second set of pages 30 6.9 (1.2)
Order of presentation of pages for explaining
First set of pages 30 5.8 (1.1) F=12.61; df=1,28; P<O.OOl
Second set of pages 30 6.7 (1.3)
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Table 33: SIMS scores by order of page presentation
Table 34:Reanalysed SIMS scores by order of page presentation
• Participants' views on. the ease of use by order of page presentation
Thor was no diff r n in participants' f lings about ease of use by order of page
pr S nt tion ( abl 35).
Table 35:PSSUQ total by order of page presentation
Participants' written feelings about the ease of use of the pages
E eh PSSUQ tat m nt had a r lated follow-up que tion which let participants explain
th ir ratin . Qu stions of this typ provide an insight into their views of the ease of u of
th p ge . Four common th m s cmcrg d from the data: praise for the current page ;
prais for th r d sign d page i criticism of the old/new pages; criticism of the t st d sign.
For xampl , omm nts ab ut 'not having tim to r ad v rything', and 'having to jump
b tw n th p , w r at gori ally similar and ond n d as I criticism ofth te t
d ign'.
• Praise for the current pages
Parf ipants pr i d th layout f th curr nt p g s. Itwas felt th t the layout of th
inform non m d it a y to find th information:
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"For immediate access to the information I found the bullet points were helpful and
headers." (Participant is referring to the heading opioidslnon-opioids). "The way drugs
like morphine were broken down into 'immediate release', 'slow release' enabling the
viewer to assess the best way to understand dosage" (P29, old pages viewed tot).
The layout of the old pages made them satisfying to use because the information could be
easily found: "The pages contained relevant information that was easy tofind, and more
importantly, understand." (P4, old pages viewed tot). The information was felt to be
understandable because it outlined "the uses, strengths, advantages and disadvantages of each
medication in a straight forward manner" (P34, old pages viewed tot). Participants as a whole
felt the information on these pages was dearly organised. For example, it was said of the
old pages that they: "were not too long. Not too much information squeezed in. Not a lot of
medical jargon" (P29, old pages viewed tst).
• Praise for the redesigned pages
Participants had similar praise for the redesigned pages. It was felt that the information
was easy to find on the new pages because of its layout: "an easier format on screen" (P24,
new pages viewed 2nd), and 'Links clearly presented could take you to required information
quickly. The information is presented clearly in headers at the top of each page. ' (P4, new pages
viewed 2nd). Asked what made the new pages satisfying to use, the additional bullet points
were acknowledged: "Use of bullet points more easy and clearly set out" (plO, new pages
viewed 2nd). The information was felt to be clearly organised, making "Good use of lists
rather than paragraphs of information" (ptO, new pages viewed 2nd). While there was a lot of
information to negotiate on the pages, it was felt "breaking it up into smaller chunks made it
more easily navigable" (P36, new pages viewed tit). The information was said to be
understandable:
"Although a lot of medical terminology was used, it was expressed without resorting to
jargon, and therefore someone with little or no medical knowledge would hopefully be
able to make sense of the information. " (P26, new pages viewed lit); and "Good use
of language; clear, simple, but not patronising" (P28,new pages viewed 2nd).
• Criticism of the current and redesigned pages
There was an equal amount of criticism about both sets of pages. It was felt that the
amount of information on the current pages overwhelmed some participants: for example,
252
"Seemed to be a lot of information to read through before you got to the part which answered the
question" (P18, old pages viewed 1"1).To rectify this perceived problem with the current
pages, it was suggested there needed to be changes to its layout: for example, "l had
difficulty finding some of the answers. Would prefer better headings and smaller chunks of text"
(P3S,old pages viewed 2nd). A similar criticism was made of the redesigned pages, with
the amount of text again criticised: "Links to information did not stand out from the main body
of the text. Too many blocks of text; bullet points would be easier to understand" (P12,new pages
101);and "Too much print in large blocks" (PI, new pages viewed 111).There was also a
criticism that the information was too rudimentary on these pages:
"Not easy to understand because there should have been fuller answers. Perhaps one
criticism would be the information was too basic. Too much brevity. The pages were
too simple" (PS,new pages viewed z=).
• Limitations of the study
Participants repeatedly said they did not like having to navigate between pages to answer
the questions. For example, it was felt: "Hard to navigate and jump backwards/forwards for
information. Would have preferred to have printed offinjormation" (P2, old pages 1.1);and "Felt l
had to jump around the pages a lot" (P23,old pages 111).Most participants said they did not
have enough time for looking at the pages before undertaking the User Test. For example,
"l think it would have been easier to find all the answers if there had been more time to read the
pages" (p19, new pages viewed 1.1).
The task was felt to have impeded some participants' attempts to find the indicative
information, making it "more difficult than if I'd been looking myself in a relaxed atmosphere"
(PI, new pages 1.1).It was also remarked that participants may have found the information
with greater ease not because of the page design, but because of increasing familiarity with
the pages during the task. For example, a participant said: "lwas ftmrilillr with the
information at this point with the three different pages, so it was easier to assess the in.fomuztion
than at the beginning" (P29, old pages viewed 1at). It was also felt that the questions were
.' .
easier the second time around "[found the second set of questions easier to answer than the first,
but this may simply be due to having already viewed the information in the first part of the test"
(P26, new pages viewed 1at). Some participants felt they would have liked longer on the
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tasks: "Maybe more time to look at the pages would alter my opinion?" (p2S, old pages viewed
1st).These factors may have impacted on the participants' performance during the tasks.
Additional questions
Three common themes emerged from the points participants made in the section with
additional questions: appraisal of the current pages; appraisal of the redesigned pages;
and feeling there was no difference between the websites.
• Appraisal of the current pages
Participants gave several reasons for favouring the current pages. Perceived ease of use
was a common reason: for example, "the second did strike me as being slightly easier to
navigate" (P20, old pages viewed 2nd). This participant did not offer a reason to explain
why she felt the navigation to be easier. On the other hand, another participant offered a
reason; stating:
"l thought the second version seemed to be simpler to use. All the necessary
information appeared to be there without too much text to read through. The first
version seemed to be a lot longer and not as easy to find answers to some questions"
(P19, old pages viewed 2nd).
• Appraisal of the redesigned pages
Similar reasons were offered by the participants for favouring the redesigned pages.
Viewing the new pages second; a participant offered: "Lots of information in both but the
layout of information is better in the second" (P19, new pages viewed 2nd). Another participant
said: "Preferred website two. It seemed more logical;slightly easier to use; less links and less
jumping around" (P25, new pages viewed 2nd). A participant viewing the new pages first
found them to be "quite dense with language and more technical too, making it difficult to taJce in
and comprehend. However, finding information on this page was easier to pick out" (p36, new
pages viewed 1.1). Another participant said: "I thought thefirst one was harder to retrieve
injormationjrom, although it was all there clearly laid out" (p13, new pages viewed 111).
Accessing the new pages second, a participant felt:
"There was more information in the second one which could be confusing and "'IlY put
you off if you thought the disadvantages would outweigh the advantages. It "'IlY make
you more anxious about treatment. But it did give more information if this was
something that you were going to go through. " (P34, new pages viewed 2nd).
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• Feeling of no difference in the web pages
There was no difference in results for the current and redesigned versions of the web
pages for the User Test; time taken on the User Test; or the PSSUQ and SIMS
questionnaires. The vast majority of participants reflected this in their feedback: for
example, "1 did not notice any significant difference between the two versions of the web pages"
(P26, new pages 181); "There was very little difference between the pages" (P21, new pages
viewed 181);and "There didn't appear to be a huge difference between the two sites" (P20, new
pages viewed 18t). On a couple of occasions, participants felt there was a difference; but
that this was far from explicit: "It was interesting to see how the two versions differed even
though from the start they both looked the same" (PI4, old pages viewed 1&1);and "subtle
differences between the sites in how the information is presented" (P24, new pages viewed 1&1).
6.5.4. Discussion: Consideration of the methods piloted in stage three
This pilot study has been a valuable exercise, indicating the methods limitations of this
pilot, and there is need to reconsider the methods adopted, if it were run as a full trial of
changes to the web pages and their impact on finding and understanding the information.
It is important to consider that the results were near' ceiling level' for the current web
pages, which suggests they were already designed adequately enough for the indicative
information to be found and explained.
Firstly, the crossover study design may not be appropriate. Despite the effort to reduce a
carryover effect, it is likely that this will have impacted on the outcomes. The five minute
wash-out period may not have been a sufficient length of time. This was not tested, but
could have been by randomising participants to receive different lengths of wash-out
period, and comparing the length of wash-out period with their scores on the outcome
measures. However, if the period was for a greater length of time, participants could have
potentially accessed the web pages outwith the study, thereby invalidating their outcomes
on the second half of the RCT.
Running a parallel groups trial would probably be the more appropriate study design in a
full trial. The appeal of running a crossover design in the full trial was that it removed
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between group differences, and increased statistical power. However to account for an
order effect, four randomisation groups were required, presenting a practical challenge for
the pilot. Running a parallel groups ReT would have been simpler, and would not have
introduced a potential carryover effect. Therefore it would be advisable to run a parallel
groups study design in a full trial.
Secondly, the intervention (changes to the content and minor content formatting) of the
web pages was not significantly different enough to have had a differential effect on the
outcomes. Furthermore some participants felt that there was no difference in the web
pages. A full trial should implement greater changes in a mock version of the website,
making significant changes to the format and interactivity of the pages which may
improve participants' navigation of the pages and understanding of the information.
Thirdly, there were only eight questions per User Test; which was lower than the
convention of 12 to 15. Had there been more questions in the User Test, there may have
been greater variability in the results, reducing the 'ceiling effect' that was found. The
adoption of the SIMS and PSSUQ tools were valuable because they could be completed by
the participants independent of the researcher in a full trial. This could enable several
participants to be tested simultaneously if the User Test was completed by the participants
(see below). However, by removing the need for the researcher to be present, this would
make the study an indirect measure of usability. See 5.2.2 for problems with indirectly
measuring usabiity.
Fourthly, participants were University employees, and so they may have been more adept
at using a PC and therefore found the task less challenging than the websites target
audience. This could be examined by running the study again with participants from the
websites target audience, (i.e, people with cancer-related illness, their friends and family).
It may be beneficial to run the study with a sub-group of computer naive participants, to
examine ease-of-use of the site for such people. However, it remains to be seen if such
people are deterred or not from accessing this or other e-health/lBMI sites it in the real
world
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Fifthly, a full trial would need to be adequately powered, enrolling larger numbers of
people to find a significant effect size. If the task had self-completing outcome measures,
many people could be tested simultaneously, making it possible to examine larger
numbers of participants in the same period as this pilot, which only examined one person
at a time.
6.6.Concluding remarks
Running the pilot to examine the feasibility of the study design, intervention, and outcome
measure tools was beneficial as it highlighted changes that would need to be made to
these aspects if the study were run as a full trial.
The next and final chapter pulls together the stands of the four empirical studies in this
thesis. There is a summary review of the main findings, and then a discussion of the
limitations of the work as a whole. It is noted what the work in this thesis adds, and there
is an exploration of the implications arising from the findings.
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Chapter seven
Discussion
7.1.Introduction
This chapter brings together the work reported in this thesis. Following a summary, it
addresses the broad limitations of the research. There is an examination of what this work
adds, for the provision of leaflet-based and Internet-based information about medicines,
and for the use of mixed methods. The implications arising from the findings are
considered for written medicines information, and Internet-based medicines information.
Recommendations are made for future research. This chapter concludes by providing final
remarks on the usefulness of leaflet-based and Internet-based information about medicines
for consumers.
7.2.Summary
The research in this thesis has evaluated the usefulness of leaflet-based and Internet-based
medicines information. Grounded in HSR, in particular Medicines Management, it has
drawn on theory and methods from Cognitive Psychology and Human Computer
Interaction research. Evaluating WMI is important because medicine users need good
quality information that will enable them to know how to take a medicine effectively, to
understand the benefits and side effects of taking it, and, it is hoped, to make an informed
decision about taking the medicine or not.
Chapter one set out the background and aims of this thesis. It found no previous studies
that had evaluated Internet-based medicines information (mMl), and so the main focus of
this thesis has been to examine such information. Chapter two critically examined mixed
methods research and concluded that this approach would benefit the examination of
WMI, because it is driven by a real world problem, and enables a well-rounded overview
of WMI both quantitatively and qualitatively. A mixed methods approach was used in
three of the empirical studies to enable a comprehensive evaluation of WMI.
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Chapter three reported the first empirical study: a systematic review of the effectiveness of
WMI, with stakeholder input through two sequential workshops. There was little evidence
that leaflet-based WMI is effective for changing attitudes or behaviours. The review found
some evidence that WMI can change knowledge. The workshops highlighted that leaflets
are not valued by medicine takers. No previous trials evaluating mM!were found,
reinforcing its examination in the remaining empirical studies. Problems were identified
with previous research evaluating WMI, and ways to resolve these were raised.
Chapter four reported a content analysis ofmM! sites with information about simoastaiin
and found variation in their design features and quality indicators. From a medicines
management perspective, there was concern at the inconsistency in information that was
examined across the websites.
InChapter five a purposive sample of websites derived from this study was examined for
usability and readability examined. A User Test examined medicine takers' ability to
locate and explain specific information to answer a set of questions using these websites.
Three usability methods (observation, think aloud, and online tracking) ran concurrently
to examine how the participants navigated the websites. This study found that the way the
sites were written and designed impacted on their ease of use, and the readability of their
content. A set of evidence-based recommendations for the design ofmM! sites was
derived to make them easier to use and read, and this is an important output of this thesis.
The study in chapter six piloted the appropriateness of a repeated measure with counter
balance study design, an intervention redesigning an mM! site, and the proposed outcome
measures tools. The crossover study design and limited redesign of the web pages may
not be appropriate for a full trial to examine differences in the usability and readability of
web-pages with information about medicines.
7.3.Limitations of this thesis
Each study has examined in detail the limitations of the methods used. This section looks
at broader limitations of this work as a whole.
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7.3.1. The transferability of the findings
In the content analysis, the five most accessed UK and US developed websites were
analysed. The findings from these ten sites may not be transferable to other less frequently
accessed IBM! sites. Transferability to other less frequently accessed sites may be less
important because medicine users in the usability study did not look beyond the first ten
links generated from a search engine. The study only examined information about one
medicine, simvastatin. There is the possibility that the findings may not be generalisable to
pages on the same sites about other medicines, although websites tend to have a generic
style for presentation and writing. This is an empirical question that invites further work.
A key principle of usability research and User Testing, is that it is the information and
website that is tested, and not the participant. This was explicitly stated to the participants
in the third and fourth studies. However, variation in performance using websites can also
reflect individual differences, and not just the design of the site. Participants in the
usability study were mainly older adults, while people who access IBMI will be of a wider
age range, have varying levels of Internet familiarity, and different experience of
medicines taking. Participants in the pilot study for a trial were university employees,
many of whom use the Internet daily, making them more experienced Internet users than
many people who access IBM!. Therefore the performance of the participants in these
studies and their responses in the interviews may not be generalisable to all medicine
takers, or to people who access IBM!. Future research should examine the readability and
usability of IBM! sites, enrolling other groups from the general public.
7.3.2. Usability studies and User Testing
The examination of usability reported in Chapters five and six was conducted under
controlled conditions. Ina more natural setting, different findings may have been made;
e.g. some participants said that they would have searched for IBMI differently in their own
home, looking at other sources to cross-reference the information. People accessing IBMI
may leave a site that they find difficult to navigate, to access another site. In the User Test
they had to persevere at using the site they were allocated to.
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The aim of these studies was to identify what factors made the sites easy to use and their
information readable; not to examine how people use them'in the real world'. Examining
this in a natural setting would have been problematic because extraneous variables may
have affected the results. For this reason it was decided to forego some ecological validity
in these studies in favour of controlled conditions, in order to increase the findings'
reliability. Future research could examine people interacting with IBM!sites in a natural
setting.
The focus of examination in this thesis has primarily been the websites, and not the user;
driven by the grounding in the ideas of usability (see 1.5.2).But the individual was not
ignored. For example, the usability study highlighted where participants' assumptions
and previous experiences determined how easily they navigated an IBM! site and
understood its content. That said; greater attention could have probably been given to
individual differences in participants interacting with the web pages, and the
consequences that this has on the outcomes measured.
7.3.3. The option to personalise IBMI
The ability to personalise the information on the sites was found to be a rare option in the
sample of sites examined. Only one of the sites examined, Medicines Guide offered the
option to customise information, limiting this to age and sex. None of the others offered a
personalisation option. Therefore this thesis cannot draw any firm conclusions on the
usefulness of a personalisation option on an IBM!site. There may be sites (that met the
inclusion criteria) that offer personalisation options, but were less frequently accessed than
the sample examined, because they were not identified using the search strategy
employed. Sites that do not take advantage of the interactive nature of the Internet may
miss the chance to customise information to make it more relevant to the individual. The
issue of personalisation is clearly important to IBM!For example, Dickinson and Raynor
(2003)proposed that personalisation is a key feature of an ideal source of information
about medicines. Future research may seek to examine the usefulness of an IBMI site
prOviding this feature or not. From a usability perspective, it can be argued that before an
individual can personalise information or customise a site, they first have to be able to
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navigate it with ease, and be able to understand the information. For example, Sillence et
al. (2006) have noted that the personalisation of an e-health site will be important for the
person's long-term engagement with it. But in the short term their engagement is based on
site design. mM! sites need to have a basic level of usability and readability for all users.
Personalisation of an mM! site is an important option, but it is argued that this will be of
secondary importance to a site being easy-to-use.
7.3.4. The challenges of using a mixed methods approach in this thesis
Using mixed methods in three studies (reported in Chapters three, five and six) was a
challenge. Running the sequential workshops before and after the systematic review was
difficult because there was a gap of nearly a year between them. Some of the first
workshop attendees did not attend the second workshop, and SO some participants who
expressed their needs from the systematic review at the initial workshop were unable to
provide comment on the findings. Their loss to follow-up may have potentially resulted in
valuable feedback being lost.
The studies in Chapters five and six used different methods for examining the usability of
the web pages. In Chapter five, usability was examined by observing the participants' use
of the website in real time, tracking their online activities, and asking them to think aloud.
This yielded a rich data set from 15 participants, by which point data saturation had been
reached. Running this study demanded great attention to record observations while
conducting the User Test. Transcribing the protocols verbatim and noting further
observations from viewing back the recordings, was a lengthy process. Analysing the
usability data in relation to the User Test results was also time consuming. By comparison,
piloting the outcome measures for a proposed full RCf assessing the usability of the
original and redesigned sets of web pages (in Chapter six) was relatively straight forward
to run and analyse. However, this method did not have as great an insight as the previous
study into the ease of use of the site, as it was indirectly measured (see 5.2.2).
7.3.5. Piloting minor content and formatting changes of webpages
Piloting the intervention that made minor content and formatting changes of webpages in
chapter six was important. The pilot study data did not suggest any difference in
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participants' perceptions of the usability of the original or redesigned pages. TIUs
corresponds with some participants' suspicion that they could not distinguish between the
pages. These points suggest that the changes to the web pages were probably too limited.
Making minor content and formatting changes would not be advisable in a full trial.
7.4.What this work adds
7.4.1. Leaflet-based medicines information
Leaflet-based medicines infonnation can improve knowledge
Study one found evidence from some individual trials that provision of WMI can increase
knowledge about medicines. There was clearer evidence that the understanding and
perception of the risk of a side effect are determined by the way that the risk is presented
(descriptively or numerically), which has implications for EU legislation.
Itwas argued that knowing and understanding are not the same (see 1.5.2.). People may
increase their knowledge about medicines by reading the leaflet, but this does not
necessarily mean that they will understand more.
No evidence that leaflet-based medicines information improves attitudes or
behaviour
The systematic review found no evidence to suggest that WMI is effective for changing
attitudes towards taking a medicine, or that it can improve adherence to taking a
medicine. TIUs reflects the systematic review by Haynes et al (2008) that found no evidence
that individually applied interventions (including written information) were effective for
improving adherence to taking a medicine. No conclusive evidence of the effectiveness of
WMI was found; and no trials reported an adverse effect from providing WMI.
Leaflet-based medicines infonnation is not valued
An important finding from the workshops reported in Chapter three was that medicine
users do not value leaflet-based information. It is unclear whether this results in the
information being ignored; but it is known that not everyone reads the information that
accompanies a medicine when they receive it for the first time, and fewer people still read
the information provided with repeat prescriptions (Raynor et al., 2007b). IfWMI is
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ignored and not valued by people, its usefulness to aid their understanding about their
medicine may be doubted.
7.4.2. Internet-based medicines information
The role of search engines
The findings from Chapter five were based on robust observational methods. This has
provided valuable knowledge on how people search for mMI, adding to findings from
forus groups by Peterson et al. (2003). The Department of Health (2006) report 'Better
information, better choices, better health' suggested that an NHS-licensed search engine would
be popular with Internet users looking for healthcare information. In the search task, only
one participant used NHS Direct to search for online information about simvastatin. This
reflects the finding of Eysenbach and Kohler's (2002) that an 'official' healthcare portal
may be under-utilised for finding online information about healthcare. In April2008
around 60 people per million Internet users accessed NHS Direct. However, only 6% of
those people accessed it to use it as a search tool (Source:http://WUlW.alexa.com/accessed
April 2(08).
The rare use of a healthcare portal for searching may reflect the general dominance of
Google™ as the search engine of choice for all purposes. From a usability perspective, the
uncluttered Google™ homepage can be easily processed; whereas health portals (and other
websites) often have an abundance of text that may impair some users' processing of the
information, and be off-putting to them.
Adams (2006b) has proposed that information found on the Internet is a product of the
search strategy adopted. In the usability study, only one participant Specified the search
strategy by typing more than the drug name: 'simvastatin - drugfor cholesterol'; and no-one
looked beyond the first page of links on the results page. Participants were led directly to a
specific page with information about the drug on the site, therefore bypassing the site's
homepage. Doing so may make the homepage potentially redundant for some users;
therefore site designers should ensure that any information on the homepage that is
relevant to the medicine, or about the site, is repeated elsewhere on the site.
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Mager (personal communications) has proposed that to become an informed patient, a
person using a search engine (such as Google™) needs to be aware that this process
deconstructs the information from its original context. She argues that this leaves the
individual to make sense of the information by trying to reconstruct it, and therefore
create their own information. Such an argument is in line with Adams' (2006b)proposal
that the user constructs the reliability of information from different sources, including
information found from sites accessed via search engines. It is argued that the processes of
deconstructing and constructing the information are interwoven because they are two
dimensions of the same search and ordering process (Mager, personal communications).
The approach of this thesis seems to dovetail with these arguments. Where Adams talks
about information being constructed, this can be said to reflect the person's internal
representation ofmMI.Where Mager talks about the information having been
deconstructed, she is referring to the external representation of the online information.
IBMI can empower some patients
Participants in the usability study spoke about accessing mMI before consulting their GP,
or to expand upon the information that they received from their GP after the consultation.
mMI thereby has the potential to inform and empower medicine users, providing a
balance in the doctor-patient relationship. It is a legal requirement for PILs to be given to
the medicine taker. There is no legislation for the provision ofmMI, and so it is likely to be
sought by the user in a quest for knowledge. This might make a difference to the user's
perceptions of the information. Leaflet-based WMI is not valued by medicine users, but
mMI may be more appealing as access to it is independent of receipt of the prescription or
the medicine being dispensed. For example, some participants would value mMI being
accessible at the GPs surgery (at the point of prescribing), or at the dispensing pharmacy.
It remains to be seen if this is achievable and if it is effective in aiding concordant relations
between the health professional and medicine taker. Although mMI appealed to many
participants, there was a strong preference for receiving spoken information from their GP
first. Medicine users in the stakeholder workshops similarly placed greater value on
spoken information over leaflet-based information.
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lBMl has mixed potential as an ideal source of WMI
The evidence reported in this thesis suggests that mM! sites are currently not easy to use
by everybody, and so they are probably not an ideal source of WMI for everyone. Study
two found an abundance of online information about simvastatin,while Study three found
that most participants used limited search strategies. A consequence is that many mM!
sites may be rarely accessed.
Chapter four highlighted the variable quality of the five most frequently accessed US and
UK developed mMI sites. Itwill be important that people looking for mM! (or e-health),
consider the quality of the information. For example, most of the sites provided some
information that corresponded with each of the five EU categories of information; but the
precise detail was inconsistent. When the sites were piloted for the User Test, only half
were found to provide the necessary indicative information. The implication is that
medicine users who rely on sites that do not provide complete information for the correct
and safe use of the medicines may not be able to make an informed decision about taking
the medicine. In addition they could act on the information, and suffer potentially serious
health consequences.
Because of the difficulties that some of the participants had in using the mM! sites, and
because of less than rigorous search strategies, at this time the Internet will probably not
be an ideal source of WMI for everyone. This will only be an issue into the near future, as
most people will be probably be 'Internet savvy'. A conclusion is that what the person can
find and understand is not only determined by her or his knowledge, Internet competence,
or motivation. It is affected also by the input of the website designers and information
writers.
The importance of well designed IBMI
Participants in Study three were mostly able to find and explain information on the
websites. When they failed to do this, analysis highlighted three recurring problems.
Firstly, some participants struggled to find information on web pages that had cluttered
text and links. Secondly, tables of contents were commonly missed by participants, and
when noticed, rarely used. Similarly, hyperlinks designed in an obscure manner were not
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noticed. Thirdly, when the site content did not reflect the participant's expectation of the
answers, they were unable to locate the information to answer the question. The problem
in these examples related to the way that the information was written and presented.
From identifying these problems, this thesis has developed an original and important set
of evidence-based guidelines that offer concrete recommendations for the design and
content ofmM! sites. These recommendations could make mM! (and e-health) easier to
navigate and read. IfmM! is easy to use and understand, this may be valued by users.
How medicine users assess the trustworthiness of IBMI
Participants in the interviews (in Study three) said that they did not trust mMI developed
by pharmaceutical companies. Study two highlighted that some (USdeveloped) websites
promoted a pharmaceutical product, while other websites (UK and US developed) had
connections with the pharmaceutical industry. None of the mM! sites in the sample were
developed by a pharmaceutical company. Company sites' ranking by search engines
probably reflects their lower number of hits by Internet users. This may be a consequence
of medicine users' distrust for the pharmaceutical industry.
Participants in Study three also said that they did not trust websites with commercial
interests, such as industry related websites, or sites with advertising. For example, they
spoke of having reservations about promotional websites, which would make them
consider looking to discussion sites for a more balanced perspective, where they could
read about the experiences of people taking the medicine, particularly regarding side
effects. Participants also reported a lack of trust for US developed mM! sites, but said that
they trusted sites that were developed by healthcare organisations.
Participants were in principle aware of the need to assess the trust of websites, and
described 'lay-techniques' for doing so: e.g. cross-referencing the information with that
found on other sites, or trusting a site that was recommended by a GP. These techniques
reflect the use of heuristics by people when accessing a new healthcare website for the first
time (Sillence and Briggs, 2(07); and Adams' (2006b)assertion that the general public
construct reliability of e-health from cross-referencing sources of information.
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Participants in the usability study did not adopt rigorous means for assessing the
trustworthiness of IBMI, and made their judgement based on the assumed 'professional
appearance' of the site. Peterson-Oarke reported that pharmacists adopt a similar method,
using the 'professionalism' of a website as an indicator of its quality (Savage, 2(08).
7.4.3. Methods and methodology
Usability and User Testing can be successfully applied to evaluate IBMI
Chapters five and six reported the first known studies to have applied a User Test to
evaluate web pages. This was a novel way to examine the readability of online information
for the participants, and provided a real-life scenario in which to study their use of ffiMI.
The use of mixed methods is beneficial for the examination of WMI
A mixed methods approach was adopted to provide a well-rounded overview of WMI
both quantitatively and qualitatively. This was a challenge (see 7.3.4), but on the whole
benefited the examination of WMI. The sequential stakeholder workshops ran before and
after the systematic review. This enabled the medicine information stakeholders to input
to the aims at the outset of the review, and to give feedback on the findings at the end.
Around half of the stakeholders were medicine users, and so this enabled the review to
have patient input.
Concurrent verbal protocols enabled insight into the cognitive processes of the person
interfacing with the site during the task. This highlighted not only the difficulties that
participants had when using the sites; but also their perceptions of why they were able (or
not) to find and explain the indicative information on the site. Conducting an interview
with the participants immediately after the User Test was essential, because in usability
studies an interview is an indirect means for assessing usability (see 5.2.2). By asking
participants to talk about using the site immediately after User Test, this study sought to
increase the chance that this was the sole focus of their responses, and so reduce the
indirectness of the interview.
No known previous studies have mixed a battery of usability methods for examining
mMI, making this an innovative approach for evaluating ffiMI. Ina study evaluating a
Dutch e-health site, Senior Gezond (Senior Health) (http://unuw.seniorgezond.nl); Alpay et al.
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(2004)used different usability methods (questionnaires, observations, focus group
discussions, and individual interviews). They concluded that usability methods were
beneficial because they enabled the needs, expectations and abilities of participating
patients to be considered when the site was designed. It is similarly argued in this thesis
that the evaluation ofmMI using the mix of usability methods and enrolling medicine
users was advantageous because it highlighted the problems and needs of medicine users
accessing mMI.
Sequential methods were used in Chapter six to pilot a study design, intervention and
outcome measures, for a full Ref. This enabled the recording of stakeholders'
recommendations for the redesign ofmMI, implementing some of them, and examining
their effects on a User Test. Using questionnaire to examine how easily they felt that they
navigated the pages, and their reported satisfaction with the information, were efficient
means for examining their performance on the main task.
Utilising a mixed methods approach, while a practical challenge; was immensely
beneficial to the research in this thesis. The combining of quantitative and qualitative
research has provided great insight into the usefulness of WMI, thereby achieving the aim
of using this approach. This is an important finding of this thesis.
7.S.Implications
The findings of the research have practical implications for the design and delivery of
WMI in general, and specifically for mMI, and for further research of WMI and mMi.
7.5.1. Written medicines information
WMI that is understandable can be useful for medicine users
IfWMI is understandable, it may be useful to the medicine user. This will depend upon
the purpose for which the person uses WMI (see below). WMI should reflect the
knowledge and expectations of the medicine user, because the usability study showed that
information on a website about a medicine was,less easily found and understood, or even
misunderstood, when it did not correspond with the reader's knowledge. This can reflect
individual differences in interfacing with mMI sites. Furthermore, there is probably no
reason why this does not also apply to leaflet-based WMI.
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The risk of a side effect should be presented numerically because the systematic review
showed that medicine takers are better able to understand information presented this way,
than if presented using verbal descriptors. The review by Berry (2006)recommends this
numerical information should be presented as a natural frequency (for example 1 in 100
people may be at risk of a side effect), because this is more easily understood than
information presented as a percentage.
Medicine users want information that is specific and relevant to their needs; and would
(probably) value it being personalised. They want condition-based information, and to
know about other patients' experiences of taking the medicine. Producers of WMI should
recognise that, because people want and need different levels of information depending
on the nature and severity of their illness, there is a need for different versions of the same
information. Furthermore, the information in a leaflet or on a website can quickly be
superceded. Therefore there needs to be a means for alerting users who regularly take a
medicine, that the information has been updated.
These points highlight the importance of tailoring WMI (leaflet or website) to the needs of
the medicine user. The information needs of patients differ between them, and within the
same patient, over time. Because of its interactive nature, IBM!could offer personalised
information. However, this was a feature of only one site, to a very limited degree. This
represents a failure of the potential of IBM!, and there is a need for IBM!sites (in general)
to offer the option of personalising information.
If and how people trust WMI
Two common themes emerged from the examination of participants' trust for WMI:
(i) Participants did not trust information developed by pharmaceutical companies;
(ii) Participants employed lay-techniques for assessing trust and were unaware of
formal methods for assessing the quality of e-health.
Pharmaceutical companies are the main producer of WMI;and the participants' lack of
trust for leaflets (see Chapter five) cannot be ignored. EU legislation requiring the User
Testing of leaflets has led many pharmaceutical companies to contract out the user-testing
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of their leaflets to other organisations (Knapp, personal communications). A result of the
legislation should be the improved readability of the PILs, but it may not necessarily
increase public trust in the leaflets.
In early 2008 the Royal Pharmaceutical Society of Great Britain introduced a logo to help
Internet users identify websites that belong to pharmacies registered in the UK (Connelly,
2(08). The hope is that people accessing the websites would see the logo and be assured
that the site belongs to a credible retailer selling genuine medicinal products. This logo
was introduced after the completion of the empirical research in this thesis, and it remains
to be seen if this is helpful for the general public. As with the HoN Code seal, the logo will
be useful only if the person notices it on sites that display it, and recognises what it stands
for. Furthermore, the logo says nothing about the credibility of the content on the site, and
so will not benefit the person searching for information.
WMI should be designed to be easy to use
The importance of good design of leaflet-based and Internet-based WMI cannot be over-
stated. The usability study found that the design of the sites impacted on how easily
participants navigated them, how easily they understood their information, and their trust
of the site. To ensure mMI (and PILs) are useful, in terms of their information being
locatable and understandable, will necessitate best design practice for mMI (and PILs)
with user involvement at the design stage. This is already recommended for PILs by SIess
(2001), in his proposed good design principles for communicating medicines information.
The importance of good design in PILs is legislated for in the EU, and it is hoped that this
will have beneficial effects by improving the readability of the leaflets, making them more
understandable for medicine takers. Raynor (2008b)has argued that the legislation will
raise the level of quality of the leaflets patients receive now and in the future. However,
this does not guarantee that people will read and understand the information and mMI is
not regulated.
Applying the evidence-based recommendations for the design ofmMl (see 5.8.3) could
make the sites easier to use. For example, the addition of a find bar would enable users to
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search for a keyword on the page. Navigation may also be improved with the addition of a
hyperlinked table of contents, when not currently available, or by making this feature
more prominent, if not easily noticeable.
The purpose of WMI
The purpose of WMI was not specifically addressed in this thesis, which focused on
examining usability and readability. However at various points in the research reported in
this thesis, participants spoke about the purpose of WMI for themselves, healthcare
professionals, and the pharmaceutical industry, therefore this cannot be entirely ignored.
For example, they said that they want WMI to complement and not replace spoken
information from the health professional (see 3.3.2or 5.7.5).This will have consequences
for the role healthcare professionals assign to WMI (see below). For example, Raynor
(2007)has recommended that pharmacists focus on providing spoken information, and
use WMI as a means for reinforcing messages for the patient.
Making a similar point, Narhi (2007)has contended that IBM! does not, cannot, and will
not replace PILs and spoken information from health professionals, because PILs and
spoken information are still trusted more by the general public. The implication of this is
that leaflet-based or Internet-based medicines information will not be the primary source
of information about medicines for many people, but it may still be a source of
information for them. Therefore WMI is not without purpose. While not everyone will rely
on WMI as their primary source of information, some people will. For example, Gray and
Blenkinsopp (2007)have acknowledged that IBM!has the potential to empower some
people to challenge their health professional's treatment recommendations. Medicine
users in the usability study gave this as a reason for accessing IBM! (see 5.7.2.).
It has been noted that medicine users perceive a purpose of WMI is to meet legislation
requirements (Raynor et al., 2007a).This can suggest that it is incidental if it enables an
informed choice to bemade. For example, Janse-de Hoog has suggested that
pharmaceutical companies focus solely on ensuring that their leaflets pass User Tests to
meet the requirements of legislation, rather than focusing on improvements indicated by
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the test results (Savage, 2(08). Therefore if the leaflet passes a User Test, then the company
has achieved its legal duty of providing information that is deemed to be "readable".
Provision of WMI by health professionals
Following on from above, ifWMI is to have a role in the consultation process, this will
necessitate its provision by healthcare professionals. This could be achieved by using
leaflet-based or internet-based WMI to reinforce the consultation. This information would
need to be good quality, i.e. accurate and complete, and readable; informing about the
condition as much as the medicine.
Latter and Courtenay (2004) have noted that patients value nurse practitioners in
particular because of their accessibility and approachability and their provision of
information. It remains to be seen if nurses (and CPs) are able to facilitate the use of WMI
during consultations, (see also 7.5.3).
Pharmacists are more likely than CPs to be shown information that medicine users have
found from the Internet (McCaw et al., 2007). This will necessitate pharmacists having the
skills and competence to assess the quality of mM! that is shown to them, or before
recommending it to medicine users.
7.5.2. Internet-based medicines information
Examining the usefulness of redesigned IBMl
No known previous studies have examined whether the redesign of mM! improved
people's finding and understanding of specific information. Research has examined the
effect of redesigning leaflet-based information. Fuchs and Hippius (2007) made evidence-
based changes to the design of a PIL, and found that participants significantly improved
their location and explanation of the information using the redesigned leaflets. Similarly,
Dickinson et al. (2001) reported that participants found and explained the information in a
redesigned leaflet (based on principles of best practice in design) more easily than when
using a leaflet based on the EU recommendations for PILs in force at the time. These
findings show that it is possible to redesign (leaflet-based) information to make it easier to
locate and understand.
273
No evidence was found that the redesign of the web pages improved their usability or
readability. It is argued that this does not negate the importance of good design practice in
mMI, because the changes were limited to content and content formatting alone. It
remains to be seen if implementing the recommendations for the design of mMI sites
could improve their usability and readability.
7.5.3. Recommendations for future research
The last set of implications is for future research evaluating WMI.
Improving research examining WMI
The systematic review highlighted the poor conduct of some trials of WMI, and the
generally poor reporting of their methods. It is recommended that future research should
be conducted in a more rigorous manner (following the CONSORT guidelines), using
theory-based or evidence-based interventions, and that valid outcome measures that
reflect the needs of medicine users are consistently used across trials.
People overestimate the risk of a side effect when it is presented in words. Future studies
of risk perception should examine participants' concurrent thinking aloud when
estimating the risk, to attempt to unpick the processes underlying their incorrect risk
estimates.
Examining how medicine users searched for mMI, and navigated web pages to find and
understand information was illuminating. However, the sample of participants was not
representative of everyone who uses mMI. Gray and Blenkinsopp (2007) have noted that
the full potential of the Internet has not yet been realised for aiding people with sensory
impairments or low health literacy. It is recommended therefore that future research
replicates the usability study with a wider sample of the general public - people with
disabilities, for example.
Examining provision 01WMI at the point 01prescribing
Participants in the workshops stated a need for the availability of WMI at the point of
prescribing. Nurse prescribers or pharmacists may have better scope than doctors for
introducing WMI to the consultation process. Future research should examine the
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consequences of making available leaflet-based or Internet-based WMI during patient
consultations. It would be important to examine if this is achievable; what barriers there
are to implementing this successfully, if it is valued when it is given, and how this impacts
on the decisions taken by a healthcare professional and patient.
Examining how people search for mMI
Observing how people search for WMI on the Internet revealed neglect for healthcare
portals. Future research should explore the barriers to the public conducting searches from
healthcare portals. It remains to be seen if healthcare portals are considered by the public
less appealing to use than a search engine, or if this just reflects the popularity or
familiarity of search engines. Medicine users may trust search engines more than
healthcare portals for searching for sites with information about medicines. They may be
more aware of search engines and less knowledgeable of healthcare portals; or they may
find search engines easier to use.
Examining new Internet applications
With the emergence in the near future of Web 3.0 there will be a need for a robust
evaluation of the usefulness of this and similar applications for people using the Internet
to find information about medicines. The Internet can provide information in different
formats: for example, as text alone or as broadband sound and vision (e.g. 'You Tube'
http://UlWW.youtube.com/t/about).Wheninformationisprovidedasspokenwords,itis
processed via auditory channels, leaving visual channels free to process images, and
having the potential to decrease cognitive load (Moreno, 2006). It is therefore
recommended that future research compares IBMIprovided via different formats to see if
one way is more effective than another for finding and locating specific information, or
more favoured by medicine users. Using a mixed methods design, a trial could be run
with participants randomly allocated to receive either identical IBMIcontent as text only,
or in video format, providing the same information verbally and visually. They would be
asked to think aloud concurrently while performing a User Test; and a follow-up
interview could provide further insight into their thoughts about using the different
modalities.
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Examining the information-seeking behaviours of medicine users
I<hechine et al. (2008) have shown that patients access e-health (in part) at the treatment
identification stage. This is consistent with the finding in this thesis that medicine users
said they would access mMI after consulting a GP, where they may have had a condition
and its treatment identified for the first time. The final recommendation is therefore to
examine the information-seeking actions of the person once she or he has been prescribed
a medicine for the first time. There are many aspects that can be focused upon. For
example, does the patient seek out information about the medicine, and if so, what sources
does she or he use for searching?
Barriers would need to be overcome to examining these important questions. Firstly there
would be ethical issues to address as the research would necessitate the invasive tracking
of the person having been told for the first time about a condition and their reaction to this
news. Secondly conducting this research would require the collection of a vast array of
ethnographic data. For example, it might include observation of GP consultations,
individual interviews, and focus groups of people who have recently been prescribed a
medicine for the first time.
7.6.Concluding remarks on leaflet-based and Internet-based WMI
People reading leaflet-based WMI can increase their knowledge about their medicines.
However, this does not guarantee that the person will necessarily increase their
understanding. There is no evidence that people reading WMI will change their attitudes
or behaviours relating to taking their medicines. WMI is generally not valued by medicine
takers, who value spoken information about medicines from healthcare professionals
more than information available as a leaflet, or on the Internet.
The Internet has mixed potential in its usefulness in enabling patients to understand
information about medicines. Because of problems with the design of the sites, current
IBMI will not be a useful source of medicines information for some people. Oumges to the
design of the sites could make them easier to navigate. However, the design of IBM! is not
(and probably cannot be) legislated for like WMI, and so improvements to the design of
sites may not be universal.
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How WMI is written in part determines how easily a person understands it; therefore
designers of websites (and leaflets) need to ensure that the information reflects the
knowledge and expectations of the medicine user, so that it can be understood. As
increasing numbers of people accessmMI, the need for websites that are easy to use and
that have content that can be easily understood, becomes greater. This could be achieved
by involving end-users in the design stage of the website, and evaluating this by adopting
a study design that compares the ease of use of the site and the readability of its content
with an earlier version of the same website.
mMI can benefit those who can access it. Therefore it is important that efforts are made to
encourage and improve universal access to mMI. It is vital that the usability and
understandability of the mMI sites are improved, to make them more useful to the
medicine user seeking to make an informed choice from reading this information.
The work reported in this thesis has applied User Testing to evaluate websites with
information about medicine, which is probably an original contribution to knowledge.
Using a mixed methods approach has been both original and beneficial to the research,
and again is probably an original contribution to knowledge. The evidence reported in this
thesis has shown that improvements are needed to make leaflet-based and Internet-based
WMI easier to use; i.e. to read and understand the information. This could make WMI
more useful for medicine users who seek to make an informed choice about taking their
medicines, or be better informed about the safety and efficacy of taking the medicine.
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• M thods d sign - DJN devised the matrix for analysing the results
• 0 la 0]] tion - DJN collated the main themes reported in the published reviews
• Data analysis - DJN led the data analysis
• Writing - OJN wrot all drafts
if;rL__
nald Nicolson was a joint author of the following reports that are referred to in his
thesis.
2. Raynor OK, Blenkinsopp A, Knapp P, Grime Jf Nicolson OJ, Pollock K, Dorer G,
Gilbody S,Dickinson 0,Maule AJ, Spoor P. A systematic review of quantitative and
qualitativ r arch on the role and effectiveness of written information available to
pati nts about individual medicines. Health Technol Assess. 2007Feb; 11(5):1-178.
• at coll tion - DJN was the primary reviewer and led data extraction for the
RCT tudies
• la an lysis - DJN] d the analysis of the quantitative results
• OJN drafted the quantitative results and the quantitative section of the discussion
ii
3. Nicolson D, Knapp P, Raynor DK (Theo), Spoor P. Written information about
individual medicines for consumers. Cochrane Database of Systematic Reviews, In
press.
Contribu ion:
• Research id a - PK, DKR and DJN conceived the idea for the review
• Data collection - DJN was the primary reviewer and led data extraction
• Data analysis - DJN and PK analysed the data
• Writing - DIN and PK wrote all drafts
Silmatur of another author:
onald Nicols n has been the lead or joint author of the following conference
pr ceeding which arc referred to in his thesis.
4. Using consumer t sting to determine the most effective design of web pages
containing information about medicines. Nicolson, D.J., Knapp, P., Gardner, P.,
Raynor, D.K 2008 International Social Pharmacy Workshop Queenstown, New
Zealand.
ontribution:.
• R s arch idea - DJN, PK, PG and DKR devised the aims for this study
• M thods design - DJN, PK, PG and DKR devised the methods for this study
• Data coU tion - DJN conducted the study, observing the participants using the
w bsit s
• Data analysis - DJN analysed all study data
• Writing - DJN wrote all drafts of the presentation
iii
5. Is the Int met useful for finding and understanding information about medicines?
Nicolson, D.J., Knapp, P., Gardner, P., Raynor, D.KHealth Services Research and
Pharmacy Practice Conference 2008Liverpool John Moores University, United
Kingdom. International Journal of Pharmacy Practice; Supplement 1;A33-A3S.
• Research idea - DJN, PK, PG and DKR devised the aims for this study
• Methods design - DJN, PK, PG and DKR devised the methods for this study
• Data coll ction - DJN conducted the study, observing the participants using the
websttcs
• D ta analysis - DJN analysed all study data
• Writing - DJN wrote all drafts of the presentation
fIL___S,ignaturc of another uthor:
6. How do p ople find w bsites with information about medicines? Knapp, P.,
Nicolson, D.J., Gardn r, P., Raynor, D.KHealth Services Research and Pharmacy
Practice Conf renee 2008Liverpool John Moores University, United Kingdom.
International Journal of Pharmacy Practice; Supplement 1;A19-A32.
~ontribution: ,
• Research idea - DJN, PK, PG and DKR devised the aims for this study
• M thods design - DJN, PK, PG and DKR devised the methods for this study
• Data collection - DJN conducted the study, observing the participants using the
w bsites
• Data analysis - DJN analysed all study data
• Writing - DJN wrote an drafts of the presentation
Silmature of another author: ~
iv
7. omparing the quality, content and design of internet-based medicines information
ites, DJ Nicolson, N Carrigan, P Knapp, DKRaynor. EArn 2006Conference.
1nt rnational Conference on Communication in Healthcare. September 2006Basel,
Switzerland.
• Rc arch idea - DJN, PK, and DKR devised the aims for this study
• M thods design - DJN, PK, and DKR compiled the methods for analysing the
quality, content and design features of the websites
• Data 011 ction - DJN conducted the search for Internet sites
• Data analysis - DJN analysed the sites quality, content and design features
• Wri ting - DJNwrote all drafts of the presentation
8. arising from a systematic review evaluating the effectiveness of
writt n m dicin s information. D Nicolson, DKRaynor & P Knapp. 2006 IJPP 14(1)
All [14th Int rnational Social Pharmacy Workshop, St Anne's College Oxford)
...ontribution;
• R arch id a - DJN, PK, and DKR devised the aims for this study
• M thods d sign - nfa (discursive paper)
• Data coll tion - nf (discursive paper)
• D ta analy is - nf (discursive paper)
• Writing - DJN wrot all drafts of this presentation
Signature of another author: 6L
vAppendix 2: Tools used in the assessment of the quality of IBMI
content
Health on the Net Code of Conduct (HONCode)
The following summarises the information available at
http://www.hon.ch/HONcode/Conduct.html. For a site to receive this accreditation, it must
m t th following eight terms.
Term Definition
1. Authoritative Medical/health advice is only offered by
trained and qualified professionals, unless
otherwise stated.
2. Complementarity The information complements but does not
replace the patient-physician relationship.
3. Privacy Respects the privacy and confidentiality of
personal information submitted.
4. Attribution Information is supported by clear reference to
evidence.
5. Justifiability Provides evidence to back up its claims.
6. Transparency Contact details are clearly presented.
7. Financial disclosure All sources of funding accounted for.
B. Advertising policy Gear distinction of advertising from editorial
content.
VI
The DISCERN Instrument
The following is a summary of the questions recommended to be asked in the DISCERN
instrument available at http://www.discern.org.ukldiscern.pdf
It proposes a good quality publication about treatment choices will:
1. Have explicit aims
2. Achieve its aims
3. Be relevant to consumers
4. Make sources of information explicit
5. Make date of information explicit
6. Be balanced and unbiased
7. List additional sources of information
8. Refer to areas of uncertainty
9. Describe how treatment works
10. Describe the benefits of treatment
11. Describe the risks of treatment
12. Describe what would happen without treatment
13. Describe the effects of treatment choices on overall quality of life
14. Make it clear there may be more than one possible treatment choice
15. Provide support for shared decision-making
vii
Appendix 3: Programmes of the MILK Stakeholder Workshops
Consultation Workshop
riday October 1st 2004, Leeds
11.00
11.30
11.40
12.05
12.20
12.35.
12.45
13.00
13.45
13.55
14.50
15.05
15.30
Programme
Registration and coffee
Introduction and welcome
Theo Raynor
Table Discussion 1: Good and bad examples
• Discu s a previous personal (or friend/family) example of written
medicines information.
• Was the information useful?
Report back to wbole group
Ali n Blenkin opp
Why is medicines information important?
David Dickin on
What kind of research have been done?
Alison Blenkinsopp
How are we going to do this systematic review?
Peter Knapp
• What is a systematic review?
• What is your input as a consumer?
Lunch
Table Discussion 2 - Introduction
ill rer
• What we'd like you to do
Table Discus ions
• What are the important things about medicine information leaflets?
• What i th role (purpose) of medicine information leaflets is?
• What makes medicine information leaflets effective?
• What make medicine information leaflets valuable?
offi e Break
eedback & umming up heo Raynor
lose
viii
2nd Stakeholder Consultation Workshop
Monday September 12th2005, Leeds
Programme
] J .00 Re_gistration and coffee
] 1.31 Introduction and welcome
heo Raynor
11.41 What you hope will come out of the review
John Maule introduction, then individual group discussions
12.00 Role and value review: Summary of main findings
Janet Grime
12.]5 "able di cussions of role and value review findings
12.45 Lunch
13.15 ffectiveness review: Summary of main findings
onald Nicolson
13.30 Table discussions of effectiveness findings
14.00 Feedback on information design
14.10 General feedback of overall findings
Chaired by Peter Knapp
14.50 offee Break
14.35 Recommendations
• For priorities for future research
• Other general recommendations
Alison Blenkinsopp
15.10 Feedback on usefulness of stakeholder workshops
John Maule
15.15 umming up and what's next
Thco Raynor
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Appendix 4: References of trials in the effectiveness review
Trials com,parinl the relative effectiveness of the presentation of WMI
• Clark, C.M., & Bayley, E.W. (1972). Evaluation of the use of programmed Instruction for
patients maintained on Warfarin therapy. Am J Public Health, 62, 1135-1139.
• Des s G van MG Schelll JL. Com of tient-oriented e insert tor
Trials comparing the absolute effectiveness of WMI
• Arthur, V., & Clifford, C. (1998). Evaluation of information given to rheumatology patients USing
non-steroid anti-inflammatory drugs. J Clin NUTS, 7,175-181.
• Baker, D., Roberts, D.E., Newcombe, RG., & Fox, KA (1991). Evaluation of drug information
for cardiology patients. Br J Clin Pharmacol, 31, 525-531.
• Clark, C.M., & Bayley, EW. (1972). Evaluation of the use of programmed instruction for
patients maintained on Warfarin therapy. Am J Public Health, 62,1135-1139.
• Dodds, LJ. (1986). Effects of information leaflets on compliance with antibiotic therapy. Pharm
J, 236, 48-51.
• Gibbs, S., Waters, W.E, & George, C.F. (1989). The benefits of prescription information leaflets
(1). Br J Clin Pharmacol, 27, 723-739.
• Johnson, MW., Mitch, W.E., Sherwood, J., Lopes, L., Schmidt, A, & Hartley, H. (1986). The
impact of a drug information sheet on the understanding and attitude of patients about drugs.
JAAlA,256,2722-2724.
• Kumana, C.R, Ma, J.T., Kung, A, Kou, M., & Lauder, I. (1988). An assessment of drug
information sheets for diabetic patients: only active involvement by patients is helpful. Diabetes
Res Clin Pract, 5, 225-231
• Little, P., Griffin, S., Kelly, J., Dickson, N., & Sadler, C. (1998). Effect of educational leaflets and
questions on knowledge of contraception in women taking the combined contraceptive pill:
randomised controlled trial. Brit Med J, 316, 1948-1952.
• McBean, B.J., & Blackburn, J.L. (1982). An evaluation of four methods of pharmacist-
conducted patient education. can Pharm J, 115, 167-172.
• Morris, L.A., & Kanouse, D.E (1982). Informing patients about drug side effects. J Behav Med,
5,363-373.
• Peura, S., K1aukka, T., Hannula, AM., & Eerikainen, S. (1993). Electronically produced
information leaflets increase patients' understanding of antibiotics. Int J Pharm Prad, 2, 22-25.
• Peveler, R, George, C., Kinmonth, AL., Campbell, M., & Thompson, C. (1999). Effect of
antidepressant drug counselling and information leaflets on adherence to drug treatment in
primary care: randomised controlled trial. Brit Med J, 319, 612-615.
• Pope, J.E., Stevens, A., & Rooks, M. (1998). A randomized double blind trial of verbal NSAID
education compared to verbal and written education. J Rheumato/, 25, n1-n5.
• Regner, M.J., Hermann, F., & Reid, L.D. (1987). Effectiveness of a printed leaflet for enabling
patients to use digoxin slde-effect information. Drug Intell Clin Pharm, 21, 200-204.
• Robinson GL, Gilbertson AD, Litwack L. The effects of a psychiatric patient education to
medication program on post-discharge compliance. The Psychiatric Quarterly. 1986;58:113-8.
• Savas, S., & Evcik, D. (2001). Do undereducated patients read and understand written
education materials? A pilot study in Isparta, Turkey. Scand J Rheum.oI, 30, 99-102.
• Strydom, A, & Hall, I. (2001). Randomized trial of psychotropic medication information leaflets
for people with intellectual disability. J Intellect Disabil Res, 45, 146-151.
• Vander Stlchele, RH., Thomson, M., Verkoelen, K., & Droussin, AM. (1992). Measuring patient
compliance with electronic monitoring: lisinopril versus atenolol in essentlai hypertension. Post
Market SUM/II, 6, 79-90.
• Vesco, D., Toumi, M., Faraj, F., Razzouk, H., & Orehek, J. (1990). Manufacturer's infonnation
insert and subjective theophylline side-effects. Eur Respir J, 3, 1162-1165.
xTrials comparing the relative effectiveness of the presentation risk of side
effect information
• Bergus, G.R, Levin, LP., & Elstein, A.S. (2002). Presenting risks and benefits to patients: the
effect of information giving on decision making. J Gen Intern Med, 17,612-617.
• Berry, D., Knapp, P., & Raynor, T. (2002). Is 15 per cent very common? Informing people
about the risks of medication side effects. Int J Pharm Pracl, 10, 145-151.
• Berry, D., Raynor, T., Knapp, P., & Bersellini, E (2004). Over the counter medicines and the
need for immediate action: A further evaluation of European Commission recommended
wordings for communicating risk. Patient Educ Couns, 53, 129-134.
• Berry, D.C., Michas, I.C., & Bersellini, E (2002). Communicating information about medication
side effects: effects on satisfaction, perceived risk to health, and intention to comply. Psychol
Health, 17,247-267.
• Berry, D.C., Michas, I.C., & Bersellini, E (2003). Communicating information about medication:
the benefits of making it personal. Psychol Health, 18, 127-139.
• Berry, D.C., Raynor, OK, & Knapp, P. (2003). Communicating risk of medication side effects:
An empirical evaluation of EU recommended terminology. Psychol Health Med, 8, 251-263.
• Berry, D.C. (2004). Interpreting information about medication side effects: Differences in risk
perception and intention to comply when medicines are prescribed for adults or young children.
Psychol Health Med, 9, 227-234.
• Knapp, P., Raynor, OK, & Berry, D.C. (2004). Comparison of two methods of presenting risk
information to patients about the side effects of medicines. QSHC, 13, 176-180.
benzodiazepines [Etude comparative d'une nouvelle notice d'emballage pour benzodiazapines
adaptee sux malades). Schweiz. Med. Wochenschr.1982;112:1376-82.
• Dolinsky, D., Gross, S.M., Deutsch, T., Demestihas, E, & Dolinsky, R (1983). Application of
psychological principles to the design of written patient information. Am J Hosp Pharm, 40, 266-
271.
• Labor, S.L., Schommer, J.C., & Pathak, D.S. (1995). Information overload with written
prescription drug information. Drug In' J, 29, 1317-1328.
• Little, P., Griffin, S., Kelly, J., Dickson, N., & Sadler, C. (1998). Effect of educationalleafJets and
questions on knowledge of contraception in women taking the combined contraceptive pill:
randomised controlled trial. Brit Med J, 316, 1948-1952.
• van Haecht, C.H.M., Vander Stichele, R, Debacker, G., & Bogaert, M.G. (1991). Impact of
Patient Package Inserts on Patients Satisfaction, Adverse Drug-Reactions and Risk Perception
- the Case of Nsaids for Posttraumatic Pain Relief. Patient Educ Couns, 17,205-215.
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Appendix 5: Descriptive information about the trials in the
effectiveness review
Medicine information provided by the trials
• Nineteen trials provided information for medicines for long-term conditions:
(Arthur and Oifford, 1998, Gibbs et al., 1989, Pope et al., 1998, Savas and
Evcik, 2001, van Haecht et al., 1991) .
• Five trials provided information for non-steroidal anti-inflammatory drugs
(NSAIDs):
(Baker et al., 1991, Clark and Bayley, 1972, Dolinsky et al., 1983, Gibbs et
al., 1989, Johnson et al., 1986, McBean and Blackburn, 1982, Regner et al.,
1987, Vander Stichele et al., 1992).
• Nine trials provided information for cardiovascular medicines:
(Desponds et al., 1982, Dodds, 1986, Labor et al., 1995, Peura et al., 1993,
van Haecht et al., 1991).
• Five trials provided information about a medicine to treat an acute condition:
(Dolinsky et al., 1983).
• One trial provided information about medicines used to treat a chronic
condition (methyldopa for high blood pressure), and an acute condition
(ampicillin for bacterial infection):
(Bcrgus et al., 2002).
• Ten trials that examined perception of the risk of a side effed used information
about a hypothetical antibiotic
Berry et al., 2oo2a; Berry et al., 2002b; Berry et al., 2003a; Berry et al., 2003b;
Berry 2004.
• Three trials that examined perception of the risk of side effects provided
information about the following respective real medicine
aspirin (Berry et al., 2004); ibuprofen (Knapp et al., 2004), and simtHlStlltin.
CateDO' of Qutcomes mg.ured by the trial.
• Twenty-nine trials (reported in 24 papen) measured knowledge:
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Arthur and Gifford, 1998, Baker et al., 1991, Berry et al., 2002a, Berry et al.,
2002b, Berry et al., 2003a, Berry et al., 2003b, Berry et al., 2004, Berry, 2004,
Clark and Bayley, 1972, Dodds, 1986, Dolinsky et al., 1983, Gibbs et al.,
1989, Johnson et al., 1986, Knapp et al., 2004, Kumana et al., 1988, Little et
al., 1998, McBean and Blackburn, 1982, Morris and Kanouse, 1982, Peura
et al., 1993, Pope et al., 1998, Regner et al., 1987, Robinson et al., 1998, Savas
and Evdk, 2001, Strydom and Hall, 2001.
• Seventeen trials (reported in 13papers) measured an attitude:
Baker et al., 1991, Bergus et al., 2002, Berry et al., 2002a, Berry et al., 2002b,
Berry et al., 2003a, Berry et al., 2003b, Berry et al., 2004, Berry, 2004,
Desponds et al., 1982, Gibbs et al., 1989, Knapp et al., 2004, Labor et al.,
1995, McBean and Blackburn, 1982.
• Nine trials (reported in nine papers) measured behaviour:
Dodds, 1986, Dolinsky et al., 1983, McBean and Blackburn, 1982. Morris
and Kanouse, 1982, Peveler et al., 1999, Robinson et al., 1986, van Haecht et
al., 1991, Vander Stichele et al., 1992.
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Appendix 6: Source of identified websites
Sites from Doupi " van der Lei (1999),and Hatfield, May and Markoff (1999)
1. Cheshire Medical Centre: http://www.cheshire-med.com/
2. Druginfonet http://www.druginfonet.com/
3. HealthPhillyNews http://www.philly.com/mld/phiUy/living/health/
4. HeaJthtouch Online http://www.healthtouch.coml
5. Infomed Drug Guide http://infomed.org/lOOdrugs/
6. Intelihealth http://www.intelihealth.com/IH/ihtIH/WSlliWOOO/408/408.html
7. Mayo Clinic http://www.mayoclinic.com/
8. MedicineNet http://www.medicinenet.com/script/main/hp.asp
9. Mediconsult http://mediconsult.8media.org!
10. Medscape http://www.medscape.com/home
11. On-Health http://on-health.com/
12. PharmlnfoNet http://pharminfo.8media.org!
13. Rx-Advisor http://e-pharmacy.com/HTML/health_infor/rx_advisor .html
14. Rxlist. http://www.rxlist.com/
15. Thrivconline http://www.thriveonline.com.au/
Sites found from search enpnes Harch
16. Australian Prescription Products Guide Online
http://www.appco.com.au/appguide/default.asp
17. Best Treatments http://www.besttreatments.co.ulcJbtuklhome.html
18. Educate before You Medicate (National Council on Patient Information and
Education) http://www.talkaboutrx.orglindex.jsp
19. Medicine Guides http://medguides.medicines.org.u.k/
20. MedlinePlus http://www .nlm.nih.gov/medlineplusldruginformation.html
21. Net Doctor http://www.netdoctor.co.u.k/
22. Patient Health International http://www.patienthealthintemational.com/
23. Patient Information on Medicines http://www.nmhct.nhs.uklpharmacy/cclg-
pat.htm
24. Patient UK http://www.patient.co.u.k/
25. PharmWeb http://www.pharmweb.net/pwmirrorlpW7Jpharmwebz.html
26. SafeMedication.com h ://www.saiemedication.com/resuItsList.cfm via
xiv
http://www.intelihealth.com/IH/ihtlH/WsrnwOOO/408/408.html
27. US Food and Drug Agency http://www.fda.gov/
28. Patient Health UK http://www.patienthealthuk.net/node!home.aspx
29. Zocor http://www.zocor.com/simvastatin/zocor/consumerrmdex.jsp
30. Simvastatin Disease Database Information
http://www.diseasesdatabase.com/ddb12128.htm
31. Drugs.com http://www.drugs.com/cons/Simvastatin.html
32. eMedicine Health http://www.emedidnehealth.com/articles/53048-7.asp
33. Answers.com http://about.com!health/
34. dmoz open directory project
http://dmoz.org!Health/Pharmacy /Drugs_and_Medications/S/Simvastatin/
35. Vytorin ezetimibe/simvastatin tablets patient information
http://www.vytorin.com/ezetimibe_simvastatin/vytorin/consumer/index.jsp
36. About health and fitness http://aids.about.com/od!misceUaneousmeds/p/zocor.htm
37. myDNA
http://www.mydna.com/resources/resources/meds!leaflets/d0S348Al.html
38. worstpills.org http://www .worstpills.orglresults.cfm ?dru~id=584
39. The Cleveland Clinic Health Information Centre
http://www.clevelandclinic.org!health/health-info/docs/0700/cm.9.asp?index=4927
40. Health Square http://www.healthsquare.com/newrx/cxl500.htm
41. Medic8 Family Health Guide
http://www.medic8.com!healthguide/articles/simvastatin.html
42. Why Generic http://www.why-generic.com/drugs/generic/zocor .html
43. Online Pharmacy http://www.alldrugin!o.com/s/simvastatin/
44. Talk medical http://www.talkmedical.com/medications/5600/Simvastatin
45. GP notebook http://www.gpnotebook.co.uk/simplepage.cfm?ID--227868642
46. Canadian Pharmacy North
http://www.canadarxgroup.com/drugs/zocor _simvastatin.html
47. Yahoo Health http://health.yahoo.com/drugl_dOO746al
48. Health Digest http://www.healthdigest.org/prescription-drug-
reference/simvastatin-oral-tablet-9572.htm
49. Healthopedia.com http://www.healthopedia.com/drugslquicklsimvastatin/
SO.Electronic medicines compendium http://emc.medicines.org.uk/
51. Medic Direct
xv
http://www.medicdirect.ro.uk/med_cabinet/medicine.ihtml?pid=333&step=4
52. Wikipedia http://en.wikipedia.orglwiki/Statin
53. Zetia.corn http://www.zetia.com/ezetimibe/zetia/ronsumer/index.jsp
Additional sites found from Patient.Co.UK
54. BNF http://bnf.orglbnf/
ss. CancerHelp UK http://www.cancerhelp.org.uk/
56. Medicine Chest Online http://www.medicine-chest.ro.uk1
57. Health Supplements Information Service http://www.hsis.orgl
58. NWMHP Pharmacy Medicine Information http://www.nmhct.nhs.uk/pharmacy/
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App ndix 7: Protocol for data analysis of e-health websites
d sign, quality and content
2. • In tructions or help page for
navig ting site
4.
• for xarnple to sit s with condition
inform tion
•5.
6. link §
7.
8.
9.
• ontact link to w bite
• of font
•
• A hort summary providing the
main tion headings (can be
hyp rlinkcd or not)
Quality
2.
•
•
•
•
•
xvii
policy
8. Confidentiality/privacy statement § • Provides confidentiality statement
1998 European Commission Directive categories
• What the medicine is and what it is
used for
1.
•
2. • Before you take or us the medicine
3. • How to take or use the medicine
4. •
5.
Recommendations 011 medicines package leaflets by QRD group
• Provides information about action
to take if overdose is taken
6.
• Sp cifically warns of possibility of
statin having an interactive effect
with sp cific other drugs, and not
just to notify GP if taking other
drugs
• In particular, notify re serious side
effects
8.
• R ports the cons qu nee to health
if treatm nt not taken for a p riod of
time
9.
• What to do if miss a dose
• Provides information about
omplementary or alt rnative
tr tm nt(s) (for example di tor
ex rcise)
12. • Provides information about
13. •
xviii
• Provides patients experiential
comments
14. xp ri nti J c rnrnents ¢
• Site promotes a pharmaceutical
product for sale
• Pharmaceutical company site but
do s not promote a product for sale
2.
• Provides the purpose/rationale of
th site
3.
• rovid s content that xplicitly
s ks to nable shar d decision
m king, abov mer ly informing.
• Provides FAQ's (Frequ ntly Asked
Qu stions) about simvastatin or
high chol sterol
tion ¢ • Information about mcdicin s
app ars understandable
6.
• Other information on sit
und rstandable
7.
• Off TS translations in olh r
languag s
8.
Items in ¥ are from the Discern Handbook.
Items with § are from the Health on the Net Code of Conduct.
Items with" are from 1998 EU directive.
Items with t are from the European Medicines Agency recommendations on medicines package leaflets.
Items with ¢ are derived from remarks made from stakeholders at the MILK workshops.
• Charnock, D. (1998). The DISCERN Handbook Quality criteria for consumer health information on treatment
choices Oxon: Radcliffe Medical Press
• Health On the Net Foundation (2005). HON Code of Conduct (HONcode) for medical and health Web sites.
• European Commission Directorate-General III (1998). A Guideline on the readability of the label and
package leaflet of medicinal products for human use. Brussels: European Commission.
• Quality Review of Documents Group (2005). Product Information Templates: Human Medicinal Products:
European_Medicines_Agency.
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Appendix 8:Data extraction form for IBMI analysis
c ~I: ~
C :a c::41 ....~ '> "0< ....
et) t ea <1.1 0.
0 Cl-El ';n
o 0%
o 0%
o 0%
o 0%
o 0%
o 0%
o 0%
oo 0 0 0 000Total no design
£ atures pres nt
o 0 o
0 0%
0 0%
0 0%
0 0%
0 0%
0 0 0
btl
C btl:a c.... :a;:.
0 '>... e~
Cl) e,
~.;;;....
0
00000000
o 0%
o 0%
o 0%
o 0%
o 0%
o 0%
o 0%
o 0%
o 0%
o 0%
o 0%
mpl m ntry r 0 0%
alt m tiv tr tnt nt
nditi n 0 0%
information
h dd o in 0 0%
making
QUt Iity H( impel 0 0%
Expcri nti I 0 0%
~ommcnts
Provides FAQ' 0 0%
PI in Engli h 0 0%
inf rm ti n
PIon !.ngli h it 0 0%
Oth r langu g 0 0%
Tot I no ont nt 0 0 0 0 0 0 0 0 0 0 0
c ture pr cnt
..
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Appendix 9: Sites considered for inclusion in Study two
Identified sites Reconciled
decision
Medscape http://www.medscape.com/home Exclude-
infonnation
not primarily
for patients
HealthPhillyNews http://www.phiUy.com/mld/philly/living/hea1th/ Exclude-no
statin
infonnation
Patient Information on Medicines Exclude-
http://www.nmhct.nhs.uk/phannacy/cclg-pat.htm policy
document
Simvastatin Disease Database Information Exclude-
http://www.diseasesdatabasc.com/ddb1212B.htm portal to other
sites
Intelihealth Exclude-
http://www.intelihealth.com/lH/ihtll-l/WSll-IWOOO/40B/40B.html portal to other
sites and no
infonnation
of its own
On-Health http://on-health.com/ Exclude-
portal to other
sites and no
information
of its own
Educate before You Medicate (National Council on Patient Exclude-
Information and Education) http://www.talkaboulrx.org/index.jsp portal to other
sites and no
information
of its own
PharmWeb Exclude-
http://www.pharmweb.net/pwmirror/pwz!pharmwebz.html portal to other
sites and no
information
of its own
dmoz open directory project Exclude-
http://dmoz.org/Health/Pharmacy/Drugs_and_Medications/S/Simvasta portal to other
tin/ sites and no
information
of its own
worstplll. http://www.worstpills.org!results.cfm?drug_id-584 Exclude-
registration
xxiii
required
Infomed Drug Guide http://infomed.org/lOOdrugs/ Exclude _ site
explicitly
aimed at
medical
students and
professionals
Rx-Advisor http://e- Exclude - this
pharmacy.com/HlML/health_infor/rx_advisor.html site could not
be found
Cheshire Medical Centre http://www.cheshire-med.com/ Exclude-no
statin
information
Mediconsult http://mediconsult.8media.org! Exclude-
access except
homepage
downon3
separate
occasions in
Dec05&Jan
06
PharmInfoN et http://pharminfo.8media.org! Exclude-
access except
homepage
downon3
separate
occasions in
Dec05&Jan
06
Thrive online http://www.thriveonline.com.au! Exclude - not
medicines
information
Answers http://www.answers.com/topic/simvastatin Exclude-
portal to other
sites and no
information
of its own
GP notebook http://www.gpnotebook.co.uk!simplepage.cfm?ID-- Exclude - not
227868642 aimed at
medicine
users
xxiv
Patient Health International Met inclusion
http://www.patienthealthintemational.com/ criteria, but
excluded
because
information is
duplicated on
Patient
Health UK
site, and site
directs UK
visitors to
PHUKsite
Wikipedia http://en.wikipedia.orglwikilStatin Exclude - not
aimed at
medicine
users
BNF http://bnf.org/bnf/ Exclude - not
aimed at
medicine
users
Cancer Help UK http://www.cancerhelp.org.ukl Exclude-no
stalin
information
Medicine Chest Online http://www.medicine-chest.co.uk/ Exclude-no
stalin
information
Health Supplements Information Service http://www.hsis.orgl Exclude-no
stalin
information
NWMHP Pharmacy Medicine Information Exclude-no
http://www.nmhct.nhs.uk/pharmacy/ stalin
information
Druginfonet http://www.druginfonet.com/
Include
Healthtouch Online http://www.healthtoudt.com! Include
Mayo ainic http://www.mayoclinic.com/ Include
MedicineNet http://www.medidnenelcom/script/mainlhp.asp Include
LUst http://www.rxlist.com! Include
Australian Presaiption Products Guide Online
h~!Iwww.appco.com.au!appguideidefault.asp Include
Best Treatments http://www.besttreatments.co.uk/btuk/home.htmI
Include
Medicine Guides http://medguides.medidnes.org.uk/ Include
xxv
MedlinePlus
http://www.nlm.nih.gov/medlineplus/druginfonnation.html Include
Net Dodor http://www.netdoctor.co.uk/
Include
Patient UK http://www.patient.co.uk/ Include
Safe Medication http://www.safemedication.com/resultsList.cfm via
http://www.intelihealth.com/lH/ihtlli/WSll-lWOOO/408/408.html Include
US Food and Drug Agency http://www.fda.gov/
Include
Patient Health UK http://www.patienthealthuk.net/ Include
Drugs.com http://www.drugs.com/cons/Simvastatin.html
Include
eMedicine Health http://www.emedidnehealth.com/articles153048-
7.asp Include
Vytorin ezetimibelsimvastatin tablets patient information
http://www.vytorin.com/ezetimibe_simvastatin/vytorin/consumer/inde
x.jsp Include
About health and fitness http://cholesterol.about.com/
Include
myDNA
http://www.mydna.com/resources/resources/meds/leafiets/d0S348Al.ht
ml Include
The Cleveland Clinic Health Information Centre
http://www.clevelandclinic.orglhealthlhealth-
info/docs/0700/0729.asp?index-4927 Include
Health Square http://www.healthsquare.comlnewrxlcxl500.htm
Include
Medic8 Family Health Guide
http://www.medic8.com/healthguide/index.htm
Include
Why Generic http://www.why-generic.com/drugs/generic/zocor.html
Include
Online pharmacy http://www.alldruginfo.com/s/simvastatin/
Include
Talk medical
http://www.talkmedical.com/medications/5600/Simvastatin Include
Canadian Pharmacy North
http://www.canadarxgroup.com/drugs/zocor_simvastatin.html Include
Yahoo Health http://health.yahoo.com/drugl_dOO746al
Include
Health Digest http://www.healthdigest.orglprescription-drug-
reference/simvastatin-oral-tablet-9572.htm Include
Healthopedia http://WWW.healthopedia.com/drugs/quick/simvastatin/
Include
xxvi
Electronic medicines compendium http://emc.medicines.org.ukl
Include
Medic Direct
http://www.medicdirect.co.uklmed_cabinet/medicine.ihtml?pid=333&:st
ep=4 Include
Zetia http://www.zetia.com/ezetimibe/zetia/consumer(mdex.jsp
Include
MerckZocor
http://www.zocor.com/simvastatin/zocor/consumer(mdex.jsp Include
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Appendix 10: Screenshots of homepages of ten IBMI sites in
January 2006 analysed in study two
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Appendix 11:Descriptive data about ten IBMI sites analysed in
Study two
Descriptive information about sample of 10 included e-health web sites
MedidneNet http://www.medidnenet.com/script/main/hp.asp
US developed site Accessed January-February 2006 Online Since: l8-Oct-1995
Home page was cluttered with information that had to be scrolled down. There were
three columns with a mass of information options, including conditions, medications,
symptoms and 'daily health news', many of which were links. Advertising of
pharmaceutical products and healthcare treatment, using flash graphics was prominent
on the home page and throughout the site. There were six possible second pages to click
on, including 'medications' and 'diseases and conditions'. There was a scroll down menu of
medical conditions. No icons were available, and there was limited use of pictures.
HonCode accredited site. Search bar was prominent, top centred. Typing the name
simvastatin in search bar returned a large number of different links relating to this drug,
some relating to 'disease and control', 'medication', 'doctors views', etc. Medicines
information was for Zocor brand. Provided verbal side effect risk descriptor information:
"rare/minor side effects". Information about conditions in relation to medicines
information was available. The medicines information page contained dense text in AriIll
font. Headings and important information was in bold print. Medicines information was
minimal. Disclaimer information was very discrete. Provided 'suggested reading by our
doctors', links to further information, and evidence about the drug. Information last
updated less than 3 months before date site was accessed.
US Food and Drug Agency http://www.fda.gov/
US developed site Accessed January-February 2006 Online Since: 13-Apr-93
Home page was cluttered with information that had to be scrolled down. There were
three columns of different text links. There was a limited use of pictures. Itwas difficult
to immediately find the correct WMI. Information was for the Crestor brand. Provided
xxx
verbal side effect risk descriptor information: "rare side effects". No icons were
available. Site had links for subscribing to FDA Consumer magazine. Search bar was in
the top, left hand comer. Typing crestor produced a vast array of different links, similar
in content; thus it was not at all clear what link to click on. Medicines information was
available as HlML page, or one page PDF, and found by going to COER page on FDA
site, clicking on 'Index to Drug-Specific Information', then rosuvastatin, and finally on
'Patient Information Sheet'. Information was written in Times New Roman font and used
two columns. Section headings were written as questions. Used bullet point text. Other
information was also available, for example 'Prescribing Information', which was 20 page
PDF, but not primarily aimed at patients. Information last updated between 6 and 12
months before date site was accessed.
Mayo Clinic http://www.mayoclinic.com/
US developed site Accessed January-February 2006 Online Since: 22-Jul-1997
Home page was cluttered with information that had to be scrolled down. There were
links to 'managing condition', 'healthy living centres', 'diet advice', and 'health tools'.
Advertising of pharmaceutical products and healthcare treatment was prominent on the
home page and throughout the site. Pictures were used throughout the site. Use of icons
was limited to font enlargement and print options. There were two separate drop-down
menus for' disease and condition centres' and 'healthy living centres'. HonCode accredited
site. Search bar was in the top, right hand comer. Medicines information link for Vytorin
brand was found by typing name in search bar. Provided verbal side effect risk
descriptor information: "less common side effects". Provided information about 19
conditions separate to medicines information. The medicines information had ArlJU font,
and used bold headings and bullet point text. Disclaimer information was very discrete.
There was further information ('Statin: Is this cholesterol-lowering drug right for you ?'). This
was not easily found or sign-posted. This page was extremely informative, providing
information about advisable complementary lifestyle changes, the benefits of taking
statin and further information about side effects. Refers to evidence, ('a study to reduce the
xxxi
risk oj colon cancer with statin consumption '), but did not provide a reference. Information
last updated between 6 and 12months before date site was accessed.
Drugs.com http://www.drugs.com/cons!Simvastatin.html
US developed site Accessed January-February 2006 Online Since: 18-Dec-I998
Home page was cluttered with information that had to be scrolled down. There were
three separate rows with a mass of links to information about drugs and conditions. No
icons were available. Had a box with links to the 12most popular Internet drug searches,
but no evidence to show why these were the twelve most popular searches. Advertising
of pharmaceutical products and healthcare treatment, using flash graphics was
prominent on the home page and throughout the site. Bar the adverts, there was no
other use of pictures by the site. HonCode accredited site. Search bar was prominent, top
centred. Medidnes information link for the ZocOT brand was found after typing name in
search bar, but it was unclear which of the different options for information should be
selected. Provided verbal side effect risk descriptor information: "rare side effects".
Medicines information was written in Verdana and Arial font. Section headings were
phrased as questions. Used bullet point style for main text. Running mouse over
highlighted words opened links to sponsored sites, for example the term liver disease
referred to a site which detects early liver disease. Provided an additional link to a page
that uses a question and answer format. Information last updated less than 3 months
before date site was accessed.
Rxlist http://www.rxlist.com/
US developed site Accessed January-February 2006 Online Since: 14-Nov-I995
Home page was cluttered with information that had to be scrolled down. There were
three columns with a mass of information. The middle column contained links in faint
blue font for 150medicines. Pictures were used throughout the site. Provided external
link to condition information. No icons were available. Advertising of pharmaceutical
products and healthcare treatment, using flash graphics was prominent on the home
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page and throughout the site. Home page contained a list of 'Top 150 Drug Name Searches
on RxList' - a mass of drug names that were not clearly distinguishable at first. One
search bar' search for a drug name' was prominent, top centred; and there were three
further search bars: 'medical abbreviation finder', 'can't find what you need' and 'drug search'.
Medicines information link for the Zocor brand was returned amongst a mass of different
links relating to this drug, after typing name in search bar. Provided verbal side effect
risk descriptor information: "less severe/severe side effects". The information was well
laid out into clearly defined sections and makes use of short paragraphs. Text was
written in Arial font. Different sections of information were accessed by clicking on the
hyper-link, or scrolling down the screen. Information last updated between 3 and 6
months before date site was accessed.
Net Doctor http://www.netdoctor.co.uk!
UK developed site Accessed January-February 2006 Online Since: 25-Aug-1998
Home page was cluttered with information that had to be scrolled down. A number of
rows contained a vast amount of information options, including conditions, medications,
and examinations. Advertising of healthcare treatments (for smoking) and non-
healthcare related products, using flash graphics was prominent on the home page and
throughout the site. There were many photos as well. Made some use of icons, for
example a pill for medicines and a question mark for investigation. HonCode accredited
site. Search bar was prominent, centred. Medicines information link for the Zocor brand,
along with a choice of many other links, was available after typing name in search bar.
Provided verbal side effect risk descriptor information: "occasional side effects".
Medicines information page had VerdRna font. Information was available in printer
friendly format. Links to other site information was on the right hand column, making
the information pages very busy. Had a large section on the dangers of statin interacting
with other drugs. Used clear headings for different sections, and often put information
across in bullet points. Information last between 13 and 24 months before date site was
accessed.
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Patient UK http://www.patient.co.uk/
UK developed site Accessed January-February 2006 Online Since: 22-Apr-l997
A relatively uncluttered and well organised home page makes for easy navigation. No
scroll was necessary on the home page. There were two separate columns; one with links
for information about conditions, medications, and lifestyle issues, examinations, etc.
Other column allowed users to book an online appointment with their GP using the
EMIS service. Contact links provided a standardised feedback form. Provided links to
external UK sites for a range of medical conditions. Used icons to relate to different types
of information (for example patient experience or information leaflet). Advertising of non-
healthcare related products, using flash graphics was contained throughout the site, but
not on the home page. Site provided a translation of information for certain conditions in
one or more of 11different languages, but not for medicines information. Search bar was
prominent, centred. Search bar returned three different medicine information leaflet
links: 'patient experience' (provided twice), 'medicines', and 'information leaflet'. Did not
specify a brand of statin. Did not provide side effect risk descriptor information.
Medicines information page had Helvetica font. Printer friendly option was available.
Names were in italics, and crucial information was in bold. Interaction information was
vague, only requesting medicines users to inform their GP if they currently take any of
the medicines named. No explanation was given for why to do this. Section headings
were clear, and information was often presented in bullet point style. Information last
updated between 6 and 12months before date site was accessed.
Best Treatments http://www.besttreatments.co.uk/btuk/home.jsp
UK developed site Accessed January-February 2006 Online Since: IO-Jan-2003
Home page was cluttered with information that had to be scrolled down. One column
had a vast array of links. The other had further links, and two prominent drop-down
menus: one for patients and the other for doctors. Minimal use of photos. Had a print
icon, but no other icons. Site provided a range of different information options,
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including conditions, lifestyle treatments and symptoms. It received the Internet Crystal
Mark accreditation from the Plain English Campaign, to show its commitment to using
plain English language. A search bar was at the top of the screen, and prominently
placed were two drop-down menus: clearly specified for patients or doctors.
Information about treatments (including statin therapy) was available after typing
simvastatin information in search bar. WMI was not sole focus of this site. By clicking on a
statin hyperlink, more information about the drug was available. Did not specify a brand
of statin. Did not provide side effect risk descriptor information. Provided good, explicit
links to other sites. Medicines information text was written in Arial font. Different
sections of information were accessed by clicking on the hyper-link, or scrolling down
the screen. Explicitly stated all information was based on best available evidence, and
that the information should be used to enable shared decision making. Provided
medicines information in the context of the condition, thus the site discussed statin
therapy and other treatments for hypercholesterolemia. Information last updated less
than 3 months before date site was accessed.
Medicine Guides http://medguides.medicines.org.uk!
UK developed site Accessed January-February 2006 Online Since: 03-Jun-l999
Home page was relatively uncluttered, although it requires to be scrolled down. Site was
in development, so therefore a lot of information was either missing or scant; for example
condition-based infonnation was for 8 conditions only (when accessed). Pictures were
used throughout the site. No icons present. It received the W3C accreditation to show it
conformed to technical specification standards. There was no search bar. When the site
was accessed in early 2006, it only had comprehensive coverage for medicines for three
conditions: cholesterol, epilepsy, and influenza. Provided specific information for both
Zocor and Vytonn brands. Did not provide side effect risk descriptor information.
PrOvided a great amount of information about the medicine. Medicines information text
was written in Verdana font. Different sections of information were accessed by clicking
on the hyper-link, or scrolling down the screen. Different sections were colour coded -
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the same colours apply to the same sections, for example purple for side effect
information. Running the mouse over certain words generated a pop-up box which
provided a definition or explanation of the word(s). These were also listed at the end of
the information as a glossary. Bullet point text was used in places. Information last
updated between 13and 24 months before date site was accessed.
Electronic medicines compendium http://emc.medicines.org.uk/
UK developed site Accessed January-February 2006 Online Since: 03-Jun-1999
Home page was cluttered with information that had to be scrolled down (as well as
across if the 'favourites' function was turned on. Had a table that lists all products whose
information had been updated in the last 14days, but was not immediately clear. No
pictures were used on the site. There was an information icon showing what details have
changed, but no others. Site did not contain explicit advertisements, but as information
was provided by pharmaceutical companies, there logos and company name were
displayed throughout the site. There was no text size change option, but there was a
Zoom function, although this was not clearly labelled. There was a search bar at the top
right, permitting search by product or company. Medicines information for the 5imvador
brand was found after typing the search term. Provided verbal side effect risk descriptor
information: "rare side effects". Medicines information was available as a two page PDF,
written in Frutiger-Roman font. Section headings were written in bold as questions.
Other than this, it was very difficult to distinguish between the different sections. Also
provided copies of summaries of product characteristics, which could perhaps be
confused by the patients for information intended for them. Interaction information was
implicit, only requesting medicines users to inform their GP if they currently take any of
the medicines named. No explanation was given for why to do this. Information last
updated more than 24 months before date site was accessed.
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Appendix 12: Pilot of e-health web sites to assess for indicative
information
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Appendix 13: Copy of participant information leaflet
Are health information web sites useful?
• I m studying how websites help people to understand their medicines. This
r arch is part of my PhD tudi s at Leeds University. If you are able to use the
int m t, and hav ver tak n a median ; Iwould like to recruit you to this project.
• Th study will tak part at Leeds University, and will take around 60 minutes. You
c n withdrawal any point, and/or refuse to answer any questions for any reason.
You win b comp nsat d for taking part in this study and your travel costs will be
r p id.
• B f re th study, Iwill ask you to com pI te a questionnaire about medicines you
h v t k n, nd y ur xp ri ne of using the internet. You will then perform some
t k u ing h alth w bsite. Jwill a k you to think out loud whilst using it.
Afterwards r will a k what you thought of it. A softwar program will record the
Int m t on er n, and your voi as you talk about using the site.
• xtra t f wh lyou y about th website will be reported in my PhD report, as
w II a journ 1arti I s. No-on will b able to identify you from the extracts, or any
oth r inf rmati n; and your nam will not appear anywh re, or be revealed to
ny n . All information ab ut you and your task p rformance will only be
v it bl t m ,my sup rvisors, and one co-res archer who will check Ianalyse
th d t orr tIy. Th study will not pose any risk of physical harm to you.
• If you r still int r sted in taking part in this study, please contact me for further
t il . Thank you for showing n int r st in this study.
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Appendix 14:Copy of consent form for Study three
Consent to take part in research stud
Title of Proiect: An evaluation of the usability and usefulness of intemet.based.
medicines information (IBMI) to support peoples' understanding of medicines
Nam of Researcher: Donald Nicolson, School of Healthcare, University of Leeds
PI a tick the box to say yes for each question
r d th information h t for this study. 0
lund rstand the r a on for this study, and how Iwill be involved. 0
Any qu ti nIh v about th study hav be n answ red. 0
n ugh tim to think about wh ther I want to take part 0
I un r l n by t king part in th study rwill not get any direct personal 0
b n fil from it, and lh t my m dical car will not b affected.
h Id in confid nee. 0
Tund r t nd in ny r port from th tudy, my p rsonal details will be 0
T m vd.
I gr t my v i bing re ord d. o
to nsw r all qu stions, and can wi thdraw from 0
ny ran.
tudy. o
Sign d Date
Sign d Oat
xl
Appendix 15:Questionnaire
UNIVERSITY OF LEEDS
Questionnaire about using the Internet to find
information about medicines
Confidential
PI a will you mpl t this qu stionnaire, and then return to me (Donald Nicolson) in
lh pr - <lid nv 1 p .
. .
xli
Part one: Information about you
Participant id number. _
Yourname: _
[Will be completed by researcher]
Sex:
Mal Female
thnic group you belong to:
Whit
Mix d (Whit and Black
rib nlBl k
Afri n/Asian/ th rmix d
b gr un d)
Asian or Asian British
Black or Black British
Chinese or other ethnic groups
Do you speak more than one language?
Y (Ify 5, what languag do you most often speak?)
No
Your data of birth: d d m m y y
Your level of education:
r duat
quival nt
Compl t d ducation b tw n 14-16years of age
xlii
Your current job status
Full-tim mployed (State job)
P rt-tirnc employed (State job)
Unemploy d
R tired (Stat main job when employed)
Oth r (Stat) _
Part two: Use of medicines and medicines information
1. H w long hav y u b n taking medicines for? (please name them)
Th v b n taking m dicin for 12 months or longer
I h v b gun taking m dicin s in the la t 12 months
I h v tak n h rt-term our of m dicin s at some point in the last 12 months (for
xarnpl ntibioti s)
J h v not tak nny m di inc in the last 12 months
on't know/ nit r m mb r
2. AT Y u aw r f th P tientinform Han] afl t accompanying your medicin s?
y
No
..
xliii
3. Do you read the patient information leaflet accompanying your medicines?
Always
Often
Sometimes
Rarely
Never
(Please explain your answer)
4. Which sections of the leaflet would you read?
What this medicine is for
Before taking this medicine
How to take
Possible side effects
How to store
How strongly do you agree or disagree with the following statements?
5. I get enough Strongly Tend Neither Tend to Strongly No
infonnation about agree to agree nor disagree disagree opinion
medicines agree disagree
6. It is valuable to
have different
types of
xliv
information about
m dicines from
diff rent s urces
7. It would b better
to hay only one
ourc of
information about
m dian s
Part three: Experience of using the internet
8. D you u th Inl rn t at home?
y
No
9. Wh r do y umo toft n use th internet?
10. or how long hay you us d the internet?
Mor than 5 y ars
B tw n 1 y ar and 3 y ars
than 1Y ar
11. H w ft n d y u curr ntly u th intern t?
v ry oth r month
M nthly
W kly
xlv
Daily
12. Why do you use the internet?
Part four: Experience of health information sites
13. Hav you ever used the Internet to find information about health?
Yes (Please state which site/s)
No
14. Hav you ev r used the Internet to find information about medicines?
Y s (please state which site/s)
No ( 0 to qu stion 22)
15. idyou us th Intern t to find information about health/medicines b cause of
s m on's recomm ndation?
Yes (Please state whom)
No
16. Why did you look for information about medicines on the Internet (rather than
1s wh r )?
17. How did you find the information?
18. Thinking b ck to th informati n, how was th w b ite to use?
tat which w bite you ar talking about] _
v ry difficult
xlvi
Difficult
N ither asy r difficult
asy
V ry easy
19. H w u fuJ or not was th information (on the website) for you?
Not at all us fu1
Not u fu1
N ith r u fulorn tu ful
U tu]
V ryus ful
20. id Y u wonder if th information (on the website) was accurate?
y
No
21. ow did Y u t 11if th information (on the website) was accurate?
22. Will you 1 k for inform tion bout m dicin s on the Intern t in the future?
xplain why you will do 0)
hank ~ou for com~leting the guestionnaire
xlvii
xlviii
Appendix 16:Copy of usability study form
UNIVERSITY OF LEEDS
Usability.Luser test stud
Confi dential
R ad out the following set of instructions before the interview begins.
Th nk y u for gr ing to tak part in this study to examine how useful and usable
inl m t-b 5 d m di in s information sites ar . There are two parts to the study.
4. An x rei u ing a m dicin s information site on the Internet to find
p ifi information, and to s if it is understandable.
5, A h rt int rvi w wh r J will ask you some questions about using the
m di in information site.
B ( r w t rt, d y u hay any qucs ions you would like to ask?
" ,
xlix
Participant information
Participant id number: Date:
Name of observer present
ime session started _ Time session ended-----
IBMI usabilit~ and usefulness stud~
Th fir t part of th rudy has two tasks and r quires you to imagine you have been
pr ib d simuasiatin. Th first task r quires you to find a site that has information
but simuastatin. Th s cond task r quire you to find ten items of information
ut simuastatin using asp eifie website. The aim of these tasks is to examine how
u abl nd u ful the w b it is. It is not how skilful you are at using the Internet
th t i ing x min d, but how asy to us th website is. I am interested inwhat
you y t y ur ]f a you find the information. To do this I will ask you to talk
1 ud you p rf rm th tasks. So J want you to say out loud everything you
w uld Yt Y ur 1£ ilently. Just try to act as if you are alone in the room
p king t y ur f. If you ar sil nt for a length of time, I will remind you to keep
t lking loud. Do you understand what you hav to do?
t m n w show you an exampl of talking aloud.
o en BBC news www to find the weather for teed
I would like you to imagine the following situation. You
have been prescribed simvastatin by your GP for the first
time and you decide to look for information about the
m dicine on the internet.
ask one:
Please use Internet explorer to find any site with information about simvastatin.
Show card with name simvastatin.
• Note name of site & url
• A k: why did Y u search for the information this way?
Task two:
N wI w uld lik you to find information about simvastatin using a specific
• an you show m where you found the answer to this question?
• In y ur wn words, tell m what it says in answer to this question.
U ection Question Information Information
found? explained?
1. What it is WhyshouJd O=no O=no
and wh t i you use
'sus d fo simvastatin? 1 =yes 1 =yes
Indicative
answer: it
lowers the
amount of
cholesterol and
fats in your
blood (to
protect against
heart disease
or stroke)
2. Sid cH Is Please name three O=no O=no
unwanted effects
from taking l=y 1 =y s
imvastatin
Indicative answers:
Ii
ANY3FROM
muscle wastage/pain,
constipation, wind,
flu-like symptoms,
headache, etc
3. eforeyou Is it okay to drink O=no O=no
aka alcohol when
taking simvastatin? 1 =yes 1 =yes
Indicative answer: yes
but take care if you
drink large amounts
of alcohol
4. How to tak What should you O=no O=no
do if you forget to
take simvastatin? 1 =yes 1 =yes
Indicative answers:
take as soon as
possible (but not two
hours before the next
dose); and do not take
two doses at once
5. ow to tak Is there specific O=no O=no
food or drink you
should not have 1 ""yes 1 =yes
when taking
simvastatin?
Indicative answer:
'grapefruit juice'
6. Beforeyo Suppose you are O=no O=no
tak taking
Erythromycin, an 1 =yes 1 =yes
antibiotic, and the
doctor starts you
on simvastatin. Is
it okay to take it?
(Shownam
lerythromycin' on
card)
Indicative answer:
'You slwuld check
Iii
with the doctor'
7. What it is What effect could O=no O=no
and what if having too much
is used fOll cholesterol in your 1 =yes 1 =yes
blood have on your
body?
Indicative answers:
Any of 'It could lead
to (coronary) heart
disease, clog the
arteries and cause
atherosclerosis, cause
chest pain', lead to a
stroke
8. Side ffc t Suppose you take O=no O=no
simvastatin and
you find that your 1 =yes 1 =yes
joints start to ache.
What should you
do?
Indicative answer:
'Stop taking it and see
a doctor or go to the
hospital straight
away' (prompt for
urgency)
9. Wh t it is Name me two O=no O=no
and what i things you can do
is us d f to improve your 1 =yes 1 =yes
health while taking
simvastatin
Indicative answer:
ANY 2 OF: take
exercise/ stop
smoking/ to e weight/
eat lower fat dietl
reduce alcohol intake
]0 efore you If you arc pregnant O=n O=no
t k or considering
becoming 1=ye 1 =y s
pregnant, should
'----
vou take
liii
simvastatin?
Indicative answer: do
not take simuasiaiin
11 Do you think the Information is O=no
trustworthy?
1 =yes
ollowup •
Please explain your answer
Post-study interview about the usefulness and
ease of use of using an internet-based medicines
information site
N w I will k you om qu stions about using the site and the tasks you
p rform d. PI a xplain th r asons for your answers as fully as you can. Before
w tart, d yuh ve ny qu stions?
1. site was to use?
(Follow-up qu stions)
a. Did you f el it was easy to use the site?
b. Did you feel the site was pleasant to use?
Did you f el the site was helpful for finding the information?
2. Did you f 1 the information on th site was us ful?
(Foll w-up qu stion)
a. Did you und rstand th information?
3. Will you u
(PI s giv r ons)
Iiv
4. Did thinkin& aloud affect your task performance?
Only if they ask for clarification of this q:
a. (For example was it more easy or difficult to perform the task?)
s. Is there anythin& about the site I haven't asked you about which you'd like
to mention?
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Appendix 17:Copy of further information leaflet Study
four part one .,
UNIVERSITY OF LEEDS
Information sheet for a study of a medicines information website
As part of my PhD research, I am looking to see if your opinions and recommendations on the design
and content of a website with medicines information will make it easier for the general public to use
and understand. If you agree to take part, we will discuss your opinions about the web pages. This
will be done by telephone. I will record the interview to then make notes about what you said. No-one
apart from me will have access to the recording and it will be deleted after I make my notes. The
results of this study will be reported in my PhD, as well as articles in research journals. Your name
will not appear anywhere, and will not be revealed to anyone. All information from the interview will
only be available to me and my supervisors, who will check I have analysed the information correctly -
they will not know your name, or hear the recording.
There are three web pages about pain control I will ask you to look at, on the CancerHelp UK website
(http://www.cancerhelp.org.uklhelp/default.asp?page=5899). The three pages are called: what
painkillers are; types of painkillers; and side effects of painkillers. You can get to these pages by
typing in the link above in the address box. I will ask you to comment on the web pages regarding:
• How easily you believe people could find information using these pages.
• How satisfied you believe people would feel using these pages.
• How easily you believe people would understand the information on these pages.
• How well organised you believe people would feel the information is on these pages.
The outcome of your interview will help me to make recommendations about the redesign of the
CancerHelp UK web pages with information about analgesics. The study should not pose any risk of
harm to you, and a contact number will be available if you have any questions you wish to follow-up
after the study. If you have any further questions before the study, you are welcome to contact me:
ds
Lead su ervisor
Dr Peter Knapp
School of Healthcare
Bain sWing
Univ r ity of Le ds, LS2 9UT
T 10113 343 1237 ax 0113 343 1284
P.R.Knapp@1 cds.ac.uk
onald Nicolson BA (Hons), MSc
S 1ofH alth ar
01133437 52
d.j.ni 1 on@l ds.a .uk
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Appendix 18: Copy of consent form for Study four
art in research stud and anaI_ysis
A study of a medicines information website
Name of Researcher: Donald Nicolson, School of Healthcare, University of
Leeds
Please tick the box to say yes for each question
• I have read the information sheet for this study. 0
• lund rstand th reason for this study, and how Iwill be 0
involved.
• Any qu stions Ihave about the study have been answered. 0
• Ihave had nough tim to think about whether Iwant to 0
tak part
• lund rstand by taking part in the study Iwill not get any 0
dir ct p rsonal b nefi t from it, and that my medical care
will not b aff ct d.
• lund rstand all data collected will be held in confidence. 0
• lund rstand in any reports from the study, my personal 0
d tails will be r moved.
• Iagr to my voi being record d. 0
• lund rstand Ido not have to answ r all qu stions, and can 0
withdraw from th study at any point for any reason.
• la to tak part in this study. o
P rti . Sign d
d
Nam: Dat
Date
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Appendix 19: Copy of recommended changes sent to CRUK
Th foll wing usability issues were id ntified with the web pages (in bold, grey
had ), and th r comm ndations for changing the content and formatting to
alleviat those difficulties ar in indented bullets.
Strengths of the CancerHelp UK web pages
• Stak hold r prais d the web pages for being written in an empathic style, and
f It P pI living with cancer would value the information.
• It was f It the pages provided important information dearly, for example the
n d t t k painkillers regularly, not to expect painkillers to provide
ntinu us p in r li f irnm diately, dispelling the myth that there is a threshold
wh r t king mor painkillers will not be beneficial, and the concept of the
'analgesic ladder'.
• M di in u rs said th y felt th information was understandable.
• M dicin u r valu d h w medical words (for example about treatments) had
links to Furth r information to xplain them.
• M dicin us r valu d the way that the site sp lied out very long medical
w rds phon ti ally, b cause if they had trouble with it, they might skip it.
• Th print option is important b cause it can provide a copy of the information
without th distra ting links or navigation columns of an HTML page.
Navigating the pages
(i) Participants had difficulty navigating the pages at times; for example th
eadings were felt to be unclear about the information underneath it~
and specific information (for example for J?,arti cular medicines) was felf
to b quite deep within the site, making itmore difficult to locate.
• R commendation: dd m T bull ts and headings to make the information
ta n ut b tt r nd to br ak up dens t xt. Numb r titles to differentiate
b tw on th "Types oj painkillers page", on for opiat s, two
• R commendation: m k it d ar r how th nt nt is structured on each page;
f r x mpl h v hi rar y of headings and subheadings
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• Recommendation: provide a clearly referenced table of contents with
hyp rlinks to diff rent s mons on the pages. The inclusion of left-hand
navig ti n, sub-h adings and/or a flow chart could also improve navigation.
• Recommendation: colour code different areas of the site to help make the sign-
po ting ( aying wher the person is on the site) clearer. (This change may also
b sugg st d by th study evaluating the usability of the CancerHelp UK site,
nd s itmay be more appropriate to make such a change in light of that
tudy's r ommendations).
• R commendation: add symbols, figures or pictures to break up the dense text,
and m k th pag s more appealing to readers (for example pictures
TT sponding t the diff rent m dicines).
• Recommendation: add a 'find bar' for locating keywords or phrases easily.
(m The layout doe not account for people who only occasionally visit the
pages, and th refore viewers may miss crucial information if only
looking at specific pages.
• R commendation: cl arly indicat on th pages what s mons have been
r ntly u d t d, and r omm ndations on s ctions that are considered
nti 1 forth vi wer to r ad, ev n if only browsing.
(iii) Some pag swere felt to be too long.
• Recommendation: pag s with larg amounts f information should have the
nt nt split v r parate linked p ges to make th m manageable, for example
til "Types of painkillers page".
(iv) The wording of URLs are not conducive for finding the information.
• R comm ndation: h v the nam 5 of th pag s includ d in the URLs.
(v) The banner and crumb links are not clear and ma not be useful to
eopl unfamiliar with them.
• R commendation: th 'crumb' Ions ould b r pIa d with arrows and th
b nn r link rdinat d to h lp th m st nd out.
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(vi) inks for tabbing down (for example at the top of the "side effects of
painkillers" page) were unclear; so although something ha pened, the
user was still on the same age which caused confusion.
• Recommendation: add a 'back-to-top' link to show when a user had tabbed
d wn the pag , and spare their need to scroll back up the page.
(vii) he link to NHS Direct, whilst helpful, may lead to the site losing
visitors.
• Recommendation: th consequences of clicking on links should be indicated so
th urn ti s the ffect, that she or he is leaving the website.
Difficulties with content
(vifi) he pages are felt to not provide specific information about painkillers.
• R commendation: add a n w 5 tion on th different ways of treating cancer
pin, nd n dot from us rs to personalise the information.
• Recommendation: add links to the BNF/Medicines Guides from the site, which
will provid Furth r information about the medicines.
(ix) The site xplained the NSAID acronym, but stakeholders failed to notice
this.
• Recommendation: make th explanation of th NSAlD acronym more explicit.
(x) The pa es do not mention pharmacists as a source for information about
, edicines
• R commendation:th pages couJd r omm nd pharmacists along with GPs
nd nur s a a s ur of information about medicines in the community.
(xi) Information about side effects was 'provided verbally, which research has
hown to b not easily understood by most people.
• R comm ndation: wh r the data ar available, pr sent the information about
th risk or as numb r, or h ve a num rical accompaniment to the
v rb ] t rm.
Ix
(xii) Some professional stakeholders felt the information is currently based
on compliance, not concordance framework with the focus on type of
drug rather than experience, and/or s ecific methods of pain control.
• Recommendation: content could be structured to focus on experience rather
than m didne, because of users' different experiences and needs on finding out
about ways of treating pain, reflected in the titles of the pages.
• Recommendation: content could be structured by choices the patient has to
make, or specific methods for pain control, rather than how to comply with
your doctor's instructions. This change in approach, if considered appropriate,
could b introduced over time.
Difficulties with quality assurance markers
(xiii) The Plain English Campaign 'Crystal Mark', Most Popular Health Site
and Best Health Site logos were not links, and did not explain why they
were on the pages.
• Recommendation: make the accreditation logos 'clickable' to let the user access
information about what they mean.
• Recommendation: a hyp rtext explanation may work as well as a link to an
xtemal site .
. .
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Appendix 20: Copy of further information leaflet Study
four part two .,
UNIVERSITY OF LEEDS
nformation sheet for a study of a medicines information website
I am examining whether websites help people to understand information about medicines.
This research is part of my PhD studies at the University of Leeds.
If you agree to take part, the study will take up to one hour, at the University of Leeds, and
you will receive a £10 gift voucher as a token of appreciation. The study will require you to
look at two versions of pages on a website which provides information about medicines which
can be bought 'over-the-counter' (without prescription) at pharmacies. You will be asked to
find information using the web pages, to answer questions and then to give your opinions
about using the web pages.
You can withdraw from the study at any point, or refuse to answer any questions for any
reason.
The results of this study will be reported in my PhD, as well as articles in research joumals.
Your name will not appear anywhere, and will not be revealed to anyone. All information
about your performance in the study will be stored securely, and will only be available to me
and my supervisors, who will check I have analysed the information correctly - they will not
know your name.
The study should not pose any risk of harm to you, and a contact number will be available if
you have any questions you wish to follow-up after the study. If you have any further
questions before the study, you are welcome to contact me:
Donald Nicolson BA (Hons), MS
5 h 1 fH Ilh ar
Bam Wing
Univ r ity f ds
ds S29UT
0113 343 7952
Lead supervisor
Dr Peter Knapp
School of Healthcar
Bain sWing
Univ rsity fL eds, LS2 9UT
T 101133431237 Fax 01133431284
.uk
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Appendix 21: Instructions for CRUK Study
Th nk you f r agr -ing to take part in this study. I am looking to see if there is a difference
in th u fuln s of two versions of the same three web pages on the CancerHelp UK
w b it which hav information about painkillers.
• Have you ever looked at this website before?
Th r aT thr parts to th study, which will take up to one hour to complete.
1. You will I ok at th first version of the web pages. Using these pages, you have to
find th answers to 8 qu stions about the medicines. You will then fill in a short
u tionnairc about what it was like to use the pages and how satisfied you were
with th inform tion.
2. Aft r hart br ak, you will look at the s cond version of the web pages and
p rf rm th same tasks.
3. At th nd y u will have a chanc to tell me what you thought about the web
pg.
n t ; th im of this study is to xarninc how asy-to-usc the web pages are and
h w und r tand bl the information is. I am not testing your intelligence or Internet skills.
I m g ing to r ord th study, solely to act as an aide m moir for me. This computer
progr m will r ord your onlin actions, and I would like you to wear this headset so I can
h v r ord of your an w rs. No-one will be privy to this recording apart from me.
B for w tart, d you hav any questions you would like to ask?
• Open the envelope to see the order of pages to view and questions to ask
• Press Fll to hide URL
• ask one: user test questionnaire
Iwould Jik you to p nd a.f w minutes looking at the following three pages only: Types
f p inkill r , Ibuprofen, and o-codamol.
Five minutes readin time but don't state the amount of time!
Using th thr w b pag s you h v b n looking at, I want you to find information to
n w r th following 8 questions that Iwill ask you. It is important that you only use the
thr pag s l an w r th qu tions. PI se do not ttempt to answer from general
kn wl dg r u any oth r w bsites. For ach qu stion, I will ask you to show me where
y u fund th n w r on th screen. Rather than r ad the answer out, wher possible I
w uld lik you to try to xpl in it in your own words. Do you understand what you have
to d ?
URN ON MACROMEDIA CAPTIVATE NOW
1. A k P rticip nt the U r T t qu stions and not answers and any important
b rvations
Ixiii
2. Hand the workbook over to the participants and let them fill in the PSSUQ and
SIMS questionnaires.
• Task two: user test questionnaire
Iwould like you to spend a few minutes looking at the following three pages only: Types
of painkillers, Ibuprofen, and Co-codamol, I will show you where the three pages are on
the site.
Using the thr e web pages you have been looking at, Iwant you to find information to
answer the following 8 questions that I will ask you. It is important that you only use the
three pages to answer the questions, Please do not attempt to answer from general
knowledge or use any other websites. For each question, Iwill ask you to show me where
you found the answer on the screen. Rather than read the answer out, where possible I
would lik you to try to explain it in your own words. Do you understand what you have
to do?
, I
1. Ask participants the User Test questions and note answers and any important
observations
2. Hand the workbook over to the participants and let them fill in the PSSUQ and
SIMS questionnaires.
• Task three
3. Using the final page in the workbook, I would like you to tell me if there is
anything about the versions of the pages that Ihaven't asked you about which
you'd like to mention?
• Closing request
PI ase listen carefully to the following request which is essential to the successful running
of this study.
PI as do not discuss in any specific detail the study with your colleagues. Please do not
t II th m th name of th website you looked at, nor the specific pages. If you were to do
so, th Y could th n look at the w bsite in advance and have a better advantage of
p rforming th tasks, which will not help me to understand about the usefulness of the
pag s bing xamined. If they ask you about the study, Iwould recommend you say
s m thing lik : 'you had to look at w b pages with information about medicines and
omm nt on th m; but you have been asked not to say which website by Donald'. Thank
you f r your und rstanding and cooperation on this point, as well as your time for taking
p rt in th study.
• Give participants the £10 gift voucher and get them to sign lor it
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Appendix 22: Copy of battery of tests for CRUK Study
UNIVERSITY OF LEEDS
ComRaring the usability of different versions ot;
the same website with information about
medicines
Confidential
Pages order version
New» Old
or
Old» New
Questions order version
Participant ID #:D
Date of tudy: I did I m I m I v I v I
Have you ever looked at this website before? I Yes/No I
Ixv
User Test number one
Prompts to use:
a. on't forget it's a test of the web page and not 0
b. ould you like me to repeat the question?
c. Would you like to keep looking or shall we go on to the n...e_xt""",,-,=
d. So you are saying ..
e. Can you expand on your answer?
f. Can you show me where on the page you saw the answer
g. think you may be getting confused. This guestion is about .... and y'0u are talking
about ...
Question EU
estion cate
1. When should you not Factual What O=no O=no
take non-opiods? medicine is 1 =yes 1 =yes
Indicative answer: if you for
have a history of stomach
ulcers, bleeding, taking
warfarin (need only one
answer)
2. Why are opiods the best Explanation What O=no O=no
way of treating cancer medicine is 1 =ycs 1 =yes
pain? for
Indicative answer: they
(are based on morphine
which is) the most effective
(or
3. How likely is the risk of Factual Side effect O=no O=no
suffering damage to the 1=yes 1 =yes
kidneys when taking
ibuprofen?
Tndicative answer: its not;
its rare
4. If you have black stools Action Side effect O=no O=no
or are vomiting blood 1 =yes 1=yes..
when taking ibuprofen,
what should you do?
Indicative answer: stop
and tell GP
Ixvi
immediately. Mark as 'No'
for explain if immediately
is not mentioned.
5. Why should you tell
your GP if you are
taking vitamins when
taking ibuprofen?
Indicative answer: because
they can react with
Explanation Before you
take
O=no
1=yes
O=no
l=yes
6. What should you do if Action Side effect O=no O=no
you continue to be sick 1=yes l=yes
(or feel sick) a few days
after first taking co-
codamol?
Indicative answer: tell your
doctor
7. Co-codamol is a Factual What O=no O=no
mixture of what two medicine 1= 1 =yes
drugs? is for yes
Indicative answer:
and codeine
8. Why should you not Explanation How to O=no O=no
take paracetamol if you take 1= 1 =yes
take co-codamol yes
Indicative answer: because
there is already
in co-codamol
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User Test number two
om ts to us .
a. on't forget it's a test of the web page and not 0 .
b.Would you like me to repeal the question?
c.Would you like to keep-looking or shall we estion?
d.So you ar saying..
. an you expand on your answer?'
f. Can you show me where on the page you saw the answer
g. think you may be getting confused. This uestion is about .... and
about ...
Question
1. What are the Factual What O=no O=no
strongest painkillers? medicine 1=yes 1 =yes
Indicative answer: is for
2. Why would you be Explanation How to O=no O=no
given immediate take 1=yes 1=yes
reJease morphine?
Indicative answer: in
case you haue
3. Why would you be Explanation Side effect O=no O=no
given immediate 1 =yes 1 =yes
release morphine?
Indicative answer: in
case you have
4. If you suffer from Action Before you O=no O=no
asthma and you take take 1 =yes 1 =yes
ibuprofen, what
should you do?
Indicative answer:
Check with the GP
5. If you take 200mg of Factual How to O=no O=no
ibuprofen, what is the take 1=yes 1 =yes
maximum number of
tablets you can take
in 24 hours?
Tndicativ answer: 12
Ixviii
Co-codamol page
6. What should you do Action How to O=no O=no
if yow: bowels don't take 1= 1=yes
move for more than yes
two days when
taking co-codamolt
Indicative answers: tell
your doctor
7. How common is the Factual Side O=no O=no
risk of suffering a effect 1= 1=yes
skin rash when yes
taking co-codamol?
Indicative answer: it
will only occur rarely
8. How does co- Explanation What O=no O=no
coda mol work? medicine 1= 1=yes
Indicative answer: it is for yes
controls pain by
blocking prostaglandins
(pain messages) to the
brain.
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PSSUQ: Questions about the ease oruse orthe pages
I want you to tell me whether you agree with the following statements; and then answer
th follow-up questions. Please explain the reasons for your answers as fully as you can.
[Note: Participants completed this twice - after completing both User Tests using the both sets of pages]
. It was easy to find the information on these pages to answer the uestions.
STRONGLY
AGREE
STRONGLY
DISAGREE
1 2 3 4 5 6 7
Follow-u uestion: What made it easy (or difficult) to find the information?
2. I am satisfied with how easily I found the information on these _pages to answer the
questions.
STRONGLY
AGREE
STRONGLY
DISAGREE
1 2 3 4 5 6 7
Follow-u uestion: What was it about the pages that made them satisfying (or not) to
use?
;3. The information on the pages was easy to understand
STRONGLY
AGRE
STRONGLY
DISAGREE
1 2 3 4 5 6 7
Follow-u uestion: Please explain why the information was easy to understand (or not
easy to understand)
. Th information on the pages was organised clearly
STRONGLY
AGR E
STRONGLY
DISAGREE
1 2 3 4 5 6 7
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Satisfaction with Information about Medicines Scale (SIMS)
I would like you to rate the information you read as a whole for the following aspects. I
would like you to say whether you thought the information was: too much, about right,
too little, or if none was received. Please tick one box only.
[Note: Participants completed this twice - after completing both User Tests using the both sets of pages]
1. What the medicines are called.
Too much
About right
Too little
None received
5. How long it will take for the
medicines to act,
Too much
About right
Too little
None received
2. What the medicines are for.
Too much
About right
Too little
None received
6. How you can tell if the medicines
are working.
Too much
About right
Too little
None received
3. What the medicines do.
Too much
About right
Too little
None received
7. How long you will need to be on the
medicines.
Too much
About right
Too little
None received
4. How the medicines work.
Too much
About right
Too little
None received
8. How to use the medicines.
Too much
About right
Too little
None received
9. How to get a further supply.
Too much
About right
Too little
None received
10. Whether the medicines have any
unwanted effects (side effects).
Too much
About right
Too little
None received
11. What are the risks of you getting
side effeds?
Too much
About right
Too little
None received
12. What you should do if you
experience unwanted side effects.
Too much
About right
Too little
None received
13. Whether you can drink alcohol
whilst taking the medicines.
Too much
About right
Too little
None received
14. Whether the medicines interfere
with other medicines.
Too much
Ixxi
About right
Too little
None received
15. Whether the medicines will make
you feel drowsy.
Too much
About right
Too little
None received
16. Whether the medicines will affect
your sex life.
Too much
About right
Too little
None received
17. What you should do if you forget to
take a dose.
Too much
About right
Too little
None receive
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